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Cell-free fetal DNA (cffDNA) enrichment for non-invasive prenatal testing (NIPT):                 
a comparison of molecular techniques 
Kelly Sillence 
ABSTRACT  
Prenatal assessment of fetal health is routinely offered throughout pregnancy to ensure that 
the most effective management can be provided to maintain fetal and maternal well-being. 
Currently, invasive testing is used for definitive diagnosis of fetal aneuploidy, which is 
associated with a 1% risk of iatrogenic fetal loss. Developing non-invasive prenatal testing 
(NIPT) is a key area of research and methods to increase the level of cell-free fetal DNA 
(cffDNA) within the maternal circulation have been discussed to improve accuracy of such 
tests.  
In this study, three strategies; co-amplification at lower denaturation temperature polymerase 
chain reaction (COLD-PCR), inverse-PCR and Pippin Prep™ gel electrophoresis, were 
analysed to identify a novel approach to selectively enrich shorter cffDNA fragments from 
larger maternal cell-free DNA (cfDNA). The sensitivity of droplet digital PCR (ddPCR) 
against real-time PCR (qPCR) was compared for fetal sex and RHD genotyping. In addition 
RHD zygosity testing was carried out for non-maternal samples. Consequently, Pippin 
Prep™ gel electrophoresis was combined with ddPCR analysis for the NIPD of Down 
Syndrome (DS) in pseudo-maternal samples.  
The results revealed that the Pippin Prep™ gel electrophoresis enrichment approach 
successfully demonstrated 2-fold to 5-fold increases in the cffDNA fraction. However, 
further optimisation assays of COLD-PCR and inverse-PCR using actual maternal samples 
were required. The spike experiments for DS detection revealed that with the present assay 
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overrepresentation of the chromosome 21 target could be significantly detected for samples 
with ≥15% ‘cffDNA fraction’. In conjunction with the Pippin Prep™ enrichment method, 
this would have enabled assessment of all 10 maternal samples. Alternatively, fetal sex and 
RHD genotyping results determined that ddPCR provides a more sensitive platform 
compared to qPCR approaches, particularly for samples that express low cffDNA fractions 
(<2%). The ddPCR platform also proved to be a rapid and accurate system for the 
determination of RHD zygosity. 
This study highlights that ddPCR could be used as opposed to qPCR for accurate 
determination of fetal sex and RHD status. While sequencing approaches currently provide 
the most sensitive platforms for NIPT of fetal aneuploidy, high costs (>£400) prevent 
universal application. The combination of cffDNA enrichment with ddPCR analysis could 
provide a cheaper and more widely available platform for NIPD. However, further large scale 
validation studies using actual maternal samples are required.  
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1.1 Prenatal screening  
Prenatal screening is used to determine women at high risk for many specific pregnancy 
related disorders, such as aneuploidy, neural tube defects, congenital heart disease and 
autosomal recessive disorders. It has been estimated that there is around a 2-3% baseline 
risk that a child will be born with a congenital or genetic disorder, although, the 
probability of having an affected child is increased when there is a family history of the 
disorder (Teeuw et al., 2010). Incorporation of a screening programme within the clinic 
enables invasive testing, such as chorionic villus sampling (CVS) and amniocentesis 
(refer to 1.2), to be targeted at women who are more likely to display a positive result. 
Despite the relative success of current screening approaches (80-90% detection rate 
(DR)), advances in screening tools could further improve the specificity and sensitivity, 
thus reducing the number of women offered invasive diagnostic tests and increasing the 
DR, respectively. 
1.1.1 Definitions  
To determine the success of a screening programme, various measurements are used, 
including; the DR, the false positive rate (FPR) or more recently the screen positive rate 
(SPR), and the odds of a positive result (OAPR). The DR refers to the sensitivity of the 
test and therefore identifies the proportion of affected cases successfully determined by 
the screening programme. Low FPR (the rate of occurrence of positive results in non-
affected cases) are also required in addition to high DRs. The SPR, an alternative to the 
FPR, includes both the false positive and true positive results. The SPR illustrates the 
chance that a test will be above the cut off risk (for example 1 in 200) and the result will 
be reported as screen-positive (McEwan, Godfrey and Wilkins, 2012). Lower FPR’s/ 
SPR’s are required to reduce the number of pregnancies unnecessarily exposed to CVS or 
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amniocentesis. The OAPR refers to the likelihood that women seen to be high risk after 
screening will actually display a positive result following definitive diagnosis (Wald, 
2008).  
The threshold used to determine the cut-off point at which invasive testing is offered 
influences the DR and the FPR/ SPR. Ideally, screening tests would display a high DR 
(>90%) and a low (<2%) FPR/ SPR (McEwan, Godfrey and Wilkins, 2012). However, 
both the DR and FPR/ SPR will be lowered if the threshold is increased (for example 1 in 
100) and elevated if the threshold is decreased (for example 1 in 300) (Sillence et al., 
2013). Figure 1-1 displays the screening process, potential outcomes and measures of 
accuracy of prenatal screening for Down Syndrome (DS).  
The positive predictive values (PPV) and negative predictive values (NPV) can also be 
used to determine the performance of diagnostics tests, with high results being indicative 
of improved accuracy. The PPV and NPV refer to the proportions of positive and 
negative results that are true positive and true negative results, respectively (Pencina et al., 
2008). However, the PPV and NPV are also dependent upon the prevalence of a ‘positive’ 
result, for example Trisomy 21 (T21) fetuses in a given population.   
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Figure ‎1-1: The screening process, potential outcomes and measures of accuracy. DR 
is the proportion of affected cases successfully identified by the screening test. True 
screen positive (TSP) / (TSP + false screen negative (FSN)) = 85%. FPR: Proportion of 
positive results in non-affected cases identified by the screening test. False screen positive 
(FSP) / (FSP + (true screen negative (TSN)) = 7% [adapted from Sillence et al. (2013) 
and Buckley and Buckley (2008)].
  
1.1.2 Prenatal screening for fetal aneuploidy 
1.1.2.1 Historical overview and current practice for prenatal screening for fetal 
aneuploidy   
Aneuploidy, a divergence from the normal number of chromosomes (n=46), results in 
significant morbidity and mortality. Chromosomal abnormalities occur in 1 of 160 live 
Do have DS: 400 
DR: TSP/ (SP)* 100 = 85% 
Do not have DS: 96,000 
FPR: FSP/ (SN)* 100 = 7% 
OAPR: Ratio of TSP to FSP= 0.05 (5%) 
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births and additional copies of chromosomes 21 (DS), 18 (Edwards syndrome) and 13 
(Patau syndrome) account for the majority of aneuploidies that are not associated with sex 
chromosomes at birth (Nussbaum et al., 2007; Driscoll and Gross, 2009). DS (T21) is the 
most common fetal aneuploidy and the leading cause of developmental delay, with an 
incidence around 1 in 800 live births (Ehrich et al., 2011).  However, the risk of fetal 
aneuploidy is directly related to maternal age, from the age of 34 the risk begins to 
increase exponentially (Figure 1-2) to around 1 in 35 live births for women in their late 
40s (Morris, Mutton and Alberman, 2002). In the early 1980s, maternal age was 
effectively the only screening tool available for detection of fetal chromosomal imbalance 
such as DS and invasive diagnostic tests were offered to all women aged 35 years and 
above. Women younger than 35 years were only offered testing if there was a known 
family history of the disorder (Buckley and Buckley, 2008).  
 
 
 
 
 
 
Figure ‎1-2: The estimated risk of DS according to maternal age. The risk of having a 
DS fetus in live births gradually increases up until around 34 years of age. The risk then 
increases exponentially, and women in their late 40’s have a risk >3%. [Adapted from 
Morris, Mutton and Alberman (2002)]. 
23 
 
Since maternal age alone only provides a DR of <35%, most aneuploidy fetuses were 
undetected and an abundance of unaffected fetuses were exposed to unnecessary invasive 
testing (Haddow et al., 1992). In addition, due to increases in the average maternal age, 
resources to perform invasive testing in a growing number of patients were unavailable. 
Between 1989 and 2008, the percentage of mothers aged 35 years and above increased 
from 9% to 20%, respectively, making screening based on maternal age alone 
unsustainable. The
 
  gradual introduction of various biochemical and sonographic markers 
since the early 1980s has greatly improved the sensitivity of current screening programs 
to around 95% (Rozenberg et al., 2006; Ehrich et al., 2011) (Figure 2-3).  
 
Figure ‎1-3: Timeline summarising the key developments in DS screening. Since the 
early 1980’s multiple serum and sonographic markers have been identified to increase the 
sensitive and specificity of maternal screening. This figure highlights key markers, which 
have been introduced into the screening programme overtime, summarising the UK 
National Screening Committee (UK NSC) Model of Best Practice for 2011 to 2014 
(Sillence et al., 2013).  
The development of sonographic and maternal serum biomarkers enabled marked 
improvements to the sensitivity and reliability of screening compared to maternal age 
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alone. The discovery of different biochemical markers for aneuploidy screening, such as 
reduced alpha-fetoprotein (AFP), raised Beta- human chorionic gonadotropin (β-hCG), 
raised Inhibin A and reduced pregnancy associated plasma protein A (PAPP-A), and the 
introduction of various screening tests are illustrated in Figure 1-3. The most common 
first trimester test is the combined test, which combines maternal age, NT measurement 
and serum biomarkers, PAPP-A and β-hCG. In addition to fetal aneuploidy, AFP was 
historically used for the biochemical screening of open neural tube defects (NTD). 
However, raised AFP is not visible in fetuses that express closed NTD (10% of lesions) 
and is also associated with other abnormalities such as gastroschisis, omphalocele, 
congenital nephrosis and fetal demise (Cameron and Moran, 2009). Therefore, 
biochemical screening of NTD is not effective and has consequently been surpassed by 
sonographic methods using two-dimensional (2D) and more recently, three-dimensional 
(3D) ultrasound techniques (refer to 1.1.2.2).  
For prenatal screening of fetal aneuploidy, nuchal translucency (NT) is the most vital and 
only sonographic marker used clinically. The NT measures the thickness of the skin fold 
behind the nape of the neck and is carried out between 11 and 14 weeks gestation. All 
fetuses display some fluid at the back of the neck, which increases with gestation, and as 
a consequent the NT measurement must take into consideration the crown-rump length to 
calculate the posterior risk (Souka et al., 1998). However, fetuses with chromosomal 
abnormalities, such as DS, are associated with increased NT as a result of nuchal edema 
due a delay in lymphatic vascular development (Haak et al., 2002; Burger et al., 2015). In 
euploid pregnancies, fetuses that express increased NT often have a healthy outcome 
(Souka et al., 2005), but in some cases it can also be associated with structural 
malformations (predominantly cardiac defects), genetic syndromes, skeletal dysplasia and 
intrauterine fetal demise (Hyett, Moscoso and Nicolaides, 1997; Souka et al., 1998). 
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Many studies have identified a strong correlation of enlarged NT and cardiac defects in 
both aneuploidy and euploid fetuses (Hyett, Moscoso and Nicolaides, 1995; Hyett et al., 
1996; Zosmer et al., 1999; Jouannic et al., 2011). Similarly to aneuploidy, the risk of 
cardiac malformations is positively correlated with increasing NT (Ghi et al., 2001). 
Nicolaides et al. (1992) determined that fetal NT ≥3 mm was a useful marker for fetal 
chromosomal abnormalities between 10 and 14 weeks gestation. The study revealed that 
the presence of NT was associated with >10-fold increase and the absence of translucency 
(<3 mm) was associated with a 3-fold decrease in risk of chromosomal abnormality 
(Nicolaides et al., 1992). NT is still an important marker for risk assessment of fetal 
aneuploidy. However, invasive testing is now offered if the NT is ≥ 3.5 mm or if the risk 
determined by the combined test is ≥1 in 150 (Lichtenbelt et al., 2015). The first trimester 
combined test was first introduced in 1997, which integrates the NT measurement, 
maternal age and early detectable serum biomarkers, free beta human chorionic 
gonadotropin (fβ-hCG) and pregnancy associated plasma protein A (PAPP-A) (Wald and 
Hackshaw, 1997) (Figure 1-3).
 
Studies have identified that with the first trimester 
combined test around 85-90% of all DS cases could be detected with a 5% FPR (Spencer 
and Nicolaides, 2003; Nicolaides et al., 2005; Jaques et al., 2007; Valinen et al., 2007).
 
 
Integrated testing requires first and second trimester screening results to 
determine the risk of aneuploidy. In conjunction with maternal age, the NT and 
serum levels of PAPP-A are tested between 10+3 and 13+6 weeks gestation, and 
serum levels of AFP, fβ-hCG, unconjugated estriol (uE3) and Inhibin A are 
measured between 15 and 18 weeks gestation (Benn, 2002). Between 2003 and 
2004 an audit of the integrated test at two London hospitals, University College 
Hospital (UCH) and St Mary’s Hospital was carried out based on 15,888 women 
(Wald et al., 2009). The results revealed a DR of 87% (95% CI, 74-95) and a 
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FPR of 2.1% (95% CI, 1.9-2.3) illustrating the feasibility of this test. In an 
alternative study, the results of the Serum, Urine and Ultrasound Screening 
Study (SURUSS) for DS were assessed (Wald et al., 2003). The results revealed 
that for women who attend first trimester screening, the integrated test offered 
the most effective approach. In a summative report, Wald et al. (2004) revealed 
that the integrated test, which illustrated DRs of 85% and a FPR of 0.9%, 
demonstrates greater accuracy than the combined test (4.3% FPR) and the 
quadruple test (6.2% FPR). However women who miss first trimester screening 
can only be offered second trimester quadruple testing, which has a slightly 
lower sensitivity and thus a higher SPR than the first-trimester combined test 
(McEwan, Godfrey and Wilkins, 2012). 
Although the Integrated test increases test sensitivity in conjunction with a 
reduction in FPR, there are concerns that some women who indicate high risk (1 
in 150) following first trimester screening have to wait until after second-
trimester testing before they are offered invasive procedures for definitive 
diagnosis, which is associated with ethical complications (refer to 1.4). 
Secondly, a step-wise approach was developed. Consequently, high risk patients 
following the first trimester combined screening test are offered CVS, and low/ 
intermediate cases are offered second trimester screening (AFP, uE3 and free β-
hCG). If the combined risk is high, patient is offered second trimester 
amniocentesis (Nicolaides, 2011). This led to the development of Contingency 
screening, which only offers second trimester serum screening to women that 
present intermediate risk values between 1 in 50 and 1 in 1000. Women who 
indicate significantly high risk following first-trimester screening are 
consequently offered invasive diagnostic tests immediately. Alternatively, 
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pregnant women that indicate extremely low risk after first trimester screening 
are not offered subsequent second-trimester tests. Currently, the UK National 
Screening Committee (UK NSC) has not supported either the Integrated or 
Contingency screening tests despite improvements to DR and FPR/SPR, because 
of the complexity associated with both techniques (McEwan, Godfrey and 
Wilkins, 2012).
 
In addition, the integrated test was also not recommended by the 
UK NSC as the combined test was more cost effective, and as an additional 
appointment in the second trimester is required for the Integrated test, failure to 
attend would make the test invalid.  
In 2003 the UK NSC provided evidence for the first DS screening policy called a 
‘Model of Best Practice’. During 2004 to 2005 all trusts were expected to 
provide a screening programme that demonstrated ≥60% DR for a ≤5% FPR 
(Wald et al., 2003). Through investment in sonographic training, improved 
quality control methods for biochemical analysis and development of ultrasound 
technology the sensitivity of screening and specificity of screening began to 
improve.  In 2008 and 2011 the core screening standard set by the UK NSC for 
England was a DR of >90% and a SPR of <2% for women undergoing combined 
screening, and a DR of >75% and a SPR of <3%  for women undergoing 
quadruple screening (Figure 1-3) (The UK National Screening Committee, 2008; 
The UK National Screening Committee, 2011). The only changed made to the 
Model of Best Practice in 2011 was that the cut-off/ threshold for the quadruple 
test (second trimester), which was reduced from 1 in 200 to 1 in 150  in line with 
the combined test (first trimester) cut-off.  
The National Health Service (NHS) Fetal Anomaly Screening Programme 
(FASP) published by Public Health England (Public Health England, 2015) is 
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responsible for implementing screening policies set by the UK NSC. The aim of 
FASP is to ensure equal access of quality assured screening throughout the UK, 
which provides high quality Information to enable women to make an informed 
choice about their screening options and consequent pregnancy choices (The UK 
National Screening Committee, 2015). Table 1-1 illustrates the national 
standards for T21, Trisomy 18 (T18) and Trisomy 13 (T13) screening.  
Table ‎1-1: National UK Standards for T21, T18 and T13 screening (PHE, 2015). 
Screening Strategy 
Thresholds 
Acceptable Achievable 
T21 Standardised DR 85% 
Combined Test 
Standardised SPR 1.8-
2.5% 
Standardised SPR 1.9-2.4% 
T18/T13 Standardised DR 80% 
Combined Test 
Standardised SPR 0.1-
0.2% 
Standardised SPR 0.13-
0.17% 
T21/T18/T13 Standardised DR 80% 
Combined Test 
Standardised SPR 1.8-
2.5% 
Standardised SPR 1.9-2.4% 
Quadruple (T21) 
Standardised DR 80% 
Standardised SPR 2.5-
3.5% 
Standardised SPR 2.7-3.3% 
 
1.1.2.2 Developments of Sonographic Markers  
Pregnancy ultrasound scans are primarily carried out to determine the viability, 
gestational age and number of fetuses, but is also used as a tool to detect major 
structural abnormalities (Blaas, 2014). Sonographic imaging plays an important 
role in prenatal screening and has succeeded serum screening for detection of 
NTD’s. Classic 2D ultrasound can be used to detect cranial signs, such as lemon 
shaped head, banana cerebellum and ventriculomegaly, for the presence of spinal 
bifida (Van den Hof et al., 1990). However, the prognosis of spinal bifida can 
vary depending on the location of the lesion, with higher lesions being 
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associated with an increased chance of being wheelchair bound. The 
development of 3D ultrasound has improved diagnostic accuracy (to within one 
vertebral body in up to 80% of patients) and enables improved prediction of 
outcome and more directed genetic counselling (Cameron and Moran, 2009).   
The role of sonographic imaging in the risk assessment of aneuploidy, particularly DS 
(T21), has been extensively investigated during the first and second trimester (Benacerraf, 
Frigoletto and Cramer, 1987; Stoll et al., 1993; Hill, 1996; Nyberg and Souter, 2001; 
Rozenberg et al., 2006; Kagan et al., 2009; Abele et al., 2015). Thickened nuchal fold 
was the first ultrasound marker identified for DS and currently the only sonographic 
marker included in the combined screening test (Figure 1-3). Increase NT can also be 
used as a marker for other chromosomal abnormalities, such as Edwards Syndrome (T18) 
and Patau’s Syndrome (T13) (Cicero et al., 2003). In addition to fetal aneuploidy, NT 
measurement is important since it is associated with adverse prenatal outcomes caused by 
a variety of fetal conditions, including cardiac defects (Hyett et al., 1997), dysplasias and 
genetic syndromes (Souka et al., 1998). Similarly to aneuploidy detection, a thicker NT is 
associated with an increased probability of associated anomalies.  
 More subtle sonographic markers for the second-trimester screening of T21 were 
evaluated (Stressig et al., 2011; McEwan, Godfrey and Wilkins, 2012; Blaas, 2014). The 
results revealed that the combination of maternal age with either ductus venous (DV), 
tricuspid blood flow or nasal bone abnormalities only demonstrated a marginal improve 
in DR (33.8%, 32.4% and 31.4%) compared to maternal age alone (29%) (Stressig et al., 
2011). It has also been shown that these sonographic markers are also useful for the 
determination of other aneuploidies and structural abnormalities (Blaas, 2014). Figure 1.4 
illustrates the occurrence of these additional sonographic markers alongside NT, for 
euploid and aneuploidy fetuses. However, some of these markers express inter-racial 
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variation and therefore incorporation into the screening programme may be population 
specific. For example, hypoplasia of the nasal bone in Caucasians occurs in only 1-3% of 
normal pregnancies during late first-trimester screening, whereas this increase to around 
10% in African populations (McEwan, Godfrey and Wilkins, 2012). Therefore, if 
integrated into first trimester screening a lower FPR would be associated with Caucasian 
populations. Kagan et al. (2009) determined that it would be possible to increase the DR 
to 93-96% (with a FPR of 2.5%) by incorporating DV and tricuspid regurgitation markers 
to first-trimester combined screening test. However, checking for these additional 
markers is not only challenging, which results in variation of interpreting results, but also 
very time consuming. Therefore these markers have not been adopted into routine clinical 
practice for widespread screening.  They may have a role, but in a contingent screening 
model whereby they are offered to women with an intermediate risk from combined 
screening, In these situations further information is needed before deciding whether to opt 
for invasive testing (Nicolaides et al., 2005). 
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Figure ‎1-4: Incidence of sonographic features in Euploid, T21, T18 and T13 fetuses. 
The incidence of sonographic markers including NT measurement, absent nasal bone, 
tricuspid regurgitation and ductus venous reversed a-wave for pregnancies carrying 
euploid (black), T21 (blue), T18 (green) and T13 (orange) fetuses. (Adapted from 
(Nicolaides, 2011). (CRL; crown-rump length).  
Various structural abnormalities can be seen using ultrasound and a combination of 
certain sonographic makers can be used to differentiate between aneuploidies. In T18, 
onset intrauterine growth restriction and bradycardia (Cicero et al., 2003) are visible. In 
addition, in around 30% of cases small and large exomphalos can also be seen by 
ultrasound (Sherod et al., 1997). Exomphalos is also associated with heart defects and 
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other chromosomal abnormalities such as T13 (Groves et al., 2006).  In T13, 
holoprosencephaly or exomphalos is observed in about 30% of cases (Souka et al., 1998), 
along with fetal tachycardia and early onset intrauterine growth restriction in around 65% 
of cases (Cicero et al., 2003). Detection of these structural anomalies during either first or 
second trimester screening does not provide a definitive diagnosis and consequently, 
invasive testing should be offered. Other second trimester sonographic markers for the 
detection of T21 have been determined, including choroid plexus cysts, dilated cisterna 
magna and echogenic cardiac foci and a two vessel cord. However, due to low levels of 
sensitivity and specificity (McEwan, Godfrey and Wilkins, 2012), in 2008 the UK NSC 
recommended that a prior risk for DS should not be adjusted based on the presence or 
absence of one or more of these markers (The UK National Screening Committee, 2008). 
This was reiterated in 2015, when FASP recommended that an established screening test 
result should not be recalculated at the 18+0 to 20+6 fetal anomaly scan, as stated in 
previous report (Public Health England, 2015). However, the document stated that along 
with NT, ventriculomegaly, echogenic bowel, renal pelvic dilation and small 
measurements (compared to dating scan) should be reported and consequently women 
should be referred for further assessment (The UK National Screening Committee, 2015).  
Although chromosomal aneuploidy can be effectively detected by 2D ultrasound, 
particularly by the identification of increased NT in the first and second trimester, the use 
of 3D and 4D ultrasound to observe sonographic markers seems to provide better 
detection and identification rates (Malhotra et al., 2014). Recently, a comparative study 
between conventional 2D ultrasound and a novel volume NT™ technique (3D 
ultrasound) revealed that the latter improves the Herman score by obtaining a better 
sagittal plane, even in the hands of a less experienced operator (Haddad et al., 2015). 
Therefore, this platform should be available whenever 2D assessment is difficult to 
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obtain. This illustrates that the improved resolution associated with 3D and 4D ultrasound 
scanning can be used to improve the detection of some of the previously mentioned 
sonographic markers. Alternatively, if novel sonographic techniques facilitate increased 
sensitivity and specificity, the introduction of additional second trimester ultrasound 
markers within the current screening programme could be re-evaluated. In a recent study, 
the frontal fetal facial (FFF) angle in 80 normal fetuses and 42 T21 fetuses were 
compared using 3D ultrasound for women between 14 and 27 weeks gestation (Merz and 
Pashaj, 2015). The results revealed that the T21 fetuses demonstrated higher FFF angles 
compared to normal fetuses and that FFF angles >145° should be considered as a 
potential marker for T21. However, values ≤145° does not exclude the possibility of 
carrying a T21 fetus in the second trimester (Merz and Pashaj, 2015).  Alternatively, an 
evaluative study revealed that the addition of DV and hepatic artery (HA) Doppler 
measurements to the first trimester combined screening test could increase the accuracy 
for DS detection (Togrul et al., 2014). However, further large scale validation is required 
since only the DV Pulsatility index of veins (PIV) illustrated significantly higher 
measurements (P= 0.03) in women who illustrated high risk for fetal aneuploidy 
following the combined test.  
1.1.2.3 Development of Serum/Plasma and Urine Biomarkers  
In addition to identifying new possible ultrasound markers, novel biochemical 
screening markers to improve current DRs and FPRs/SPRs (Table 1-1, Page 28) 
have also been extensively studied (Cowans et al., 2011; Du et al., 2011; 
Akinlade et al., 2012; Munnangi et al., 2014; Iles et al., 2015). Serum 
biomarkers presently incorporated within different screening programmes 
include; PAPP-A, AFP, hCG (and its subunits), uE3 and Inhibin A (Wald et al., 
1996) (1.3.2.1).  
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Initially, the criteria for selecting proteins for analysis as potential novel 
biomarkers were based on logical reasoning and up-regulation or down-
regulation in alternative pregnancy disorders. For example, placental growth 
factor (PlGF) plays a key role in placental development and previous studies 
have also illustrated  significant decreases of PlGF in the first trimester for 
pregnancies associated with pre-eclampsia (Akolekar et al., 2008). The 
assessment of this biomarker for fetal aneuploidy screening revealed a 
significant increase in PlGF for T21 pregnancies compared to unaffected 
pregnancies at 8 weeks gestation, but significant increases were no longer 
detected at 10 weeks gestation (Cowans et al., 2011). Therefore, this biomarker 
would only be beneficial to screening in early pregnancy. Consequently, PlGF 
has not been incorporated into the combined screening test, which is carried out 
at between 10 and 14 weeks gestation.  
Microarray techniques, initially determined seven differentially expressed genes 
(Crosley et al., 2013). PAPP-A2, one of the identified genes, was selected for 
follow up analysis since previous data had also detected up-regulation in pre-
eclampsia (Crosley et al., 2013). The results revealed that PAPP-A2 was 
significantly increased and could serve as an additional serum marker for T21 
screening during the second trimester (Munnangi et al., 2014). Alternatively, 
some biomarkers were selected based on incidental discovery by western 
blotting. Disintegrin and metalloprotease domain-containing protein 12 
(ADAM12) was detected by western blotting in pregnant serum but not in non-
pregnant serum (Shi et al., 2000). Investigation of ADAM12 revealed significant 
reduction in early trimester (≤8 weeks) in T21 cases compared to normal 
controls (Christiansen et al., 2010). However, since this protein is almost non-
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existent by 9-10 weeks, like PlGF, this biomarker is unsuitable for the combined 
screening test.  
Improved proteomic technological developments have created the potential to 
identify new panels of serum biomarkers (Koster et al., 2010). The Special Non-
Invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network of 
Excellence (NoE) was established by the European Union (EU) in 2004 to 
provide worldwide cost effective routine NIPD and screening through long term 
partnerships. (Chitty et al., 2008; Maddocks et al., 2009). One of the major goals 
of the SAFE NoE was to identify a more informative panel of T21 markers. 
Since improved DR and lower FPR are currently achieved during first trimester 
screening, classification of more suitable markers for the second trimester is of 
paramount importance (Kagan et al., 2010; Miguelez et al., 2010).  
Heywood et al. (2011) set out to identify potential new plasma protein 
biomarkers using a two-dimensional - difference gel electrophoresis (2D-DIGE) 
approach. The 2D-DIGE approach uses amine reactive dyes, which assures that 
proteins common to both samples (ran on the same gel) express the same relative 
mobility regardless of tagged-dye used and consequently prevents the need to 
compare multiple 2D gels (Ünlü, Morgan and Minden, 1997) However, the 
study highlighted the inadequacies of gel-based proteomics for identification of 
plasma biomarkers for T21 and suggested that gel-free approaches may be more 
effective (Heywood et al., 2011). Kang et al. (2012) identified 31 DS 
differentially expressed maternal serum proteins (DS-DEMSPs) in the maternal 
serum of women carrying a DS fetus, and out of these ten were considered as 
potential biomarkers (Alpha-2-macroglobulin, Apolipoprotein A1, 
Apolipoprotein E, Complement C1s subcomponent, Complement component 5, 
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Complement component 8, alpha polypeptide, Complement component 8, beta 
polypeptide and Fibronectin).  
In 2012, a preliminary study evaluated the application of combining 2D-DIGE 
and mass spectrometry for determining different levels of expression of proteins 
in normal fetuses (n=6) and T21 fetuses (n=6) (Yu et al., 2012). Bioinformatics 
was then used to analyse the proteins and subsequently, candidates of interests 
were further analysed by enzyme-linked immunosorbent assay (ELISA). Out of 
the 29 proteins successfully identified in the maternal serum of women carrying 
a T21 fetuses, the top 5 up-regulated included serotransferrin, alpha-1b-
glycoprotein (A1BG), desmin, alpha-1-antitrypsin and ceruloplasmin, while the 
most down regulated protein was serum amyloid P-component (APCS). Yu et al. 
(2012) revealed that ceruloplasmin and complement factor B were significantly 
higher in the T21 cases compared to the normal cases (P <0.05). This study 
demonstrated down-regulation of APCS in second trimester samples. However, 
in an alternative study using protein chip technology/ surface enhanced laser 
desorption ionisation time of flight mass spectrometry (SELDI ToF MS), APCS 
was found to be significantly up-regulated in second trimester maternal plasma 
samples carrying T21 fetuses (P < 0.004) (Heywood et al., 2012).  
SELDI ToF MS is a variation on matrix-assisted laser desorption/ionisation 
(MALDI) that is used for the analysis of protein containing samples such as 
plasma or serum (Tang, Tornatore and Weinberger, 2004). SELDI is associated 
with an additional separation phase, which enables bound proteins to be analysed 
with more ease. The use of SELDI ToF MS for the investigation of differentially 
expressed proteins in maternal plasma samples taken in both first and second 
trimester carrying normal and T21 fetuses has been described (Heywood et al., 
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2011; Heywood et al., 2012; Narasimhan et al., 2013). The results revealed that 
the proteomic profile of maternal serum varied from first trimester (10 to 14 
weeks and second trimester (14 to 20 weeks). For first trimester samples, a 
significant up-regulation of plasma protease C1 inhibitor was identified in the 
T21 group compared to the controls (P = <0.004). In the second trimester subset, 
as previously mentioned APCS was found to be up-regulated, along with a 
significant up-regulation of transthyretin (P= <0.006) and a significant down-
regulation of complement C3-α chain (P= 0.0005). Transthyretin was also 
shown to be up-regulated in an independent study, which also used SELDI ToF 
MS to test normal cases (n=85) and trisomy cases (n=23) (Narasimhan et al., 
2013). In total, Narasimhan et al. (2013) determined 37 unique hydrophobic 
proteomic features for T21, T18 and T13 fetuses, highlighting the improved 
accuracy, sensitivity and specificity of proteomic spectrum-based screening.  
Recently, the application of direct MALDI ToF MS on maternal urine samples 
for the detection of T21 was evaluated (Iles et al., 2015). The study revealed 
spectral profile differences between T21 (n=8) and normal (n=39) groups 
between 12 and 14 weeks gestation, but illustrated poor discrimination between 
15 and 17 weeks gestation. While, this approach may provide rapid results at 
lower costs than expensive immunoassays for serum/plasma biomarker profiling, 
the accuracy is likely to be lower and urine samples are more likely to become 
contaminated.  
Currently, no additional serum, plasma or urine markers have been incorporated 
into first or second trimester screening programmes. However, developments in 
proteomic platforms currently available enables detection of an increased 
number of potential markers rather than ‘selection at random’ or choosing 
38 
 
proteins that demonstrate variation in expression in other pregnancy related 
disorders.  
1.1.2.4 NGS for NIPT of Fetal Aneuploidy  
The technological aspects of massively parallel sequencing (MPS) using 
maternal plasma containing cell-free DNA (cfDNA) for NIPT/NIPD will be 
discussed under ‘Determining Fetal Aneuploidy- MPS’ (refer to 1.3.3.3.2), since 
it was first developed as a diagnostic tool for the replacement of invasive 
procedures. However, currently it is only offered as an advanced screening tool 
and many women who receive a positive NIPT prefer to also undergo invasive 
testing for a definitive diagnosis.  
Since the introduction of NIPT for fetal aneuploidy into clinical practice in Hong 
Kong in 2011, the American College of Obstetrics and Gynecology published a 
statement indicating that cfDNA testing should only be offered to high-risk 
women (Choi et al., 2013). This is essential since NIPT only tests the placental 
DNA, thus confined placental mosaicism (CPM), caused either by mitotic non-
disjunction in a trophoblastic cell or trisomic rescue (in the fetus), results in a 
trisomic cell line in the placenta and not in the fetus. Therefore, CPM, as well as 
twin pregnancies and maternal tumours, can give rise to FPRs, thus it is essential 
that if prospective parents select to abort fetus following a positive NIPT test, 
confirmation of aneuploidy should be conducted using invasive tests. In 2013 the 
International Society for Prenatal Diagnosis (ISPD) defined that cfDNA testing 
using MPS may be considered in high-risk cases based on first or second 
trimester screening results (International Society for Prenatal Diagnosis, 2013).  
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Since the current standard is to offer NIPT of fetal aneuploidy as an intermediate 
screening step, it is not economically viable to introduce this as part of an NHS 
clinical service. It was suggested that the cut-off to offer cfDNA testing could be 
set to manage numbers and reduce costs. However, this would result in more 
cases of fetal aneuploidy being missed compared to implementing MPS 
screening as part of the combined screening (Soothill, 2014). By integrating 
cfDNA testing within the combined test is also not currently economically 
viable. Therefore, it was suggested that MPS could replace the serum screening 
aspect of the combined test to reduce costs. However, this decreases the 
information available for other pregnancy complications such as pre-eclampsia, 
which is associated with low levels of PAPP-A (Spencer, Cowans and 
Nicolaides, 2008). The availability of MPS as the primary screening method is 
currently commercially available. By screening the entire pregnancy population 
based on cfDNA sequencing alone results in high levels of sensitivity and 
specificity (Ehrich et al., 2011; Lau et al., 2013; Liang et al., 2013; Li et al., 
2015), although the costs of cfDNA sequencing within the NHS are not yet 
known (Soothill, 2014).  
It is a possibility that cfDNA testing using MPS could replace the current 
combined screening test in the near future. However, currently, the number of 
tests which do not provide a result would lead to an increase in the number of 
women offered invasive testing. In 2014 a study conducted across 21 centres 
within the United States (1914 women) was published, which compared DNA 
sequencing to standard prenatal aneuploidy screening (Bianchi et al., 2014). This 
study tested a general obstetrical population rather than just targeting high risk 
cases, since the performance of cfDNA testing in low risk populations was 
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unknown. The results revealed that the FPR was significantly lower for the 
cfDNA testing compared to standard screening for T21 (0.3% vs. 3.6%, 
P<0.001) and T18 (0.2% vs. 0.6%, P<0.03). In addition, all cases of trisomy 
were detected using DNA sequencing, resulting in higher PPV for cfDNA 
testing compared to standard screening for T21 (45.5% vs 4.2%) and T18 (40% 
vs. 8.3%) (Bianchi et al., 2014). Since higher cffDNA fractions have been 
associated with fetal aneuploidy (Lee et al., 2002), it was expected that higher 
sensitivities would be visible for high-risk populations. However, these results 
revealed that the performance of cfDNA sequencing in a general obstetric 
population corresponded to the performance previously seen in high-risk 
pregnancies alone (Bianchi et al., 2014). Although it is important to note that 
0.9% of cfDNA tests were also unable to provide results.  
In a similar study, two European centres determined the feasibility of a SNP-based NIPT 
for determining the risk of fetal aneuploidy in a general pregnant population (Comas et 
al., 2014). The results supported clinical implementation of NIPT as a safe, early and 
accurate option for the general obstetrical population. However, it is also revealed that for 
Centre A and Centre B, only 2023/2155 (93.9%) and 311/319 (97.5%) samples, 
respectively, received a NIPT result that was able to determine the risk of aneuploidy 
(Comas et al., 2014).  
Initially, it was thought that cfDNA sequencing tests were less reliable for T13 detection 
(Ashoor et al., 2013a). Although recent improvements for the detection for T18 and 
primarily T13 have been shown (Ashoor et al., 2013b). However, the UK NSC must 
review emerging evidence and evaluate the feasibility of MPS screening and whether it 
can be used to replace current screening or be offered as an additional screening test. Due 
to the high sensitivity and specificity associated with shotgun MPS (s-MPS) and targeted 
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MPS (t-MPS) sequencing it is possible that once clinical stability is established, cfDNA 
analysis could replace both combined screening tests and invasive tests currently 
available (Allyse et al., 2015). Presently, the National Society of Genetic Councelors 
(NSGC) support NIPT as an option for high-risk patients but encourages that it is only 
offered where there is informed consent and additional counselling support is provided 
(Devers et al., 2013). Patients that display abnormal results, or if results are unable to be 
determined, should also receive counselling and be offered invasive testing.  
1.1.3 Prenatal screening for monogenic disorders  
X-linked monogenic disorders are linked to single gene mutations on the X chromosome 
and as a consequence male and female fetuses are affected unequally. Therefore, NIPD of 
fetal sex (refer 1.4.3.1) is an important screening tool for couples with known disease 
status or previous family history (Hill et al., 2011). For each recessive X-linked disorder, 
such as Duchenne’s muscular dystrophy (DMD) and haemophilia, each pregnancy has a 
25% chance of an affected male fetus and a 25% chance of a carrier daughter. Thus 
identifying a female fetus predominantly indicates that the fetus will not express the 
disorder and invasive testing is not required. The incidence of affected females is 
considerably lower than males since a mutation would need to occur in two copies of the 
gene to cause the disorder. For example, the prevalence of DMD is around 1 in 7000 
(Romitti et al., 2015), therefore, the prevalence of an affected female in an unrelated 
population would be around 1 in 49,000,000. However, consanguineous mating causes 
individuals to inherit segments of their genomes from each parent which are homozygous 
and consequently this increases the incidence of X-linked and autosomal recessive 
disease within these sibships (Woods et al., 2006). Alternatively, a women with an X-
linked dominant disorder has a 50% chance of having an affected daughter or son with 
each pregnancy, whereas only female fetuses will be affected (100%) if the father carried 
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the affected X-mutation (Hartl and Jones, 2005). Therefore, determination of a female 
fetus if the father expresses the disorder allows for indirect diagnosis of the disease. In 
addition, fetal sex determination is important for conditions associated with ambiguous 
development of the external genitalia, such as congenital adrenal hyperplasia (CAH), 
since dexamethasone treatment can be targeted to female fetuses (Forest, Morel and 
David, 1998) (refer to 1.3.3.1).  
Autosomal disorders are not sex-linked and therefore males and females are equally 
affected. Autosomal recessive disorders occur when two copies of an abnormal gene are 
inherited from phenotypically normal parents who are carriers for a specific disorder. The 
risk of having an affected child if both parents are carriers for the disease is 1/4 (Woods et 
al., 2006). For autosomal dominant disorders only a single affected copy of the gene is 
required for disease manifestation and if a single parent carries this mutation the risk of 
having an affected child is 1/2. Since the disorder is dominant in most cases the affected 
parent will show symptoms of the disease. However, in Huntington’s disease, a 
neurodegenerative autosomal dominant disorder, physical symptoms do not usually begin 
until 35 years of age and a consequence the parental status at time of conception and 
throughout pregnancy is not known (Langbehn et al., 2004). Therefore, couples with 
known family history of Huntington’s or specific autosomal recessive disorders can be 
offered preconception risk assessment. Defining the presence of mutated gene for 
Huntington’s disease indicates a 50% risk that the fetus will also express the mutated 
allele. For autosomal recessive disorders, determining the carrier status of each parent, or 
maternal carrier status, prior to conception enables fully informed reproductive choices to 
be made. This can include pre-implantation diagnosis and in vitro fertilisation, or 
alternatively allow for counselling to psychologically prepare prospective parents, 
preventing couples, or individuals, having to make quick and difficult choices during the 
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antenatal screening period, such as potential termination of pregnancy (Hussein et al., 
2013). Due to the low prevalence of recessive disorders, the likelihood of a couple 
expressing the same recessive allele is low. However, as previously mentioned the 
likelihood is increased if mating is consanguineous.   
The carrier frequencies of some autosomal recessive disorders vary between individuals 
of specific ethnic backgrounds and as a consequence different carrier screening 
programmes are recommended for different populations (Table 1-2). Cystic fibrosis, Tay-
Sachs disease and sickle cell anaemia are more prevalent in Caucasians (Northern 
European origin), Ashkenazi Jewish and African populations, respectively (Wailoo and 
Pemberton, 2008). For example, the carrier prevalence of sickle cell anaemia ranges from 
1 to 40 percent from different populations (Hussein et al., 2013). Within the NHS, women 
are offered antenatal screening for sickle cell anaemia and thalassaemia with follow up 
analysis on the newborn as part of the bloodspot program (Cavanagh, McHugh and 
Coppinger, 2015). In low prevalence populations, family origin questions (FOQ) are used 
to determine if screening is necessary, but in high prevalence populations all pregnant 
women are offered screening for all haemoglobinopathies. The prenatal screening blood 
test for sickle cell anaemia and thalassaemia is carried out before 10 weeks gestation to 
increase time available for parents to make an informed decision. The test determines the 
carrier status of each parent and if both are identified to be carriers of concerned 
haemoglobinopathy, genetic counselling is offered.  
Table ‎1-2: Carrier frequencies of various autosomal recessive disorders within 
different populations.  
Population  Condition  Carrier Frequency*  
African-American  
Sickle Cell Anaemia  1 in 10  
Cystic Fibrosis  1 in 65  
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Beta-Thalassaemia  1 in 75  
Ashkenazi Jewish  
Gaucher Disease  1 in 15 
Cystic Fibrosis  1 in 26 - 1 in 29  
Tay-Sachs Disease  1 in 30 
Dysautonomia  1 in 32  
Canavan disease  1 in 40 
Asian  
Alpha-Thalassemia  1 in 20 
Beta-Thalassaemia  1 in 450 
European-American  Cystic Fibrosis  1 in 25- 1 in 29  
French Canadian  Tay-Sachs Disease  1 in 30  
Hispanic  
Cystic Fibrosis  1 in 46 
Beta-Thalassaemia  1 in 30- 1 in 50 
Mediterranean 
Beta-Thalassaemia  1 in 25- 1 in 29  
Cystic Fibrosis  1 in 29 
Sickle Cell Anaemia  1 in 40 
*Carrier frequencies obtained from Oregon Health and Science University (OHSU) 
Department of Health Services Oregon Health and Science University (OHSU) (2005,   
Section 1.3.3.4 describes various methods that have been developed for the NIPD of 
monogenic disorders, including, detection of paternally inherited mutations, relative 
mutation dosage (RMD) analysis for determination of individual monogenic disorders 
and MPS for detection of multiple monogenic disorders. Similarly to aneuploidy analysis, 
it is reasonable to suggest that these fetal specific genetic-based tests may be used as 
advanced intermediate screening tools and allow confirmatory invasive tests to be 
directed at women that are highly likely to carry an affected fetus.  
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1.2 Invasive testing  
Despite recent advances of t-MPS for NIPT of fetal aneuploidy (1.3.4), invasive tests, 
such as CVS and amniocentesis, are currently the only approaches clinically available for 
definitive diagnosis. CVS is carried out between 10 and 12 weeks gestation and involves 
the collection of placental tissue (chorionic villi) (Olney et al., 1995). This can either be 
achieved using a transcervical procedure, which obtains the tissue by inserting a catheter 
through the cervix and into the placenta, or alternatively by a transabdominal procedure, 
which collects the tissue by inserting a needle through the abdomen and uterus and into 
the placenta. The type of CVS procedure carried out is dependent upon the route 
accentuated through the physicians training and also gestational age, since the placenta 
moves away from the cervix as it increases, restricting the transcervical approach (Hallak 
et al., 1992).  
Contrastingly, amniocentesis is performed between 15 and 18 weeks gestation 
and involves the collection of amniotic fluid using a transabdominal approach 
into the amniotic sac (Olney et al., 1995). For both CVS and amniocentesis, 
ultrasound is used to monitor and guide the needle/ catheter to the correct 
location. For analysis of fetal genetic material for detection of chromosomal 
aberrations, karyotyping has been considered the gold standard for over 30 
years, and is highly accurate and reliable (Los et al., 2001; Boormans et al., 
2008). However, analysis is labour intensive and results can take between 14 to 
21 days to arrive (Boormans et al., 2008). Thus, this approach is being 
progressively replaced by alternative rapid aneuploidy tests, such as quantitative 
fluorescent polymerase chain reaction (QF-PCR), fluorescent in situ 
hybridisation (FISH) and multiplex ligation-dependent probe amplification 
(Choy et al., 2014). 
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Direct analysis of fetal genetic material enables accurate (100%) definitive 
diagnosis. However, irrespective of the downstream processing used for 
detection of chromosomal aberrations, the invasive methods used (CVS or 
amniocentesis) to obtain fetal genetic material are associated with a 1% risk of 
iatrogenic fetal loss (Ferguson-Smith, 2003; Chiu, Cantor and Lo, 2009; Ehrich 
et al., 2011).  Despite considerable developments within the field of NIPD, 
improved PPVs (refer to 1.1.1) are required before invasive tests can be 
replaced.  In addition, the cost benefits, ethical considerations and practicality of 
implementing NIPD into the clinic must be evaluated on a wide scale.  
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1.3 Prenatal diagnosis 
Screening is an effective tool to determine risk of pregnancy related disorders and fetal 
chromosomal abnormalities. However, it cannot be used for a definitive diagnosis. In 
order for a diagnosis to be made, direct analysis of fetal genetic material is required. 
Currently, confirmation of specific fetal disorders can only be routinely achieved using 
invasive tests (1.2), which are associated with a small but significant risk of miscarriage. 
Therefore, developing a reliable and highly accurate NIPD test has long been sought 
after. The discovery of fetal cells (Walknowska, Conte and Grumbach, 1969), fetal RNA 
(Poon et al., 2000) and predominantly cffDNA (Lo et al., 1998a) within the maternal 
circulation has made NIPD viable and multiple techniques have been research over the 
last two decades. Although none of these techniques have replaced invasive testing at 
present, due to high levels of sensitivity (100%) achieved by MPS, it is likely that non-
invasive testing will be implemented within the clinic in the near future.  
1.3.1 Fetal cells  
The presence of fetal cells within the maternal circulation (Walknowska, Conte and 
Grumbach, 1969) demonstrates that the placenta does not form an impermeable barrier 
between the mother and fetus, enabling bidirectional trafficking. Therefore, this 
highlights the application of intact fetal cells as a target for NIPD. Multiple complex fetal 
cell enrichment techniques have been described for purification and diagnostic analysis, 
including density gradient centrifugation (Cupp et al., 1984), Fluorescence-activated cell 
sorting (FACS) (Herzenberg et al., 1979), magnetic-activated cell sorting (MACS) 
(Gänshirt et al., 1998), charge flow separation (Wachtel et al., 1998), and 
immunomagnetic colloid systems (Lim, Tan and Goh, 1999). However, the relative rarity 
and fragility of fetal cells makes isolation difficult (Bianchi, 1999). 
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The first fetal cell identified within maternal plasma using PCR was the fetal leucocyte, 
which was identified in 1969 by detecting the presence of Y-chromosome targets in 
mitogen-stimulated lymphocytes (Walknowska, Conte and Grumbach, 1969). However, 
initial studies revealed that these cells can persist within the maternal circulation for 1 
(Schroder, Tilikai and Chapelle, 1974) and 5 (Ciaranfi, Curchod and Odartchenko, 1977) 
years following delivery. It was later revealed that rare male fetal progenitor cells can 
persist in maternal blood for up to 27 years postpartum (Bianchi et al., 1996). Therefore, 
nucleated fetal cells are unlikely to become an effective diagnostic tool since cells from 
previous pregnancies, previous miscarriages or maternal microchimerism can lead to false 
positive results in subsequent pregnancies.     
Consequently, research has focused on terminally differentiated cell types, such as 
trophoblastic sprouts and erythrocytes. Trophoblasts have a unique morphology, which 
makes then easy to identify and are rapidly cleared from the circulation following 
delivery. However, the sparsity of monoclonal antibodies specific for trophoblastic 
markers have made isolation difficult (Bertero et al., 1988). One of the fundamental 
problems associated with trophoblastic spouts is that these cells are not generally 
expressed in healthy pregnancies, but are detectable in pre-eclampsia (Sargent et al., 
1994). Though this may appear as an attractive marker for pre-eclampsia, absence may be 
a result of limited sensitivity as opposed to a healthy fetus.  
Fetal nucleated red blood cells (FNRBCs) are ideal for NIPD since they have a limit 
lifespan, contain a full representation of the fetal genome, are more predominant than 
leucocytes (improving isolation) and contain specific fetal cell identifiers (Bianchi, 1999; 
Choolani, Mahyuddin and Hahn, 2012). In a recent publication, the application of whole 
genome sequencing (WGS) of single FNRBCs from villi demonstrated 100% accuracy in 
first trimester samples (Hua et al., 2014). In addition, further analysis of FNRBCs from 
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post-termination of pregnancy maternal blood, which confirmed three unaffected cases, 
illustrates the feasibility of this approach to target cells from maternal blood. However, 
the utility of FNRBCs for NIPD has currently not reached clinical implementation due to 
rarity of the cells and inconsistencies in enrichment strategies. Research into the 
improved isolation of FNRBCs, along with other cell types is currently ongoing (Huang 
et al., 2011; Ponnusamy et al., 2012; Emad et al., 2014; Hua et al., 2014; Parikh et al., 
2014; Lo, 2015) and recent sequencing data provides a promising platform for true non-
invasive diagnostic testing, providing successful isolation of fetal cells. Although research 
into developing advanced cell sorting techniques is ongoing, predominantly research has 
focused on the application of cffDNA in the maternal circulation (refer to 1.3.3), which is 
present in significantly higher quantities (Lo et al., 1998b). 
1.3.2 Fetal RNA  
The discovery of fetal-derived messenger RNA (mRNA) within the maternal circulation 
in 2000 (Poon et al., 2000) generated an alternative class of molecular markers for 
potential non-invasive testing as opposed to fetal cells (1.4.1) and cffDNA (1.4.3). 
Similarly to cffDNA, circulating RNA has a relatively short half-life (~16 minutes) and is 
rapidly cleared from the circulation (Nigam et al., 2012). Lo et al. (2007a) identified an 
approach using digital PCR for the noninvasive detection of T21. The report identifies a 
digital RNA-SNP strategy, which uses digital PCR to determine the imbalance of a single 
nucleotide polymorphism (SNP) on PLAC4 mRNA, a placentally-expressed transcript on 
chromosome 21 (chr21), in women bearing DS fetuses. The study successfully detected 
90% of T21 cases and excluded 96.5% of euploid control cases (Lo et al., 2007a). The 
main advantage of targeting mRNA that is placentally-expressed only is that target 
amplification is free of maternal background. However, this means that the fetus has to be 
informative for SNP analysis. Despite DNA being more stable than RNA, one advantage 
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of using RNA for NIPD is that DNA is present in low copy numbers, whereas several 
subclasses of RNA (including mRNA) are highly abundant (Ladomery, Maddocks and 
Wilson, 2011). Despite the abundance of RNA in the circulation, usually, RNA is 
unstable and susceptible to nuclease attack (Lichtenstein et al., 2001). However, it has 
been postulated that ‘free’ fetal mRNA within the maternal circulation is encapsulated 
within a syncytiotrophoblast-derived microvesicle, which protects it from RNase.    
Studies have also identified microRNAs (miRNAs) within the maternal circulation, 
providing yet another set of molecular markers (Chim et al., 2008b; Kotlabova, Doucha 
and Hromadnikova, 2011; Ladomery, Maddocks and Wilson, 2011). miRNAs are short 
(19-25bp) non-coding regulatory RNAs that are capable of silencing gene expression 
(Bartel, 2009). The discovery of some miRNAs, such as miR-141, were found to be more 
stable than CSH1, a typical placentally-expressed mRNA (Ladomery, Maddocks and 
Wilson, 2011) identifying it as a more stable alternative for NIPD. Lim et al. (2015) set 
out to identify a panel of miRNAs as potential biomarkers for NIPT of T21 and 
successfully identified elevated levels of two miRNAs (miR-1973 and miR-3196) in T21 
cases compared to control placentas. This research is not diagnostic, but has the potential 
to improve the sensitivity and specificity of current screening tests (refer to 1.1.2.1).  
Because of the complexity associated with RNA processing, and the uncertainty of RNA 
stability, in conjunction with higher cffDNA being available than originally thought, the 
majority of research has focused on the application of analyzing cffDNA for NIPD for 
fetal aneuploidy. However, both types of free nucleic acids could potentially be used for 
NIPD of fetal genetic abnormalities. In addition, detecting specific miRNAs that are 
upregulated or down-regulated in T21, and potentially other aneuploidies, miRNA 
analysis may be play an important role in future screening.  
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1.3.3 Cell-free fetal DNA (cffDNA)  
In addition to fetal cells, cffDNA has also been shown to cross the placenta and enter the 
maternal circulation (Lo et al., 1997). The levels of cffDNA within the maternal plasma 
were originally said to comprise around 3% to 6% during early and late pregnancy, 
respectively (Lo et al., 1998b). However, in one study digital PCR analysis of maternal 
samples has revealed that the median fractional concentration of cffDNA was ≥2 times 
higher across all three trimesters (Lun et al., 2008). Currently, cffDNA is the gold 
standard for NIPT since the entire fetal genome is represented in the maternal circulation 
(Lo et al., 2010), and in comparison it is more readily available than fetal cells (refer to 
1.3.1) and more stable than RNA (refer to 1.3.2). In addition, the use of cffDNA instead 
of intact fetal cells avoids complexities such as microchimerism, since these cells occur at 
low numbers, thus their contribution to the cffDNA is insignificant (Nelson, 2008). The 
fetal proportion of free DNA in maternal plasma is derived from syncytiotrophoblasts that 
have undergone apoptosis and as previously stated cffDNA is rapidly cleared from the 
circulation making it a specific marker for each pregnancy (Lo et al., 1999; van der 
Schoot et al., 2006).  
When cffDNA was initially discovered, it was identified that it constituted around 3-6% 
of the total cfDNA from early to late gestation, respectively (Lo et al., 1998a). However, 
more recent reports have identified that levels may be higher than first described (10-
12 % average at early second trimester) (Nicolaides et al., 2014). The levels of cffDNA 
within the circulation can also vary due to alternative factors other than gestational age. 
Some studies have identified the following; maternal weight (Wataganara et al., 2004), 
ethnicity (Ashoor et al., 2013a), pre-eclampsia (Hahn, Huppertz and Holzgreve, 2005), 
pre-term labour (Farina et al., 2005), physical activity (Schlütter et al., 2014), blood 
processing protocols (including time before processing and storage conditions) (Chiu et 
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al., 2001), method of collection (Sparks et al., 2012b) and even fetal aneuploidy itself 
(Lee et al., 2002).  
Delays in transportation for samples collected in Ethylenediaminetetraacetic acid (EDTA) 
tubes, results in maternal leucocyte apoptosis, which results in an increase in maternal 
cfDNA (Norton et al., 2013). Women with an increased Body Mass Index (BMI) also 
express higher levels of maternal cfDNA as obese women shed more maternal DNA from 
adipose tissue (Wang et al., 2013). Therefore, increases in maternal cfDNA results in a 
decline in cffDNA fraction (Sillence et al., 2015). Alternatively, the extraction method 
used to isolate cfDNA can affect the proportion of cffDNA. Brojer et al. (2005) 
determined that (cycle threshold) Ct values for automated extractions were significantly 
lower than those for manual extractions (indicating increased gene copy number) when 
starting with ≤2mL of maternal plasma. Previous data has also identified that manual 
extractions yield 23.4% more total cell-free DNA, however, automated approaches yield 
40.7% more cffDNA (Houfflin-Debarge et al., 2000). The level of cffDNA available can 
affect detection of fetal specific targets, therefore it is important to include universal fetal 
markers (Table 1-3) to ensure presence of cffDNA.  
Detection of paternally inherited (fetal specific) sequences, such as those on the Y 
chromosome (chrY) and those on the RHD gene in RHD-negative mothers,  enables 
successful determination of fetal sex (refer to 1.3.3.1) and RHD genotype (refer to 
1.3.3.2), respectively. Furthermore, detection of variable regions, such as short tandem 
repeats (STRs) (Rong et al., 2012) and single nucleotide polymorphisms (SNPs) 
(Nicolaides et al., 2013a), can also be used to detect paternally inherited sequences. 
However, both methods rely on the fetus inheriting a paternal sequence that is absent 
from the maternal genome. In addition, for SNPs (and some STRs), the maternal and fetal 
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specific sequence will only differ by a single nucleotide base. Therefore, highly sensitive 
detection methods are essential and often selective enrichment of cffDNA (refer to 
1.3.3.5) is required (Wright and Burton, 2009).  
Alternative fetal markers such as mRNA (1.4.2) and epigenetic modifications, in 
particular DNA methylation variations, were identified. Both maspin (chromosome 18) 
(Chim et al., 2005) and RASSF1A (chromosome 3) (Chan et al., 2006) were found to be 
hypermethylated in the fetus and hypomethylated in the mother, providing the first 
clinically viable universal markers for fetal DNA. Both are useful for the determination of 
fetal DNA in female and RHD-negative fetuses, but only maspin can be used as a marker 
for the detection of fetal aneuploidy (T18). Recently, various studies have set out to 
identify more fetal epigenetic markers (Chim et al., 2008a; Papageorgiou et al., 2009; 
Tong et al., 2010; Lun et al., 2013). Since CpG islands (CGIs) often undergo DNA 
methylation, an initial study investigated CGIs located on chromosome 21 and identified 
a panel of 22 fetal epigenetic markers that illustrated methylation differences between the 
mother and fetus (Chim et al., 2008a). Out of the 22 markers identified, it included the 
unmethylated form of the phosphodiesterase 9A gene, which was later developed by Lim 
et al. (2011) as a potential marker for the NIPT of T21. An alternative approach using 
combined bisulfite and restriction analysis (COBRA), which evaluated genome beyond 
CGIs, identified that the holocarboxylase synthetase gene (M-HLCS) is hypermethylated 
in placental tissue (Tong et al., 2010). Chromosome dosage of M-HLCS against a Y-
specific sequence using various platforms has been labelled the ‘epigenetic-genetic 
approach (EGG)’ and initial results highlight its potential as a NIPD test for T21 (Tong et 
al., 2010; Lim et al., 2014). Table 1-3 summarises various fetal specific sequences within 
the maternal circulation, alongside universal DNA markers, their application and 
method(s) of detection.  
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Table ‎1-3: Fetal specific target/ universal markers and universal DNA markers, 
purpose and method(s) of detection [adapted from Wright and Burton (2009)].  
Purpose  Sequence detected  Detection method(s)  
Sex 
determination  
SRY, DYS14, DYZ1, DYZ3, 
DAZ, ZFY, amelogenin  
PCR (conventional, nested, real-
time) 
 
Haemolytic 
Disease of the 
Fetus and 
Newborn 
(HDFN) 
RHD, RHC, RHc, RHE, Kell, 
ABO  
PCR (conventional, nested, real-
time) 
 
Single gene 
disorders  
HD, FGFR3, DMPK, CFTR, 
globin, CYP21 
PCR (conventional, nested, real-
time); PCR with mass 
spectrometry (MS) 
 
Aneuploidy SNPs 
maspin  
U-PDE9A 
M-HLCS 
 
PLAC4 RNA  
 
PCR 
Methylation sensitive PCR with 
MS 
Methylation sensitive PCR with 
MS 
Methylation sensitive PCR with 
MS; dPCR; bisulphate conversion 
RT-PCR with MS; Digital PCR 
 
Universal fetal 
markers  
Fetal RNA (PLAC4, GCM1, 
ZDHHC1, PAPPA, PSG9, 
PLAC1, TFP12, KISS1) 
 
STRs, biallelic insertion/ 
deletion polymorphisms, SNPs  
RT-PCR; microarray 
 
 
 
Bisulphate conversion or 
methylation-sensitive PCR with 
MS 
 
Universal DNA 
markers  
GAPDH, CCR5, β-globin, β-
actin, β-hCG , albumin, ATL1 
Hypermethylated RASSF1A 
PCR (conventional, nested, real-
time) 
Methylation-sensitive qPCR 
 
Currently, detection of fetal specific targets is achieved using qPCR and routine testing of 
fetal gender, RHD genotype and even some paternally inherited sequences for single gene 
disorders (refer to 1.3.3.4) has been implemented within the clinic (Chitty et al., 2008). 
However, some studies have identified that digital PCR (dPCR) platforms can detect rare 
sequences, such as cffDNA, with improved sensitivity (Strain et al., 2013; Kim, Jeong 
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and Cho, 2014; Sillence et al., 2015) (refer to 1.3.3.3.1). With regard to the EGG 
approach previously mentioned, qPCR analysis revealed lower sensitivity for detection of 
T21 fetuses (90%) (Lim et al., 2014) compared to an alternative study using dPCR 
(100%) (Tong et al., 2010). However, both studies used small sample sizes for analysis 
and further large scale validation studies are required.  
 Due to the variation and relatively low amounts of cffDNA in an overwhelming 
background of maternal cfDNA, non-polymorphic analysis of fetal aneuploidy is 
significantly more challenging, especially when considering that half of the fetal genome 
is inherited from the mother (Wright and Burton, 2009). Unlike sexing and RHD 
genotyping, which involve the detection of foreign genetic sequences in the maternal 
blood, diagnosis of fetal aneuploidy requires accurate quantification of sequences that are 
shared by the maternal genome, to determine if there is under- or over-representation of a 
particular chromosome.  Currently, only MPS approaches can reliably detect fetal 
aneuploidy (refer to 1.3.3.3.2). However, selective enrichment of cffDNA (refer to 
1.3.3.5) combined with improved dPCR technology (refer to 1.3.3.3.1) could potentially 
provide a cheaper and more rapid NIPT for aneuploidy detection.  
1.3.3.1 Fetal sex determination  
Fetal sexing can be ascertained by detecting the presence of Y-specific targets within the 
maternal circulation. Many studies have achieved high accuracy (100%) using Y-specific 
primers for a region on the SRY gene (Costa et al., 2001; Sekizawa et al., 2001; Honda et 
al., 2002). However, detection of single-copy targets using conventional qPCR can 
sometimes be close to the limits of detection especially if the cffDNA concentration is 
low, which can lead to reduced sensitivity and false-negative results (Avent and Chitty, 
2006). Therefore, detection of low copy targets can be improved by using primers 
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specific for a multiple-copy target (DYS14) located on the TSPY1 gene of the Y-
chromosome (Zimmermann et al., 2005). Since single-copy targets are more reliable for 
the detection of copy-number polymorphisms, clinical assays for fetal sex determination 
often incorporate both targets.  
NIPD of fetal gender during the first trimester enables early assessment of pregnancies 
with known familial risk of sex-linked disorders and is also important for the 
management of CAH, a monogenic inherited recessive disorder (New et al., 2001) (refer 
to 1.3.3.1). In 90% of cases CAH is caused by a defect in the CYP21A2 gene that encodes 
for 21-hydroxylase, preventing effective synthesis of cortisol and as a consequence can 
cause female fetuses to become virilised by the overproduction of androgens (Speiser and 
White, 2003). However, NIPT for fetal sex can allow for dexamethasone treatment to be 
targeted to female fetuses only (New et al., 2014). The prevalence of CAH and sex linked 
–disorders in the UK are 5 per 10,000 live births and 1 per 10,000 live births, respectively 
(NHS, 2010). By determining fetal gender, up to 50% of women can avoid invasive 
testing since only male fetuses are at risk of X-linked recessive genetic disorders for 
heterozygous carriers and only female fetuses can develop ambiguous genitalia in 
pregnancies with a familial risk of CAH. Alternatively, for X-linked dominant genetic 
disorders all female fetuses will be affected if the father has the disorder, whereas both 
males and females will have a 50% chance of inheriting the affected allele if the mother 
has the disorder (Section 1.3.3). However, dominant X-linked disorders are often 
associated with infertility (Zechner et al., 2001).  
The combination of multiple- and single-copy targets using qPCR already provides 
adequate sensitivity and specificity (see above). However, dPCR has the potential to be 
used as a secondary test for inconclusive results, since the partitioning nature of dPCR 
(refer to 1.3.3.3.1) has been shown to increase sensitivity for maternal samples that 
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express low cffDNA fractions (Sillence et al., 2015). Adversely, the application of MPS 
for fetal sexing is not cost effective since accurate quantification is unnecessary and 
current PCR platforms (qPCR and dPCR) are sufficient for the detection of Y-specific 
targets.  
1.3.3.2 Fetal RHD genotyping  
Haemolytic disease of the fetus and newborn (HDFN) is caused when maternal IgG 
antibodies of RHD-negative mothers are exposed to the RhD positive antigens on fetal 
red blood cells. Subsequently allo-anti-D is produced, which crosses the placenta and 
results in destruction of the fetal red blood cells (Urbaniak and Greiss, 2000). This can 
cause mild anaemia or in more severe cases, HDFN can lead to total body edema, 
hepatosplenomegaly and heart failure, consequently resulting in intrauterine death (Eder, 
2006; Van der Schoot et al., 2006). Prior to 1970, HDFN was a major cause of fetal 
mortality with a prevalence of almost 5 per 10,000 live births in the UK alone (Bowman, 
1996). However, since the introduction of routine antenatal anti-D prophylaxis (RAADP), 
which prevents RhD alloimmunisation and consequently HDFN, the incidence has 
reduced nearly tenfold (Kumar and Regan, 2005; Fyfe et al., 2014).  
Currently, all RHD-negative women are offered RAADP in the third trimester (between 
28 and 34 weeks of pregnancy) and repeatedly following delivery in concordance with 
UK NICE guidelines (Alfirevic and Callaghan, 2014), but this is costly as it is produced 
from the plasma of hyperimmunised male volunteers. According to the National Institute 
for Health and Clinical Excellence (NICE) approximately 97,000 women receive RAADP 
each year, which costs between £54 per patient to £313.50 per patient, depending on the 
technology used (NICE, 2008). However, targeted administration of RAADP to women 
carrying RHD-positive fetuses only, has been routinely implemented in the Netherlands 
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since 2011 using qPCR (De Haas et al., 2012) and NICE has recommended the 
exploration of routine antenatal fetal RHD genotyping within the UK (NICE, 2008). 
Providing routine NIPT of fetal genotype enables administration to be targeted to women 
who are known to be carrying an RHD-positive fetus (van der Schoot et al., 2003). Since 
around 38% of pregnancies will be carrying an RHD-negative fetus this approach has 
clear financial benefits (Chitty et al., 2014). In addition, although donors are carefully 
screened for blood-borne pathogens the risk of transmitting an infection is remote, since it 
is obtained from human blood the risk is not eliminated. In the 90s anti-D IgG was 
associated with isolated cases of hepatitis C (The UK National Screening Committee, 
2013). Reducing the number of women undergoing RAADP treatment will lower the 
number of women exposed to possible infection and also mothers with RHD-negative 
fetuses avoid the discomfort of the injection.  
The various antigens of the Rh system that are present on the surface of the erythrocytes 
are coded for by two paralogous genes, RHD and RHCE, which are located on 
chromosome 1 (p34-p36).  The RHD gene is essentially a duplicate of the RHCE gene, 
and the two Rh proteins differ in only 36 of the 417 amino acids of which they each 
compromise (Flegel, 2007). In Caucasian populations, the RhCcEe protein is almost 
universally present (Daniels et al., 2009a), but the frequency of the D+ phenotype is 
predominantly lower in this ethnicity group (70-85%) compared to sub-Saharan African 
(95%) and eastern Asian (99.5%) populations (Finning et al, 2008; Daniels, 2013). 
However, although most people are D+ or D-, the presence of D variants creates a grey 
area.  
Most D-negative phenotypes are a result of a complete RHD deletion and therefore the 
entire RhD protein is absent from the erythrocyte membrane (Wagner and Flegel, 2000). 
Since the entire RHD gene is absent from the maternal plasma in D-, diagnosis is 
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relatively simple in this instance. However, the tandem arrangement of the RHD and 
RHCE genes has led to the frequent evolution of aberrant RH alleles. Some of the 
aberrant RHD alleles do not result in RhD antigen expression and consequently a 
significant number of D-negative phenotypes determined by serological analysis actual 
possess fragments or mutated RHD genes (Daniels et al., 2009a). The most predominant 
is the RHD pseudogene (RHDΨ), which possess an inactive RHD gene due to a 37bp 
insert prior to exon 4, three missense mutations in exon 5, and a nonsense mutation and a 
missense mutation in exon 6 (Singleton et al., 2000; Avent, 2008). The RhD negative 
blood is only found in 3-5% of black Africans, and is even rarer in Chinese populations 
(Bianchi et al., 2005). In one study which tested 82 D-negative black Africans only 18% 
of D-negative individuals are a result of RHD deletion (Singleton et al., 2000). Instead, 
66% had RHDΨ and 15% had the RHD-CE-DS (or r’S,) variant, respectively (Singleton 
et al., 2000). Though the majority of the RHD gene is present, neither variant produces 
any epitopes of D (Daniels et al., 1998; Rouillac-Le Sciellour et al., 2004).  
In addition to D-negative serological phenotypes, hybrid RHD-RHCE genes (and also 
SNPs) can produce weak D and partial D variants (Daniels, 2013) (refer to 5.1.1). Both 
weak D and partial D will produce all or some of the conventional antigens, respectively, 
but with a weakened expression (Rizzo et al., 2012). Although production of alloanti-D is 
more common in individuals with partial D since a number of D epitopes are not 
expressed, although some weak D variants have also been shown to produce alloanti-D 
(Wagner et al., 2000). Confirming the RhD variant status of each mother during 
pregnancy prevents women with partial D being incorrectly labelled as RHD positive by 
serological tests and therefore enables RAADP to be targeted to women that require 
treatment (refer to 5.1.1).  Though this review focuses on the prevention of RhD 
alloimmunisation since it is predominantly the major cause of HDFN, it is important to 
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note that other alloantibodies can sometimes lead to HDFN. Therefore, first trimester 
screening of other antigens become more of a focus and in 2002 screening for irregular 
erythrocyte antibodies (IEAs) in all pregnant women was introduced in the Netherlands 
(van der Schoot et al., 2003). The most frequent IEAs after anti-D are anti-E, anti-K1, -D, 
-c and –C, however, occurrence of these antibodies is less common (1 in 300) and not all 
alloantibodies will induce HDFN (van der Schoot et al., 2003). 
The presence of RHD pseudogenes and D-variants complicates NIPT of fetal genotype, 
since all or part of the RHD gene may be present but phenotypically the fetus is 
considered to be RHD negative. Therefore, assays have been developed to target 
sequences that will distinguish between RHD-positive and RHDΨ/ RHD-CE-DS 
genotypes (Finning et al., 2008; Müller et al., 2008; De Haas et al., 2012; Banch Clausen 
et al., 2014). With regard to Caucasian populations multiple studies have illustrated 
accuracies close to 100% by amplifying sequences from two or three exons (Rouillac-Le 
Sciellour et al., 2007; Müller et al., 2008). However, higher false negative rates can occur 
for first trimester screening and limited data is available on RHD genotyping in mixed 
ethnic populations for the determination of RHD variants. Grande et al. (2013) 
determined that by including assays that amplified sequences on RHD exons 5, 7 and 10, 
high accuracy (>99%) of fetal RHD genotype during the second trimester could be 
achieved in a mixed ethnic population. This also included detection of seven cases that 
were compatible with RHD variants and only a single false positive result was observed 
due to twin pregnancy. Consequently, administration of RAADP was avoided in 95% of 
RHD negative fetuses.  
The qPCR platform is the current gold standard for detection of fetal specific targets and 
many studies have reported the used of the StepOnePlus™ Real-Time PCR System for 
fetal RHD genotyping (Daniels et al., 2009b; Scheffer et al., 2011; Sillence et al., 2015; 
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Thurik et al., 2015). The system uses an LED-based optical detection system that can 
record four colour fluorescent readings (FAM™/SYBR® Green, VIC®/JOE™, 
NED™/TAMRA™, and ROX™ dyes), which enables multiple targets to be analysed in a 
single reaction, providing a high throughput and cost-effective platform. While four 
separate colour references are available, often only three targets can be multiplexed in a 
single reaction since ROX™ is often used as a passive reference dye.  
The use of standards in each qPCR assay also allows for indirect absolute quantification 
of starting DNA. However, the exponential nature of amplification on this platform only 
permits detection differences down to a 2-fold change in copy number. High throughput 
methods using robotic isolation of plasma DNA and qPCR analysis revealed higher 
accuracies for determining fetal RHD status at 30 weeks gestation the Netherlands 
(99.4%) (Van der Schoot et al., 2006) compared to samples tested at 28 weeks gestation 
in the UK (95.7%) (Finning et al., 2008). Similar accuracies have been recorded in France 
(Rouillac-Le Sciellour et al., 2004), however, initial false-negative results were all re-
tested making the test uneconomical. Though highly sensitive, all studies revealed false-
negative results even though third trimester samples were tested. Early testing during the 
first trimester, as previously stated, will only increase the number of false negative results 
encountered (Lo et al., 1998c). This is detrimental since if applied in a clinical setting, 
mothers would not receive RAADP and would be at risk of HDFN, particularly if a 
previous sensitisation event has occurred. Sensitisation events can arise during previous 
pregnancies, threatened miscarriage, ectopic pregnancy, invasive testing, antepartum 
haemorrhage, closed abdominal injury, and intrauterine injury (Kumar and Regan, 2005). 
Consequently, third generation dPCR approaches were developed (refer to 1.3.3.3.1). 
Recent publications have described the application of dPCR for the detection of low-level 
targets with improved precision, resulting in reliable quantification well below the limit 
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of quantification of qPCR (Strain et al., 2013; Miotke et al., 2014). In  addition, Lun et al. 
(2008) illustrated that higher cffDNA fractions were calculated when using dPCR, 
highlighting the capability of this platform to detect more fetal specific targets as a result 
of its partitioning nature (refer to 1.3.3.3.1).  Recent data published by our research lab 
has also shown that increased sensitivity is achieved using dPCR (100%) compared to 
qPCR (83.4%) for determining fetal RHD genotype (Sillence et al., 2015). Therefore, it is 
possible that dPCR could replace qPCR for non-invasive testing of fetal sexing and RHD 
genotyping, or alternatively, it could be used as a secondary platform for conformation of 
inconclusive/ negative results.  
In additional, multiplex ligation-dependent probe amplification (MLPA) which can target 
many more regions of interest, enables determination of various Rh and other blood group 
antigens in a single reaction (refer to 5.3.1). Whilst fetal genotype can be determined with 
100% accuracy using DNA microarray and MPS (Fichou et al., 2013; Halawani et al., 
2014; McBean, Hyland and Flower, 2014), at present it is not economically viable. T-
MPS assays for developing a full panel of blood group genes, which can be used to screen 
blood prior to transfusion, is a key area of interest and as costs continue to decrease it is 
likely that this approach will become more utilized. However, due to the high levels of 
sensitivity associated with dPCR and various qPCR approaches, it is currently 
unnecessary and not economically viable since 1/3 of all women will require NIPT for 
targeted administration of antenatal and postnatal anti-D.  
1.3.3.3 Determining fetal aneuploidy  
The majority of fetal aneuploidies result in spontaneous miscarriage during early 
pregnancy, since the over- or under-representation of certain genes causes alterations in 
the stoichiometry of multi-protein complexes and disrupts normal cellular functions 
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(Huettel et al., 2008). Some chromosomal imbalances are viable but are associated with 
multiple birth defects, and the most frequent include; Monosomy X (Turner syndrome), 
T21 (DS), T18 (Edward’s syndrome) and T13 (Patau syndrome). T21 is the most 
common aneuploidy (refer to 1.1.2.1), and consequently is the most predominant reason 
why women choose to undergo invasive testing if identified to be high risk following 
screening for a definitive diagnosis (refer to 1.1.2.1).  
Over the last decade research has focused on developing a highly accurate (100%), cost-
effective and robust platform for the NIPD of fetal aneuploidy, which enables accurate 
quantification and identification of chromosomal imbalances without the need for 
invasive tests. The most successful results for non-invasive detection of fetal aneuploidy 
have been achieved using both s-MPS and t-MPS (refer to 1.3.3.3.2), which typically 
express >99% DR with a false positive of 0.1-1% (Ashoor et al., 2012; Norton et al., 
2012; Sparks et al., 2012a; Futch et al., 2013; Liang et al., 2013). Despite the decline in 
costs of MPS in recent years, routine testing is currently not economically viable and tests 
are only available through commercial providers costing between £400 and £900 
(Antenatal Results and Choices, 2013). Initially, these tests were developed for definitive 
diagnosis of fetal aneuploidy by directly assessing fetal material. However, at present it 
has been established that NIPT of aneuploidy should be offered as an advanced screening 
tool (Morris et al., 2014). Though this is currently only available commercially (Allyse et 
al., 2015), in time, it is likely that this test will become the primary screen for detection of 
chromosomal abnormalities or alternatively replace invasive testing. However, further 
assessment of the costs and benefits of MPS testing are required to determine its place 
within the screening programme before NIPT can be implemented into routine practice 
(refer to 1.3.3.3.2).  
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As further large scale validation studies are carried out, it is possible the reliability of 
NIPT may become consistent with that achieved by CVS and amniocentesis, and thus 
could potentially replace invasive testing as the primary diagnostic procedure. Though 
research has focused on the application of MPS for NIPT/ NIPD, other cheaper 
alternative platforms have been studied, such as dPCR (Lo et al., 2007b; Lun et al., 2008; 
Tsui et al., 2011), which could provide rapid assessment of fetal aneuploidy at a fraction 
of the cost.   
1.3.3.3.1 Digital PCR  
To detect the presence of a T21 fetus, NIPD tests must be capable of detecting a 1.5-fold 
increase in only a fraction (around 5-10%) of the total cfDNA (Zimmermann et al., 
2002). Conventional qPCR can only detect a difference of one Ct value, which 
corresponds to a 2-fold change in copy number, thus making detection of a 1.5-fold 
increase of chr21 in only ≤10% of the total cfDNA unattainable on this platform. 
Contrastingly, dPCR enable quantification of nucleic acids from single molecules by 
means of sample partitioning. Thermal cycling is used to amplify DNA which will be 
present is some, but not all, of the individual partitions ready for end-point analysis 
(Figure 1-5). Subsequently, the concentration of each target is calculated by determining 
the fraction of positive droplets (for example see 2.9.4) (Pinheiro et al., 2011). Figure 1-5 
highlights the principle of dPCR. 
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Figure ‎1-5: Principle of dPCR. Initially DNA is diluted so that the average 
concentration of target DNA in each compartment is less than 0.5 molecules to ensure 
only a single target is present in a single compartment. However, due to the low levels of 
cffDNA maternal plasma samples are not diluted. Once diluted (or following maternal 
plasma DNA extraction), samples are separated into the discrete compartments. 
Subsequently, partitioned molecules are amplified by PCR using fluorescent probes to 
detect the reference/ wild-type (blue) and the target/ mutant (red) molecules in a single 
reaction. [Adapted from Sun, Jiang and Chan (2015)]. 
In 2006 Fluidigm launched the first commercial microfluidic system for dPCR analysis 
(BioMark HD) using integrated fluidic circuits (Baker, 2012). Lo et al. (2007b) revealed 
Sample containing reference/ wild-
type molecules (blue) and target/ 
mutant molecules (red).  
Sample distributed to discrete 
compartments.  
PCR amplification.  
Sample readout using fluorescent 
probes specific for reference/ wild-
type and target/ mutant molecules.   
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two approaches for the NIPD of fetal aneuploidy using this platform; the RNA-SNP 
strategy and the digital relative chromosome dosage (RCD) method. The SNP-RNA 
approach (see 1.4.2), uses dPCR to determine the imbalance of a SNP on placentally 
derived mRNA in women bearing DS foetuses. An alternative method for aneuploidy 
detection using SNPs located in the PLAC4 gene has also been described using reverse 
transcriptase (RT) MLPA (Deng et al., 2011). This studied used five SNP loci on PLAC4 
and using RT-MLPA, followed by capillary electrophoresis and demonstrated diagnostic 
sensitivity and specificity of 92% and 100%, respectively (Deng et al., 2011). Though 
this highlights the application of SNP-RNA dPCR and RT-MLPA analysis, both methods 
rely on the presence of heterozygous SNPs (Lo et al., 2007a; Lo et al., 2007b; Deng et 
al., 2011). 
The RCD method is not reliant on heterozygous SNPs and instead determines the relative 
dosage by calculating the aggregate (maternal and fetal) number of copies of the 
aneuploidy chromosome against a reference diploid chromosome in maternal plasma. For 
example, in a T21 pregnancy, the chr21 dose will be 50% higher than the reference for 
the fetus (3:2 ratio, respectively).  Therefore, for maternal plasma samples expressing 
10% cffDNA, a 5% increase in the chr21 target is expected (Chiu and Lo, 2012). By 
dividing the target loci concentration by the reference loci concentration the RCD ratio is 
calculated, and for a maternal plasma sample containing a cffDNA fraction of 10% a ratio 
of 1.05 would be expected due to the 5% increase of the chr21 target. However, Lo et al. 
(2007a) determined that a minimum cffDNA fraction of 25% (giving a ratio of 1.125) 
was required for accurate detection of T21 using the Fluidigm system. 
Microfluidic systems, such as the BioMark HD (Fluidigm) and the QuantStudio 3D 
Digital PCR System (Life Technologies), were initially developed to automate the 
original dPCR manual approach, which was labour intensive and the number of replicates 
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were limited to 96 or 384, depending on plates used (Table 1-4) (Sykes et al., 1992). 
Typically, each microfluidic chip contains a few thousand nano-litre sized reaction 
vessels, and thus has greatly improved the throughput of dPCR (Chang et al., 2006). In a 
study by (Fan et al., 2009), this method of microfluidic dPCR accurately identified all 
cases of fetal trisomy in all of the 40 specimens analysed, however the results were 
obtained from CVS samples and not maternal blood samples. To achieve this level of 
accuracy using maternal plasma samples is significantly more challenging due to the high 
level of background maternal DNA.  
Microfluidic chips are expensive, which has limited its widespread use for routine clinical 
practice. The emergence of droplet-based dPCR, primarily the QX200 (advanced version 
of the QX100) Droplet Digital PCR™ System (Bio-Rad), has provided a cost-effective 
platform for analysis of a large number of molecules. The QX200 uses an oil-emersion 
approach under a vacuum to separate each sample into a maximum of 20,000 1nL 
droplets per well (see 2.9.2). Each droplet serves as an individual compartment for PCR 
amplification, which are read using a dual fluorescent detection system (VIC/HEX and 
FAM) to determine the fraction of positive droplets for both the reference and target 
(chr21) DNA molecules (Figure 1-5). The fraction of positive droplets (p), from 0 (all 
droplets are negative) to 1 (all droplets are positive), for each sample is automatically 
aligned to a Poisson algorithm (Figure 1-6) to determine the absolute copy number 
(copies per µL) using the following equation (Pinheiro et al., 2011); 
Copies per droplet = -In(1-p)  
It is important that Poisson corrections are applied, since the number of targets can 
exceed the number of positive droplets if high concentrations are used (Figure 1-6). Thus 
without aligning samples to the Poisson algorithm, quantification is incorrect as we 
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assume each positive droplet only contains 1 target molecule. However, when low 
concentrations of target DNA are present it is likely that each positive droplet will contain 
a single target (Figure 1-6). Consequently, the automatically calculated concentration of 
the reference and target gene loci can be used to determine the digital RCD as previously 
described.   
 
Figure ‎1-6: Determining target concentration using the Poisson algorithm. For 
samples that contain low concentrations of target molecules, the number of targets is 
equal to the number of positive droplets, since each droplet contains a single molecule. 
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Contrastingly, for samples that contain high concentrations of target molecules, the 
number of targets present exceeds the number of droplets, and thus some droplets contain 
multiple (2 to 3) target molecules. In order to calculate the correct quantification the 
number of positive droplets (p) is aligned to the Poisson algorithm. [Adapted from Koo 
(2014)].  
The RainDance® Digital PCR System (RainDance™ Technologies) also uses droplet-
technology to produce up to 10,000,000 PCR reactions per sample. This system far 
exceeds the number of partitions per sample than any other dPCR platform available, 
although the claimed detection sensitivity is comparable to the QX200 system (Table 1-
4). In addition, the throughput of the QX200 is far greater than the RainDrop (Table 1-4) 
and costs are 10-fold less per sample ($3 and $30, respectively) (Roberts, 2014). Table 1-
4 summarises the various commercially available digital PCR platforms.  
Table ‎1-4: List of commercially available dPCR platforms [adapted from Sun, Jiang 
and Chan (2015)].  
System Maximum no. 
of samples per 
run 
No. of PCR 
reactions per 
sample 
Reaction volume 
per sample (µL) 
Claimed detection 
sensitivity 
Fluidigm  
BioMark HD 
48 770 0.65 Single copy 
Life Technologies 
QuantStudio 3D 
24 20,000 14.5 <1% target in a 
reaction 
RainDance 
RainDrop 
8 1,000,000- 
10,000,000 
25-100 0.0001% target in a 
reaction 
Bio-Rad 
QX200/QX100 
96 20,000 20 0.0001% target in a 
reaction 
 
Studies have shown the application of dPCR for the detection of multiple 
haemoglobinopathies and other monogenic disorders (refer to 1.3.3.4) using the principle 
dPCR described in Figure 1-5 for the detection of wild-type and mutant molecules. Due 
to the increased sensitivity of more recent, droplet-based, platforms it is likely that lower 
cffDNA (<25%) are feasible for the detection of fetal aneuploidy using the RCD method 
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as opposed to detection of fetal specific targets. The magnitude of chromosome dosage 
alterations in maternal plasma is dependent upon the cffDNA fraction, since lower 
cffDNA fractions are associated with less chromosome dosage aberrations (as previously 
described). Therefore, when lower cffDNA fractions are present, more molecules must be 
analysed to achieve the same diagnostic accuracy as samples expressing higher cffDNA 
fractions.  
Computer simulation models have determined that around four-times more molecules are 
required to attain the same diagnostic accuracy using dPCR when the cffDNA 
concentration in maternal plasma is halved (Lo et al., 2007a). Further computer 
simulation analysis revealed that for 5% cffDNA fractions, a minimum of 100,000 
molecules from the target chromosome (chr21) and reference chromosome would need to 
be analysed to achieve a sensitivity of 95% and specificity of 99% (Sun, Jiang and Chan, 
2015). Technically, it would be difficult to achieve this many reads for a single target 
locus. Therefore, by increasing the number of targets per chromosome, it is feasible that 
dPCR could be used as an alternative platform to MPS (refer to 1.3.3.3.2) for aneuploidy 
detection, provided a reasonable volume of plasma is obtained. Although, at present, 
effective counting of a large number of molecules from maternal plasma is only achieved 
using MPS approaches. However, the PPV of this test is relatively low since there is a 
low prevalence of fetal aneuploidy (Sun, Jiang and Chan, 2015). Consequently, these tests 
are only available commercially as an advanced screening tool. Recent developments 
using targeted approaches has enabled accurate detection subchromosomal aberrations 
down to 2 Mb (Zhao et al., 2015), which require less reads per sample making this 
approach more economically viable (see below).  
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1.3.3.3.2 MPS 
The cost of massively parallel sequencing (MPS) has decreased dramatically since the 
beginning of the 21
st
 century (Figure 1-7) (Wetterstrand, 2015). Three variations of 
sequencing methodologies are currently used for the detection of fetal aneuploidy, 
particularly T21. These include; s-MPS (Table 1-5), t-MPS for specific chromosomal 
segments (Table 1-6) and t-MPS for direct sequence analysis of SNPs (Table 1-7).  
 
 
 
 
 
 
 
 
Figure ‎1-7: Cost per raw Mb of DNA sequencing from 2001 to 2014. The graph 
illustrated actual cost of sequence per Mb each year against the hypothetical data 
reflecting Moore’s Law based upon the doubling of ‘computer power’ every two years. 
[Taken from Wetterstrand, (2015)].  
The s-MPS approach allows cffDNA obtained from maternal plasma to produce millions 
of short-sequence tags that can be aligned and uniquely mapped to specific chromosomes 
against a human reference genome (Sonek et al., 2012). The reliability for fetal 
aneuploidy detection using this method is determined by the depth of sequencing and 
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subsequent counting statistics. Fan et al. (2008) were the first to propose counting 
chromosomes using high-throughput s-MPS technology. In this initial small scale study 5 
million sequence tags were obtained per patient on average, which provided sufficient 
data to detect the over- or underrepresentation of chromosomes and allow for correct 
classification of aneuploidy fetuses (Fan et al., 2008).  
Since the initial s-MPS study, variations in sequence analysis to further improve test 
accuracy have been developed. Studies determined that sequencing biases occurred 
relative to the GC-content of each chromosome in a linear fashion, and thus consequent 
studies have allowed for adjustments to be made with respect to the DNA base 
composition (Fan et al., 2010; Liang et al., 2013). Intra-run and inter-run variability 
caused by alterations in sample handling, DNA extraction or the sequence itself, were 
also shown to alter the chromosomal distribution of sequence reads for each sample 
(Turan et al., 2010).  To minimize the intra- and inter-run sequencing variation, 
normalised chromosome values (NCVs) from the sequence data were incorporated 
(Sehnert et al., 2011). NCV values >4.0 were required for classification of affected 
aneuploidy state, and NCV values <2.5 were used to classify unaffected cases. NCV 
values between 2.5 and 4 were classified as ‘no call’. Using these parameters, Sehnert et 
al. (2011) demonstrated 100% correct classification of samples with T21 and T18, but 
was unable to detect the T13 case (‘no call’) (Table 1-5). Multiple studies have reported 
the success of using sequence tag mapping and chromosome counting to detect 
aneuploidies such as T21, T18 and T13, illustrating sensitivities >99% for a FPR of <1% 
in most cases (Table 1-5).  
The chromosome-specific t-MPS approach, requires an additional step compared to the 
first approach, which allows for selective amplification of chromosome regions of interest 
(such as chr21, chromosome 18 (chr18) and chromosome 13 (chr13)) to determine the 
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excess of a particular chromosome relative to another (Sparks et al., 2012b). The Illumina 
HiSeq® 2500, which uses reversible terminator-based sequencing-by-synthesis, delivers 
the highest daily throughput and total yield (160 Gb/ day) compared to all other 
sequencing platforms currently available (Illumina®, 2015). This consequently enables 
more samples to be simultaneously sequenced at greater depth. The primary advantage of 
t-MPS is lower sequencing costs, since fewer reads are required per patient, enabling 
more samples to be multiplex in a single run. For example, the HiSeq® 2500 can process 
8 human genomes at 30x coverage, or alternatively, 150 human exomes can be processed 
per run (Illumina®, 2015). Therefore, by targeting an even smaller region of exomes 
(such as chr21, chr18 and chr13) even more samples can be processed with greater 
sequencing depth for each chromosome targeted (Table 1-6).  
The third approach uses t-MPS that relies upon the analysis of SNPs, and thus determines 
paternally inherited sequences to assess the relative contribution of maternal and fetal 
DNA within the plasma (Benn, 2014). Similarly to the second approach described, an 
additional amplification step is required before sequencing, although SNP sequences 
rather than chromosome specific sequences are amplified. Figure 1-8 demonstrates the 
use of SNP analysis for determination of T21. By genotyping fathers to determine the 
SNP profile improved test accuracy can be achieved but paternal genotyping is not 
essential. The commercial test Panorama™ (Natera, 2015) provides NIPT using this 
approach, which uses multiplex PCR to amplify almost 20,000 SNPs in each individual 
reaction (Zimmermann et al., 2012). Subsequently, SNPs are aligned to corresponding 
chromosomes and each product is evaluated based on the hypothesis that the fetus is 
monosomic, disomic or trisomic. Once the possibility of recombination has been 
considered, the maximum likelihood that the fetus is normal, aneuploid or triploid can be 
calculated (Benn, 2014). As there is identification of fetal specific fragments, this 
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approach can be used for detection of microdeletions and duplications (Wapner et al., 
2015). In addition, theoretically, NIPT using SNP analysis should also provide the most 
promising approach for determining fetal aneuploidy in multiple pregnancies and also for 
diandric triploidy, although such testing is not currently offered (Benn, 2014). Table 1-7 
summarises data for determining fetal aneuploidy using t-MPS for SNP based analysis.  
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Table ‎1-5: Summary data for NIPT/ NIPD of fetal aneuploidy using shotgun massively parallel sequencing (s-MPS). [Adapted from Benn 
(2014)].   
 Detection of T21 (DS) Detection of T18 (ES) Detection of T13 (PS)  
Study DS DR DS FPR DS NR ES DR ES FPR ES NR PS DR PS FPR PS NR  
(Fan et al., 
2008) 
9/9  
(100%) 
0/9  
(0.00%) 
0/18  
(0.00%) 
2/2 
(100%) 
0/16  
(0.00%) 
0/18  
(0.00%) 
1/1 
0/17  
(0.00%) 
0/18  
(0.00%) 
(Chiu et al., 
2011) 
86/86 
(100%) 
3/146 
(2.05%) 
11/764 
(1.4%) 
      
(Ehrich et 
al., 2011) 
39/39 
(100%) 
1/410 
(0.24%) 
18/467 
(3.9%) 
      
(Palomaki et 
al., 2011) 
209/212 
(98.6%) 
3/1471 
(0.20%) 
13/1686 
(0.8%) 
      
(Sehnert et 
al., 2011) 
13/13 
(100%) 
0/34 
(0.00%) 
1/48 
(2.08%) 
8/8 
(100%) 
0/39 
(0.00%) 
1/48 
(2.08%) 
0/1 
(0.00%) 
0/46 
(0.00%) 
1/48 
(2.08%) 
(Palomaki et 
al., 2012) 
   
59/59  
(100%) 
5/1688 
(0.30%) 
17/1988 
(0.9%) 
11/12  
(91.7%) 
16/1688 
(0.95%) 
17/1988 
(0.9%) 
(Liang et 
al., 2013) 
40/40 
(100%) 
0/372  
(0.00%) 
12/435  
(2.8%) 
14/14  
(100%) 
0/372  
(0.00%) 
12/435  
(2.8%) 
4/4  
(100%) 
1/408 
(0.25%) 
12/435 
(2.8%) 
(Song et al., 
2013) 
8/8  
(100%) 
0/1733 
(0.00%) 
73/1916 
(3.8%) 
2/2  
(100%) 
1/1739 
(0.01%) 
73/1916 
(3.8%) 
1/1  
(100%) 
0/1740 
(0.00%) 
73/1916 
(3.8%) 
(Stumm et 
al., 2014) 
39/40 
(97.5%) 
0/430  
(0.00%) 
32/504  
(6.3%) 
8/8  
(100%) 
1/472  
(0.21%) 
32/504  
(6.3%) 
5/5  
(100%) 
0/472 
(0.00%) 
32/504 
(6.3%) 
(Bianchi et 
al., 2014) 
5/5  
(100%) 
6/1909 
(0.31%) 
17/2042 
(0.8%) 
2/2  
(100%) 
3/1905 
(0.16%) 
17/2042 
(0.8%) 
1/1  
(100%) 
1/899 
(0.11%) 
 
 47/47  
(100%) 
0/136 
(0.00%) 
11/183  
(4.8%) 
      
DS, Down syndrome; ES, Edward’s syndrome; PS, Patau syndrome; T21, trisomy 21; T18, trisomy 18; T13, trisomy 13; DR, detection rate; 
FPR, false positive rate; NR, no result. 
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Table ‎1-6: Summary data for NIPT/ NIPD of fetal aneuploidy using target massively parallel sequencing (t-MPS) for specific 
chromosomes. [Adapted from Benn (2014)].   
 Detection of T21 (DS) Detection of T18 (ES) Detection of T13 (PS)  
Study DS DR DS FPR DS NR ES DR ES FPR ES NR PS DR PS FPR PS NR  
(Nicolaides 
et al., 2012) 
8/8  
(100%) 
0/1939 
(0.00%) 
100/2049 
(4.9%) 
2/2  
(100%) 
2/1929 
(0.01%) 
100/2049 
(4.9%) 
   
(Norton et 
al., 2012) 
81/81  
(100%) 
1/2888 
(0.03%) 
148/3228 
(4.6%) 
37/38  
(97.4%) 
2/2888 
(0.06%) 
148/3228 
(4.6%) 
   
(Ashoor et 
al., 2012) 
50/50  
(100%) 
0/297  
(0.00%) 
3/400  
(0.8%) 
49/50  
(98.0%) 
0/297  
(0.00%) 
3/400  
(0.8%) 
   
(Ashoor et 
al., 2013a) 
      
8/10  
(80%) 
2/1939 
(0.05%) 
53/2002 
(2.6%) 
(Verweij et 
al., 2013) 
17/18 
(94.4%) 
0/486  
(0.00%) 
16/520  
(3.1%) 
      
(Fairbrother 
et al., 2013) 
- 
0/284  
(0.00%) 
4/288  
(1.4%) 
- 
0/284  
(0.00%) 
4/288  
(1.4%) 
- 
0/284 
(0.00%) 
4/288  
(1.4%) 
(Gil et al., 
2013) 
11/11 
(100%) 
0/946  
(0.00%) 
48/1005 
(4.8%) 
5/5  
(100%) 
1/952  
(0.11%) 
48/1005 
(4.8%) 
1/1  
(100%) 
0/956 
(0.00%) 
48/1005 
(4.8%) 
(Stokowski 
et al., 2015) 
107/108  
(99.1%) 
0/533 
(0.00%) 
8/799 
(1.0%) 
29/30  
(96.7%) 
0/611  
(0.00%) 
8/799  
(1.0%) 
12/12 
(100%) 
0/629 
(0.00%) 
8/799 
(1.0%) 
DS, Down syndrome; ES, Edward’s syndrome; PS, Patau syndrome; T21, trisomy 21; T18, trisomy 18; T13, trisomy 13; DR, detection rate; 
FPR, false positive rate; NR, no result.    
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Table ‎1-7: Summary data for NIPT/ NIPD of fetal aneuploidy using targeted massively parallel sequencing (t-MPS) for SNP based 
analysis. [Adapted from Benn, (2014)].   
 Detection of T21 (DS) Detection of T18 (ES) Detection of T13 (PS) 
Study DS DR DS FPR DS NR ES DR ES FPR ES NR PS DR PS FPR PS NR 
(Nicolaides 
et al., 
2013a) 
25/25 
(100%) 
0/204 
(0.00%) 
13/242 (5.4%) 3/3 (100%) 0/226 (0.00%) 13/242 (5.4%) 1/1 (100%) 
0/228 
(0.00%) 
13/242 
(5.4%) 
(Pergament 
et al., 2014) 
58/58 
(100%) 
0/905 
(0.00%) 
88/1051 (8.4%) 24/25 (96%) 1/939 (0.11%) 
87/1051 
(8.3%) 
12/12 (100%) 
0/953 
(0.00%) 
86/1051 
(8.2%) 
DS, Down syndrome; ES, Edward’s syndrome; PS, Patau syndrome; T21, trisomy 21; T18, trisomy 18; T13, trisomy 13; DR, detection rate; 
FPR, false positive rate; NR, no result. 
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Figure ‎1-8: SNP analysis for the determination of T21: an example of the general 
principle. Fetal DNA (red) and maternal DNA (blue) SNP analysis for normal (left) and T21 
(right) fetus. In this example the father is genotyped GG and the mother GA. For a normal 
pregnancy (left) if the fetus inherits a G allele from the father and an A allele from the 
mother, the G/A DNA fragment ratio will be 1.0, regardless of the cffDNA fraction. For a 
T21 fetus, who has inherited a G from the father and a G and an A from the mother due to a 
maternal non-disjunction, which gives rise to a fetus with the AGG genotype (right). 
Therefore for a fetal fraction of 15% the G/A DNA fragment ratio will be approximately 
((15% x 2) + (85% x 1))/((15% x 1) + (85% x 1)) = 1.15 [Adapted from Benn, (2014)].   
In 2011, NIPT was first released in Hong Kong (Lau et al., 2012) and later introduced 
commercially in the USA (Agarwal et al., 2013). In 2014, four predominant US companies 
provided commercial-based NIPT including; Materni21Plus™ (Sequenom, CA, USA), 
verifi™ (Illumina, CA, USA), Harmony™ (Ariosa Diagnostics, CA, USA) and Panorama™ 
(Natera, CA, USA) (Allyse et al., 2015). While the verifi™ and MaterniT21Plus™ tests use 
s-MPS, the Harmony™ and Panorama™ tests use t-MPS, and the t-MPS based on SNP 
analysis, respectively. Prior to 2015, maternal samples collected within the UK were shipped 
to Hong Kong or the USA for commercial testing. However, in February 2015, Premaitha 
Health (Manchester, UK) launched the IONA® test; the first ever CE-marker NIPT product 
for pregnant women (Premaitha Health PLC, 2015). Therefore, Premaitha Health is currently 
the only company authorised by the European Regulatory agency to sell products to enable 
Normal T21 
A A 
G 
G 
G 
G 
G A A 
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laboratories to offer NIPT services within the UK. In a subsequent validation study, results 
revealed that the test enabled 100% accuracy for the determination of fetal T21, T18 and T13 
(Poon et al., 2015).  
In a recent study, the results for NIPT of targeted cfDNA analysis using Digital Analysis of 
Selected Regions (DANSR) and Fetal-fraction Optimised Risk of Trisomy Evaluation 
(FORTE) with microarray quantification was combined with all published clinical 
performance studies, which also used the DANSR/FORTE methodology (Stokowski et al., 
2015). The consorted data included more than 23,000 pregnancies and revealed 
sensitivities >99% for T21, 97% for T18 and 94% for T13, with a specificity of >99.9% for 
all trisomies. This approach is also adopted by the Ariosa Diagnostics Harmony™ test. 
Despite the success of NIPT, low cffDNA concentrations can result in false negative results, 
and placental mosaicism, vanishing twins or maternal tumours can alternatively give rise to 
false positive results (Dondorp et al., 2015). In addition, because of the low prevalence of 
fetal aneuploidies, many studies that express high sensitivity and specificity (>99%), are 
associated with lower PPVs. For example, one study demonstrated 100% sensitivity 
and >99% specificity, but revealed a PPV of 45.5% (95% CI: 16.7-76.6)) for T21, therefore 
over 50% of the general risk population were false alarms (Bianchi et al., 2014). Despite this 
PPV being 10 times better than current first-trimester screening, PPVs of 100% are required 
for diagnostic testing (Dondorp et al., 2015). Although the accuracy of NIPT is superior to 
conventional screening (see 1.3.2), unlike traditional methods, failure to obtain a result occurs 
in around 2% of all NIPT’s performed (Benn, Cuckle and Pergament, 2013).  
The costs for NIPT ranges from £400 to £900 (Allyse et al., 2015), and with continued 
technological and statistical developments it is likely that not only will costs continue to 
decline but PPVs are likely to show improvement, which could build evidence for the 
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application of NIPD using MPS-based technologies. However, at present most studies have 
focused on high risk cases and consequently NIPT is only implemented as a commercial 
secondary screening test. The UK NSC is currently working with clinicians to assess the 
performance of NIPT in the NHS, and thus will make a recommendation on whether to 
introduce this screening based once results have been obtained (The UK National Screening 
Committee, 2015). Routine first trimester screening is being carried out as normal, and 
women identified as high risk are subsequently offered NIPT as a second screening test. 
Therefore, only women considered high risk following secondary screening will be offered 
diagnostic tests, and thus the number of women undergoing invasive testing should be 
reduced (refer to 1.1.2.1). In a recent press release, Benn (2015) determined that DRs for fetal 
aneuploidy would increase by implementing the universal application of NIPT. In addition, 
using NIPT as a replacement for conventional screening (refer to 1.1.2.4) would reduce 
health costs, provided that it can be carried out for $744 (~£490) or less (Benn et al., 2015). 
Further reports have also identified the use of NIPT as a cost effective screening option for all 
women, regardless of age or risk (Fairbrother et al., 2015; Walker et al., 2015).  
1.3.3.4 Determining fetal monogenic disorders  
Section 1.3.3 highlights the inheritance of multiple autosomal and sex-related monogenic 
disorders, and describes the importance of fetal sexing and determination of ethnic 
background within the screening programme. However, determination of fetal sex in 
pregnancy with previous family history of haemophilia, only illustrates a 25% chance of 
disease if the fetus is male and invasive testing is currently required for confirmation.  
The application of NIPD for autosomal recessive disorders as well as other monogenic 
disorders, such as X-linked recessive DMD and autosomal dominant polycystic kidney 
disease, requires the detection of a paternally inherited mutation that is not present within the 
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maternal genome (Chiu et al., 2002). For autosomal recessive disorders, the lack of a 
paternally inherited mutation suggests that the fetus is not homozygous for the disease-
associated allele and confirmatory tests are not required. However, if the paternally inherited 
mutation is detected, invasive testing is required to confirm disease status of the fetus (Lo, 
2013). For example, detection of mutated paternally inherited polymorphic STRs on the 
CYP21A2 indicates that there is a 50% chance of CAH in female fetuses, whereas normal 
alleles indicate that female fetus will be unaffected (Krone and Arlt, 2009).  In addition, 
exclusion of paternally inherited β-thalassaemia mutations using informative SNPs that differ 
between maternal and paternal alleles, can also determine unaffected fetuses. This approach 
has been well reported using multiple detection systems such as qPCR (Chiu et al., 2002), 
allele specific arrayed primer extension (AS-APEX) technology (Papasavva et al., 2006), 
conventional PCR - DGGE (Lazaros et al., 2008) and MALDI-TOF MS (Li et al., 2009). 
However, since maternally inherited sequences will be undistinguishable from the large 
background of maternal DNA, the main disadvantage of this approach is that disease status 
cannot be confirmed in cases where a paternally inherited sequence is detected. However, 
more sensitive techniques have been described for the determination of β-thalassaemia and 
other recessive haemoglobinopathies, such as  dPCR (Barrett et al., 2012), 
pyrophosphorolysis-activated polymerisation  and melting curve analysis (Phylipsen et al., 
2012) and MPS approaches (Lam et al., 2012), which allow dosage analysis for accurate 
diagnosis.  
Many studies using MPS and digital PCR platforms have successfully discriminated between 
unaffected and affected fetuses for dominant and recessive traits, despite high background of 
maternal DNA signal (Lench et al., 2013). Lun et al. (2008) described an approach for NIPD 
of essentially all monogenic disorders. The approach was defined as relative mutation dosage 
(RMD), and through the use of dPCR enabled the determination of slight differences in 
82 
 
concentration between either; a mutant and normal gene or between two alleles for a 
particular SNP. Currently, the application of this approach has been successfully 
implemented for the NIPD of fetal haemophilia (Tsui et al., 2011) and sickle cell anaemia 
(Barrett et al., 2012). This platform can be adapted for multiple monogenetic disorders, but it 
is likely that only one or a few disorders could be analysed in a single run dependent upon the 
platform used (refer to 1.3.3.3.1).  
Alternatively, MPS platforms enable polymorphism dosage analysis and detection of 
paternally inherited mutations for multiple genes by sequencing millions of cfDNA 
molecules from maternal plasma. Consequently, the maternal inheritance of the fetus for 
recessive disorders can be determined in regions where the mother is heterozygous (Lo, 
2013). Disease presence in the fetus can then be determined by mapping the SNP alleles to 
each of the maternal haplotypes and determining a significant increase in concentration of the 
mutant SNP. This method has previously been used for the NIPD of β-thalassaemia using 
both s-MPS (Lo et al., 2010) and t-MPS (Lam et al., 2012).  
The advantage of digital PCR is that it is a simple and cheaper alternative to MPS. However, 
since MPS approaches analyse a substantially increased number of molecules, the robustness 
of digital PCR for NIPT is likely to be reduced (Lo, 2013). In addition, the decline in costs of 
MPS associated with target approaches could enable a conceivably cost-effective platform for 
clinical implementation. However, the application of digital PCR may still be a vital tool for 
prenatal screening and diagnosis for prospective parents with a risk of a known specific 
monogenic disorder.  
1.3.3.5 cffDNA enrichment  
The low concentration of cffDNA, particularly during the first trimester of pregnancy (1-3%), 
makes accurate quantification of chromosomal imbalance considerable more challenging and 
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is often the reason why false-negative results are encountered. Consequently, methods to 
selectively enrich the relative proportion of cffDNA have been developed.  
Dhallan et al. (2004) identified that the addition of formaldehyde to maternal blood samples 
helped to increase the relative proportion of free fetal DNA, from 7.7% in untreated samples 
to 20.2% in the formaldehyde-treated samples. These results illustrate that the addition of 
formaldehyde yield higher cffDNA fractions by inhibiting maternal cell lysis during sample 
collection, transportation, handling and processing. It has been suggested that the 
formaldehyde allows for an increase in the percentage of free fetal DNA by two mechanisms, 
1) it reduces the amount of background free maternal DNA by decreasing the amount of cell 
lysis through formaldehyde-mediated cell membrane stabilisation and 2) it helps to preserve 
free fetal DNA by nuclease inhibition. However, since this initial publication, different 
groups have attempted to replicate the preservation of cffDNA fractions using formaldehyde 
without success (Chinnapapagari et al., 2005; Chung et al., 2005). Alternatively, the 
introduction of Streck Cell-Free DNA™ Blood Collection Tubes (Streck BCTs, Streck, 
Omaha NE) has been shown to increase the preservation of both cffDNA (Wong et al., 2013) 
and cffRNA (Qin, Bassett and Fernando, 2014) compared to standard EDTA tubes. Streck 
BCTs contain the anticoagulant K3EDTA and an unspecified cell preservative in liquid 
medium, which is used as an alternative to formaldehyde (Risberg, 2013). Das et al. (2013) 
determined that Streck Cell Preservative and Cell-Free DNA BCT reagents do not contain 
any free formaldehyde, and thus provide safer alternatives for preserving samples whilst 
protecting the integrity of the biomolecules. Similarly to formaldehyde, the preservatives in 
Streck BCTs are included to stabilise leukocytes, which prevent cellular degradation and 
subsequent release of maternal genomic DNA into the plasma (Wong et al., 2013). Since the 
amount of maternal cfDNA is reduced, the cffDNA is less dilute resulting in higher overall 
cffDNA fractions. The most significant differences in cffDNA fractions have been observed 
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when samples have been stored for up to 72 hours (Barrett et al., 2011), highlighting the 
application of this collection method for preservation of samples that may be transported over 
long distances. In addition, maternal blood collected in Streck BCTs yields higher cffDNA 
fractions at ≥23°C for up to seven days, and thus samples can be transported at room 
temperature (Wong et al., 2013).  
The application of cffDNA within the clinic rapidly expanded following its discovery in 1997 
(Lo et al., 1997). However, the molecular characteristics of cffDNA were not extensively 
studied until many years later. In 2004, it was reported that DNA derived from plasma 
consists of mainly shorter fragments and that maternal-derived cfDNA molecules are longer 
than cffDNA molecules (Chan et al., 2004). Li et al. (2004) later compared the bands present 
in maternal and non-maternal plasma extracted DNA samples using southern blot analysis. 
The results identified that the major portion of cffDNA had an approximate size of <0.3Kb, 
whereas the majority of maternal cfDNA was >1kb (Li et al., 2004).   
Recent publications have identified that the size discrepancies between maternal cfDNA and 
cffDNA may not be as considerable as first described (Lo et al., 2010; Stephanie et al., 
2014). Lo et al. (2010) studied the size distribution of fetal-derived and maternal-derived 
cfDNA at a single-base resolution using paired-end MPS. The results illustrated that both 
cffDNA and maternal cfDNA show a series of peaks, primarily a major peak at 166bp and a 
smaller peak at 143bp. However, cffDNA showed an increase of molecules <150bp and a 
reduced proportion of molecules at 166bp, illustrating that the larger 166bp peak is 
predominantly maternal in origin. Stephanie et al. (2014) also illustrated that samples which 
express higher cffDNA fractions illustrate a higher proportion of short fragments (<150bp) 
and a lower proportion of larger fragments (≥166bp) in comparison to samples expressing 
low cffDNA fractions. In 2010 an alternative study, also using paired-end sequencing for size 
distribution of fetal and maternal cfDNA, identified that cffDNA had a major peak at around 
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162bp and a minor peak at around 304bp (Fan et al., 2010). The study revealed that selective 
analysis of shorter fragments led to an increase in cffDNA fraction, but did not increase the 
sensitivity of aneuploidy detection since less sequence reads were counted for quantification. 
This research illustrates that maternal plasma contains a complex mixture of short cffDNA 
fragments (predominantly <150bp), larger maternal cfDNA fragments >1kb; particularly if 
there is maternal leucocyte degradation (Sillence et al., 2015), and smaller maternal cfDNA 
fragments of various sizes (166bp and 304bp have been shown).  Previous data has also 
demonstrated that during pregnancy the fragmentation of plasma DNA shifts towards 
fragments of longer length compared to non-pregnant plasma DNA (Chan et al., 2004). Since 
plasma DNA is thought to be derived from hematopoietic stem cells, which play an important 
role in the release of plasma DNA, it is likely that due to physiological and hormonal changes 
during pregnancy larger DNA molecules are released (Lurie, 1990; Lui et al., 2002). 
To help increase the relative proportions of cffDNA within the maternal circulation, methods 
exploiting the size difference between the maternal cfDNA and cffDNA have been developed 
(Li et al., 2004; Li et al., 2005; Li et al., 2008; Galbiati et al., 2011). In addition to cffDNA, it 
has also been identified that tumour-derived circulating cell-free DNA fragments are shorter 
than nuclear DNA in plasma (Diehl et al., 2005; Jiang et al., 2015).  Both cffDNA and 
tumour DNA are present in low proportions in a maternal cfDNA or wild-type backgrounds, 
respectively, and are often undetectable by conventional PCR. Methods that allow for an 
increase in the percentage cffDNA would make it easier to distinguish cffDNA from maternal 
cfDNA and increase test reliability, particularly for the determination of fetal aneuploidy 
where accurate quantification is imperative (Lo et al., 1998b).  
Initial studies focused on the use of separating smaller cffDNA from larger maternal 
cfDNA using gel electrophoresis (Li et al., 2004). Although, this approach has been 
shown to successfully enrich cffDNA for detection of point mutations in β-
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thalassaemia (Li et al., 2005), widespread use is not feasible since this approach is 
associated with extensive loss of total cfDNA, time consuming and prone to 
contamination (Go, van Vugt and Oudejans, 2010). Subsequently, an alternative 
size-selective enrichment strategy known as co-amplification at lower denaturation 
temperature- polymerase chain reaction (COLD-PCR) was described (refer to 3.1), 
which exploits differences in the melting temperature (Tm) of variant or 
mismatched sequences compared to wild-type ones (Li et al., 2008; Galbiati et al., 
2011). Consequently, by using a critical denaturation temperature (Tc) lower than 
the melting temperature (Tm) minority mutated alleles are selectively amplified. 
However, one disadvantage of this approach is that selective amplification relies 
upon the fetus displaying mutations that are unique to maternal mutations within 
chromosome region of interest.  
1.4 Ethical considerations   
Providing highly sensitive screening and non-invasive testing for pregnancy related 
disorders reduces or eradicates the risk of miscarriage that is associated with 
invasive techniques (refer to 1.2), respectively. However, the implementation of 
safer non-invasive tests within the clinic also raises many ethical concerns.  
Fundamentally, there is a growing concern that the ease and safety of NIPT may increase the 
number of women undergoing diagnostic testing, and thus increase the uptake of abortions 
for women carrying affected fetuses (Hall, Bostanci and Wright, 2010). This is evident, 
particularly in many lower middle income countries (LMICs), such as China and Mexico, 
where giving birth to a baby with a genetic abnormality is often seen as a burden (Wang and 
Michaels, 2010). Offspring with disabilities are seen to threaten the family support network 
as children are expected to provide care to parents/ grandparents in old age. In one Chinese 
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study it was reported that 83% would consider abortion if diagnosis revealed that the fetus 
had a disability (Su and Macer, 2003). In such countries, prenatal testing is seen as necessary 
for the prevention of giving birth to an affected child. Therefore, the wider availability of 
NIPT is likely to increase the number of women seeking abortions not just legally but also 
illegally, which is often unsafe and poses a risk to maternal health (Allyse et al., 2015). In 
addition, activists have argued that lowering the number of individuals with disabilities in 
society reduces society’s ability to value such individuals and prevents the provision of 
necessary services (Kellogg et al., 2014). 
Concerns have also been raised regarding the implementation of safer non-invasive diagnosis 
as it could potentially create a platform for selective abortion of fetuses with minor 
abnormalities, undesired sex or unwanted paternity (de Jong et al., 2010). Technological 
developments associated with many non-invasive techniques allow for a broad spectrum of 
abnormalities to be detected compared to current karyotyping, and thus the potential clinical 
introduction of these techniques raises further ethical challenges. However, the application of 
NIPD could enable broad or narrow testing. Broad testing allows for the detection of any 
disorder but it is suggested that only severe disabilities are brought to attention (de Jong et 
al., 2010). Increasing the diagnostic scope of NIPD is seen as ethically problematic, 
essentially because of the difficulty associated with defining which disorders are severe, and 
with regards to Down syndrome and other disorders, the severity of symptoms can vary 
dramatically. In addition, diagnosis of late onset disorders can be seen as an invasion of the 
autonomy of the child that has been prenatally diagnosed (Human Genetics Commission and 
the UK National Screening Committee, 2005).  
Narrow testing of specific disorders reduces the occurrence of unexpected or unclear 
findings, which prevents difficult counselling situations arising. In a recent study, the ethical 
issues surrounding NIPD of autosomal recessive disorders were reviewed (Skirton, 
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Goldsmith and Chitty, 2014). Results determined that all mothers felt such tests should be 
available on request, but it is vital that fathers that declined carrier testing should also be 
made aware that the fetal result may reveal their status. In conclusion the paper suggested that 
consent forms for NIPD should be signed to reiterate the gravity of the test and guidance 
should be provided to manage sensitive information (Skirton, Goldsmith and Chitty, 2014). 
Despite fewer moral implications being associated with a narrow approach, withholding 
results would deprive a couple of their autonomous reproductive choice if they wish to attain 
all NIPD information (Ogilvie, Yaron and Beaudet, 2009). Therefore, it is likely generic 
consent for a broad NIPD test will be implemented, which enables mothers to indicate 
specific disorders they would prefer to be told about following counselling on categories of 
abnormalities (de Jong et al., 2010). This approach requires comprehensive counselling, 
which will be problematic since it is probable that this will be too time consuming and costly 
to implement on a wide scale (Childbirth Connection, 2012).   
First trimester testing can allow for early reassurance or enable longer time periods in order 
for women to make informed choices. Subsequently, if women do decide not to continue with 
pregnancy, termination may be physically and psychologically less encumbering when 
performed in early pregnancy (Hall, Bostanci and Wright, 2010). In addition, in most western 
countries the gradualist view is commonly adopted, where the moral status of the 
embryo/fetus progresses with its development (de Jong et al., 2010). However, the timing of 
abortion is ethically irrelevant if the embryo is assigned with high moral status from the start, 
or alternatively, if no status is attributed.  
It has been suggested that appropriate counselling and informed consent will become more 
challenging when offering NIPD on a wide scale (Schmitz, Netzer and Henn, 2009; Wright, 
2009). While the replacement of the current two-step model (screening and invasive 
diagnosis) with a single NIPD tests creates a conceptually easier platform, it is likely that the 
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provision of adequate information and pre-test counselling will become increasingly difficult 
(Wright, 2009). This can result in normalisation of NIPD, which will occur if the test is 
portrayed as routine and uptake increases as a result of thoughtlessness or pressure to take the 
test due to its relative ease and safety, as opposed to making an informed decision (Hall, 
Bostanci and Wright, 2010). Thus, autonomous reproductive decision making is not 
promoted. Alternatively, it is feasible that high uptake could be a result of positive reception 
to the new NIPD test, which safely facilitates parental reproductive choice (Wright, 2009). 
Regardless of where NIPD fits into the current screening/ diagnosis procedure, it is vital that 
the quality of present guidelines for informed consent and pre-test counselling does not 
diminish. Additionally, since screening programmes in current practice have shown that the 
uptake of testing is not always a result of adequate understanding (Green et al., 2004), 
improvements to current guidelines of pre-test screening should also be considered.  
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Study Aims  
 To test various molecular techniques for the selective enrichment of cffDNA from 
maternal plasma using either pseudo-maternal samples or actual maternal samples, 
including; COLD-PCR, inverse-PCR and Pippin prep size selective methods.  
 To develop a novel assay for the quick assessment of RHD zygosity in non-maternal 
samples using ddPCR.  
 To compare the sensitivity of ddPCR for the determination of fetal sex and RHD 
status using ddPCR compared to conventional q-PCR platforms.  
 To combine size-selective enrichment of cffDNA and ddPCR analysis to provide a 
novel and cost-effective test for the NIPT/ NIPD of fetal aneuploidy.  
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2.1 Sample collection  
2.1.1  Pre-ordered samples  
Male genomic DNA (gDNA) (G1471, Promega, Southampton, UK) and female gDNA 
(G1521, Promega) each pooled from multiple anonymous donors were used as templates 
for standards, control samples and optimisation experiments throughout this study. 
Samples were diluted to 20ng/µL and stored as 50µL aliquots at -20°C for up to 10 
months.   
 T21 gDNA 5µg (100ng/µL) samples (PHE Culture Collection, Salisbury, UK) was used 
as a positive DS control sample. Samples were diluted to 50ng/µL and stored as 5x 20µL 
at -80°C for up to 6 months.  
2.1.2 Human whole blood samples  
Human whole blood was supplied by the National Health Service Blood and Transplant 
(NHS BT) (Bristol, UK). Samples were collected in EDTA tubes (5 mL total blood 
volume). The blood was spun at 3500 x g for 5 minutes (mins) and plasma was removed 
using a sterile Pasteur pipette and placed in a clean 2 mL microcentrifuge tube. The 
plasma was then re-centrifuged at 16 000 x g for 5 mins and the second supernatant was 
then removed and placed in a clean 2 mL microcentrifuge tube. Subsequently, the buffy 
coat layer was also removed using a fresh Pasteur pipette and placed in a clean 2 mL 
microcentrifuge tube with 200 µL 1x phosphate buffer saline (PBS) to dilute the starting 
material.  
2.1.2.1 DNA extractions of whole blood samples  
DNA was extracted from 1 x 2mL aliquot of plasma using the QIAamp Circulating 
Nucleic Acid kit (CNA kit) (Qiagen, Hilden, Germany) within 24-72 hours of collection. 
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The extraction process was carried out using QIAamp mini columns on the QIAvac 24 
Plus vacuum manifold (Qiagen).Although longer lysis incubation periods have not been 
associated with increased DNA extraction, samples were lysed for 45 mins as opposed 30 
minminss to maximise yield.  After the wash stages using buffer ACB, buffer ACW1 and 
ACW2, a final wash phase was carried out using Molecular Biology Grade Ethanol 
(99.5%) (BPE2818-4, Fisher Scientific, Loughborough, UK). Samples were then spun 
down (20 000 x g for 3 mins) and incubated for 5 mins with 50-70 µL of Buffer AVE 
(RNase free water containing 0.04% (w/v) sodium azide). Finally, DNA samples were 
eluted by centrifugation (20 000 x g for 1 minute) into 1.5mL elution tubes. Following 
DNA extraction, samples collected during early experimentation were quantified using 
the NanoVue Plus Spectrophotometer (GE Healthcare, Life Sciences, Buckinghamshire, 
UK) (2.6.1). However, due to the variation in readings associated with this approach, 
quantification was subsequently carried out using the Qubit® 2.0 Fluorometer (Life 
Technologies, Paisley, UK) (2.6.2). The method used for DNA quantification in each 
assay has been specified throughout. Samples expressing DNA concentrations >25ng/µL 
were diluted to 10ng/µL. All samples were stored at -20°C.  
2.1.2.2 DNA extraction of buffy coat from whole blood samples 
DNA was extracted from buffy coat in 200 µL PBS using the QIAamp DNA Blood Mini 
Kit (Qiagen) following manufacturer’s instructions for the spin protocol. The additional 
centrifugation step in a clean 2 mL collection tube following wash phase with Buffer 
AW2, was carried out to help reduce the chance of possible Buffer AW2 carryover. To 
elute the DNA, the QIAamp mini spin column was placed in a clean 1.5 mL 
microcentrifuge and 200 µL of Buffer AE was added to the column. This was incubated 
at room temperature for 5 mins in an attempt to increase DNA yield. Samples were 
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quantified using the NanoVue Spectrophotometer (GE Healthcare) (2.6.1) and stored at -
20°C as 4 x 50 µL aliquots.  
2.1.3 Pseudo-fetal DNA samples  
The external primers (Table 2-1) were used to amplify 280-320 bp fragments from the 
Male gDNA (2.1.1), to produce the pseudo-fetal DNA (psfDNA) samples. Following 
PCR amplification (2.3.1) and agarose gel electrophoresis (2.4), psfDNA fragments were 
excised from the agarose gel and purified using the QIAquick gel extraction protocol 
(Qiagen, Hilden, Germany) (refer to 2.5).  
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Table ‎2-1: Summary of primers used. External and internal primer sequences and 
product sizes (bp) for multiple regions on chromosomes 1, 13, 18, 21, X and Y.  
Chr Gene 
External Primers 
(5’-3’) 
Product 
size (bp) 
Internal Primers 
(5’-3’) 
Product 
size (bp) 
Probes 
(5’‎– 3’) 
1 
EIF2C1F 
AAAGCATCAGA
GCTGGCATT 1 
317 
GTTCGGCTTTCA
CCAGTCT 1 
81 
CTGCCATGTGG
AAGATGATG 1 
EIF2C1R 
AGTGTGGTCACT
GGACTTGG 1 
CTCCATAGCTCT
CCCCACTC 1 
13 
SPG20 F 
TGGGTGGGAATC
TGCTAGAC 
297 
GCACCAGGCTGG
AAATTCT 
80 
TGCCACTTCTC
TGCAGAATG 
SPG20 R 
GCTGGACAACTT
TGTGATGG 
TGGATATAACTT
GGGCACCTC 
13 
ZIC2 F 
GCAACTCCACAA
CCAGTACG 
297 
GGTGCCTTTTTC
CGCTATATG 
90 
AATCTGCAAGT
GGATCGACC 
ZIC2 R 
CACTCCTCCCAG
AAGCAGAC 
CTTGGGATTGCT
CAGTTGCT 
13 
ATPZB F 
AGGATCTTGGGC
ATGACTTG 
300 
TTCCAATTTGAA
AGGCATCA 
82 
AAGGTTTCCCT
GGAACAAGG 
ATPZB R 
TTCAATGGAGCT
GACACAGG 
CACAACCGATGG
CACATATT 
18 
APCDD1 F 
CAAAGGCAGAC
CTGACCATC 
 
297 
CACCCCACCTTC
TCCATCTA 
97 
GTCCTCTCGTC
CAGGGTCAT 
APCDD1 R 
AGGGCTGTTTAT
TGGCTGTG 
 
TCCTACCTTTGA
ACACGAACTC 
18 
TTR F 
CACCAATCCCAA
GGAATGAG 
282 
ACCTGAAGGACG
AGGGATG 
98 
CTAAAGCAGT
GTTTTCACCTC
A TTR R 
GCGTTCTGCCCA
GATACTTT 
TGCCTGGACTTC
TAACATAGCA 
18 
TNFRSF11A 
F 
GAAGATGCCAG
GATGCTCTC 
285 
CAGATGCCCACA
GAAGATGA 
85 
CCAGCCCACA
GACCAGTTAC 
 TNFRSF11A 
R 
CATGGGAGTCCA
ATCAGTCC 
ATTTGCTTCCAG
GCTCAGTG 
21 
DSCR3 F 
GCGTGGTGGTCA
TATCGAGT 
315 
CCAACACCAGGG
AGTGTCTT 
87 
TAAACCTCCAG
CTCAGTGCC 
DSCR3 R 
ATGGGGTCTTGC
TATGTTGC 
GCTTCAAACACA
CCCACACTT 
21 
RCAN1F 
TGACCCTGCGAT
TATTTTCC 
292 
AGTACACGCCGA
TCCACCT 
97 
GAGGACGCAT
TCCAAATCAT 
RCAN1R 
CCACCTCCGAAG
AAGTCGT 
ACCAGCCACCTC
CACAGTAA 
21 
APP F 
GAGGAGGAAGA
AGTGGCTGA 
286 
AAGAAGCCGAT
GATGACGAG 
96 
GAGGAAGAGG
CTGAGGAACC 
APP R 
ATGTTTTTGATT
GGGGAAGG 
TGCTGGTGGTTC
TCTCTGTG 
X 
FOXP3 F 
GAAAGGAGGAT
GGACGAACA 
288 
AAACTGGTGGGA
GGCAGAG 
94 
GATGATAGGC
CCTGGATGTG 
FOXP3 R 
CTGTGTGGCTGG
TTGTGAAG 
CAGGCAAGACA
GTGGAAACC 
X 
NROB1 F 
CCCACGAGCACA
AATCAAG 
293 
CGCTCAAGAGTC
CACAGGT 
89 
GTTGAAGACG
CTGCGCTT 
NROB1 R 
GGCTCCGAGACT
TCCACAGT 
CTGGAAGCAGG
GCAAGTA 
X 
PRPS1 F 
CCATATTGGTCA
GGCTGGTC 
259 
GCTTTCTACATC
CCACATCAGG 
88 
TGGGAATAAG
CTCGCTTTTT 
PRPS1 R 
GGGAGGCTGAA
GAAGGAGAA 
AGGTAGGAGGTC
CCAGCAGT 
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               1 
Taken from Fan et al. (2009) 
2.1.4 Pseudo-maternal samples   
PsfDNA samples (2.1.3) and Female gDNA (2.1.1) were used to produce the pseudo-
maternal samples containing 5% ‘fetal’ DNA using a dilution approach and a genomic 
equivalent (GE) approach. 
For the dilution approach both the psfDNA samples and the female gDNA (‘maternal’ 
cfDNA portion) were diluted to 2ng/µL. Spike samples containing one psfDNA gene 
regions (e.g. target gene region; APP) were produced by adding 5% psfDNA (2ng/µL) to 
95% Female gDNA (2ng/µL).   This dilution was used to test each fragment and to 
produce pseudo-maternal samples carrying a ‘female fetus’ (5% Xp22.3). Spike samples 
containing two psfDNA gene regions (e.g. APP (target gene) and EIF2C1 (reference 
gene)) were produced by adding 2.5% psfDNA target fragment (2ng/µL) and 2.5% 
psfDNA reference fragment (2ng/µL) to 95% female gDNA (2ng/µL). This dilution was 
used to produce pseudo-maternal samples carrying a ‘male fetus’ (2.5% SRY (target) and 
2.5% Xp22.3 (reference)) and a ‘normal fetus’ (2.5% APP (target) and 2.5% EIF2C1 
X 
Xp22.3 F 
CACAAGCTCGCT
TAGCAACA 
315 
GATGAGGAAGG
CAATGATCC 1 
86 
CTGTTTCTCTC
TGCCTGCA 1 
Xp22.3 R 
TAGCCCTTAGGC
ACTCGAAA 
TTGGCTTTTACC
AAATAGGG 1 
Y 
SRY F 
(K.A.S.) 
GGCACCTTTCAA
TTTTGTCG 
300 
CGGAGAAGCTCT
TCCTTCCT 
89 
TCAGTGTGAA
ACGGGAGAAA SRY R 
(K.A.S.) 
TTTCGCATTCTG
GGATTCTC 
TCCTGGACGTTG
CCTTTACT 
Y 
SRY F 
(H.P.T.) 
GAATGCGAAACT
CAGAGATCA 
287 
TGGGATACCAGT
GGAAAATG 
96 
ATTCTTCCAGG
AGGCACAGA SRY R 
(H.P.T.) 
CTGGTGCTCCAT
TCTTGAGT 
TCGGGTATTTCT
CTCTGTGC 
Y 
TSYP1 F 
TACATGGTCAGC
CTGGAGGT 
293 
GGGGAGGGTAA
GGGAAATAA 
88 
CAAGAGTGAG
CACCTCACCC 
TSYP1 R 
TCCTTCCACTAC
CCATCCTG 
CAGGACAAGGT
GGAGAAAGC 
Y 
DDX3Y F 
AGCAGCCTAACC
CTGTCAAG 
296 
CCACTCAGCTTT
CCTCAGGT 
89 
ATCCTGCAGA
GGGACCTTCT 
DDX3Y R 
CCAACTAGCCGT
CACCTACC 
CAATCTTCAGGT
TAGGGAGGTG 
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(reference)) to give a ratio of 1. To produce pseudo-maternal samples carrying a ‘DS 
fetus’, 3% psfDNA APP target and 2% psfDNA EIF2C1 reference was added to 95% 
Female gDNA to give a ratio of 1.5 in the 5% ‘fetal’ proportion.  
For the GE approach, the initial step was to calculate the molecular equivalent of gDNA 
(Plasma extracted sample (2.1.2)) and psfDNA for a 5% spike (Appendices 1). 
Subsequently, the molecular mass of the fake fetal DNA fragment was calculated in order 
to determine the moles per microliter of fetal fragment using Avogadro’s constant. This 
was then used to dilute the fetal fragment to determine how much of each fragment was 
required per 1 µL of plasma DNA. A worked example is illustrated in Appendices 1. To 
produce the pseudo ‘DS’-spike, the APP psfDNA fragment constituted 3/5 of the 5% fetal 
spike GE/µL and the EIF2C2 psfDNA fragment constituted 2/5 of the 5% ‘fetal’ spike 
GE/µL (Appendices 1). To produce the pseudo ‘normal’-spike, APP and EIF2C1 
psfDNA fragments constituted 1/2 of the 5% ‘fetal’ spike GE/µL each (Appendices 1).  
2.1.5 Maternal samples  
Maternal samples were recruited at Plymouth Hospitals NHS Trust, Plymouth, UK with 
informed consent, from October 2013 to January 2015. Ethics approval was granted by 
the United Bristol Healthcare and Trust Research and Ethics Committee (REC) (ref: 
13/SW/0148).  
Maternal peripheral blood samples were collected in EDTA tubes (5-10 mL total blood 
volume) and centrifuged at 1 600 x g for 10 mins at room temperature. The plasma was 
carefully removed and transferred to a 15 mL tube. The plasma was then re-centrifuged at 
16 000 x g for 10 mins. All samples were processed within 4 hours of collection and 
plasma aliquots (1 mL) were stored at -80°C.  
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Maternal peripheral blood samples collected in Streck BCTs (10-20 mL total blood 
volume) were centrifuged at 1 600 x g for 15 mins at room temperature. The plasma was 
carefully removed and transferred to a 50 mL tube. The plasma was then re-centrifuged at 
2 500 x g for another 10 mins. All samples were processed within 48 hours of collection 
and plasma aliquots (1 mL) were stored at -80°C. 
DNA was extracted from two 1 mL aliquots of plasma (mixed) using the CNA kit 
(Qiagen) on the QIAvac 24 Plus vacuum manifold (Qiagen). The extraction process was 
carried out according to the manufacturer’s protocol as previously described (2.1.2) and 
each sample was eluted in 60 µL of Buffer AVE (RNase free water containing 0.04% 
(w/v) sodium azide). No DNase or RNase treatment was used. Following DNA 
extraction, samples were quantified on the Qubit® 2.0 Fluorometer (Life Technologies) 
using the Qubit® dsDNA high sensitivity (HS) assay kit (Life Technologies) (2.6.2). 
Samples were stored at -20°C as single 60 µL aliquots for up to four weeks. Due to the 
fragmented nature of cfDNA, template DNA was expected to be in a primary linear 
structure, therefore no template modification steps such as sonication or restriction digest 
were necessary. 
2.2 Primer Design 
2.2.1 Polymorphic STR amplicon (D21S1890)  
The chosen region of interest was a fragment on chromosome 21 (D21S1890), which 
contained a CA- STR region. Primers for amplification (Figure 2-1) were designed by 
Alice Bruson (Universita delgi di Padova, Italy) using the Primer3 software 
(http://fodo.wi.mit.edu/primer3). Following primer design the sequences were 
subsequently BLASTed to ensure primer specificity for chromosome using Primer-
BLAST on the NCBI website (http://www.ncbi.nlm.nih.gov/). Figure 2-1 shows the 
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amplicon region, highlighting the internal primers (blue), external primers (green) and the 
probe (pink), which was labelled with a 5’FAM reporter label and a black hole quencher 
1 (BHQ1) quencher dye attached to the 3’ end. All primers and probe were high 
performance liquid chromatograph (HPLC) purified (Eurofins MWG Operon, Acton, 
London, UK).   
GTATTTTTTAAGCCTGAGGACCCATTTGGGAGTTAGATTCTGGATCGAGCCTAGGGTC
AGTTTTCCTTGTGTTAAATAACACTACTTCACAGAAGGGGGAACGAGAATTCAGGGG
AGTTGGCACAAAACTTGGAACCCTTCTCGGGAGGCTTTCCTGCCTGGACGGACGCCT
GGGAGGAGGGCCCGGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGA
CCACAGATTTCCCAATCGCCACACACACACACACACACACACACACACACACACACA
CACGGGTTGTTTGGGAGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAATGAAGAGTCC
CAAAGTTTTCCTTAATCGTTCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAA
TACGGGGGAATATTTTTAGTTCCTTTCAGCTGAACAGTGTACAACTGCCTTTTTTCCTT
TTGGAGGTCCCAACACCCTGTTAATCCGCTCCTAGGAGAACTAAACAAAAACAAGGC
TGGACGTCGTGTCTCCCGCCTGTAATCCCAGTGCTTTGGGAGGCTGAGGCAGGAGGA
TCAGTTGAGCTCAGGAGTTTGAG 
Figure ‎2-1: D21S1890 STR fragment amplicon region on chromosome 21 (21q22.3). 
External primers (green), internal primers (blue) and probe (5’FAM and 3’ BHQ1) (pink) 
for D21S1890. The underlined sequence illustrates the CA STR region. 
2.2.2 Non-polymorphic amplicon regions  
Internal primers, external primers and probes for various regions on five different 
chromosomes (chromosomes; 13, 18, 21, X and Y) were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/) (Table 2-1). Internal primers for chromosome 1 
(EIF2C1) were taken from Fan et al. (2009, , but the external primers and probe were 
designed using Primer3 software (Table 2-1). In addition, the internal primers and probe 
for the Xp22.3 amplicon on chromosome X were also taken from Fan et al. (2009, , 
unless stated otherwise. Internal primers and probes for two RHD-specific gene regions 
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(RHD exon 5 and RHD exon 7) were taken from Finning et al. (2008,  (Table 2.1). For 
inverse PCR experiments internal and external primers that were consensus for both RHD 
and RHCE exon 7 (RH7) were designed in house using Primer3 software 
(http://frodo.wi.mit.edu/primer3/) (Table 2-2, Figure 2-2). Unlike conventional primer 
pairs which face inward to overlap amplification of the region of interest (ROI), the 
internal inverse PCR forward and reverse primers (purple) were designed to be facing 
away from eachother (Figure 2-2).  
Table ‎2-2: Internal primers and probes for RHD exon 5 (RHD5), RHD exon 7 
(RHD7) and CCR5.  
Amplicon 
location 
Primer Sequence‎(5’‎- 3’) 
Dual-Labelled 
Hydrolysis‎Probe‎(5’‎- 
3’)
 
Length 
(bp) 
1p36.11  
Exon (5) 
RHD5 
Forward* 
CGCCCTCTTCTTGTG
GATG 
FAM-
TCTGGCCAAGTTTCA 
ACTCTGCTCTGCT-
BHQ1
 
82bp 
RHD5 
Reverse* 
GAACACGGCATTCTT
CCTTTC 
1p36.11  
Exon (7) 
RHD7 
Forward* 
CAGCTCCATCATGGG
CTACAA 
FAM-
AGCTTGCTGGGTCTG 
CTTGGAGAGATC-
BHQ1
 
75bp 
RHD7 
Reverse* 
AGCACCAGCAGCAC
AATGTAGA 
3p21.31 
CCR5 
Forward 
TACCTGCTCAACCTG
GCCAT 
FAM/HEX**-
TTTCCTTCTTACTGTC
CCCTTCTGGGCTC-
BHQ1 
91bp 
CCR5 
Reverse 
TTCCAAAGTCCCACT
GGGC 
*Taken from Finning et al. (2008). ** Two version of the CCR5 (FAM- and HEX-
labelled). 
Table ‎2-3: Inverse PCR internal and external primers for RH7.  
 
 
RH7 Primer Sequence (5’‎– 3’) 
Figure 
2-2 
External forward GAAGGGCTTCTTTGAGGTGA 1 
External reverse  GTAAGCCCAGTGACCCACAT 2 
Internal (inverse) forward  TCAGCTTGCTGGGTCTGCTTG 3 
Internal (inverse) reverse GTGTTATTATAAGCAGATTGGCAGGTGAG 4 
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Figure ‎2-2: Sequence alignment of RHD and RHCE for exon 7. Illustrating sequence 
mapping of inward facing external primers (orange, forward (1) and reverse (2)) and 
outward facing internal primers (purple, forward (3) and reverse (4)). 
All internal primers and probes were HPLC purified (Eurofins MWG Operon), and all 
external primers were HPSF (high purity salt free) purified (Eurofins MWG Operon, 
Acton, London, UK). Probes were labelled with a black hole quencher 1 (BHQ1) 
quencher dye attached to the 3’ end and either a 5’FAM or 5’HEX fluorescent reporter 
label, unless stated otherwise (Appendices 2, Table 2-2, Table 3-2). 
In house primers were analysed using OligoAnalyzer 3.1 (Integrated DNA technologies, 
https://www.idtdna.com/calc/analyzer) following recommended guidelines, including; 
primer length (18-22bp), primer melting temperature (52°C to 58°C), GC-content (40-
60%), GC clamp (≤3 G’s or C’s), hairpins (ΔG ≥ -2 kcal/mol), self/cross primer-
dimerization (ΔG ≥ -6 kcal/mol), di-nucleotide repeats (≤4), single-base runs (≤4) and 
3’end stability (less negative ΔG). Results for primer analysis are illustrated in 
Appendices 2. Following primer design/analysis the sequences were subjected to BLAST 
analysis to ensure primer specificity for each chromosome using Primer-BLAST on the 
NCBI website (http://www.ncbi.nlm.nih.gov/). 
1 
2 
3 
4 
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2.3 Conventional and COLD PCR  
2.3.1 Conventional PCR  
Conventional PCR reactions were performed in individual RNase-free PCR tubes (0.2 
mL) (Life Technologies). Each reaction was carried out in a 25 µL solution containing 
12.5 µL of 2x Fast TaqMan Universal MasterMix (Applied Biosystems), which contains 
a highly purified DNA polymerase (UP) which enables instant hot start and minimizes 
non-specific product formation, 300nM of each primer, Nuclease free Water (AM9937, 
Applied Biosystems) and a standard volume of template DNA/ non-template control 
(NTC) (5 µL). However, reaction volumes were doubled for gel extraction experiments 
when producing psfDNA fragments (50 L) (refer to 2.5) and the total amount of DNA 
added per reaction was specified throughout each experimental chapter. PCR cycling was 
carried out on the Veriti® 96 Well Thermal Cycler (Applied Biosystems) at the following 
conditions; 50ºC for 2 mins (optimization of UNG activity); 95ºC for 10 mins (activation 
of TaqMan); 50ºC for 2 mins (allows DNA to re-nature); 35 cycles of 95°C for 30 s 
(denaturation phase), optimised Ta for 30 s (annealing phase) and 72°C for 60 s 
(extension phase). The 35 cycles were then followed by 10 minutes at 72°C and a 4°C 
hold step. The annealing temperature used and any other variations from this standard 
PCR set-up were outlined in each experimental results section.  
2.3.2 COLD-PCR  
To determine the optimal annealing temperature of the internal primers (Table 2-1), the 
Male gDNA (used for all chromosomes except X) and Female gDNA (used for 
chromosome X) were amplified by conventional PCR for each primer set (2.3.1). Once 
the optimum annealing temperature had been determined, the denaturation temperature 
was tested using a fundamental gradient from 95°C down to 70°C. The following PCR 
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conditions were used; 50ºC for 2 mins; 95ºC for 10 mins; 50ºC for 2 mins; 35 cycles of 
95°C/ 90°C/ 85°C/  80°C/ 75°C/ 70°C  for 30 s, optimised Ta for 30 s and 72°C for 60 s. 
Samples were held at 4°C.  
To establish the critical denaturation temperature (Tc) down to 1°C, a consecutive 
gradient was carried out between the temperature at which product was last amplified and 
the Td directly below this from the initial gradient experiment results (5°C below). The 
PCR reaction was the same as described above, but with a smaller range Td gradient. The 
refined Td gradient tested for each internal primer set is specified in Chapter 3 (3.2).   
2.4 Agarose gel electrophoresis  
PCR amplicons were analysed using agarose gel electrophoresis. Samples were run on 
2% agarose (w/v) gels, which were produced by mixing 1 x TAE buffer (40 mM Tris-
acetate [pH 8.0], 1mM EDTA) with 1X GelRed Nucleic Acid Stain (Cambridge 
Bioscience, Cambridge, UK). 10 µL of the PCR Ranger 100bp DNA Ladder (Norgen, 
Manchester, UK) was loaded and used as a marker for all gel electrophoresis runs. DNA 
gel loading buffer (100 mM Tris–HCl pH 8.3, 10% (v/v) glycerol and 0.05% (w/v) 
Orange G) was added to a proportion of the PCR reaction at a final concentration of 20% 
on Parafilm M Sealing Film (Fisher Scientific). The remainder of each PCR reaction was 
stored at 4°C for up to 48 hours for secondary gel electrophoresis analysis (if required). 
The PCR reaction- loading buffer mix was subsequently added to corresponding wells. 
Due to the large volume of loading buffer-mix added for gel extraction protocols for 
psfDNA fragments (50 µL), two wells were taped together to double the maximum 
volume of each well (2 x 53 µL). Electrophoresis was carried out at 120V for 45 mins in 
1 x TAE buffer. Following the run, gels were removed and placed in the EC3 imaging 
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system (UVP BioImaging system, Cambridge, UK) and results were analysed using the 
Launch Vision WorksLS program (Chemi Doc 410). 
2.5 Gel Extraction  
DNA fragments were excised from the agarose gel (2.4) using a clean sharp scalpel on the 
EC3 imaging system (UVP BioImaging system) under UV light rays. The gel segments 
containing each fluorescent band were then weighed and the DNA was purified using the 
QIAquick gel extraction protocol (QIAGEN, Hilden, Germany) according to 
manufacturer’s instructions. To summarise, three volumes of buffer QG were added to 
one volume of gel and mix was incubated at 50°C for 10 mins, with repeated vortexing 
every 2-3 mins to help completely dissolve the gel. To increase the yield of DNA 
fragment obtained, one gel volume of isopropanol was added. Samples were then added 
to QIAquick spin columns (Qiagen) and centrifuged for 1 minute. The flow through was 
discarded and the recommended additional wash step using 0.5mL of Buffer QG was 
carried out. After the wash phase using buffer PE, the samples were finally eluted in 
50µL of Buffer EB (10 mM Tris-Cl, pH8.5). Once DNA band had been extracted, the 
psfDNA samples were quantified using the NanoVue Plus Spectrophotometer (GE 
Healthcare) (refer to 2.6.1). 
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2.6 Assessment of DNA quality and concentration  
2.6.1 Quantification by UV spectrophotometry  
The NanoVue™ Plus Spectrophotometer (GE Healthcare) was used to measure DNA 
concentration and quality of samples for earlier experiments following manufacturer’s 
instructions. The optical density was assessed at 260 nm and 280 nm and the DNA quality 
threshold for the A260/A280 ratio was set between 1.6 and 1.95.  
2.6.2 Quantification by fluorescence  
Because of the variation in results associated with the UV spectrophotometry approach 
due to non-selective quantification (2.7.1), the determination of DNA concentration was 
later assessed using the Qubit
®
 dsDNA HS assay kit (Life Technologies). This method is 
highly selective for double stranded DNA (dsDNA), and therefore has a higher tolerance 
to contaminants, such as salts, free nucleotides, solvents, detergents or even protein. 
Quantification was carried out following manufacturer’s instructions (Life Technologies). 
The total volume of Qubit 
®
 working solution and Qubit
®
 standard/ sample is always 200 
µL. 10 µL of the standard is added to 190 µL of working solution, but the amount of 
sample added can be anywhere between 1-20 µL. For all experiments 2 µL of sample was 
added to 198 µL of working solution. After 2 mins incubation at room temperature, the 
standards and samples were run on the on the Qubit
®
 2.0 Fluorometer (Life 
Technologies). The Qubit
® 
Fluorometer generates concentration in ng/ mL, which 
corresponds to the concentration of the sample after dilution. To calculate the starting 
concentration of the sample, the following calculation was used:  
Concentration of sample (ng/ µL) =   QF value =               / 1000 
 
200 
x 
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Where QF value = the value given by the Qubit
®
 2.0 Fluorometer and x = the number of 
microliters of sample added to the assay tube.  
The type of quantification used for each experiment is stated throughout. 
2.6.3 DNA Analysis  
The Agilent 2100 Bioanalyzer system (Agilent Technologies, Cheshire, UK) was used for 
analysing maternal DNA samples before and after Pippin Prep selective enrichment (refer 
to 2.11). The samples were analysed using the High Sensitivity DNA Analysis Kit (5067-
4626, Agilent Technologies) following the Agilent High Sensitivity DNA Kit Guide. To 
summarise, once the gel-dye mix was prepared, the mix was loaded into the well-marked 
‘G’ (in a black circle) on the High Sensitivity DNA chip help by the chip priming station. 
Consequently, the plunger was lowered and held in position for 60 seconds (s) before 
slowly pulling the plunger back to the 1mL position. More gel mix was loaded into the 
remaining ‘G’ wells (no black circle) to complete loading of the gel-dye mix. 
Subsequently, the marker, ladder and samples were loaded into allocated wells. Once the 
chip had been vortexed for 1 minute at 2400 rpm it was loaded onto the Agilent 
Bioanalyser 2100 instrument within 5 mins. Results were generated on the 2100 Expert 
Software (version B.02.08, Agilent Technologies).  Before reviewing individual sample 
Gels and Electropherograms, the Gel and Electropherogram of the High Sensitivity DNA 
Ladder was evaluated to ensure that; 15 peaks were visible, all peaks were well resolved, 
the baseline was flat and there was correct identification of both markers.  
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2.7 Real-time PCR (qPCR) 
2.7.1 qPCR  
qPCR measures DNA template at the exponential phase, as opposed to the plateau stage 
when using traditional PCR. This enables more accurate quantification since the cycle 
threshold (Ct) can be compared against a series of standards with known concentrations, 
whereas traditional PCR only provides a qualitative representation. In addition the use of 
fluorophores enables multiple targets to be amplified in a single reaction, which is known 
as multiplexing. Multiplex qPCR reactions were set up in MicroAmp fast optical 96-well 
reaction plates (0.1mL) (Life Technologies). Reactions were performed in a 25 µL 
solution containing 12.5 µL of 1x TaqMan Universal PCR Master Mix (Applied 
Biosystems), 300nM of forward and reverse primers for two separate targets, 250nM of 
each probe and a standard volume of template DNA (5 µL). Maternal samples yielded 
low DNA concentrations; therefore a standard volume of template DNA was used. 
However, for other experiments, such as Ta optimisation, a known concentration of DNA 
was added. The total amount of DNA added per reaction is specified throughout each 
experimental chapter. For singleplex reactions the same reaction set-up as described for 
multiplexing was used, however the total volume of the second primer set and probe was 
replaced with Nuclease free Water (Applied Biosystems).  
Standard curves were generated for each assay by completing a four step 10-fold serial 
dilution of Male gDNA (20ng/ µL (S1), 2ng/ µL (S2), 0.2ng/ µL (S3) and 0.02ng/ µL 
(S4)). Positive and negative control samples, as well as a NTC were included in each 
assay, the samples used as controls are detailed throughout. Analysis of all DNA samples, 
control samples and standards was performed in triplicate unless stated otherwise.  
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PCR cycling was carried out on a Life Technologies StepOnePlus™ qPCR System under 
the following conditions: 95°C for 10 mins, 45 cycles of 95°C for 15 s and optimised Ta 
for 1 min. Samples were held at 4°C. Data was collected during the exponential phase of 
PCR amplification and analysed using the StepOnePlus™ Software v2.3.  
2.7.2 qPCR to determine critical denaturation temperature  
To enable multiplexing of targets, the Tc was further optimised using the StepOnePlus 
Real-Time PCR (qPCR) System (Life Technologies).The qPCR reactions were set up in 
MicroAmp fast optical 96-well reaction plates (0.1mL) (Life Technologies). Reactions 
were performed in a 25 µL solution containing 12.5 µL of 1x TaqMan Universal PCR 
Master Mix (Applied Biosystems), 300nM of each primer, 250nM of each probe and 
10ng DNA. Variations in the amount of DNA added have been specified through the 
results section of Chapter 3 (refer to 3.2). Standards and control samples used for each 
assay were the same as describe previously (refer to 2.8.1). All DNA samples, control 
samples and standards were performed in triplicate unless stated otherwise.  
PCR cycling was carried out on a Life Technologies StepOnePlus™ qPCR System under 
the following conditions: 95°C for 10 mins, 50°C 2 mins, 45 cycles of 95°C/Tc for 15 s 
and optimised Ta for 1 min. Samples were held at 4°C. The Td was altered based on 
results from previous experiments to determine the Tc. For each run, the lower Td and 
optimum Td (95°C) were tested on a single 96-well plate by enabling the VeriFlex™ 
Block on the StepOnePlus™ qPCR System. If the number of samples tested exceeded one 
plate, two separate plates were run, one at the optimum Td and one at the lower Td’s. Data 
was collected during the exponential phase of PCR amplification and analysed using the 
StepOnePlus™ Software v2.3. 
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2.7.3 Quantifying DNA targets using Ct values  
To accurately determine the quantity of a particular target within a reaction it is important 
that the point of measurement be accurately determined. The point at which the 
fluorescence generated within a reaction crosses the threshold, is known at the Threshold 
Cycle (Ct), which is now more commonly referred to as the Quantification Cycle (Cq). 
To determine the Cq, first the baseline value and the threshold must be set. For many 
reactions the StepOnePlus™ Software automatically determined the threshold and the 
baseline value (3-15 cycles).However, for some experiments the threshold was manually 
set to ensure consistency across multiple runs for example when testing a large number of 
samples. The threshold levels set have been specified in the relevant sections. The 
baseline value was constantly kept at 3-15 cycles.  
The Cq values generated from the standards by the StepOne Plus™ Software were 
exported to [Excel]. In [Excel] the mean Cq values of the four standards (S1-S4) were 
used to plot the linear standard curve. The linear trendline was selected to illustrate the 
equation for the regression line and the R² value. The DNA concentration of the 
unknowns was subsequently estimated using the following equation: 
[DNA] = 10
(Cq-b)/m  
Where Cq is the mean Cq value of each unknown, b is the Y-intercept and m is the slope 
of the linear regression line. The units of quantity are determined by the dilutions used to 
define the standard curve, which is ‘ng/ µL’ in this study.  
The R² value illustrates how well the data fits the regression line. For all 
quantification experiments an R² value of >0.985 was accepted. The efficiency 
values were generated by the StepOnePlus™ Software. Efficiencies close to 
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100% illustrate that the assay is robust and reproducible. Low efficiencies can be 
caused by poor primer design or suboptimal conditions. Alternatively 
efficiencies >100% are more likely to be a result of co-amplification of non-
specific product or pipetting errors in the serial dilution. For all quantification 
experiments an amplification efficiency of 90-110% was accepted, but for 
qualitative experiments lower efficiencies were tolerated (75-110%).  
2.8 Inverse PCR  
2.8.1 EcoR1 Restriction Digest to obtain purified RH fragment   
The consensus RH 7 external primers (Table 2-3) were used to amplify the region of 
interest. Following PCR amplification (refer to 2.3.1) and agarose gel electrophoresis 
(refer to 2.4) samples were then gel extracted (refer to 2.5) to produce 285bp fragments. 
The 285bp RH fragments were then cloned to generate pure RHD and RHCE colonies (as 
described in 2.10).  
The purified fragments were then excised from each plasmid using EcoRI restriction 
enzyme digest (Promega, Southampton, UK) (refer to 4.2.4). The restriction site and 
enzymatic reaction carried out is illustrated in Figure 2-3. Following restriction digest, 
fragments were run on a 2% agarose (w/v) gel (refer to 2.4) and products between 300-
400bp were gel extracted (2.6). The extracted fragments were then ethanol precipitated; 
2.5 volumes of cold 100% ethanol (Fisher Scientific) was added to 1 volume of sample 
followed by centrifugation at 14 000 x g for 30 mins at room temperature. The 
supernatant was then removed and rinsed with 70% ethanol (diluted with nuclease free 
water). Following re-centrifugation for 10 mins any remaining supernatant was removed 
and pellets were left to dry for 5 mins at room temperature. Samples were finally re-
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suspended in 50 µL of TE Buffer (10 mM Tris-HCl [pH 8.0], 1mM EDTA) and 
quantified using the NanoVue Plus Spectrophotometer (GE Healthcare) (refer to 2.6.1).  
 
 
 
 
 
 
Figure ‎2-3: pCR®2.1 Vector and EcoR1 restriction site to excise region of interest 
containing PCR insert and produce sticky-ended fragments following cloning. The 
pCR®2.1 vector incorporates the DNA sequence during transformation stage of cloning 
(refer to 2.10.5). This figure shows the vector and the multiple cloning site (MCS) 
sequence within the P lacZ region, highlighting the EcoR1 restriction site, PCR insert 
EcoRΙ‎Restriction‎Digest 
 2.5 µL purified plasmid  
 1 µL 10X buffer H                         Reaction incubated for  
 0.1 µL BSA                                   1 hour and 30 mins at  
 6.15 µL ddH2O                             37°C 
300bp  
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region and M13 primer sequences. Once fragments have been cloned and isolated, the 
DNA can be excised from the vector using restriction enzymes, such as EcoR1.The 
EcoR1 restriction digest (shown below vector) subsequently produces fragments with 5’ 
end overhangs of AATT, which are referred to as sticky ends (or cohesive ends) since 
they easily ligate to complementary sequences (or self-ligate). The combination of the RH 
external fragment (285bp) (refer to Table 2-3) and the incorporated MCS region 
following EcoR1 digest (15bp) should produce a product 300bp in size.  
2.8.2 Ligation using T4 DNA Ligase  
100ng of the PCR products that were excised from the pCR®2.1 vector were 
subsequently ligated with T4 DNA Ligase (2 Weiss units/ µL) (Promega, Southampton, 
UK) at three separate dilutions (4 Weiss units/ reaction, 2 Weiss units/ reaction and 1 
Weiss unit per reaction) and incubated at 4°C overnight (O/N). Figure 2-4 illustrates the 
protocol carried out for fragment ligation and the three dilution reactions tested.  
Following O/N incubation the ligated DNA fragments were ethanol precipitated 
following the same procedure as described above (2.8.1).  
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Figure ‎2-4: The dilute ligation process. Linear product generated from EcoRI restriction 
digest is hypothesised to self-ligate, rather than ligate to other fragments when the amount 
of T4 DNA ligase present is highly dilute. Following ligation incubation overnight (O/N), 
ligated product is subsequently ethanol precipitated and resuspended in TE Buffer. 
2.8.3 Inverse PCR  
The internal (inverse) primers for the RH 7 fragment (Table 2-3) were added to 7.4 µL of 
2X MyTaq DNA polymerase (Bioline, London, UK) and nuclease free water to a final 
concentration of 200nM each in a 40 µl total reaction volume. Follow ligation samples 
were not quantified and therefore a standard volume of DNA (10 µL) was added to the 
reaction mix to give a total volume of 50 µL. Reactions tested using IMMOLASE™ 
(Bioline), were set up as follows; 200nM (final concentration) of each internal inverse 
PCR primer (Table 2-3), 4 µL 10xImmoBuffer, 1 µL dNTP Mix (100mM), 1 µL MgCl2 
solution (100mM), 1 µL IMMOLASE™ made up to 50 µL with nuclease free water. A 
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standard volume of DNA (10 µL) was added to the reaction mix to give a total volume of 
50 µL. Samples were run on the Veriti® 96 Well Thermal Cycler (Applied Biosystems) 
as follows; 95ºC for 5mins (activation of 2X MyTaq); 35 cycles of 95°C for 30 s, 48°C 
for 1 min and 68°C for 2 mins.  The samples were then subsequently run on a 2% agarose 
(w/v) gel (refer to 2.4) to check that amplification of the ligated fragments yielded a linear 
product ~230bp in size (Figure 2-5). Figure 2-5 also illustrates the sequence that should 
have been generated from the inverse PCR following successful restriction digest and 
ligation when using cloned Rh fragments. PCR products were quantified using the 
NanoVue Plus Spectrophotometer (refer to 2.7.1).  
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Figure ‎2-5: Hypothesised sequence following restriction digest (EcoRI), ligation (T4 
DNA polymerase) and inverse PCR (internal primers Table 2-3). A) Binding of the 
forward and reverse inverse PCR primers (RH exon 7) to the circularised product. B) 5’ – 
A) 
B) 
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3’ nucleotide sequence that should be generated for each forward and reverse inverse 
PCR primer (indicated in purple). The 5’- 3’ Sequence generated by the forward primer is 
the bottom sequence, and the 5’- 3’ sequence generated by the reverse primer is the top 
sequence. The sequence region highlighted in white indicates where the sticky-ends 
produced by the EcoRΙ restriction digest should have self-ligated.  The grey region 
illustrated part of the pCR®2.1 Vector (Figure 2-3) that should also be included in 
generated sequence.  
2.8.4 Sequencing   
The gel extracted products (refer to 2.5) generated by inverse PCR, were consequently 
diluted to 10 ng/ µL and sent for sequencing with 2 µL of forward primer to Eurofins 
Genomics (Ebersberg, Germany) as described in section 2.10.7.  
2.9 Droplet digital PCR (ddPCR)  
2.9.1 ddPCR reaction  
The ddPCR reactions were performed in a 20 µL solution containing 10µl ddPCR™ 
Supermix for Probes (Bio-Rad, Herfordshire, UK), 300nM primers, 250nM probes and 5 
µL DNA/ NTC sample in individual RNase-free PCR tubes (0.2 mL) (Life 
Technologies). The recommended dynamic range of DNA for the QX100™ Droplet 
Digital™ PCR System is from 1 to 120 000 copies/ 20 µL reaction. For control samples 
such as Male and Female gDNA (2.2.1) or RHD positive and RHD negative samples 
(2.2.2) 30ng of DNA was added per reaction (equivalent of ~ 9 000 copies or 18 000 
copies per haploid and diploid expressed genes). Alterations in the amount of DNA added 
for optimisation experiments are noted throughout each experimental chapter. Due to the 
low proportions of cffDNA circulating in maternal plasma, samples were not diluted and 
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a standard volume of template DNA (5 µL) was added per 20 µL reaction (range: ~150 to 
300 copies/ 20 µL reaction for Streck BCT samples and ~10 000 to 40 000 copies/ 20 µL 
reaction for EDTA samples).  In addition to control samples and maternal samples, NTCs 
were included in every assay to check for contamination. Each sample was tested in 
duplicate unless stated otherwise.  The reaction mix was vortexed (15 s) and briefly 
centrifuged before droplet generation.  
2.9.2 Droplet generation  
The individual 20 µL PCR reactions were transferred to the centre row of a DG8™ 
cartridge (186-4008, Bio-Rad) for use with the QX100™ Droplet Digital™ PCR System 
(Bio-Rad), which is held in place by the DG8™ Cartridge Holder (186-3051, Bio-Rad) 
(Figure 2-6). Any unused wells on the cartridge were filled with 1x ddPCR buffer control 
(186-3052, Bio-Rad). Once eight samples per cartridge had been loaded, 70 µL of QX100 
Droplet Generator Oil for Probes (186-3005, Bio-Rad) was loaded into the bottom row of 
the cartridge (Figure 2-6). The cartridge was then sealed using DG8™ Gaskets (186-
3009, Bio-Rad) and loaded onto the QX100™ Droplet Generator (186-3002, Bio-Rad). 
Using an oil emersion approach the sample were drawn through the cartridge under a 
vacuum where ~20 000 1 nL droplets were formed in just under 3 mins/ eight samples. 
The generated droplets (40 µL total volume) were then transferred to an Eppendorf Twin 
Tec PCR 96-well Plate (Sigma-Aldrich, Dorset, UK) by gentle pipetting using a multi-
channel pipette. This process was repeated until all 20 µL PCR reactions had been 
converted to droplets (ranging from 11,000 to 15,000 droplets/ reaction) in batches of 
eight and loaded onto the 96-well plate. The plate was then sealed using a Pierceable Foil 
Heat Seal (181-4040, Bio-Rad) on the PX1™ PCR Plate Sealer (181-4000, Bio-Rad).  
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Figure ‎2-6: Loaded‎DG8™‎cartridge‎for‎QX100‎system. A) Center row for 20 µL PCR 
reaction. B) Bottom row for 70 µL of Droplet Generation Oil. C) Collection well for 
droplet generation. 
2.9.3 ddPCR amplification  
The 96-well plate was subsequently loaded onto the C1000 Touch™ Thermal Cycler 
(185-1148, Bio-Rad) and cycling conditions were as follows; 95°C for 10 mins, 40 cycles 
of 95°C for 30 s and optimised Ta for 1 min, after which a final 98°C step for 10 mins 
was carried out (as recommended by Bio-Rad). Samples were held at 10°C. These cycling 
conditions were also used for COLD-PCR experiments; however, in addition to the 
control Td (95°C), lower Td’s were also tested (for temperatures tested see section 3.2.5). 
A 2.5°C/s ramp rate was used to ensure each droplet reached the correct temperature for 
each step during cycling.  
2.9.4 Analysing droplets following PCR amplification 
Experimental set up was created using the QuantaSoft™ Software v1.2 (Bio-Rad) 
following manufacturer’s instructions. The software was used to designate the experiment 
type, sample name and which gene region corresponds to each fluorescent channel (FAM 
and HEX). All samples were tested using absolute concentration (ABS) analysis.  
A) 
B) 
C) 
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Following amplification samples were loaded onto the QX100™ Droplet Reader (186-
3003, Bio-Rad). The droplet reader and QuantaSoft software were then used to count 
PCR-positive and PCR-negative droplets to provide ABS of target DNA. QuantaSoft 
software automatically determined the threshold above which droplets were considered 
positive. However, the threshold was manually adjusted using the 1D-amplitude plot and 
2D-amplitude plot on a well-by-well basis for singleplex and multiplex reactions, 
respectively, unless stated otherwise. Thresholds were determined when intermediate 
droplets between two clusters did not alter the calculated concentration (Miotke et al., 
2014). Figure 2-7 illustrates a 2D amplitude plot and the manual thresholds set for both 
the FAM (SRY taken from Lo et al. (1997, ) and HEX (Xp22.3) signal for a Male gDNA 
sample (30 ng/ 20 µL reaction).   
 
 
 
 
 
 
Figure ‎2-7: 2D-Amplitude plot for male gDNA. Sample illustrated negative droplets 
(grey), SRY-FAM positive droplets (blue), Xp22.3-HEX positive droplets (green) and 
dual positive droplets (Orange). The diagram also illustrated the threshold set manually 
for the SRY-FAM (channel 1) amplitude (horizontal) and the Xp22.3-HEX (channel 2) 
amplitude (vertical). 
FAM‎Positive‎ 
HEX Negative  
FAM‎Positive‎ 
HEX‎Positive‎‎ 
FAM Negative  
HEX Negative  
FAM Negative  
HEX‎Positive‎ 
HEX (channel 2) 
threshold  
FAM 
 (channel 
1) 
threshold  
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Target concentration is estimated using Poisson algorithm to fit the fraction of positive 
droplets, in order to determine the ABS concentration (Figure 2-8) (Poisson 95% 
confidence interval). This is automatically calculated by the QuantaSoft software using 
the following equation: 
Number of Molecules = - ln [(N – n)/N] × N 
Where N is the total number of wells counted and n is the number of target or reference 
positive wells. 
Results are automatically converted from copies of target in 20µL reaction to copies/ µL 
using the Poisson distribution. Poisson correction statistics are required since reactions 
with higher DNA concentrations (≥2 copies per positive droplet) express a higher number 
of targets than number of positive droplets. However, the number of positive droplets is 
equal to the number of targets for samples expressing low concentrations of DNA (1 copy 
per positive droplet).  
 
 
Figure ‎2-8: Estimating 
target concentration using 
Poisson distribution to 
ddPCR data. The curve 
represents the relationship 
between the fraction of positive droplets, the number of target copies per droplet and the 
number of copies of target in a 20 µL reaction. 
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The cffDNA fractions in maternal samples were calculated based on the 
concentrations (copies/ µL) of the target and reference genes generated by 
ddPCR. For single-copy targets (SRY, RHD5 and RHD7) expressed by the fetus 
only, the following equation was used:  
2 x Target-FAM (copies/ µL) 
Total copies/ µL* 
Since we assume that there are 30 copies (Barrett et al., 2012) of DYS14 (where 
amplicon is located) on the TSPY1 gene, the following equation was used for this 
multiple-copy target:  
2 x (Target-FAM (copies/ µL) / 30) 
Total copies/ µL* 
*Target-FAM (copies/ µL) + Reference-HEX (copies/ µL). 
For samples tested in duplicate, the positive and negative droplets from both wells were 
combined by selecting the merged button. This enabled data to be analysed together as a 
single experiments, increasing the number of droplets per sample. In addition, the ratio of 
the target gene (FAM)/ reference gene (HEX) was calculated for multiplex experiments 
(FAM copies/ µL / HEX copies/ µL).  
2.9.5 Statistical analysis 
Statistical analysis for comparing sample variation was carried out using the Mann 
Whitney U Test in SigmaPlot Version 12.5 and significance was accepted at p<0.05. To 
x 100 
x 100 
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compare the expected and observed fractional abundance (%) generated in Chapter 6, the 
Chi-Squared test was carried out in [Excel]. 
2.10 Cloning  
2.10.1 Producing PCR products  
External primers were used to generate PCR fragments for insertion into the pCR
®
2.1 
vector using the TOPO TA Cloning® kit with One Shot® TOP10 Chemically Competent 
E. coli  (K2040-01, Invitrogen, Carlsbad, CA) following manufacturer’s instructions. 
Conventional PCR experiments using external primers for; 1) the D21S1890 STR 229bp 
fragment (Table 3-1) and 2) the RH7 285bp fragment (Table 2-4), were carried out as 
described (2.3.1), but using higher final concentrations (500nM) of each external primer.  
Following PCR amplification, PCR products were run on a 2% agarose (w/v) gel (refer to 
2.4) and gel extracted using the QIAquick Gel Extraction Kit (Qiagen) (refer to 2.5). 
Fragments were then quantified using the NanoVue Plus Spectrophotometer (GE 
Healthcare) (refer to 2.6.1).  
2.10.2 Producing Luria Bertani Media (LB Media) 
The LB media was produced by recipe shown in Table 2-4. Once dissolved the solution 
was autoclaved and kept at room temperature until required. 
Table ‎2-4: Recipe for LB Media. 
Tryptone 5g 
Yeast Extract  2.5g 
NaCl 2.5g 
Distilled water Up to 500 mL 
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2.10.3 Producing Luria Bertani Agar Plates (LB Plates)  
To produce LB Agar (LA), the same recipe was used (Table 2-4) with the addition of agar 
to a final concentration of 1.2%. The solution was then autoclaved for sterilization. If the 
LA had re-set, the mixture was re-heated in a boiling water bath for 1 hour (~100°C). 
Once the LA had cooled to 55°C (also using a water bath), kanamycin (Sigma-Aldrich) 
was added at a concentration of 50µg/ mL. Working near an opened Bunsen burner, ~20 
mL of the LA containing kanamycin was added per 10cm polystyrene Petri dish (~25 
plates in total/ 500 mL). Each plate was covered with lids and swirled to evenly distribute 
the LA-kanamycin mix. Plates were then left to cool for around 30-60 mins. Once 
solidified plates were inverted to avoid condensation on the agar and stored at 4°C O/N.  
For Blue/White colony screening, 40 µL of 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) (Sigma-Aldrich) (which was produced from dissolving two 
tablets  into 500 µL of Dimethylformamide (DMF) (Fisher Scientific)), was spread across 
the top of each Agar plates under aseptic conditions. Plates were then left to dry for a 
minimum of 30 mins before adding transformed competent cells (refer to 2.10.5).  
2.10.4 Cloning into pCR®2.1 
The following formula was used to estimate the amount of PCR product needed to ligate 
with 50 ng of pCR®2.1 vector:  
(Y bp PCR product) (50ng pCR
®
2.1 vector) 
(size in bp of the pCR
®
2.1 vector: ~3900) 
Where X ng is the amount of PCR product of Y base pairs to be ligated for a 1:1 (vector: 
insert) molar ratio.  
X ng PCR product = 
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To perform the cloning reaction, 1 µL of fresh, diluted (see above equation), PCR product 
was added to 1 µL of 10X ligation buffer, 2 µL of  pCR
®
2.1 vector (25ng/ µL) and 1 µL 
of T4 DNA ligase (4.0 Weiss units) and made up to a total volume of 10 µL using 
nuclease free water. All reagents (except nuclease free water and PCR product) were 
supplied in the TA Cloning
®
 Reagents (Invitrogen). Reactions were gently mixed and left 
O/N at 14°C. The map and features of the linearized pCR®2.1, within the LacZα gene (1-
545 bases), are illustrated in Figure 2-9.  
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Figure ‎2-9: Map of the linearized pCR®2.1 multiple cloning site (MCS). The map 
highlights key features of the MCS including restriction enzyme sites, M13 primer 
binding sites and the T7 promotor site (Taken from Invitrogen TA Cloning
®
 Kit Manual, 
Version V, April 2004).The complete sequence of the pCR
®
2.1 plasmid is available from 
the Invitrogen website (www.invtrogen.com). 
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2.10.5 Transforming competent cells  
Once fragment was ligated into the pCR
®
2.1 vector, the construct was ready for 
transformation into competent E.coli. One Shot
®
 cells (K2040-01). Before carrying out 
transformation, a water bath was set to 42°C and the S.O.C. medium (Super Optimal 
broth with Catabolite repression; 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) (Life Technologies) was 
equilibrated to room temperature. S.O.C. medium is used to obtain maximum 
transformation efficiency of E.coli. 
After a brief centrifugation, 2 µL of each ligation reaction was added to 50 µL vials of 
frozen One Shot
®
 TOP10 Competent Cells (Invitrogen) (one for each transformation) and 
were gently mixed by pipetting. The vials were incubated on ice for 30 mins, and the 
remaining ligation reaction was stored at -20°C. The competent cells were then heat 
shocked for 30 s at 42°C to create pores in the competent cells and allow the supercoiled 
plasmid DNA to enter. Once the plasmid had been taken up by the cells, 250 µL of 
S.O.C. medium was added to each vial, which were then placed in a shaking incubator 
and shaken horizontally at 37°C for 60 mins at 225rpm. Consequently, 25 µL and 100 µL 
of each vial was spread across LA plates containing X-gal (refer to 2.10.3) and 
kanamycin (50 µg/ mL) (2.10.3) using aseptic conditions. The plate were then incubated 
O/N at 37°C, followed by 2-3 hours at 4°C to allow for proper colour development.  
2.10.6 Colony PCR  
Conventional PCR using M13 forward (5’-GTAAAACGACGGCCAGT-3’) and reverse 
(5’AACAGCTATGACATG-3’) primers was used to analyse positive transformants. 
Multiple white colonies and a single blue colony (negative control) were selected and 
resuspended in 300 µL of nuclease free water and then heated on a heat block at 95°C for 
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5 mins. Primers were used at a final concentration of 100 nM, the PCR reaction was 
carried out using IMMOLASE™ DNA Polymerase (Bioline, London, UK) and 
conditions are shown in Table 2-5. The cycle sequence was run on the Veriti® 96 Well 
Thermal Cycler (Applied Biosystems) as follows: 95°C for 10 mins followed by 40 
cycles of 94°C for 30 s, 56°C for 30 s, then 72°C for 60°C. Succeeding 40 cycles, there 
was a final elongation step at 72°C for 5 mins before holding samples at 4°C. PCR 
samples were then run on a 2% agarose (w/v) gel (refer to 2.4) to check for product size 
~300bp.  
Table ‎2-5: PCR‎conditions‎for‎IMMOLASE™‎PCR‎Polymerase. 
10x ImmoBuffer 2 µL 
100mM dNTP Mix 0.4 µL 
50mM MgCl2 Solution 1 µL 
Forward primer (10 µM) 0.25 µL 
Reverse primer (10 µM) 0.25 µL 
IMMOLASE™ 0.3 µL 
ddH20 15.8µL 
Plasmid DNA* 5 µL 
dNTP; deoxynucleotide mix (containing all four nucleotide bases; A, T, G, C)*Suspended 
in nuclease free water  
2.10.7 Isolation of Plasmid DNA  
Multiple white colonies were selected from each plate for plasmid isolation and 
restriction analysis. Each colony was resuspended in 5 mL LB Medium (2.10.2) 
containing 50 µg/ mL kanamycin and incubated O/N at 37°C at 180rpm (horizontally 
shaken). 2 mL of the bacteria/ LB medium/ kanamycin mix was pipetted into a 2 mL 
Eppendorf tube and centrifuged at 6 800 x g for 3 mins at room temperature (15-25°C). 
The supernatant was carefully removed using a 1 mL pipettor, leaving the bacterial pellet. 
The plasmid DNA was then purified using the QIAprep Spin Miniprep Kit (Qiagen) and a 
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microcentrifuge, following manufacturer’s instructions. Briefly, the pelleted bacterial 
cells were resuspended in 250 µL Buffer P1 and transferred to a microcentrifuge tube, 
ensuring no cell clumps remained. Buffer P2 (250 µL) was added and mixed gently by 
inverting tube 10 times, which turned the solution a homologous blue colour after enough 
inverting. Buffer N3 (350 µL) was immediately added and mixed by inverting 10 times to 
avoid localised precipitation. Finally, the resuspended bacterial cells were centrifuged at 
18 000 x g for 10 mins to produce a compact white pellet.  The supernatant, which 
contained the precipitated plasmid DNA, was then removed and placed in a QIAprep spin 
column (Qiagen) and centrifuged for 30-60 s at 20 000 x g. Once centrifuged the flow 
through was discarded and the spin column was washed twice using buffer PB with an 
additional 1 minute centrifugation to remove any residual wash buffer. The QIAprep 
column was then placed in a clean 1.5 mL microcentrifuge tube. Finally 50 µL of Buffer 
EB (10 mM Tris-Cl, pH 8.5) was added and left for 1 minute before the purified plasmid 
DNA was eluted by centrifugation at 20 000 x g for 1 min. Samples were then quantified 
(refer to 2.6.1) ready for dilution and sequencing.  
Once the correct clones had been identified following sequencing, the original colony was 
re-streaked on LB plates containing 50 µg/ mL kanamycin. A single colony was then 
isolated and inoculated into 2 mL of LB Medium containing 50 µg/ mL kanamycin. 850 
µL of culture was mixed with 150 µL of sterile glycerol and purified using the QIAprep 
Spin Miniprep Kit (Qiagen) (see above). Samples were eluted in 50 µL Buffer EB 
(Qiagen) and stored at -80°C. 
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2.10.8 Sequencing 
2.10.8.1 Out of house sequencing  
Purified plasmid DNA samples were sent to Eurofins Genomics (Ebersberg, Germany) 
for sequencing (refer to 2.10.7). Sequencing was carried out using internal 
oligonucleotides for both the D21S1890 STR (Table 3-1) and the RH7 amplicons. 
Samples were first diluted to 10 ng/ µL and then 15 µL of each diluted sample was added 
to 2 µL of internal forward primer and another 15 µL was added to 2 µL of internal 
reverse primer in separate 1.5 mL Eppendorf
®
 safe lock microcentrifuge tubes (Sigma-
Aldrich). All samples sent for sequencing were labelled with prepaid barcodes (Eurofins 
MWG Operon) and the barcode serial numbers were recorded with the corresponding 
sample. Results were analysed using ClustalW2 Multiple Sequence Alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and GeneDoc Software (v2.7.000) for 
alignment against expected sequence (Figure 2-3).  
2.10.8.2 In house sequencing 
For the RH fragments (4.2.3), colonies that produced a band between 400 to 500bp were 
sequenced in house using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies) according to manufacturer’s instructions by Dr Michele Kiernan. Briefly, 
1.5 µL of amplified product (10ng/ µL) was added to 4 µL of Big Dye Terminator Mix, 
3.5 µL of Sequencing Buffer and 1 µL of M13 forward primer (5pmol/ µL), made up to 
20 µL with nuclease free water. This was carried out for all samples IN A 96-well plate. 
Consequently, the plate was run on the Veriti® 96 Well Thermal Cycler (Applied 
Biosystems) under the following conditions; 96°C for 1 min, 35 cycles of 96°C for 10 s, 
50°C for 5 s and 60°C for 4 mins, followed by 1 cycle at 60°C for mins and a 10°C hold 
step. The 20 µL PCR reaction was then transferred to 1 clean 1.5 mL microcentrifuge 
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with 5 µL of 125mM EDTA (pH8) and 60µL of ethanol. The reaction was then incubated 
at room temperature for 20 mins and centrifuged at top speed on the benchtop 
microcentrifuge at 4°C for 20 mins. The pellets formed, were washed with 100 µL 70% 
ethanol and air dried for 10 mins. Finally samples were resuspended in 15 µL HiDi 
Formamide and transferred to a 96-well sequencing plate for running on the Applied 
Biosystems ABI 3130 Genetic Analyzer (Applied Biosystems).     
The data generated for each colony was downloaded as a .ABI file and the sequences 
generated were analysed using BioEdit Sequence Alignment Editor Software (Ibis 
Biosciences, CA, USA). Base calls recorded as ‘N’ were analysed and if a clear 
nucleotide was visible, the base was manually updated using the BioEdit Software. The 
sequence for each colony was individually aligned to the RHD and RHCE exon 7 external 
285bp product using ClustalW2 Multiple Sequence Alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and GeneDoc Software (v2.7.000). The 17 
SNPs between RHD and RHCE within this 285bp were used to determine the isolated 
gene fragment of each colony. The unpurified PCR products of colonies that were 
unsuccessfully sequenced in house were sent to Eurofins Genomics (Ebersberg, 
Germany) for sequencing (see above).   
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2.11 Pippin‎Prep™‎size‎selective‎enrichment‎ 
2.11.1 Pippin prep™ size selective gel electrophoresis  
DNA samples extracted from maternal samples (refer to 2.1.5) and non-maternal 
samples (2.1.2) were quantified using the Qubit® dsDNA HS assay kit (2.6.2) 
and subsequently loaded onto the Pippin Prep™ DNA Size Selection System 
(Sage Science, MA, USA) following manufacturer’s instructions (Operation 
Manual Software v.6.00). Maternal samples were not diluted and based on 
individual sample concentration; 30-300ng of DNA was loaded per reaction 
well. Non-maternal samples were diluted and 500-1000ng of DNA was loaded 
per reaction well for maximum elution. Pippin Prep samples were run in pre-cast 
2% agarose (w/v) gel cassettes, pre-stained with ethidium bromide (Sage 
Science). Once the gel cassette had passed the continuity test, the samples, 
which were pre-prepared with Pippin Prep loading solution (3:1) (Sage Science, 
Inc.), were loading into individual sample wells. Each cassette contained 5 wells, 
which enabled four samples plus the Marker B (100-600bp) (Sage Science) to be 
loaded per run. Following the LED calibration, samples were run using the 
Cassette 2% Marker B Overflow Detection Protocol and target size selection 
was set at 150bp (100bp start, 200bp end). The elution timer records the length 
of the time of the elution. When the elution is complete the elution timer will 
show the elapsed time of elution (~60 mins) and the elution indicator light will 
turn green on the lane status panel. Samples collected in the elution modules 
were recovered in a fixed volume of 40µL in TE buffer. 
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Figure 2-10: Pippen‎Prep™‎Gel‎Electrophoresis.‎A) Image of the Pippin Prep™ DNA 
Size Selection System. B) A schematic diagram of a Gel Cassette. C) An illustration 
showing the DNA migration and the branch point between the separation and elution 
channels, which are downstream from the detector position (LED Detector). Following 
gel electrophoresis 40 µL of eluted samples can be collected from the elution module (B) 
for subsequent analysis.   
Separation 
 
     Elution 
A) 
B) 
C) 
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2.11.2 Analysis of Pippin Prep™ enrichment  
Both the original sample aliquots and elution of each sample following Pippin 
Prep gel electrophoresis were analysed on the Agilent 2100 Bioanalyzer system 
(see 2.6.3). No purification step was carried out prior to run on the Bioanalyzer 
to preserve the amount of size-selected cfDNA. However, this resulted in 
unobtainable data for some samples following the Bioanalyzer run. To determine 
if enrichment had occurred, regardless of Bioanalyzer data, both sample aliquots 
were analysed using qPCR (see 2.7.1) and ddPCR (2.9) for the initial 
experiment. However, all consequent experiments for determining the proportion 
of selective enrichment were conducted using only the ddPCR platform for Y-
specific targets (TSPY1 and SRY) and RHD-specific targets (RHD exon 5 and 
RHD exon 7) (refer to chapter 6). 
2.12 Analysis of T21 spike samples using ddPCR 
To determine the minimal cffDNA fraction required to identify a T21 fetus, T21 
gDNA (2ng/ µL) was used as psfDNA and spiked into male gDNA (2ng/ µL), 
female gDNA (2ng/ µL) or individual Disomy 21 (D21) cfDNA samples (2.1.2) 
from 50% down to 1% (assay dependent). Consequently, the spiked samples, 
100% male/ female gDNA/ D21 cfDNA (2ng/ µL), 100% T21 gDNA (2ng/ µL) 
and non-template controls were run in quadruplets on the ddPCR platform (2.9) 
for analysis. The mean ratio of each T21 spiked-sample was analysed against the 
mean ratio of the D21 control to determine if significant differences were 
obtained using the comparative T-Test on SigmaPlot Version 13.0. Significance 
was accepted at P<0.05. 
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Chapter 3  
 
 
 
 
Selective enrichment of shorter psfDNA fragments by 
co-amplification at lower denaturation temperature- 
polymerase chain reaction (COLD-PCR) in pseudo-
maternal samples 
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3.1 Introduction  
The presence of cffDNA within the maternal circulation has enabled routine NIPD of 
fetal sex and RHD genotype in many laboratories worldwide using qPCR analysis 
(Finning et al., 2008; Avent & Chitty, 2006; De Haas et al., 2012; Banch Clausen et al., 
2014). More recently, due to a decline in costs of NGS, the application of NIPT for fetal 
aneuploidy is also more readily available. NIPT for fetal aneuploidy is only offered 
privately as a secondary screening tool for high risk pregnancies and at present invasive-
testing is still required for a definitive diagnosis (Hill et al., 2014; Morris et al., 2014; 
Quezada et al., 2015). Despite the high levels of sensitivities associated with qPCR for 
fetal sex/RHD determination (>95.7%) and MPS for aneuploidy detection (>99%), it has 
been identified that both platforms can produce false negative or inconclusive results if 
low levels of cffDNA are present (<4%) (Finning et al., 2008; Ashoor et al., 2013; 
Porreco et al., 2014). 
The disparity in fragmentation between maternal cfDNA and cffDNA instituted the 
development of research into the application of size selective purification to improve 
detection and quantification of dilute fetal DNA fragments (refer to 1.3.3.5). One size-
selective enrichment strategy described was COLD-PCR (Li et al., 2008; Galbiati et al., 
2011), which selectively amplifies minority alleles from a background of wild-type 
alleles, based on the principle that even a single nucleotide difference will alter the 
critical denaturation temperature (Tc). The Tc is defined as the optimum dissociation 
factor, at which the selective amplification of minority alleles is enriched. The COLD-
PCR results illustrated exclusive amplification and isolation of the mutants from the wild-
type, highlighting the capability of selective enrichment through sequence dissimilarities. 
Li et al. (2008) also highlighted in their discussion the possibility of the application of 
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COLD-PCR for selective amplification of other minority alleles such as cffDNA 
circulating in maternal plasma.  
Macher et al. (2012) focused on the application of COLD-PCR in conjunction with HRM 
analysis for the NIPD of multiple endocrine neoplasia type 2A (MEN2A). Fetuses with 
MEN2A were non-invasively diagnosed by the presence of the C634Y mutation in the 
maternal plasma. The results illustrated 100% accuracy since all pregnancies carrying a 
fetus with the C634Y mutation matched the melt-curve analysis of the positive control. 
Presence of mutation was also confirmed by sequencing of the COLD-PCR amplified 
product. However, for detection of fetal aneuploidy mutations cannot be targeted due to 
sequence similarities, instead accurate quantification is required for detection of 
chromosomal imbalance.  
Rather than exploiting SNPs for separation, it may be possible to selective enrich shorter 
cell-free DNA fragments (fetal and tumour) using the same approach. Figure 3-1 
illustrates the proposed application of selective amplification using COLD-PCR. We 
hypothesized that the shorter cffDNA may be selectively amplified at the Tc, whereas 
larger maternal cfDNA fragments will remain partially double-stranded and therefore will 
not be amplified. By increasing the overall proportion of cffDNA it may be possible to 
determine allelic-imbalances using qPCR or dPCR platforms, which are considerably 
cheaper (~10-fold) than predominant MPS approaches currently available (refer to 
1.3.3.3.2).  
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Figure 3-1: Representation of denaturation of shorter fetal DNA fragments and 
longer maternal DNA fragments at critical Td. Amplification at the critical Td 
illustrates full denaturation of the shorter fetal fragments and only short stretches of DNA 
denaturation for longer maternal fragments.  
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The aims of this study were:  
 To determine why smaller products are formed at lower Tds when amplifying 
pseudo-fetal DNA fragment containing a short-tandem repeat region (STR).  
 To optimise the Td of multiple internal primers for highly conserved regions of 
DNA, which do not contain an STR, on chromosomes X, Y, 1, 21, 18 and 13. 
 To produce pseudo-maternal DNA samples and further optimise the Td for two 
targets in singleplex and multiplex reactions using qPCR to selectively amplify 
the pseudo-fetal proportion.  
 To transfer multiplex reactions onto a dPCR platform for accurate detection and 
quantification of selective enrichment. 
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3.2 Results  
3.2.1 Cloning of an STR fragment (D21S1890) on chromosome 21 for analysis of 
product formation at the optimal (95°C) and the critical (80°C) denaturation 
temperature.  
Initial experiments were continued from previous work carried out by Tara Miran (ResM 
student, Plymouth University, UK), which focused on the use of COLD-PCR to 
selectively amplify psfDNA (Miran, (2012)). The investigation focused on a fragment of 
chromosome 21 that contained a CA STR (D21S1890). The psfDNA fragments were 
produced using external primers designed by Alice Bruson (a visiting PhD student from 
Universita delgi di Padova, Italy) (Table 3-1) and spiked into female gDNA at 5% as 
described (refer to 2.1.4).  
Table 3-1: Oligonucleotides for D21S1890 STR fragment (HPLC purified (Eurofins 
MWG Operon) (for mapped sequences refer to Figure 2-1). 
 
Forward primer 
sequence (5’-3’) 
Reverse primer 
sequence (5’-3’) 
Hybridisation 
probe sequence 
(5’-3’) 
Size 
(bp) 
D21S1890 
internal 
oligonucleotides 
TCGCCCGAGGG
TCTGA 
AAACCAACTGAC
TCCCAAACAAC 
FAM-
AGATTTCCC
AATCGCCA-
BHQ1 
101 
D21S1890 
external 
oligonucleotides 
GGAGAAACGAG
GATGAGCTTC 
TATTCCCCCGTAT 
TCTTGGT 
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Optimisation of Tc was repeated by performing a denaturation temperature gradient (Td). 
Conventional PCR identified the Tc of D21S1890 to be 78.2°C (Figure 3-2). However, 
when repeated on a qPCR platform psfDNA fragment was not amplified at this Td, 
therefore a higher gradient was tested and the Tc was determined to be 80°C on this 
platform (Figure 3-3), which comply with previous results achieved by Tara Miran 
(Miran, 2012).  
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Figure  3-2: COLD-PCR for D21S1890 fragment using Td gradient from 83°C to 
73.2°C. Lane 1 represents marker (Ranger 100 bp DNA ladder), lanes 2, 4, 6, 8, 10 and 
12 represent amplification of Male gDNA at Td 83°C, 78.8°C, 78.6°C, 78.4°C, 78.2°C 
and 73.2°C, respectively. Lanes 3, 5, 7, 9, 11 and 13 identify negative water controls at 
each temperature. Clear identification of 101bp product amplified at both 83°C and 
78.8°C. Product was also amplified at Td 78.6°C, 78.4°C and 78.2°C but smaller than size 
of fragment DNA. There was no amplification at all presented at 73.2°C Td. Lane 3 
illustrated contamination of similar size to target. Lanes 5, 7, 9 and 11 all showed 
contamination of a secondary product <101bp. 
 
 
 
 
 
 
Figure  3-3: Real-Time PCR amplification of D21S1890 psfDNA fragment and 
control Female gDNA at 95°C and 80°C Td. A) Amplification of female gDNA (0.2 ng/ 
µL) at 95°C Td (33.14 Ct). B) Amplification of ‘fetal’ fragment D21S1890 at 95°C Td 
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(14.21 Ct). C) Amplification of female gDNA (0.2 ng/ µL) at the Tc 80°C (undetermined 
Ct). D) Amplification of ‘fetal’ fragment D21S1890 at the Tc 80°C (29.62 Ct). 
Previous data for the same STR region illustrated that the psfDNA fragments presented 
lower melting temperatures (Tm) at 80°C Td compared to 95°C Td using melt-curve 
analysis (78.06°C Tm and  81.3°C Tm, respectively), which also indicated smaller 
product formation (Miran, 2012). The presence of shoulder peaks from the melt-curve 
analysis demonstrated possible heteroduplex formation. In addition, fragment analysis 
(ABI Genetic analyser 3130 with Peak Scanner™ Software) carried out by a senior 
research technician showed multiple stutter peaks when only two peaks were expected for 
heterozygous samples since each individual expresses two alleles. 
To continue on from this research, cloning experiments were carried out to compare 
psfDNA sequences amplified at 80°C and 95°C Td. External primers were used to create 
the psfDNA fragment D21S1890, which was used as a template for conventional PCR 
amplification at 80°C and 95°C Td using D21S1890 internal primers (refer to 2.3.2) 
(Table 3-1). Following PCR amplification products were gel extracted and quantified 
using the NanoVue Plus™ Spectrophotometer (GE Healthcare, Buckinghamshire, UK) 
(refer to 2.5 and 2.6.1, respectively).The psfDNA fragments yielded 14.7ng/µl and 
18.8ng/µl of DNA at 80°C and 95°C Td, respectively. Purified PCR products were then 
cloned into pCR
®
2.1 vectors and transformed into competent E.coli. One Shot
®
 cells (TA 
Cloning Kit) (refer to 2.10). The pCR
®2.1 cloning vector expresses single 3’ 
deoxythymidine (T) residues, which allow PCR inserts to ligate efficiently. Surrounding 
the PCR insert region of the vector are multiple restriction enzyme sites and M13 forward 
(-20) and reverse priming sites. For this experiment a single colony from each plate was 
analysed by colony PCR (refer to 2.10.6) using the M13 primers, and products were ran 
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on an agarose gel (refer to 2.4) (Figure 3-4). The results illustrate that the PCR product 
(~300bp) was only successfully inserted when 100 µL of transformation vial was loaded 
for psfDNA amplified at 95°C Td. However, the psfDNA amplified at the Tc (80°C) 
showed product insert from a single colony for one duplicate of each loading volume 
(Figure 3-4).  
 
 
 
 
   
Figure  3-4: 2% agarose (w/v) gel of colony PCR for pseudo-fetal fragments using 
M13 forward and reverse primers. M= 100bp DNA ladder. Lanes 1-4 represent 
psfDNA amplified at 95°C and lanes 5-8 represent psfDNA amplified at 80°C. Lanes 1, 
2, 5 and 6 represent colonies selected from LB agar plates that were spread with 100µl of 
transformation vial. Lanes 3, 4, 7 and 8 represent colonies selected from LB agar plates 
that were spread with 25µl of transformation vial. 
These colonies were subsequently selected for plasmid DNA purification and sent for 
sequencing with the forward M13 primer (Prepaid barcodes, Eurofins Genomics, 
Wolverhampton, UK). The sequencing results were aligned to the M13 primer binding 
region of the pCR2.1 vector, which included the D21S1890 internal sequence, using 
ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and GeneDoc 2.7 Software. The 
results for alignment against this 301bp reference sequence for psfDNA amplified at 95°C 
 M         1           2         3          4          5          6           7          8 
400bp  
300bp  
200bp 
100bp 
50bp 
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Td and 80°C Td are illustrated in Figure 3-5. The results show a 52-base deletion of the 3’ 
end of the vector (including the M13 reverse primer binding region) for psfDNA 
amplified at both temperatures, which is a result of only sequencing samples in one 
direction (due to limited supply). For the remaining 249 bases, the PCR product amplified 
at 95°C Td shows complete (100%) alignment (Figure 3-5). However, the PCR product 
amplified at 80°C Td only illustrates 77% alignment (192/249), since 57 bases of the 
D21S1890 internal sequence (including CA-repeat region) were absent. These cloning 
results illustrated that when the psfDNA fragment was amplified at the Tc, the CA-repeat 
region and surrounding nucleotide bases were deleted possibly as result of hairpin 
formation, which is why shorter products were presented at the lower 80°C Td. 
 
 
 
 
 
 
Figure  3-5: Sequence alignment of cloned psfDNA product amplified at 95°C and 
80°C Td. Both sequences were mapped against a region of the linearized vector 
(pCR
®
2.1), which included the D21S1890 PCR product insert (reference). The M13 
Primers are highlighted in blue and the internal D21S1890 primers are highlighted in 
green. The psfDNA product amplified at 95°C Td showed complete sequence alignment 
of the internal D21S1890 amplicon. The psfDNA product amplified at 80°C Td only 
M13+ insert 
psfDNA 95°C 
psfDNA 80°C 
M13 reverse 
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demonstrated 77% sequence alignment of the internal D21S1890 amplicon, since 57 
bases were absent including the entire CA repeat region. 
3.2.2 Optimisation of critical Td for amplicons that do not contain STR regions  
Since the D21S1890 target illustrated sequence hairpin formation at 80°C Td, internal and 
external primers were designed (or taken from previous publications), which did not 
contain any STRs, for multiple-targets on chromosomes 1, 13, 18, 21, X and Y (Table 2-
1). Following annealing temperature (Ta) optimisation of the primers, the Tc was 
optimised for two target regions APP, located on chromosome 21, and EIF2C1, located 
on chromosome 1 (Figure 3-6 and Figure 3-7). The Tc in these experiments is defined as 
the highest temperature at which Male gDNA (control for longer DNA fragments) is no 
longer amplified. The fundamental Td gradient from 95°C down to 70°C (with a 5°C 
decline) for both targets illustrated product amplification at 80°C but no product 
amplification at 75°C (Figure 3-6). Consequently, the next temperature gradient for both 
APP and EIF2C1 internal products was carried out between 75°C and 80°C Td with a 1°C 
decline in temperature (Figure 3-7). The results demonstrated that the highest temperature 
at which Male gDNA is not amplified (the Tc) is 78°C for both APP and EIF2C1 internal 
products, respectively. In succession the optimal Ta and critical Tc was determined for all 
other targets (Table 3-2). The final column in Table 3-2 lists the rank of all primer pairs 
for each chromosome. The rank was decided based on the following criteria; a) the 
intensity of the fluorescent signal shown on a 2% agarose (w/v) gel, b) the appearance of 
any secondary bands and c) the primer concentration necessary for successful 
amplification. The oligonucleotide pairs for each gene were ranked within each 
chromosome sub-set. High ranking oligonucleotide pairs (Rank 1), such as APP, 
illustrated higher levels of fluorescence from low starting concentrations of primers (200-
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300nM) and only expressed a single band. Low ranking oligonucleotide pairs (Rank 3), 
such as TTR (chromosome 18) and FOXP3 (chromosome X), illustrated low fluorescence, 
secondary bands or required high starting concentrations of primers for amplification 
(Table 3-2).  
 
Figure  3-6: 2% agarose (w/v) illustrating initial COLD-PCR gradient (from 70°C to 
95°C) for APP (A) and EIF2C1 (B). The Td was graded from 70°C to 95°C for Male 
gDNA and non-template controls (NTC) to optimise the critical Td for the  APP and 
EIF2C1 internal primers (200 nM final concentration). A) The 96bp product produced by 
the APP internal primers. For each temperature Male gDNA was tested at S1 and S2 
concentrations (20ng/ µL and 2ng/ µL) against NTC.  B) The 81bp product produced by 
the EIF2C1 internal primers. For each temperature Male gDNA was tested at S1 
concentrations against NTC.  The Tc for both APP and EIF2C1 is 75°C. 
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Figure  3-7: 2% agarose (w/v) gel illustrating secondary COLD-PCR gradient (from 
75°C to 80°C) for APP (A) and EIF2C1 (B). The denaturation temperature was graded 
from 75°C to 80°C, with a 1°C decline in temperature, for Male gDNA and non-template 
controls (NTC) to further optimise the critical Td for the APP and EIF2C1 internal 
primers (200 nM final concentration). A) The 96bp product produced by the APP internal 
primers. For each temperature Male gDNA was tested at S2 concentrations (2ng/ µL) 
against NTC.  B) The 81bp product produced by the EIF2C1 internal primers. For each 
temperature Male gDNA was tested at S2 concentrations against NTC. The Tc for both 
APP and EIF2C1 is 78°C. 
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Table 3-2: Summary of optimisation experiments for all chromosomes of interest. 
Results for the optimisation of the Ta, primer concentration and the Td for target regions 
on chromosomes 1, 21, 18, 13, X and Y. 
1
 The critical Td at which only pseudo-fetal DNA is successfully amplified.  
2 
Taken from Fan et al. (2009). 
3
 Designed in house by Kelly A Sillence.  
4
 Designed in house by Hannah P Thompson.  
3.2.3 Real-time PCR optimisation  
The Tc for Male gDNA was further optimised by qPCR using a Td gradient from 78°C 
down to 77°C for targets APP and EIF2C1 (Figure 3-8). Although this initial experiment 
was carried out in a singleplex reaction, different 5’-fluorescent-labelled probes were 
used for APP and EIF2C1 targets (FAM and HEX, respectively), in preparation for 
consecutive multiplex reactions. In addition to the Male gDNA, psfDNA fragments (280-
320bp) produced from external primers were also tested on the qPCR platform (Figure 3-
Chr Target Region 
Optimal 
Ta (°C) 
Lowest Primer 
Concentration 
(nM)
 
Lowest Td at 
which product is 
amplified (°C) 
TC  (°C) 
1 
Rank 
1 EIF2C1 
2 
60 200 79 78 1 
21 
DSCR3 60 100 78 77 2 
RCAN1 56 100 79 78 3 
APP 60 100 80 79 1 
18 
APCDD1 60 200 75 74 1 
TTR 60 200 75 74 3 
TNFRSF11A 58 200 84 83 2 
13 
SPG20 58 200 77 76 1 
ZIC2 62 100 81 80 2 
ATP7B 58 400 
Poor 
amplification 
N/A - 
X 
FOXP3 60 200 82 81 3 
NROB1 58 200 83 82 4 
PRPS1 60 100 75 74 2 
Xp22.3 
2 
58 100 76 75 1 
Y 
SRY (K.A.S) 
3 
60 200 76 75 2 
SRY (H.P.T) 
4 
60 200 76 75 2 
TSYP1 58 200 77 76 1 
DDX3Y 60 200 80 79 3 
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8 and Figure 3-9) (refer to 2.1.3).  Amplification of both targets was also tested at 95°C 
Td, which was used as a positive control temperature for all samples. Figure 3-8 and 
Figure 3-9 demonstrated successful amplification of APP and EIF2C1, respectively, for 
both samples at 95°C Td. The APP and EIF2C1 targets were also successfully amplified 
at all three lower Tds (78°C, 77.5°C and 77°C) for the psfDNA samples (Figure 3-8 and 
Figure 3-9). Late amplification of Male gDNA at Ct 37.5 and Ct 40 for target APP 
(Figure 3-8), and Ct 39 and Ct 39.5 for target EIF2C1 (Figure 3-9), was shown at 78°C Td 
and 77.5°C Td, respectively.  Although the EIF2C1 target did show some amplification of 
Male gDNA at 77°C Td, because amplification occurred under the threshold (0.050∆Rn), 
it can be stated that there was no amplification for this target at this temperature; equally, 
target APP also demonstrated no Male gDNA amplification at 77°C.   
 
 
 
 
 
 
 
 
Figure  3-8: qPCR amplification to determine drop out of psfDNA against Male 
gDNA for APP target on chr21 from 78°C down to 77°C. Amplification of Male 
77.5°C 
78°C 
77°C 
95°C 
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gDNA (2ng/ µL) and psfDNA (2ng/ µL) using APP primers (200 nM concentrations) for 
the following Tds; 95°C (control) 78°C, 77.5°C and 77°C. 
 
 
 
 
 
 
 
 
 
Figure  3-9: qPCR amplification to determine drop out of psfDNA against Male 
gDNA for EIF2C1 target on chr1 from 78°C down to 77°C. Amplification of Male 
gDNA (2ng/ µL) and pseudo fetal DNA (2ng/ µL) using EIF2C1 primers (200 nM 
concentrations) for the following Tds; 95°C (control) 78°C, 77.5°C and 77°C. 
Following the optimisation of the Tc for the Male gDNA, qPCR was ultimately used to 
optimise the critical denaturation temperature of the psfDNA (Figure 3-10). Figure 3-10A 
demonstrated that when the Td was set to 73°C, 74°C, 75°C and 76°C there was no 
amplification of the psfDNA for both APP and EIF2C1. One psfDNA (EIF2C1) replicate 
did show amplification of the EIF2C1 (HEX) target at 76°C Td (36 Ct), but the other two 
replicates showed no amplification (Figure 3-10B). Successful psfDNA amplification was 
only illustrated when the Td was increased to 77°C for EIF2C1 and APP targets (25 Ct 
95°
C 
77.5°C 
78°C 
77°C 
95°C 
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and  26 Ct, respectively) (Figure 3-10C). The gradient was then further optimised from 
75.8°C to 76.6°C (with a 0.2°C incline in temperature) to determine the critical Td of 
each target when amplifying psfDNA (Figure 3-11). Table 3-3 shows the final Tc for 
psfDNA and Male gDNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-10: Optimisation of the Td for the amplification of psfDNA for target APP 
(FAM) and target EIF2C1 (HEX). A) qPCR amplification at 73°C, 74°C and 75°C, B) 
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RT-PCR amplification at 76°C and C) RT-PCR amplification at 77°C. Cut-off thresholds 
were set at 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-11: Further optimisation of the Td for the amplification of psfDNA for 
target APP (A) and target EIF2C1 (B) from 75.8°C to 76.6°C using qPCR. For target 
EIF2C1 the original gradient included the following temperatures; 75.8°C, 76°C, 76.2°C, 
76.4°C and 76.6°C (same as target APP). The temperature was further optimised to 
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determine if the psfDNA would be amplified at a temperature lower than 76.6°C. Cut-off 
thresholds were set at 0.05. 
Table 3-3: Summary of the Tc determined for Male gDNA and psfDNA for targets 
APP and EIF2C1.  
Target Sample 
Final Td at which 
product is amplified (°C) 
Tc (°C) 
APP 
Male gDNA 77.5 77 
psfDNA 76 75.8 
EIF2C1 
Male gDNA 77.5 77 
psfDNA 76.5 76.4 
 
Following the optimisation of the Tc for the Male gDNA and psfDNA, qPCR was carried 
out at 76.7°C Td for both Male and psfDNA. This temperature was chosen as it was in-
between the highest psfDNA Tc (EIF2C1 (76.5°C)) and the highest Male gDNA Tc (77°C 
for both APP and EIF2C1) (Table 3-3). At 76.7°C Td both APP (FAM) and EIF2C1 
(HEX) targets illustrated successful amplification of pseudo-fetal fragments (23 Ct and 25 
Ct, respectively), but showed no amplification of larger Male gDNA fragments (Figure 3-
12). The results indicated that using the mean Td, allowed for the most efficient selective 
amplification and 76.7°C Td was defined as the Tc for non-spiked samples.  
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Figure 3-12: qPCR Amplification of APP (FAM) (A) and EIF2C1 (HEX) (B) 
at 76.7°C for Male gDNA, psfDNA and NTC. The experiment was carried out 
in singleplex reactions and the results reveal that at 76.7°C on the psfDNA 
fragments are successfully amplified.  
3.2.4 psfDNA spiking experiments for singleplex and multiplex reactions  
5% ‘fetal’ spikes (2.1.3) were subsequently tested at this Tc (76.7°C). Controls included; 
NTC, 100% psfDNA (APP) (2ng/µL), 100% psfDNA (EIF2C1) (2ng/µL), Male gDNA 
(2ng/µL) and 100% (non-spiked) plasma extracted DNA (2ng/µL). Figure 3-13A and 
Figure 3-13B demonstrated successful amplification of APP (FAM) and EIF2C1 (HEX), 
respectively, for all samples, except the NTC. However, at the Tc (76.7°C) only the 100% 
psfDNA and the 5% ‘fetal’ spike were amplified for both targets (Figure 3-13C and 
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Figure 3-13D, respectively). The 5% GE spike did not show amplification at the Tc 
(Figure 3-13C, D) (2.1.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) APP amplification at 95°C. 
NTC  
APP psfDNA (2ng/µL) 
5% (2ng/µL) APP spike  
5% (GE) APP spike  
Non-spiked plasma DNA (2ng/µL) 
Male gDNA (2ng/µL) 
  
  
C) APP amplification at 76.7°C. 
Male gDNA 
(2ng/µL) 
Non-spiked 
plasma DNA 
(2ng/µL) 
5% (GE) 
APP spike 
NTC   
APP psfDNA (2ng/µL) 
5% (2ng/µL) APP spike  
B) EIF2C1 amplification at 95°C. 
EIF2C1 psfDNA (2ng/µL) 
5% (2ng/µL) EIF2C1 spike  
5% (GE) EIF2C1 spike  
Non-spiked plasma DNA (2ng/µL) 
Male gDNA (2ng/µL) 
  
  
NTC  
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Figure  3-13: qPCR amplification at optimum Td (95°C) and lowered Td 
(76.7°C) to determine the selective amplification of 5% Spike psfDNA (refer 
to 2.4.1). The spikes were produced using both the dilution and genomic 
equivalent method (2.1.4). Male gDNA and non-spiked plasma DNA were used 
as controls to compare ‘fetal’ DNA amplification with genomic DNA 
amplification. NTC was used a negative control throughout.  qPCR amplification 
was carried out for target APP (FAM) at 95°C Td (A) and 76.7°C  (C), and target 
EIF2C1 (HEX) at 95°C (B) and 76.7°C (D).  
The initial multiplex experiment for APP-FAM and EIF2C1-HEX, demonstrated no 
‘fetal’ amplification at 76.7°C for both targets (data not shown). Therefore, the Td was 
increased to 78°C. Since the GE spike did not illustrate any selective ‘fetal’ enrichment 
(sample too dilute), only the dilution spike was analysed. Figure 3-14 shows the 
amplification plots for all samples (Male gDNA, EIF2C1 psfDNA, APP psfDNA, non-
spiked plasma extracted DNA, 5% T21-spike, 5% D21-spike and NTC) (2.7.1). Before 
testing the samples at the new Tc (78°C), the control Td (95°C) was tested. Male gDNA, 
D) EIF2C1 amplification at 76.7°C. 
EIF2C1 psfDNA (2ng/µL) 
5% (2ng/µL) EIF2C1 spike  
Male gDNA 
(2ng/µL) 
Non-spiked 
plasma DNA 
(2ng/µL) 
5% (GE) 
EIF2C1 
spike 
NTC   
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non-spiked plasma extracted DNA, 5% T21-spike and 5% D21-spike all illustrate 
successful amplification of both targets at the control Td, whilst the NTC shows no 
amplification. The APP psfDNA fragment only showed amplification of APP-FAM. 
However, the EIF2C1 psfDNA fragment illustrated amplification of APP-FAM in 
addition to EIF2C1-HEX at both temperatures (Figure 3-14C and Figure 3-14I). When 
the Td was reduced to 78°C both the psfDNA fragments (100%) (Figure 3-14H and 
Figure 3-14), 5% ‘DS’-spike (Figure 3-14K) and 5% ‘normal’-spike (Figure 3-14L) 
showed successful amplification of both targets. The Male gDNA dropped below the 
threshold at 78°C Td (∆Rn0.05), and therefore can be considered to be ‘dropping-out 
(Figure 3-14G). However, the non-spiked plasma DNA showed very last minute 
amplification (39 Ct) at this temperature just above the threshold (Figure 3-14J). 
Therefore, the experiment was repeated at 77.5°C Td. Due to the increased level of 
fluorescent emitted by the FAM-fluorescent dye for target APP compared to the HEX-
fluorescent dye for target EIF2C1 (0.4∆Rn and 0.2∆Rn, respectively) a dye swap was 
carried out. Swapping over the fluorescent labels (APP-HEX and EIF2C1-FAM) was 
used to determine if the increased levels of fluorescence and lower Ct amplification of 
APP-HEX was a result of increased  levels of fragmentation of chromosome 21 (in 
comparison to reference chromosome 1), or if this was caused by increased efficiency of 
the FAM-labelled reported.  
The result of this dye-swap experiment revealed that the increased Ct values are 
associated with the efficiency of the FAM-fluorescent reporter, since the results were 
inversed. In this run the EIF2C1-FAM target illustrated higher fluorescence compared to 
the APP-HEX target (1∆Rn and 0.2∆Rn, respectively) for Male gDNA control at 95°C Td 
(Figure 3-15A). At the lowered Td (77.5°C), the amplification of Male gDNA remained 
below the threshold limit, but the non-spiked plasma DNA still demonstrated late 
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amplification (38.5 Ct) (Figure 3-15J).  Like the previous multiplex assay, this 
experiment also identified minimal change in amplification levels of target APP and 
target EIF2C1 between the ‘DS’-spike (Figure 3-15K) and ‘normal’-spike (Figure 3-15L) 
at lower Td.  
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Figure 3-14: Amplification of multiplex reaction APP (FAM)/ EIF2C1 (HEX) for 
samples amplified at 95°C Td (A-F) and 78°C Td (G-L). When amplified at 95°C Td, 
both Male gDNA (A) and plasma extracted DNA (D) sample illustrated successful 
amplification of both targets (APP/ EIF2C1), but also showed late amplification of 
78°C 95°C 
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EIF2C1 at 78°C Td (39.9 Ct (G) and 37.4Ct (J), respectively). The psfDNA (APP) sample 
only displayed successful amplification of the APP target at 95°C Td (B) and 78°C Td 
(H). However, the psfDNA (EIF2C1) sample demonstrated amplification of both targets 
at 95°C Td (C) and 78°C Td (I) (33.1 Ct and 33.9 Ct, respectively), indicating sample 
contamination. The 5% ‘DS’-spike (E and K) and the 5%-‘normal’ spike (F and L)  show 
amplification of both targets at both Tds (95°C and 78°C).  
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Figure  3-15: Amplification of dye-swap multiplex reaction EIF2C1 (FAM)/ 
APP (HEX) for samples amplified at 95°C Td (A-F) and 77.5°C Td (G-L). 
When amplified at 95°C Td, both Male gDNA (A) and plasma extracted DNA 
77.5°C 
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(D) illustrated successful amplification of both targets (APP/ EIF2C1), but also 
showed late amplification of EIF2C1 at 78°C Td (37.1 Ct (G) and 36.5 Ct (J), 
respectively). The psfDNA (APP) sample only shows successful amplification of 
the APP target at 95°C Td (B) and 77.5°C Td (H). However, the psfDNA 
(EIF2C1) sample shows amplification of both targets at 95°C Td (C) and 77.5°C 
Td (I) (26.3 Ct and 36.4 Ct, respectively), also indicating sample contamination. 
The 5% ‘DS’-spike (E and K) and the 5%-‘normal’ spike (F and L)  show 
amplification of both targets at both Tds (95°C and 78°C).    
Three new Td temperatures were tested; 77.2°C, 77.3°C and 77.4°C, and the results are 
shown in Figure 3-16. The APP fragment is also amplified in the psfDNA (EIF2C1) 
fragment at 95°C Td; this is likely due to contamination of the psfDNA (EIF2C1) since 
the NTC is clean (A-D). Both Male gDNA and plasma extracted DNA show no target 
amplification at 77.2°C, 77.3°C and 77.4°C Td. Spike samples and pure psfDNA 
fragments show successful amplification at all three Tds (77.2°C, 77.3°C and 77.4°C). 
The ratio of APP/EIF2C1 for Male gDNA, plasma extracted DNA and 5% ‘normal’- 
spike all demonstrated ratios close to 1 (1.05,  1.02, and 1.04, respectively), but the 5% 
‘DS’- spike sample illustrates a slighter higher ratio (1.14). When the Td was reduced the 
ratio for the 5% ‘normal’- spike sample should remain close to 1, however at 77.4°C, 
77.3°C and 77.2°C is reduced (0.59, 0.55 and 0.69, respectively). The drop in ratio is a 
result of selective amplification of the EIF2C1 target, which yields higher EIF2C1 
concentrations and subsequently reduces the ratio to <1 (0.39 – 0.75) (Figure 3-16A-C). 
Furthermore, if selective enrichment of shorter pseudo-fetal fragments is occurring, then 
the ratio for the 5% ‘DS’- spike sample should begin to increase (closer to 1.5). However, 
the results only illustrate a higher ratio for the ‘DS’ spike compared to the ‘normal’ spike 
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at 77.4°C Td (0.75 and 0.69, respectively) (Figure 3-16). 77.2°C Td and 77.3°C Td both 
illustrated high ratios for the 5% ‘normal’ spike (Figure 3-16).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-16: Clustered bar charts illustrating the concentration (ng/ µL) of 
APP-FAM (blue) and EIF2C1-HEX (green) with ratio analysis (black) for 
the following samples; NTC, Male gDNA, psfDNA (APP), psfDNA (EIF2C1), 
Plasma extracted DNA, 5% ‘DS’-spike and 5% ‘normal’-spike. The results for 
all samples were collected at three lower Tds; 77.2°C (A), 77.3°C (B), and 
77.4°C (C), and at the optimal 95°C Td (D) for determination of the Tc in a 
multiplex reaction. The psfDNA samples only showed amplification of the 
A) B) 
C) D) 
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corresponding target at all three lower Tds (A-C), however small amounts of 
APP (0.92ng/µL) were present in the psfDNA (EIF2C1) sample when amplified 
at 95°C Td (D). Male gDNA and Plasma extracted DNA illustrate no DNA 
template amplification for both targets at 77.2°C and 77.3°C  (A, B), but the 
plasma extracted sample did show minimal amplification of the EIF2C1 target 
(0.007ng/µL) at 77.4°C (C). Both Male gDNA and plasma extracted DNA 
illustrate DNA template amplification of both targets at 95°C expressing a ratio 
of 1.05 and 1.02, respectively (D). Both DNA targets (APP and EIF2C1) are 
present for 5% ‘DS’-spike and 5% ‘normal’-spike at all temperatures (A-D). 
However, at the lower Tds the ratios are reduced <1 (0.4 – 0.7) (A-C). When 
amplified at 95°C Td, the 5% ‘DS’-spike and the 5% ‘normal’-spike samples 
illustrate ratios of 1.14 and 1.04, respectively.  
In addition to the APP and EIF2C1 multiplex reactions, Xp22.3 (HEX) and SRY 
(H.P.T)
 
(FAM) were also tested. Initially, 14 unknown blood samples from NHSBT (Bristol, UK) 
were sexed using the SRY 
(H.P.T)
 internal primers by conventional PCR following genomic 
DNA extraction (Table 2-1) (refer to 2.3.1). Figure 3-17 shows the agarose gel image for 
all 14 samples and two NTCs. Eight samples illustrated a band between 50-100bp and 
were determined to be Male (976K, 386P, 671X, 8023, 936C, 279X, 141W and 708A). 
The other seven samples did not illustrate a band and were therefore classified as female 
(583G, 5510, 650F, 816G, 6547 and 155P) (Figure 3-17).  
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Figure 3-17: 2% agarose (w/v) gel showing sexing results for 14 unknown samples. 
M= 100bp DNA ladder. Lane 8 and 16 represent NTC controls. Lanes 1, 2, 3, 4, 7, 9, 13 
and 14 represent samples 976K, 386P, 671X, 8023, 936C, 297X, 141W and 708A, 
respectively. All these samples show SRY 
(H.P.T)
 amplification and were classified as Male 
samples. Lanes 5, 6, 10, 11, 12 and 15 represent samples 583G, 5510, 650F, 816G, 6547 
and 155P, respectively. These samples did not show any SRY (H.P.T) amplification and 
were therefore classified as female samples.   
The Tc was optimised for both Xp22.3 and SRY 
(H.P.T)
 in a singleplex reaction on the 
qPCR (data not shown) (Table 3-2). Even though the singleplex experiments revealed a 
Tc of 75°C, an initial Td of 76°C was chosen due to the increase in Td observed for the 
APP/EIF2C1 multiplex reactions.  The Xp22.3 (HEX) and SRY 
(H.P.T)
 (FAM) multiplexing 
results are illustrated in Figure 3-18. Samples were all diluted to 2ng/µL before 
amplification. The Male gDNA sample only showed amplification of both targets 
(SRY/Xp22.3) at 95°C Td (Figure 3-18A). However, sample 8023 (Male) showed 
amplification of both targets at 95°C Td, and also demonstrated late amplification of 
Xp22.3 (HEX) at 76°C (38.9 Ct) (Figure 3-18B). The psfDNA (Xp22.3) and psfDNA 
(SRY) only show amplification of corresponding targets at both Td temperatures (95°C 
and 76°C), illustrating no sample contamination (Figure 3-18).  
100bp
50bp 
 M        1       2       3      4      5       6       7      8      9      10     11    12    13     14     15     16    
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Figure  3-18: Amplification of SRY (H.P.T) (FAM) / Xp22.3 (HEX) multiplex 
reaction at 95°C Td and 76°C Td for samples; Male gDNA (2ng/µL) (A), 
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male plasma extracted DNA (8023) (B), psfDNA (Xp22.3) (C) and psfDNA 
(SRY
 H.P.T
) (D). Male gDNA only shows SRY 
(H.P.T) 
(FAM) and Xp22.3 (HEX) 
amplification at 95°C Td (28.7 Ct and 30.9 Ct, respectively) (A). However, 
plasma extracted DNA sample 8023 also shows amplification of Xp22.3 (HEX) 
amplification at 76°C Td (38.6 Ct) in addition to SRY (FAM) and Xp22.3 (HEX) 
amplification at 95°C Td (25.4 Ct and 27.7 Ct, respectively) (B). The psfDNA 
(Xp22.3) sample only shows amplification of Xp22.3 (HEX) at 95°C Td and 
76°C Td (16.1 Ct and 18.3 Ct, respectively) (C). The psfDNA (SRY) sample only 
showed amplification of SRY at 95°C Td and 76°C Td (17.9 Ct and 23.6 Ct, 
respectively) (D). 
3.2.5 Optimisation of COLD-PCR for multiplex reactions using ddPCR  
 Following qPCR analysis, the Ta was re-optimised on the ddPCR platform for the 
following multiplex reactions; APP (FAM)/ EIF2C1 (HEX) and SRY 
(H.P.T) 
(FAM)/ 
Xp22.3 (HEX) (2.9).  Figure 3-19 illustrates the Ta gradient tested (61.6°C to 56°C). All 
targets show improved separation of droplets at the two lowest annealing temperatures 
(56.5°C and 56°C). The expected ratio for both multiplex reactions was 1. The 
APP/EIF2C1 multiplex reaction illustrated a ratio closer to 1 at 56.5°C Ta compared to 
56°C Ta (1.11 and 1.13, respectively). The SRY/Xp22.3 multiplex reaction also illustrated 
a ratio closer to 1 at 56.5°C Ta compared to 56°C Ta (0.978 and 0.976, respectively) 
(Figure 3-20). Therefore, 56.5°C Ta was used for the initial Td gradient experiment. The 
APP/EIF2C1 multiplex reaction was also carried out using higher primer concentrations 
(900nM) in an attempt to produce a ratio closer to 1. However, the ratio produced was 
slighter less sufficient (1.13) than the previous experiment using lower primer 
concentrations (300nM) (1.11, respectively).  
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Since the installation of the ddPCR in December 2013, ethical approval for maternal 
samples had been successfully granted (refer to 2.1.5). This allowed analysis of COLD-
PCR to be determined using actual maternal samples on this platform as opposed to 
pseudo-maternal samples, which were used in previous qPCR analysis.  
 
 
 
 
 
 
 
 
Figure  3-19: 1D amplitude plots illustrating Ta gradient from 61.6°C to 56°C for 
target genes (blue, left), APP and SRY, and reference genes (green, right), EIF2C1 
and Xp22.3. A) APP (FAM)/ EIF2C1 (HEX) multiplex reaction. B) SRY 
(H.P.T) 
(FAM)/ 
Xp22.3 (HEX) multiplex reaction. The pink line in all plots illustrates the threshold that 
was set manually for best separation of positive droplets (above threshold) and negative 
droplets (below threshold). All targets illustrate optimal separation at 56.5°C Ta and 56°C 
Ta.   
    61.6°C    60.9°C    59.8°C    58.4°C     56.5°C   56°C  
    61.6°C    60.9°C    59.8°C    58.4°C     56.5°C   56°C       61.6°C   60.9°C    59.8°C    58.4°C     56.5°C     56°C  
    61.6°C    60.9°C    59.8°C    58.4°C     56.5°C    56°C  
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Figure  3-20: Bar chart demonstrating ratios achieved for APP/EIF2C1 
multiplex reactions (black) and SRY/Xp22.3 multiplex reactions (grey) at 
varying Tas (62°C to 56°C). The optimum Ta achieved was 56.5°C (highlighted 
green), since this Ta produced ratios closet to 1 (dashed line) for the 
APP/EIF2C1 and SRY/Xp22.3 multiplex (1.11 and 0.978, respectively). When 
amplified at 62°C, droplet separation for one amplicon, or both amplicons, was 
impaired and ratio could not be generated for either of the multiplex reactions.  
Following optimisation of primer concentration (300nM) and sample concentration (20-
30ng/ reaction) (data not shown), three maternal samples (ST1, ST2 and 1A) were tested 
at 95°C Td (control), 78°C Td and 76°C Td. In addition, Male gDNA (4ng/µL) and NTC 
were tested at all temperatures (2.9.3) and plasma extracted DNA from a female donor 
(583G) (4ng/µL) was tested at 95°C Td as a negative control for SRY amplification. 
Despite qPCR optimisation of multiplex reactions (including SRY 
(H.P.T) 
(FAM)/ Xp22.3 
(HEX)), the ddPCR results clearly highlights the variation in amplification efficiencies at 
Annealing temperature 
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reduced temperatures (Table 3-4). The results illustrated depletion of both target-genes at 
the lower Td (SRY and Xp22.3), but show increased efficiency for the Xp22.3 
oligonucleotides, since there is a considerable decline in the ratio at 78ºC/76ºC Td 
compared to 95ºC Td for the Male gDNA control (0.29/0.21 and 0.98, respectively) (Table 
3-4). Furthermore, it is expected that the ratio for maternal samples carrying male fetuses 
will increase at the Tc, since the larger-maternal fragments of Xp22.3 should not be 
amplified (depleted), thus reducing the HEX-signal. However, maternal samples ST1 and 
1A illustrate higher ratios at 95°C Td (0.24 and 0.02, respectively) compared to 78°C Td 
(0.122 and 0.014, respectively) (Table 3-4). Target concentrations can also be used to 
calculate cffDNA fractions (2.9.4). Higher ratios can also be equated to increased 
cffDNA fractions, therefore both ST1 and 1A maternal samples illustrated a reduction in 
cffDNA fractions at 78°C Td, showing depletion of fetal DNA as opposed to enrichment 
(Table 3-4). The SRY target was not amplified for maternal samples (ST1 and 1A) at 76ºC 
Td, indicating that this temperature is too low for SRY amplification even though Xp22.3 
(reference gene) was still successfully amplified at this Td (15.6 copies/µL).  
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Table 3-4: ddPCR results for SRY 
(H.P.T) 
(FAM)/ Xp22.3 (HEX) multiplex reaction at 
95°C Td, 78°C Td and 76°C Td. Results show the concentration (copies/ µL) of each 
target, the ratio generated (FAM / HEX) and calculated cffDNA fraction (refer to 2.9.4).  
 
95ºC Td 78ºC Td 76ºC Td 
 
Concentration 
(Copies/µL) Ratio 
cffDNA 
fraction 
(%) 
Concentration 
(Copies/µL) Ratio 
cffDNA 
fraction 
(%) 
Concentration 
(Copies/µL) Ratio 
cffDNA 
fraction 
(%) 
 
SRY Xp22.3 SRY Xp22.3 SRY Xp22.3 
Male 
gDNA 
(20ng)  
287 294 0.975 N/A 28.7 98.1 0.292 N/A 0.564 3.39 0.166 N/A 
583G 
(female) 
(20ng) 
0 204 N/A N/A 
   
 
   
 
Maternal 
sample 
ST1 
(male 
fetus)*  
5.28 41.4 0.128 22.6% 1.91 37.6 0.0507 9.7% 0 15.6 N/A N/A 
Maternal 
sample 
ST2 
(female 
fetus)* 
0 17.4 N/A N/A 0 12.5 N/A N/A 0 3.58 N/A N/A 
Maternal 
sample 
1A 
(male 
fetus)** 
4.49 224 0.02 3.9% 1.38 102 0.014 2.7% 0 1.53 N/A N/A  
*Obtained from Dr Svetlana Trivodalieva (2013), Research Center for Genetic Engineering and 
Biotechnology, Macedonian Acadamy of Sciences and Arts, Krste Misirkov 2, 100 Skopje, Republic 
of Macedonia. ** Maternal samples from Plymouth Hospitals NHS Trust (Plymouth, UK). 
Therefore, the SRY 
(H.P.T)
 (FAM) target was multiplexed against the EIF2C1 (HEX) 
reference, since this target illustrated higher Td dropout compared to Xp22.3 (78°C and 
75°C, respectively) from the initial conventional PCR results (Table 3-2). In this 
experiment only two maternal samples were tested (ST1 and ST2), alongside Male gDNA 
(5ng/ reaction), Female gDNA (4.8ng/ reaction) and a NTC at all three Td temperatures 
(95°C, 78°C and 76°C). Lower concentrations of Male and Female gDNA were tested 
171 
 
(5ng/ reaction) to be more representative of maternal sample concentrations (2-5ng/ 
reaction). The results in Table 3-5 showed that at 76°C Td there was no amplification of 
both targets, even though the SRY target was successfully amplified at this Td (for Male 
gDNA control only) in the previous experiment. This is likely to be attributed to the lower 
concentration of Male gDNA used.  
Table 3-5: ddPCR results for SRY 
(H.P.T) 
(FAM)/ EIF2C1 (HEX) multiplex reactions 
at 95°C Td, 78°C Td and 76°C Td. Results show the concentration (copies/ µL) of each 
target, the ratio generated (FAM / HEX) and calculated cffDNA fraction (refer to 2.9.4).  
*obtained from Dr Svetlana Trivodalieva (2013), Research Center for Genetic Engineering and 
Biotechnology, Macedonian Acadamy of Sciences and Arts, Krste Misirkov 2, 100 Skopje, Republic 
of Macedonia.  
Amplification of Male gDNA at 95°C illustrated a ratio of 0.558, which is close to the 
expected ratio (0.5), since male samples will express 1 copy of SRY and two copies of 
EIF2C1. The lower Td (78°C) displayed an increased ratio (4.01) for Male gDNA 
 
95ºC 78ºC 76ºC 
 
Concentration 
(Copies/µL) Ratio 
cffDNA 
fraction 
(%) 
Concentration 
(Copies/µL) Ratio 
cffDNA 
fraction 
(%) 
Concentration 
(Copies/µL) Ratio 
cffDNA 
fraction 
(%) 
 
SRY EIF21C1 SRY EIF2C1 SRY EIF2C1 
Male 
gDNA 
(5ng)  
26.6 47.6 0.558 N/A 4.18 1.04 4.01 N/A 0 0 N/A N/A 
Female 
gDNA 
(5ng) 
0 42.8 N/A N/A 0 5.32 N/A N/A 0 0 N/A N/A 
Maternal 
sample 
ST1 
(male 
fetus)*  
3.4 56.2 0.0605 12.1% 4.66 12.2 0.383 76.4% 0 0 N/A N/A 
Maternal 
sample 
ST2 
(female 
fetus)* 
4.22 22.6 N/A N/A 2.41 3.32 N/A N/A 0 0 N/A N/A 
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indicating biased amplification of SRY 
(H.P.T) 
(FAM) over EIF2C1 (HEX). Though there 
was selective amplification of the SRY target, the concentration was dramatically reduced 
for both SRY and EIF2C1 targets at the lower Td (78°C) (4.01 copies/µL and 1.04 
copies/µL, respectively) compared to the optimal Td (95°C) (26.6 copies/µL and 47.6 
copies/µL, respectively) (Table 3-5). The maternal sample carrying a female fetus (ST2) 
should only indicate amplification of the EIF2C1 reference gene, however at 95°C Td and 
78°C Td there was SRY amplification (Table 3-5).   In repeated experiments, with new 
sample aliquots it was identified that the SRY 
(H.P.T) 
(FAM) target was being amplified in 
random female samples. Therefore, future sexing experiments were carried out using SRY 
primers designed by Lo et al. (1997). The maternal sample carrying the male fetus (ST1) 
illustrated a decreased cffDNA fraction for the SRY/EIF2C1 multiplex compared to the 
previous SRY/Xp22.3 multiplex (12.1% and 22.6%, respectively). However, it is possible 
that multiple (2-3 times) freeze-thawing of the sample led to a decline in the cffDNA 
fraction.  
In contrast to the previous SRY/Xp22.3 multiplex reaction, the SRY/EIF2C1 multiplex 
reaction saw an increase in ratio, and subsequently cffDNA fraction, at the lower Td 
(78°C) compared to the optimum Td (95°C) (0.0605 and 0.383 ratios, respectively) 
(Table3-5). This resulted in a 6.3-fold increase in cffDNA fraction. Because the data is 
contradictory between the two multiplex reactions, it cannot be conclude that the increase 
in fetal proportion in the SRY/EIF2C1 multiplex is a result of COLD-PCR selective 
amplification. It is likely that the difference is caused due to difference in primer 
efficiencies at the lower Td, since the previous experiment illustrated biased amplification 
of the reference gene (Xp22.3), reducing the ratio and consequently cffDNA fraction. 
Whereas in the second multiplex reaction (SRY/EIF2C1) the target gene (SRY) showed 
biased amplification at 78°C Td, increasing the ratio (Table 3-4 and Table 3-5). These 
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results illustrate that extensive primer optimisation is required to ensure equal ratios can 
be obtained even at ‘critical’ Td. Because the overall aim is to selectively enrich shorter 
fetal fragments and subsequently determine chromosome imbalances (through ratio 
analysis) for aneuploidy detection (primarily T21), the APP/EIF2C1 multiplex reaction 
Td was optimised.    
An initial Td optimisation experiment using Male gDNA (20ng/ reaction) illustrated final 
amplification of APP and EIF2C1 at 77.5°C Td and 76.8°C Td respectively (Table 3-6).  
In a secondary, singleplex, Td optimisation experiment the lowest Td at which product 
could be amplified was further refined and final amplification of APP and EIF2C1 for 
Male gDNA was shown at 77.2°C Td and 76.5°C Td, respectively (Figure 3-21). 
Additionally, Xp22.3 was also tested and final amplification was shown at 75.7°C Td 
(Figure 3-21). Therefore, Tds below the point at which amplification last occurred 
(expected Tcs) were selected for APP (76.8°C), EIF2C1 (76.2°C) and Xp22.3 (75°C) for 
the following experiment. In this experiment singleplex reactions were used to test the 
amplification of Male gDNA (30ng/ reaction), T21 gDNA (10ng/ reaction) and maternal 
sample 1B (30ng/ reaction) at the optimal Td (95°C) and expected Tc (see above). NTCs 
were also tested for each singleplex reaction at both Tds.  
The Xp22.3 target illustrated successfully amplification for all samples (except NTC) at 
95°C Td, but at 75°C Td only the Male gDNA control and maternal sample 1B illustrated 
minimal amplification of Xp22.3 (HEX) (Figure 3-22). Although, it is important to note 
that the T21 gDNA was more dilute due to limited available and high costs of sample. 
The maternal sample 1B illustrates a higher number of Xp22.3 positive droplets 
compared to the Male gDNA control at 75°C (32 events and 6 events, respectively). This 
illustrates selective amplification in the maternal sample, however to completely eradicate 
amplification of the Xp22.3 target in Male gDNA this would require further reducing Td. 
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Therefore, the experiment was repeated at 74.8°C Td using Male gDNA (20ng/ reaction) 
and maternal sample 1D (20ng/ reaction). The results demonstrated Xp22.3 (FAM) 
amplification for both Male gDNA and maternal sample 1D (6 events and 5 events, 
respectively). This illustrated no selective amplification of shorter fragments in maternal 
sample (1D) compared to Male gDNA with only contains larger cfDNA fragments 
(results not shown). Previous experiments illustrated that at 74.9°C Td Male gDNA was 
not amplified (Figure 3-21) using 5ng/ reaction of Male gDNA, but when higher 
concentrations were used (20ng/ reaction) Male gDNA was successfully amplified at 
74.8°C Td. This result illustrated that dropout is also dependant on starting quantity and 
not just Td.  
The APP target and EIF2C1 target both show amplification of all samples (except NTC) 
at 95°C Td. But at the expected Tc none of the samples illustrated successful amplification 
not even maternal sample 1B (Figure 3-22). The EIF2C1 target demonstrated 
amplification of Male gDNA and maternal sample 1B at 76.5°C Td (Figure 3-21) but did 
not show amplification of both samples at 76.2°C Td (Figure 3-22). The APP target 
showed amplification of Male gDNA and maternal sample 1B at 77.2°C Td (Figure 3-21) 
but did not show amplification of both samples at 76.8°C Td (Figure 3-22). Therefore, 
amplification of APP at 77°C Td was tested using the same samples, but both the maternal 
sample (1B) and the Male gDNA sample illustrated amplification (data not show). 
Although further Tds between 76.2°C and 76.5°C for EIF2C1 and Td 76.9°C for APP 
could have been tested, supplementary experiments were not carried out due to the 
following reasons; 1) The Td dropout for Male gDNA is too close to Td dropout of 
maternal samples, which prevents multiplexing of EIF2C1 and APP for ratio analysis. 2) 
Further primer optimisation is required, since there is too much variation in the 
efficiencies of APP and EIF2C1 oligonucleotides at the lower Tds for accurate analysis of 
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chromosome imbalance (Table 3-6). However, such primer optimisation is likely to be 
highly challenging, especially when considering the close boundaries between maternal 
sample dropout and Male gDNA dropout.  
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Table 3-6: ddPCR results for  APP
 
(FAM)/ EIF2C1 (HEX) multiplex reactions at 95°C Td, 77.5°C Td, 76.8°C Td and 75.5°C Td. Results 
show the concentration (copies/ µL) of each target and the ratio generated (FAM / HEX). 
 95ºC 77.5ºC 76.8ºC 75.5ºC 
 
Concentration 
(Copies/µL) Ratio 
Concentration (Copies/µL) 
Ratio 
Concentration 
(Copies/µL) Ratio 
Concentration 
(Copies/µL) Ratio 
 
APP EIF2C1 APP EIF2C1 APP EIF2C1 APP EIF2C1 
Male 
gDNA 
(40ng) 
878 760 1.16 1.46 5.03 0.289 No call 3.08 N/A  No call No call N/A 
Female 
gDNA 
(20ng) 
475 444 1.07 1.69 3.39 0.5 No call 2.1 N/A No call No call N/A 
Female 
gDNA 
(40ng) 
892 893 0.999 No call 5.91 N/A No call 4.12 N/A No call No call N/A 
T21 
gDNA 
(40ng) 
218 152 1.45 0.61 0.915 0.667 No call 0.740 N/A No call No call N/A 
T21 
gDNA 
(40ng) 
462 310 1.49 1.62 1.93 0.84 No call 1.67 N/A No call No call N/A 
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Figure 3-21: Bar chart showing the concentration (copies/µL) of APP (FAM), EIF2C1 
(HEX) and Xp22.3 (HEX) in singleplex reactions for Td gradient (78°C to 74.9°C). APP 
(FAM) (blue) shows final amplification at 77.2°C Td. EIF2C1 (HEX) (green) shows final 
amplification at 76.5°C Td. Xp22.3 (HEX) (dark green) shows final amplification at 75.7°C 
Td. 
  78°C Td           77.8°C Td       77.2°C Td        76.5°C Td       75.7°C Td      74.9°C Td    
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Figure  3-22: 1D amplitude plot illustrating droplet separation for Male gDNA, T21 
gDNA, maternal sample 1B and NTC for singleplex reactions APP, EIF2C1 and Xp22.3 
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at 95°C Td and expected Tc. The pink line indicates threshold set manually for droplet 
separation.  
3.3 Discussion  
3.3.1 COLD-PCR for selective amplification of D21S1890 STR psfDNA  
Initial experiments revealed that amplification of the D21S1890 psfDNA fragment 
(containing CA-repeat STR) at the Tc (80°C) produced a smaller product in comparison to 
product amplified at 95°C Td (Figure 3-4).  Previous unpublished data also revealed that 
spike experiments showed multiple stutter peaks as oppose to expected three visible alleles 
(Figure 3-23), which further suggests size discrepancies between amplified products. Stutter 
peaks are a common biological artefact of STR analysis, and it is more common for stutter 
peaks to occur with di-nucleotide repeats as oppose to larger tri- or tetra-nucleotide repeat 
units (Murray, Monchawin and England, 1993).  The proposed mechanism for the production 
of stutter peaks is known as slipped strand mispairing, which is suggested to occur if the 
polymerase falls off the extension strand during amplification. Subsequently, the template 
strand and extension strand breathe apart and as a consequence a single unit can be looped 
out during the re-annealing phase, resulting in the synthesis of an extended strand which 
contains one less repeat than the template strand  (Walsh, Fildes and Reynolds, 1996).  
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Figure 3-23: Schematic diagram showing the fragment length of alleles from a 
heterozygous fetus, alongside the alleles of the heterozygous mother and 
heterozygous father. The red square highlights the three alleles which should be 
represented in the maternal plasma sample, including; a pure maternal allele (1), a 
distinguishing paternally inherited fetal allele (3) and a matching allele, which is 
expressed by both fetus and mother (2).  
Taq polymerase misreading and secondary DNA structures have also been associated with 
occurrence of stutter patterns (Miller and Yuan, 1997). The presence of stutter peaks can 
obscure results and interfere with analysis of allele determination. However, it was identified 
that the occurrence of stutter patterns could be reduced by optimising PCR conditions, such 
as primer concentration, in conjunction with hot-start PCR (Kellogg et al., 1994). Prior to 
PCR amplification, mispriming on less specific sites and primer dimerization can occur at 
temperatures below the cycling conditions. Providing a hot-start prevents unwanted DNA 
synthesis, particularly for amplifications involving multiplex reactions (multiple primers), 
high GC content of amplicon or high cycle numbers (Kermekchiev, Tzekov and Barnes, 
 
Maternal  
                        Maternal plasma  
Fetal  
 
Paternal 
Increasing fragment length 
Allele:     1                 2         3                   4  
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2003). Kellogg et al. (1994) illustrated that the higher the number of cycles the bigger the 
change visible in size distribution. This signifies that the occurrence of stutter peaks in this 
study were a result of Taq Polymerase misreading as opposed to secondary DNA structures, 
since the pattern would remain consistent during amplification if caused by secondary 
structures. More recently, it has been identified that higher stutter peaks have been associated 
with low copy number STR typing (Seo et al., 2014). Results illustrated that lowering the 
annealing/extension temperature to 56°C enhances the stability of the polymerase and DNA 
template strand, reducing the likelihood of slippage during PCR amplification (Seo et al., 
2014).   
In this study instead of decreasing the annealing temperature, the Td was reduced in an 
attempt to selectively enrich the shorter psfDNA fragments. However, the optimum 
denaturation temperature for complete dissociation and strand separation is 95°C and at the 
lower Td shorter products were visible (Figure 3-4). Therefore, the D21S1890 psfDNA 
fragments following PCR amplification at 80°C and 95°C were cloned and sequenced to 
determine the cause of stutter peaks and shorted fragment size. The sequencing results 
illustrated that at the lowest Td the entire CA repeat region was deleted and an additional 
15bp of the expected product using the internal primers (Figure 3-5). While at the optimal Td 
(95°C) the entire D21S1890 psfDNA internal product was successfully amplified (Figure 3-
5). This could have been a result of slippage due to reduced PCR efficiency at lower Td, but 
additionally may have also been caused by possible hairpin-loop formation at the Tc. 
The hairpin loop is a secondary structure caused by intramolecular base pairing that can be 
formed by DNA or RNA and often occurs when two regions of the same strand are 
complementary in nucleotide sequence. The D21S1890 internal sequence illustrates three C-
nucleotides 26 bp downstream from the start of the forward primer and three complementary 
G-nucleotides 76 bp downstream from the start of the forward primer, which incorporate the 
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majority of the missing sequence (91%). However, just prior to the three C-nucleotides are 
three T-nucleotides that are missing from the sequence alignment (Figure 3-5). Polymerase 
slippage only occurs at repeat regions, since directly repeated sequences provide multiple re-
annealing sites for the extension strand if the strands are separated. In addition, slippage to a 
matching repeat is often small, since slippage of multiple repeat units becomes energetically 
unfavourable as more bonds must be broken in the template than are reformed in the loop 
(McMurray, 1999). Therefore, due to the size of the deletion and the deletion of addition 
bases other than just the CA-repeat, it is likely that the shorter product amplified at the lower 
Td is a result of hairpin-loop formation as oppose to slippage.  
The polymorphic characteristic of STRs is the variation in the number of tandemly repeated 
units between alleles. These results have indicated that lowering the Td reduces the PCR 
efficiency and as a result does not amplify the entire internal product. More importantly the 
entire region of interest (ROI) was deleted preventing allele analysis. Stutter peaks are a 
common factor of STR marker analysis, particular for di-nucleotide repeat regions. In order 
to reduce the occurrence of these peaks all aspects of PCR amplification should be optimal, 
including annealing temperature, primer concentration and Taq used. Therefore, selective 
enrichment of psfDNA using COLD-PCR for regions containing STR markers is not reliable 
since region of interest can be completely deleted. In addition, variations in CA-repeat 
regions between maternally inherited and paternally inherited alleles for each individual fetus 
may alter the Tc required for selective enrichment.   
3.3.2 COLD-PCR for the selective enrichment of non-polymorphic DNA target regions  
Currently, NGS is at the forefront of research for NIPD and its application in prenatal testing 
is currently used worldwide (Lo, 2015). However, despite the continual decline in costs this 
method is still not routinely available for all pregnancies (high and low risk) and is currently 
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only used as a private secondary screening tool rather than a replacement for invasive 
diagnosis. The accuracy of NGS is unrivalled (99%) but false negative results can still occur, 
often as a result of low cffDNA fractions (Lo, Chiu and Chan, 2014; Porreco et al., 2014). 
Enriching the proportion of cffDNA would not only allow improved sample quality for NGS 
analysis, but could also improve detection of fetal aneuploidy on cheaper alternative 
platforms such as dPCR. The COLD-PCR selective enrichment approach was first described 
using single-nucleotide mismatch between mutant and wild-type dsDNA sequences. 
Depending on the location of the mismatch the Tm is usually altered by 0.2-1.5°C for 
products ≥200 bp (Liew et al., 2004). The Tc is lower than the Tm, and at this lower 
temperature DNA sequences with one or two nucleotide mismatches will be amplified at 
different efficiencies. Rather than separate mutant and wild-type sequences, this study aimed 
to determine the selective enrichment of cffDNA based on size variance with maternal 
cfDNA. The rationale behind determining the Tc was to find the Td at which only the shorter 
psfDNA was amplified but not the longer ‘maternal’ DNA (Figure 3-1). 
Prior to multiplexing qPCR experiments, the Tc was determined by conventional PCR for 
multiple loci on chromosomes 1, 21, 13, 18, X and Y using Male gDNA (Table 3-2). With 
multiplexing in consideration, target and reference genes that expressed similar Tcs were 
selected for aneuploidy experiments (APP and EIF2C1, respectively) and sexing experiments 
(SRY
 (H.P.T)
 and Xp22.3, respectively). Consequently, the Tc was further optimised for each 
target on the qPCR platform. The Tc of EIF2C1 psfDNA (76.4°C) was only marginally lower 
than the Tc for Male gDNA (77°C), however by selecting a mid-range Td between these two 
temperatures (76.7°C) allowed for only the smaller psfDNA to be selectively amplified 
(Figure 3-16). Sexing experiments revealed a lower Tc of 76°C (Figure 3-18). The initial Tc 
for Male gDNA was higher when running conventional PCR (78°C), but at this Td qPCR 
illustrated amplification of Male gDNA for both targets (APP and EIF2C1). This can be 
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attributed to an increased number of cycles carried out on the qPCR platform (40 cycles) 
compared to convention PCR run (35 cycles) since amplification occurred after the 35
th
 
cycle.  
Initial singleplex spiking experiments were also carried out to determine selective 
amplification of psfDNA fragments (APP and EIF2C1) at 76.7°C. However, only spikes that 
were produced by dilution as oppose to the GE method (refer to 2.1.4) showed successful 
amplification. By using the genomic equivalent approach much lower concentrations of 
psfDNA fragments were added to represent the correct number of copies of template for the 
5% fetal proportion of the spike. The results illustrated that this was too dilute for qPCR 
amplification. Since multiple dilution steps of very small volumes were required to produce 
the GE spike, it is possible that the psfDNA fragment was lost during this process, hence all 
consecutive experiments were carried out using the dilution approach. 
Multiplex PCR can help to reduce cost, time and effort by simultaneously amplifying 
multiple targets in a single reaction (Elnifro et al., 2000). However, combining multiple 
oligonucleotides requires further optimisation to prevent preferential amplification of one 
specific target and ensure successful amplification under the same reaction conditions. The 
results show that at 95°C samples which should express an equal proportion of APP and 
EIF2C1 (Male gDNA, plasma extracted DNA and 5% ‘normal’- spike) all demonstrated 
ratios close to 1 (1.05, 1.02, and 1.04, respectively) (Figure 3-16). In addition, results also 
show ratios close to 1 for the APP/EIF2C1 multiplex (0.999) and the SRY/Xp22.3 multiplex 
(0.975) when amplified at 56.5°C Ta on the ddPCR platform (Figure 3-19). This illustrates 
that there is equal amplification of both targets at the optimal Td on both platforms. However, 
when the Td was reduced (77.2°C-77.4°C) so that only targets containing ‘fetal’ DNA were 
amplified, the ratios for the 5% ‘normal’-spike and 5% ‘DS’-spike were reduced (ranging 
from 0.39 to 0.75). This shows that at lower Tds there is selective amplification of the 
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EIF2C1 (HEX) reference target. Even though the ‘DS’-spike demonstrated a slightly higher 
ratio at 77.4°C compared to the ‘normal’-spike, this was reversed when the temperature was 
reduced by 0.1°C and at 77.3°C the ‘normal’-spike showed a higher ratio (Figure 3-16). This 
illustrated that despite selective enrichment of the psfDNA, the selective amplification of the 
reference target at the lower Td made ratio analysis unreliable and highly sensitive to 
temperature change.  
The denaturation phase of PCR is responsible for strand separation and if the Td is too low 
then the gDNA is prevented from being denatured, which inhibits amplification (Auer et al., 
1996). Shorter fragments that contain less G-C nucleotide bases are likely to denature at 
lower temperatures since less kinetic energy is required for strand separation. Yakovchuk, 
Protozanova and Frank-Kamenetskii (2006) determined that the two main factors primarily 
responsible for the stability of dsDNA are base pairing (between complementary bases) and 
stacking (between adjacent bases). Since the guanine-cytosine pair (GC pair) is bound by 
three hydrogen bases as opposed to two hydrogen bases between the adenine-thymine pair 
(AT pair), more energy is required to break the additional hydrogen bonds in amplicons with 
higher GC-content (Petruska et al., 1988). Yakovchuk, Protozanova and Frank-Kamenetskii 
(2006) determined that higher GC pairing minimally contributed to increased stability, 
whereas AT pairing was always destabilizing. Producing oligonucleotides which target 
amplicons with a lower GC content could help to reduce the melting temperature and would 
possible increase strand separation of the APP target at the Tc. The differences in thermal 
stability of each target at lower Tds is shown in this study (Figure 3-16). The EIF2C1 
fragment, which is shorter (81bp) than the APP fragment (96bp), which also has a marginally 
higher GC content (54.3% and 53.1%, respectively), dropped out at a lower Td compared to 
the APP fragment (Figure 3-16). For the longer APP fragment an increased number of base-
stacking and base-pairing interactions occur, stabilising the fragment, which prevents 
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denaturation at the lower Td. Rather than altering the GC content (since both fragments are 
relatively similar), reducing the fragment size of the APP target would equalise the number of 
base-stacking interactions (and base pairing interactions), which could allow targets to 
display more comparable stability at the lower Tds.  
The Rn value given on the Y-axis of the qPCR amplification plot represents the reporter 
signal normalised to the fluorescence signal of ROX™ (Life Technologies), generally higher 
quantities of starting DNA will produce a higher Rn value (along with a lower Ct value) as 
more fluorescent signals will be generated. However, during the multiplex experiment 
samples that were considered to have an equal proportion of chromosome 1 (EIF2C1) to 
chromosome 21 (APP), for example; Male gDNA, non-spiked plasma DNA, and 5% 
‘normal’-spike DNA, all illustrated higher Rn values for target APP. This could have been 
observed for two reasons; Firstly, chromosome 21 may have been more fragmented than 
chromosome 1. Secondly, the FAM™ reporter dye (which was the label for the APP target) 
works with higher levels of efficiency compared to the HEX™ reporter dye (which was the 
label for the EIF2C1 target). Therefore, to determine whether it was the latter of the two, the 
qPCR was repeated with a dye swap, so that APP was labelled with HEX™ and EIF2C1 was 
labelled with FAM™ (Figure 3-14). The results of this dye swap experiment showed the 
opposite effects to the initial experiment; target EIF2C1 produced higher Rn values in 
comparison to APP for all samples. Consequently, it can be concluded that this study 
indicates that FAM™ illustrates more intense fluorescence than HEX™. The Life 
Technologies website itself states that FAM™ is the most intense dye and it has been 
identified that FAM reagents have numerous benefits in comparison to other fluorophores, 
for example FAM reagents give carboxamides that are more resistant to hydrolysis and also 
give better conjugation yields with increased stability, which could allow for the increase in 
reporter signals observed in this study (Hahn, Wilhelm and Pingoud, 2001). Even though 
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there appears to be a more intense fluorescent signal with FAM reporter dyes, the overall aim 
of this study is to identify over- or under-representation on chromosome 21 using a dPCR 
platform. Therefore the optimisation of these reporter dyes is unnecessary as dPCR works by 
the principal that each well contains only 1 DNA strand, so a fluorescent signal is either 
generated or it is not, the intensity of the signal is irrelevant. However the dye swap 
experiment helps to confirm that chromosome 21 is not more fragmented than chromosome 
1.   
The COLD-PCR analysis on the ddPCR platform was carried out using actual maternal 
samples rather than pseudo-maternal samples, since ethical approval was granted just prior to 
installation of the ddPCR (December 2013). The results illustrated that when testing actual 
maternal samples on the ddPCR, the difference in Td drop-out between the maternal cfDNA 
and the cffDNA (Table 3-6) was considerably less substantial than initial qPCR experiments 
with pseudo-maternal samples (Figure 3-16). The differences in primer efficiencies at lower 
Tds were further highlighted on the ddPCR, since all targets dropped out at different 
temperatures and Xp22.3 showed significantly higher concentrations of target in singleplex 
reactions (Figure 3-21). Because of the efficiency differences at the lower temperatures 
multiplexing results were highly dependent upon which primer/probe sets were paired 
together. When the SRY target was multiplex with Xp22.3, the maternal sample carrying the 
male fetus (ST1) illustrated a decrease in cffDNA fraction (22.6% to 9.7%), but when the 
SRY target was multiplex with EIF2C1, the same sample illustrated an increase in cffDNA 
fraction (12.1% to 76.4%). The lower starting cffDNA fraction for the latter multiplex 
reaction is likely a result of freeze-thawing the sample 2-3 times. Because the data is 
contradictory between the two multiplex reactions, it cannot be conclude that the increase in 
fetal proportion in the SRY/EIF2C1 multiplex is a result of COLD-PCR selective 
amplification. Instead the difference in cffDNA fraction between these two multiplex 
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reactions is attributed to variation in the primer efficiencies at the lower temperatures. If the 
reference oligonucleotides amplify more efficiently at the Tc, the cffDNA fraction will be 
reduced, and if the fetal-target oligonucleotides are more functional at the lower Td, the 
cffDNA will be increased (Table 3-4 and Table 3-5). Both examples will not give a true 
representation of actual cffDNA fraction, and thus determining aneuploidy will be unreliable 
if the reference and target do not amplify with the same efficiency.  
The singleplex Xp22.3 reaction did show an increased number of events at 75°C Td for the 
maternal sample as opposed to the Male gDNA, however no temperature was identified in 
which only the maternal sample showed amplification. Since the qPCR samples were carried 
out using pure psfDNA fragments, higher concentrations of the ROI are likely to explain why 
such clear amplification differences were visible on the qPCR platform. Lun et al. (2008) 
compared male-DNA concentrations calculated using microfluidics dPCR, qPCR and mass 
spectrometry. The results illustrated that microfluidic dPCR demonstrated the least 
quantitative bias for measuring fetal fraction, with lower imprecisions and higher sensitivity 
compared with qPCR. The increase levels of sensitivity associated with ddPCR could also be 
responsible for improved detection of small amounts of fragments from male gDNA 
amplified at lower Tds. The potential for increased sensitivity of ddPCR can be attributed to 
the partitioning of molecules, which is advantageous since rare events can be isolated from 
high levels of background DNA (in this case maternal cfDNA) (Strain et al., 2013). In 
conventional PCR it is more challenging to distinguish one target molecule in large 
backgrounds of DNA.  
Although further Tds could have been tested, supplementary experiments were not carried out 
due to time constraints. However, finding a multiplex reaction, where the chromosome 21 
target and chromosome 1 target maintain a ratio of close to 1, even at lower Td, would set the 
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basis for temperature dropout determination of large maternal DNA fragments. The need to 
find an accurate Tc in a multiplex reaction is a downside to COLD-PCR, since the reaction 
becomes highly sensitive and changeable at lower temperatures. The major advantage of 
COLD-PCR is its ability to distinguish between cffDNA and maternal DNA. Additionally, 
insufficient detection of minority alleles has been reported by Sanger sequencing and 
pyrosequencing, following traditional PCR amplification (Li et al., 2007). However, it has 
been identified that COLD-PCR has higher detection sensitivity than PCR alone for low level 
mutations (for example, KRAS) (Zuo et al., 2009). The combination of COLD-PCR on a 
dPCR platform could be used as an alternative method of detection if a mutation, which is 
suspected in fetal DNA, is undetected by conventional PCR and Sanger sequencing. In 
addition, (Lo et al., 2007) if cffDNA fractions of 25% can be achieved, digital RCD can 
determine T21.  
Since the whole fetal and maternal genome have been found within maternal circulation, 
NGS can provide accurate detection of multiple mutations in a single run, provided optimum 
level of cffDNA is available (≥4%) (Lo et al., 2010). Lo et al. (2010) suggests that genome-
wide scanning could be used to diagnose fetal disorders and produce a genome-wide genetic 
map of the mutational status of the fetus non-invasively, provided maternal and paternal 
genetic information is available. However, despite the decline in costs of t-MPS, it is still too 
costly for routine implantation (>£400.00) and is consequently only available to families of 
high economic status.  
3.3.3 Conclusion  
Fragments that contain STRs do not amplify efficiently at lower Tds, which results in the 
formation of shorter mutated DNA products are produced. Thus, subsequent ratio analysis is 
unreliable. The initial experiments using conserved regions of DNA with no polymorphisms 
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showed the success of COLD-PCR for the selective amplification of psfDNA fragments from 
pseudo-maternal samples. However, the application of this approach using real maternal 
samples on a ddPCR platform showed similar dropout Td for maternal samples and control 
samples. In addition, targets selected for multiplex reactions showed variation in temperature 
drop out. Despite the variation in primers, singleplex reactions have illustrated the potential 
for selective amplification. The size difference between fetal and maternal fragments is not as 
considerable as first identified; however alternative enrichment approaches have illustrated 
success enrichment based on size variation (Chapter 6). Therefore, provided further primer 
optimisation is carried out to ensure equal efficiencies of target amplification in a multiplex 
reaction at lower Tds, COLD-PCR has the potential to allow for the selective amplification of 
shorter fetal DNA. Provided enrichment >25% cffDNA can be achieved, COLD-PCR on 
dPCR platforms (refer to 1.3.3.3.1) could provide cheaper alternatives to NGS for the NIPT 
of fetal aneuploidy.  
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Chapter 4 
 
 
 
 
Inverse PCR (IPCR) for self-ligation of shorter 
psfDNA fragments 
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4.1 Introduction  
The discovery of the polymerase chain reaction (PCR) by Randall K. Saiki provided a 
revolutionary platform for the selective amplification and detection of DNA present in 
relatively low proportions (Saiki et al., 1985). PCR is a now a fundamental technique for 
clinical testing and is imperative in many research applications, such as DNA sequencing, 
DNA cloning, sequence-tagged siting, phylogenic analysis and gene expression (Mullis et 
al., 1986; Innis, Gelfand and Sninsky, 1999). However, the conventional approach first 
described using end-point gel electrophoresis analysis is limited since it only provides 
qualitative information and is associated with reduced levels of sensitivity. Despite 
developments in PCR technology (including qPCR and dPCR) to improve sensitivity, a 
major limitation of amplifying linear DNA using conventional primers is that only known 
sequences can be targeted (Ochman, Gerber and Hartl, 1988). Multiple modifications of 
the conventional PCR have been developed to facilitate the amplification and cloning of 
uncharacterised stretches of DNA upstream or downstream of regions that have already 
been cloned and sequenced (Weiss et al., 1993; Loeb and Christians, 1996; Glaab and 
Tindall, 1997; Kaur et al., 2002). Conceivably, the most straight forward approach 
identified was inverse PCR (IPCR) (Benkel and Fong, 1996).  
Conventional PCR amplification requires oligonucleotides which adhere to opposite 
strands that face inwards to allow extension of the fragment between the forward and 
reverse primer. In contrast, IPCR uses oligonucleotides that face outwards from each 
other, which are designed in regions of previously characterised DNA sequences (Figure 
2-2). For linear DNA fragments, this approach would only allow for a linear increase in 
the number of copies since there is no priming of DNA synthesis in the reverse direction 
(Ochman, Gerber and Hartl, 1988). However, the addition of a ligation step prior to PCR 
amplification produces circularised fragments of DNA. Therefore, when ligated 
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fragments are amplified, the primers extend away from each other allowing amplification 
of the entire circular DNA fragment containing ‘unknown’ upstream or downstream DNA 
sequences.   
The feasibility of this approach was originally shown by Ochman, Gerber and Hartl 
(1988) by amplifying sequences that flank an insertion element (IS1) of Escherichia coli 
(E.coli). The application of IPCR has since also been used for mutation detection (Leclerc 
et al., 1996; Liu et al., 2004; Rossetti et al., 2005). Rossetti et al. (2005) described the 
application of IPCR for the genotyping of Factor VIII intron 22 inversions (Inv22), which 
cause 40-45% of severe cases of haemophilia A. The results corresponded with Southern 
blotting analysis, which is more time consuming; illustrating that IPCR provided a rapid 
and robust Inv22 genotyping assay. However, standard IPCR approaches were limited 
since larger DNA fragments ligate and amplify less efficiently. Therefore, fragments of 
interest amplified by IPCR should optimally be no greater than 2-3 Kb in length 
(Ochman, Gerber and Hartl, 1988). Long range PCR (LR-PCR), which use modified 
protocols with Taq enzyme, can enable amplification of targets up to 50Kb in size (Cheng 
et al., 1994). Benkel and Fong (1996) identified that by combining long range PCR (LR-
PCR) with IPCR (LR-IPCR) led to a dramatic increase in gene characterisation by 
genome walking. Although the article only amplified fragments up to 6Kb long, the upper 
limit of LR-IPCR was not determined.   
Contrastingly, PCR amplification of cffDNA from maternal plasma for RHD genotyping, 
fetal sexing and aneuploidy determination do not require detection of unknown DNA 
sequences. Alternatively, the application of IPCR in this approach was to selectively 
amplify shorter ‘fetal’ DNA fragments. The application of size selective amplification 
using COLD-PCR has been previously described (Chapter 3), which uses lower Tds to 
selectively amplify shorter pseudo-fetal DNA fragments.  Instead of altering the 
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denaturation temperature, we hypothesized that by optimising dilute ligation reactions, 
which encourages self-ligation, selective ligation of shorter (fetal) fragments could be 
achieved, since larger fragment ligate less efficiently (see above). Consequently, IPCR 
would allow for selective amplification of the circularised (fetal) DNA fragments (refer to 
Figure 2-4 in materials and methods chapter).  
The aims of this study are:  
 To produce pure RH exon 7 colonies from amplified products using primers 
consensus for RHD and RHCE (refer to Table 2-3 in materials and methods 
chapter). 
 To optimise IPCR using purified RH psfDNA fragments expressing sticky-ends 
following EcoR1 restriction digest, which produce a 5’-AATT overhang (refer to 
Figure 2-3 in materials and methods chapter).  
 To optimise IPCR using purified RH psfDNA fragments with blunt-ends. This is 
more challenging since the ends terminate in a single base pair with no cohesive 
overhang as seen with sticky-ends. Though ligation yield are significantly lower 
compared to sticky ends, blunt ended fragments are always compatible.  
 To develop IPCR experiment for the selective amplification of shorter fetal 
fragments from actual maternal blood samples.  
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4.2 Results  
4.2.1 Production of purified 285bp RHD and RHCE fragments 
4.2.1.1 PCR amplification using consensus primers for RHD and RHCE exon 7  
External primers for a consensus region of RHD and RHCE on exon 7 (Table 2-2) were 
used to amplify a 285bp fragment from a male gDNA sample (2.10.1). The external 
primers were tested at a higher final concentration (500nM) in addition to the 100nM 
final concentration to ensure high product amplification in preparation for gel extraction. 
The primers were tested against NTC and Male gDNA (20ng/ µL (S1), 2ng/ µL (S2) and 
0.2ng/ µL (S3)) In addition the samples were tested at 56.4°C Ta, 58.4°C Ta and 60.4°C 
Ta. The results illustrated in Figure 4-1 show a faint band at ~50bp for all samples, which 
could indicate possible primer-dimer formation. With the exception of one of the NTC 
replicates, which produced an additional band between 50-100bp (Q), all the other NTCs 
tested did not show any contamination since no additional bands were present (A, B, I, J, 
and R). The male gDNA (S3) sample amplified using 500nM of each primer at 60.4°C 
did not illustrate PCR product (W), however since a band ~300bp is formed when 
amplified using the lower primer concentration (X) this is likely due to pipetting error. 
All the other male gDNA samples across all temperatures show amplification of a product 
just below 300bp for both primer concentrations (C-H, K-P, S-V and X). Samples C and 
V (highlighted) were randomly selected for gel extraction (refer to 2.5) and quantification 
(refer to 2.6.1), which yielded DNA concentrations of 18.75 ng/ µL and 7.65 ng/ µL, 
respectively. 
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Figure ‎4-1: 2% (w/v) agarose gel electrophoresis showing PCR products 
amplified at multiple Tas (56.4°C, 58.4°C and 60.4°C) using RH7 external 
primers (Table 2-2). Male gDNA samples were tested at 20ng/ µL (S1), 2ng/ 
µL (S2) and 0.2ng/ µL (S3) with a NTC for all three Tas in reactions containing 
100nM and 500nM final concentrations of primers. Lanes C and V (highlighted 
in blue) were randomly selected for gel extraction and quantification. The DNA 
concentrations for each sample were 18.75 ng/ µL (C) and 7.65 ng/ µL (G). 
4.2.1.2 Colony PCR for Fragment Insertion Analysis  
Following PCR amplification, the fragments were gel extracted and purified 
following PCR amplification (refer to 2.4 and 2.5), then individual RHD and 
RHCE fragments from the pooled male gDNA sample were subsequently 
isolated so that we could select pure RHD amplicons to spike into pure RHCE 
amplicons at 5% and 95%, respectively, to mock maternal samples once blunt-
56.4°C Ta 
A: NTC 500nM primers 
B: NTC 100nM primers 
C: S1 500nM primers 
D: S1 100nM primers 
E: S2 500nM primers 
F: S2 100nM primers 
G: S3 500nM primers 
H: S3 100nM primers 
58.4°C Ta 
I: NTC 500nM primers 
J: NTC 100nM primers 
K: S1 500nM primers 
L: S1 100nM primers 
M: S2 500nM primers 
N: S2 100nM primers 
O: S3 500nM primers 
P: S3 100nM primers 
60.4°C Ta 
Q:  NTC 500nM primers 
R: NTC 100nM primers 
S: S1 500nM primers 
T: S1 100nM primers 
U: S2 500nM primers 
V: S2 100nM primers 
W: S3 500nM primers 
X: S3 100nM primers 
A    B   C   D   E    F   G   H    I    J    K   L  M   N   O   P    Q   R    S 
T   U    V   W   X 
18.75 ng/ µL 
7.65 ng/ µL 
300bp  
200bp 
100bp 
50bp 
 
 
 
 
 
 
 
300bp 
200bp 
100bp 
50bp 
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ended assays had been optimised. Cloning was carried out using the TOPO TA 
Cloning® kit (Invitrogen) (refer to 2.10). The external RH7 285bp fragments 
(Figure 4-1, C and V) were cloned into pCR
®
2.1 vectors and transformed into 
competent E.coli. as described in section 2.10.4 and 2.10.5, respectively.  
Directly after cloning, PCR amplification using M13 primers (refer to 2.10.6) was carried 
out to ensure that the fragments had been inserted into the MCS of the pCR
®
2.1 vector 
(Figure 2-9) (refer to 2.10.6). This was completed for 15 white colonies, which should 
have expressed plasmids containing recombinant DNA and one blue colony. The blue 
colony acted as a negative control since this shows bacteria which have been transformed 
with non-recombinant plasmids. Figure 4-2 illustrates the 2% (w/v) agarose gel results 
which were run alongside the 200bp Step Ladder Marker (Promega) for all 16 colonies. 
The blue colony (well 1) illustrates amplification at ~200bp, which is expected since 
amplification of the MCS using M13 primers without the PCR fragment insert should 
generate a product 199bp in length.  Colonies 2, 4-6, 9 and 12 all produce PCR products 
between 400-500bp, which is also expected since these colonies contains the MCS region 
(199 bases) and the PCR product (285 bases), which results in amplification of a 484bp 
product. However, colonies 3, 7, 8, 10, 11 and 13-16 show a smaller product closer to that 
expressed by the blue colony, which indicates that 285bp RH exon 7 fragment has not 
been inserted into the pCR®2.1 vector. It is possible that longer time was needed for the 
blue colour to develop for these colonies or alternatively may have been caused by 
smaller products being cloned into the pCR®2.1 vector. Colonies 2, 4-6, 9 and 12, were 
subsequently purified (refer to 2.10.7) and quantified using the NanoVue™ Plus 
Spectrophotometer (GE Healthcare) (refer to 2.6.1). The DNA concentrations identified 
for colonies 2, 4, 5, 6, 9 and 12, were 99.25ng/µl, 83.25ng/µl, 92.75ng/µl, 5.3ng/µl, 
87.25ng/µl and 60ng/µl, respectively. 
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Figure ‎4-2: 2% (w/v) agarose gel electrophoresis using M13 primers to check for 
product insert in 15 white colonies. Lane 1 illustrates results for a single blue colony, 
which was used as a negative control. The blue colony (1) illustrates product at ~200bp. 
Colonies 2, 4-6, 9 and 12 all show a single band between 400bp and 500bp indicating 
successful uptake of product insert into the pCR®2.1 vector. Colonies 3, 7, 8, 10, 11 and 
13-16 all demonstrate amplification close to 200bp indicating unsuccessful uptake of the 
285bp RH exon 7 fragment. 
4.2.1.3 Sequencing results of single white colonies  
The 2% (w/v) agarose gel shown in figure 4-2, illustrates that colonies 2, 4-6, 9 and 12 
contain RH fragments, however samples were subsequently sequenced to determine 
which colonies contained the RHD external fragment and which contained the RHCE 
external fragment (refer to 2.10.7). Initially, all colonies were sequenced in house with 
only the M13 forward primer on the Applied Biosystems ABI 3130 Genetic Analyzer 
(Applied Biosystems) (refer to 2.10.7.1). However, colonies 4, 5 and 9 in house 
sequencing results were unsuccessful. Therefore, these samples were sent to Eurofins 
Genomics (Ebersberg, Germany) with both the forward and reverse M13 primers for 
sequencing (refer to 2.10.7.1). Both sets of sequencing results were aligned to the RHD 
and RHCE exon 7 285bp external fragments (Table 2-2) using ClustalW2 Multiple 
500bp 
400bp 
300bp 
200bp 
1       2     3      4      5      6      7      8      9     10    11   12     13   14     15    16          
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Sequence Alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and GeneDoc Software 
(v2.7.000). The in house sequencing results are shown in Figure 4-3 and the out of house 
sequencing results are shown in Figure 4-4. There are 17 SNPs in total between RHD and 
RHCE within the 285bp external amplicon. Table 4-1 summarises SNP alignment for 
each colony and consequently the determined RH genotype of each colony.   
 
 
 
A) Colony 2 alignment (using M13 forward primer) 
B) Colony 6 alignment (using M13 forward primer) 
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Figure ‎4-3: Alignment of in-house sequencing results for colonies 2 (A), 6 (B) and 12 
(C) against RHD and RHCE exon 7 285bp fragments. A) Colony 2 shows that out of 
the seventeen SNPs, one SNP does not align to RHD or RHCE (SNP 1), two SNPs align 
to RHCE (SNPs 2 and 16) and fourteen SNPs align to RHD (3-15 and 17), therefore this 
fragment was classified as RHD. In addition, a base deletion and mismatch base was also 
identified. B) Colony 6 was determined to be containing the RHD fragment as it 
illustrated 100% alignment with the 285bp RHD sequence. C) Colony 12 was also 
considered RHD since all seventeen SNPs aligned to the RHD fragment. However, 100% 
alignment was not achieved due to a non-SNP region ‘G’ nucleotide base deletion within 
the cloned sequence.  
 
 
C) Colony 12 alignment (using M13 forward primer) 
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A) Colony 4 alignment (using M13 forward primer) 
B) Colony 4 alignment (using M13 reverse primer) 
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C) Colony 5 alignment (using M13 forward primer) 
D) Colony 5 alignment (using M13 reverse primer) 
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Figure ‎4-4: Alignment of external sequencing results for colonies 4 (A and B), 5 (C 
and D) and 9 (E and F) against RHD and RHCE exon 7 285bp fragments using M13 
E) Colony 9 alignment (using M13 forward primer) 
F) Colony 9 alignment (using M13 reverse primer) 
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forward and reverse primers, respectively. The results illustrated here and the final 
classification of each colony are summarised in table 4-1. No other base deletions or base 
additions were identified however, colony 4 sequenced with the M13 reverse primer 
showed one non-SNP region mismatch base (G<A).  
Table ‎4-1: RH determination of six colonies (2, 4-6, 9 and 12) by alignment of in 
house and external sequencing data to the external RHD and RHCE exon 7 285bp 
fragments 
Legend- F: Forward; R: Reverse.  
a 
Sequenced in house using ABI 3130 Genetic Analyzer.  
b
 Sequence external (sent to Eurofins Genomics).  
The results illustrated that out of the six colonies collected, four contained an RHD 
fragment within the pCR®2.1 vector (2, 4, 6 and 12) and two contained an RHCE 
fragment within the pCR®2.1 vector (5 and 9). For colonies 4 (Figure 4-5 A), 6 (Figure 
4-4 A) and 12 (Figure 4-4 C), when sequenced with the M13 forward primer, 100% RHD 
SNP alignment was achieved (17/17 SNPs) (Table 4-1). Since colony 4 was sent for 
sequencing, an additional sequencing result using the M13 reverse primer was also 
Colony 
M13 
primer 
RHD 
SNPs 
/17 
RHD  
SNP 
alignment 
(%) 
RHCE 
SNPs 
/17 
RHCE 
SNP 
alignment 
(%) 
Mismatch or 
base deletion/ 
addition 
SNPs  
Mismatch or 
base deletion/ 
addition (%) 
RHD or 
RHCE 
fragment 
2a F 14 82.4 2 11.8 1 5.8 RHD 
6a F 17 100 0 0 0 0 RHD 
12a F 17 100 0 0 0 0 RHD 
4b F 17 100 0 0 0 0 RHD 
4b R 15 88.2 2 11.8 0 0 RHD 
5b F 2 11.8 15 88.2 0 0 RHCE 
5b R 2 11.8 15 88.2 0 0 RHCE 
9b F 1 5.8 16 94.2 0 0 RHCE 
9b R 1 5.8 16 94.2 0 0 RHCE 
205 
 
generated. The results for colony 4 using the M13 reverse primer illustrated a reduction in 
RHD specific SNP alignment (88.2%) since two SNPs (1 and 2) aligned to the RHCE 
fragment instead (Figure 4-5 B) (Table 4-1). Colony 2 in house sequencing results using 
the M13 forward primer provided the most varied results (Figure 4-4 A). Fourteen SNPs 
aligned to the RHD fragment (82.4%), hence why this colony was classified as containing 
an RHD fragment within the pCR®2.1 vector (Table 4-1). However, two SNPs (2 and 3) 
also aligned to the RHCE fragment and one SNP (SNP 1) also produced a mismatch ‘G’ 
nucleotide that did not align to the RHD ‘C’ nucleotide or the RHCE ‘A’ nucleotide 
(Figure 4-4A). In addition, the sequencing results for colony 2 also displayed multiple 
base deletions in the M13 forward primer binding site (Figure 4-4 A). The sequencing 
results for colony 5 generated by the forward and reverse M13 primers both demonstrated 
88.2% SNP alignment to RHCE and both sets of results illustrated alignment of SNPs 1 
and 2 to RHD (Figure 4-5 C and D) (Table 4-1).  The external sequencing data for colony 
9 generated by the forward and reverse M13 primers also show homogeny since both sets 
of results show 94.2% SNP alignment to RHCE with one SNP (3) aligning to RHD 
(Figure 4-5 E and F) (Table 4-1).  Since these colonies were produced from pooled 
samples of male gDNA (promega) it is possible that for colonies 5 and 9 where both the 
forward and reverse show the same polymorphism alignment that the colony selected for 
sequences may include a novel variant, although error in sequencing alignment is more 
feasible.  
4.2.2 IPCR analysis of sticky-ended fragments 
4.2.2.1 EcoR1 digest 
Once sequencing had been completed to determine the RH status of each purified 
fragment, the purified plasmid DNA aliquots for colonies 2, 4, 5, 9 and 12 were digested 
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with restriction enzyme EcoRI (refer to 2.8.1). Colony 6 was not included due to the low 
yield of DNA determined in alternative experiment (5.3 ng/ µL) (4.2.2). Figure 4-6 
demonstrates the 2% (w/v) agarose gel for all colonies following restriction digest. The 
restriction digest, should yield two bands; one smaller band (~300bp) containing the 
285bp fragment and a small portion of the vector, and one larger band (>1 kb) 
representing the rest of the 3.9 kb vector (Figure 2-3). In addition, undigested samples of 
each colony were also tested and used as a negative control, since these samples should 
not produce a band of ~300bp. Colonies 2, 5, 9 and 12, which underwent restriction 
digestion, successfully illustrated two bands, one at >1 kb and one at ~300bp. The 
digested colony 4 sample did not show any bands, however, since the undigested sample 
produced one clear band >1 kb it is likely that the sample was loaded incorrectly or not 
enough DNA was added to the restriction digest (refer to 2.8.1). Consequently, only 
colonies 2, 5, 9 and 9 were used for subsequent ligation and IPCR.  
 
Figure ‎4-5: 2% (w/v) agarose gel demonstrating restriction digested (EcoRI) and 
non-digested results for colonies 2, 4, 5, 9 and 12. The samples that did not undergo 
restriction digest (un-cut) show a single band at >1kb. In contrast the samples that did 
undergo restriction digest (cut) with EcoRΙ illustrate two bands, one >1kb and another 
just above 300bp (thicker red arrow). 
400bp  
300bp  
200bp  
100bp  
50bp  
               RHD           RHD           RHCE         RHCE          RHD   
  2       2 
cut  un-cut 
  4       4 
cut  un-cut 
  5       5 
cut  un-cut 
  9       9 
cut  un-cut 
  12     12 
cut  un-cut 
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4.2.2.2 Ligation and IPCR  
Proceeding on from the restriction digest, the 300bp band of colonies 2, 5, 9 and 12 were 
gel extracted and ethanol precipitated to produce purified RHD and RHCE fragments. 
Prior to ligation the extracted ‘cut’ fragments for all colonies were quantified on the 
NanoView™ Spectrophotometer. The DNA concentrations identified for colonies 2, 9 
and 12, were 23.5ng/µl, 29.5ng/µl and 27ng/µl, respectively. Colony 5 ‘cut’ fragment gel 
extraction yielded lower DNA (<5 ng/ µL) and consequently was not used in the ligation 
experiment. The RH fragments were then ligated (2.8.2) to produce circularised DNA and 
IPCR was completed directly after ethanol precipitation of the ligated RH fragments. The 
results indicated that only colony 12 produced a band between 200bp and 300bp with all 
three ligations (2.8.2) (Figure 4-6). Additionally colony 12 also produced a second, larger 
band between 500 and 600bp, which was presumed to be a result of two fragments 
ligating together just prior to self-ligation. Colony 2 and colony 9 only show 
amplification of one product (between 200bp and 300bp) for ligation 1, and ligations 1 
and 3, respectively. The internal IPCR primers (Table 2-2) should produce a fragment 
218bp in length. However, because part of the MCS of the pCR
®
2.1 vector was also 
incorporated into the circularised sequence (15bp), a band ~233bp was expected (Figure 
2-5). Therefore, the results demonstrated successful ligation and subsequent amplification 
for all colonies at varying ligation reaction concentrations (Figure 4-6). Colony 12, 
ligation reaction 3 (4 Weiss-units) was selected for sequencing.  
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Figure ‎4-6: 2% (w/v) agarose gel illustrating IPCR amplification of ligated RH 
fragments for three ligation dilutions (refer to 2.8.2). The RHD fragment from colony 
12 is represented in wells 2, 5 and 8 for each ligation. All ligation experiments show an 
amplified product at ~200-300bp. In addition, for ligation 1 and ligation 3, the colony 12 
RHD fragment also illustrates a second band between 500-600bp. The RHD fragment for 
colony 2 is represented in wells 3, 6 and 9 for each ligation. This sample only illustrates a 
faint PCR product at 200-300bp for ligation 1. The RHCE fragment from colony 9 is 
represented in wells 4, 7 and 10. PCR product is visible for this sample at ligation 1 and 
ligation 3. However, at ligation 2 no band is present. 
4.2.2.3 Sequencing results of IPCR product  
The IPCR product from the colony 12 RHD fragment (ligation 3) (Figure 4-6 well 8) 
produced the strongest band. Therefore, the unpurified PCR product for this sample was 
sent to Eurofins Genomics (refer to 2.10.8.1) for sequencing along with the forward 
   Wells:         1        2       3       4         5        6        7         8       9        10  
100bp 
1000bp 
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internal IPCR primer (Table 2-2).The sequencing results were aligned to the inverse 
internal product for both RHD and RHCE exon 7 insets (Figure 2-2) (Figure 4-7). Figure 
2-5 illustrates the product that should have been generated following successful self-
ligation of the EcoRI restriction site and amplification using consensus internal inverse 
primers (Table 2-2). Because the internal inverse primers were designed facing away 
from each other a small section of the fragment is not amplified, resulting in the exclusion 
of 8 SNP’s (Figure 2-2). However, the RH status of colony 12 was confirmed using the 9 
SNPs that remained (Figure 4-7). The results illustrated in Figure 4-7 show the point at 
which ligation occurred (EcoRI site) and the surrounding 15bp MCS sequence included in 
the amplification (highlighted orange). The remaining sequence demonstrates 100% SNP 
alignment to RHD. These results demonstrated the ability to self-ligate shorter (‘fetal’) 
DNA fragments with successful inverse amplification of circularised fragment for 
samples that express sticky ends.                                                  
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Figure ‎4-7: Alignment of colony 12 following self-ligation and IPCR (Col12IPCR) against hypothesised sequence generated for RHD 
insert (RHD+MCS) and RHCE insert (RHCE+MCS). The portion of the pCR®2.1 vector amplified is highlighted orange, and the point of 
EcoRI restriction (and consequent self-ligation point) is shown. Colony 12 illustrated 100% SNP sequence alignment to the RHD inserted 
sequences (as expected) since all 17 SNPs (blue) correspond to the RHD exon 7 gene sequence. The region of the MCS incorporated into the 
sequence following self-ligated of 5’-sticky ends produced by the EcoR1 restriction digest, is shown in orange. One of the non-polymorphic 
nucleotides generated by Col12IPCR did not match nucleotides for the RHD or the RHCE exon 7 gene sequence (shown in red).  
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This initial optimisation process to analyse the ability of shorter molecules to self-ligate was 
carried out using EcoRI restriction digest, which produced sticky-ended fragments. Sticky 
ends can ligate more efficiently than blunt-ends and therefore blunt ended fragments will 
require higher concentrations of ligase. The nature of cfDNA ends is unknown but it is more 
feasible that cfDNA fragments express blunt-ends as opposed to sticky ends, since this is the 
simplest DNA end of a double stranded molecule. Therefore, experiments were repeated 
using a restriction endonuclease that produced blunt-ends (EcoRV), before testing real 
maternal samples.  
4.2.3 Self-ligation of blunt ends  
 Colonies 2 and 5 from glycerol stocks (refer to 2.10.7) were amplified using primers that 
contained EcoRV restriction sites (Table 4-2). However, there is only a single EcoRV 
restriction site within the pCR
®
2.1 MCS and the nucleotide sequence on the alternative side 
of the product insert region expresses six restriction enzyme sites (HindIII, BamHI, KpnI, 
SacI, SpeI and BstXI), which all produce sticky-ends (Figure 2-9). Therefore, the forward 
primer created in house using Primer3 Software and OligoAnalyzer 3.1 (refer to 2.2.2) was 
designed to contain an addition EcoRV restriction site at the 5’end (Table 4-2 shown in red). 
Despite optimisation of PCR conditions, including annealing temperature gradient (Figure 4-
8) and primer concentrations (not shown), the 300bp product was not amplified using these 
oligonucleotides. Instead of producing new primers, which would require further optimisation 
or analysis on spike samples, due to the availability of maternal samples obtained from Dr 
Svetlana Trivodalieva (Macedonian Academy of Sciences and Arts Krste Misirkov 2).  
subsequent experiments were carried out using real samples as opposed to spiked samples.   
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Table ‎4-2: EcoRV oligonucleotides for MCS of pCR®2.1. The primers used to amplify 
product insert in the pCR®2.1 vector containing EcoRV restriction site in the forward primer 
(shown in red).  
Oligonucleotide  5’‎ 3’‎sequence 
Forward EcoRV   TCGATATCGCTGGAATTCGG 
Reverse EcoRV CCAGTGTGATGGATATCTGCA 
 
 
 
 
Figure ‎4-8: 2% (w/v) agarose gel illustrating annealing temperature gradient (56 - 
60°C) for colonies 2 and 5 using oligonucleotides containing EcoRV restriction sites. All 
temperatures illustrated smaller product at ~50bp as opposed to 300bp expected product. 
As previously mentioned, the fragmentation pattern of cfDNA is uncertain, and it is possible 
that the ends may be incompatible. Therefore, following DNA extraction and quantification 
of maternal samples Rh47 (15.2 ng/ µL) and Rh61 (12.3 ng/ µL) (2.1.5) (2.6.1), T4 DNA 
Polymerase (Thermo Scientific) was added to half of each sample using two concentrations 
(1 unit and 5 units) (Table 4-3). The polymerase reaction enables blunting of DNA ends, 
which is necessary if incompatible ends are expressed. However, it is also possible that 
500bp 
400bp 
300bp 
200bp 
100bp 
50bp 
56°C  Ta                     58°C  Ta                        60°C Ta 
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cfDNA typically exhibits blunt-ended DNA. Therefore, ligations reactions were also carried 
out for samples without the pre-polymerisation step.  
Table ‎4-3: T4 DNA Polymerisation reaction. 
 Polymerisation 1  Polymerisation 2  
5X Reaction Buffer  4 µL 20 µL 
Linear DNA (Rh47/ Rh61) 150 ng  150 ng  
dNTP Mix 2mM each  1 µL 1 µL 
T4 DNA Polymerase (5u/ µL) 0.2 µL 1 µL 
Nuclease free water  Make up to 200 µL Make up to 200 µL 
 
The ligation and IPCR experiments were carried out as previously described (refer to 2.8.2 
and 2.8.3). Following IPCR amplification, fragments were separated and purified by non-
denaturing polyacrylamide gel electrophoresis using a mini-PROTEAN TBE Precast Gel 
(10% acrylamide) (Bio-Rad). 3 µL of loading dye (12.5 mM Tris pH 8, 30% (v/v) glycerol, 
0.25% (w/v) bromophenol blue) was added to 15 µL of PCR product and the total volume (18 
µL) was added to the gel alongside 12 µL of marker (PCR Ranger 100bp DNA Ladder, 
Norgen). The gel was run using a mini PROTEAN Tetra System (Bio-Rad) in 1x TBE (89 
mM Tris, 89 mM Boric acid and 2mM EDTA Buffer) (10x TBE (Bio-Rad)) for 2.5 hours at 
60 volts. Following electrophoresis, the gel was transferred to a gel tray with 20 mL 1x TBE 
and 7.5 µL GelRed (Biotium) (1:10 000 dilution). This was incubated at room temperature on 
a gyro-rocker for 90 mins. The gel was viewed using the EC3 imaging System (UVP 
BioImaging system) and results were analysed using Launch Vision WorksLS Program 
(Chemi Doc 410).  The results were unsuccessful since no bands (except the marker) were 
visible (results not shown). Despite quantification using the NanoVue™ showing the 
presence of DNA qPCR was carried out to ensure presence of RHD specific targets within the 
sample (RHD5 (FAM) and RHD7 (HEX)) (2.7.1). The oligonucleotides for RHD5 and RHD7 
are illustrated in Table 2-1, although in this instance the RHD7 target was labelled with HEX 
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as opposed to FAM, so that both RHD targets could be multiplex (2.7.1). In addition, 
amplification of a reference region on chromosome 3 (CCR5 (FAM)) was also tested and the 
oligonucleotides for the CCR5 target are illustrated in Table 2-2.  Samples were run at 60°C 
Ta (2.7.1) and the results are illustrated in Figure 4-9.  
The results showed successful amplification of all three targets, demonstrating that DNA was 
present in both maternal samples (Figure 4-9 A-D). NTC replicates were clean (Figure 4-9 F), 
but the results illustrated contamination of one RHD7 replicate for the RHD negative sample 
(Figure 4-9 E). It is possible that the IPCR was unsuccessful, but it is most likely that the 
ligation step was ineffective due to the limited amount of cffDNA available, preventing 
amplification using IPCR primers (Table 2-3).  
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Figure ‎4-9: qPCR analysis to determine the presence of DNA in maternal samples Rh47 
and Rh61 (non-ligated). Sample Rh47 shows amplification of both RHD5 (FAM) and 
RHD7 (HEX) (A) and the reference gene CCR5 (FAM) (B). C) Sample Rh61 also illustrates 
successful amplification of RHD5 (FAM) and RHD7 (HEX) (C) and the reference gene 
CCR5 (FAM) (D). The RHD negative control shows successful CCR5 (FAM) amplification 
and no amplification of RHD5 (FAM), but did show amplification of one (out of three) 
replicate for RHD7 (HEX) (37 Ct) (E). All NTCs were clean (F). 
At 37 Ct the third replicate of the RHD7 
target was amplified but the remaining two 
replicates illustrated no amplification.  
216 
 
The IPCR was repeated using the same polymerase (2x Fast TaqMan Universal MasterMix 
(Applied Biosystems)) (2.8.3) (Figure 4-10 A) and an alternative polymerase, which produces 
high yields and improved specificity, (IMMOLASE™ DNA Polymerase (Bioline)) to 
determine if this would enable PCR amplification (Figure 4-10 B). The results in Figure 4-10 
only show amplification of product ~50-100bp for the 2x Fast TaqMan Universal MasterMix, 
which is likely to be a result of primer dimerization since this product is also visible in the 
NTC (well 18). The results for the IMMOLASE™ DNA polymerase show no bands for most 
samples (Figure 4-10 B). However, samples Rh61 Dilution 1 (non-polymerised) (well 28) 
and Rh61 Dilution 2 (non-polymerised) (well 29) illustrate a very faint single band ~200bp 
(Figure 2-4 and Figure 4-10 (yellow arrows)). In addition, samples Rh47 Dilution 1 
(polymerised) (well 31), Rh47 Dilution 2 (polymerised) (well 32) and Rh61 Dilution 1 
(polymerised) (well 34) all demonstrate two faint bands between 200-300bp (Figure 2-4 and 
Figure 4-10 (green arrows)). However, the amount of DNA present was minimal and 
consequently sequencing of the unpurified PCR products (well 28 and well 34) was 
unsuccessful. The experiment was repeated using IMMOLASE™ DNA polymerase for 
higher ligation concentrations (6 Weiss units/ reaction) (Figure 2-4), but the 2% (w/v) 
agarose gel electrophoresis results of repeated IPCR illustrated no product amplification (data 
not shown). Time constraints prevented further optimisation but due to the limited amount of 
cffDNA present in maternal samples it is conceivable that detection methods that express 
higher levels of sensitivity are required.  
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Figure ‎4-10: 2% (w/v) agarose gel for IPCR amplification of maternal samples Rh47 
and‎Rh61‎using‎2x‎Fast‎TaqMan‎Universal‎MasterMix‎ (top‎row)‎and‎ IMMOLASE™‎
DNA Polymerase (bottom row). Amplification using 2x Fast TaqMan Universal MasterMix 
only illustrates amplification ~50bp. Amplification using IMMOLASE™ DNA Polymerase 
shows no amplification for most samples. However, samples Rh61 Ligation 1 (non-
polymerised) (27), Rh61 Ligation 2 (non-polymerised) (28), Rh47 Ligation 1 (polymerised) 
2x Fast TaqMan Universal MasterMix 
1. Rh47 Ligation 2 Polymerisation 1 
2. Rh47 Ligation 3 Polymerisation 1  
3. Rh61 Ligation 1 Polymerisation 1 
4. Rh61 Ligation 2 Polymerisation 1  
5. Rh61 Ligation 3 Polymerisation 1  
6. Rh47 Ligation 1 (non-polymerised) 
7. Rh47 Ligation 2 (non-polymerised)  
8. Rh47 Ligation 3 (non-polymerised) 
9. Rh61 Ligation 1 (non-polymerised) 
10. Rh61 Ligation 2 (non-polymerised) 
11. Rh61 Ligation 3 (non-polymerised) 
12. Rh47 Ligation 1 Polymerisation 2  
13. Rh47 Ligation 2 Polymerisation 2 
14. Rh47 Ligation 3 Polymerisation 2  
15. Rh61 Ligation 1 Polymerisation 2  
16. Rh61 Ligation 2 Polymerisation 2  
17. Rh61 Ligation 3 Polymerisation 2  
18. NTC  
200bp 
100bp 
50bp 
 
 
 
 
 
200bp 
100bp 
50bp 
IMMOLASE™‎DNA‎Polymerase 
19. Rh47 Ligation 2 Polymerisation 1 
20. Rh47 Ligation 3 Polymerisation 1  
21. Rh61 Ligation 1 Polymerisation 1 
22. Rh61 Ligation 2 Polymerisation 1  
23. Rh61 Ligation 3 Polymerisation 1  
24. Rh47 Ligation 1 (non-polymerised) 
25. Rh47 Ligation 2 (non-polymerised)  
26. Rh47 Ligation 3 (non-polymerised) 
27. Rh61 Ligation 1 (non-polymerised) 
28. Rh61 Ligation 2 (non-polymerised) 
29. Rh61 Ligation 3 (non-polymerised) 
30. Rh47 Ligation 1 Polymerisation 2  
31. Rh47 Ligation 2 Polymerisation 2 
32. Rh47 Ligation 3 Polymerisation 2  
33. Rh61 Ligation 1 Polymerisation 2  
34. Rh61 Ligation 2 Polymerisation 2  
35. Rh61 Ligation 3 Polymerisation 2  
36. NTC  
   19    20   21   22  23  24  25  26   27   28   29   30    31   32   33   34   35   36  
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(30), Rh47 Ligation 2 (polymerised) (31) and Rh61 Ligation 1 (polymerised) (33), show a 
faint band at 200-300bp. 
4.3 Discussion  
The results illustrated successful cloning of pure RH fragments, and consequently, initial 
experiments using sticky ended fragments showed the feasibility of IPCR for self-ligation and 
amplification of fragments ~218bp in length (Figure 4-6). The 200-300bp fragment was 
visible for all colony IPCRs when previously ligated with the highest T4 DNA ligase 
concentration (4 Weiss units/ reaction (ligation reaction 1)). Therefore, ligation reaction 1 
was considered to be the optimum conditions for ligation and IPCR amplification, despite the 
secondary band visible for colony 12 (Figure 4-6). The secondary bands visible in well 2 and 
well 8 for colony 12 (Figure 4-6) is likely to be a result of intermolecular ligation of two 
fragments, since the product is double the size of the expected fragment (500-600bp).  
Higher DNA concentrations are associated with the formation of intermolecular ligation, 
whereas lower DNA concentrations (<10ng/ µL) preferentially produce intramolecular 
connections (self-ligation), forming circularised DNA (Sambrook, Fritsch and Maniatis, 
1989). Colonies 2 and 9 only demonstrate intramolecular (self) ligation (200-300bp), whereas 
colony 12 also demonstrates intermolecular ligation to another 200-300bp fragment 
producing a product between 500-600bp in size (Figure 4-6).  Though this occurred for the 
least dilute ligation reaction (1) (4 Weiss units/ reaction) and the most dilute ligation reaction 
(3) (1 Weiss unit/ reaction), it is possible that slightly higher DNA concentrations of colony 
12 were added to ligation these reactions. Despite adding 0.5-1 ng/ µL of DNA to each 
ligation reaction, small pipetting errors could have resulted in increased volume added to 
reaction. Although lower concentrations were used, sticky ended fragments are more readily 
ligated due to the cohesive nature of the overhang (5’-AATT overhang for EcoRI). 
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Quantification of each colony was carried out using NanoVue™ Spectrophotometry. This 
method is commonly used, however, it can be unreliable and inaccurate, since UV 
absorbance cannot distinguish between DNA, RNA or protein and results are affected by 
contaminants such as free nucleotides and salts (Glasel, 1995). Therefore, the sensitivity of 
this approach is insufficient, preventing accurate quantification of DNA at low 
concentrations. Consequently, future experiments were carried out using Qubit
®
 dsDNA HS 
assay kit, which uses fluorescent dyes to accurate quantify DNA nucleic acids only.  
Sticky ended-fragments produce cohesive ends that can readily ligate, whereas blunt ended 
fragments join less efficiently because they do not express complementary overhanging base 
termini but self-ligate purely by phosphodiester bonds between the 3’hydroxyl ends and 5’ 
phosphate ends of each strand. Since it is expected that cffDNA fragments will be found as 
blunt ended fragments, consequent experiments were carried out using adapted primers (with 
EcoRV site) (Table 4-2) to produce blunt ended RH exon 7 fragments. This was important, as 
ligating PCR-generated DNA fragments without the restriction enzyme digest step would 
produce dephosphorylated blunt ended fragments that are unable to self-ligate. In addition, 
PCR-generated fragments produced for ligation using Taq polymerase can leave an A-
overhang on the 3’end of the PCR product, which inhibits self-ligation without the EcoRV 
restriction digest. However, the restriction digest (EcoRV), ligation and IPCR amplification 
steps for pseudo-fetal DNA (colony 12 (RHD exon 7)) fragment proved unsuccessful so 
experiments were optimised using donated maternal samples (Rh47 and Rh61).  
When ligating DNA extracted from maternal samples, it was expected that 100-300bp bands 
would be visible for fetal fragments and bands >500bp would be visible for maternal 
fragments. Consequently, selective enrichment of the shorter cffDNA fragments could be 
achieved through optimisation of the dilute ligation reaction. However, as described in the 
previous chapter (Chapter 3), recent studies have determined smaller size differences between 
220 
 
cffDNA and maternal cfDNA (higher proportion at 147bp and higher proportion at 166bp, 
respectively) (Lo et al., 2010) making differentiation challenging. The results illustrated 
unsuccessful IPCR amplification of maternal samples using 2x Fast TaqMan Universal 
MasterMix (Applied Biosystems) but IMMOLASE™ DNA Polymerase (Bioline) 
demonstrated faint bands between 100-200bp. Although these bands were only visible when 
the image contrast and brightness was increased to +40%, illustrating limited amplification. 
The results revealed a single faint band between 100 and 200bp for samples Rh61 non-
polymerised DNA (ligation 2 (2 Weiss units)) and Rh61 polymerisation reaction 2 (5 units) 
(ligation 2). However, for samples; Rh61 non-polymerised DNA (ligation 3 (1 Weiss unit/ 
reaction), Rh47 polymerisation 2 (ligation 2) and Rh47 polymerisation 2 (ligation 3), a 
secondary band ~200bp was also visible. It is possible that the smaller band illustrates 
amplification of the shorter fetal fragments and the longer DNA represent the slightly larger 
maternal fragments, however not enough DNA was present for sequencing analysis. 
Consequently, the experiment was repeated using high concentrations of T4 DNA ligase (up 
to 20 Weiss units/ reaction) but results were also unsuccessful. As described in the 
introduction the sensitivity of end-point conventional PCR is lower than for other approaches 
such as qPCR and dPCR, which use fluorescent labelled probes for detection of specific 
targets. For future experiments it would be beneficial to design fluorescent labelled probes 
within the IPCR product to allow target detection on a digital format, since this platform is 
associated with higher sensitivity (Strain et al., 2013). 
Studies have shown that the presence of cffDNA within the maternal plasma is caused by the 
apoptosis of cyto- and syncytiotrophoblastic cells, which released fetal specific fragmented 
DNA into the circulation (Bianchi, 2004; Tjoa et al., 2006; Alberry et al., 2007). Whereas, 
the maternal portion of cfDNA predominantly originates from apoptosis of hematopoietic 
cells (Sekizawa et al., 2000; Lui et al., 2002). Although apoptosis is the most viable, other 
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mechanisms such as active secretion of DNA and terminal differentiation have also been also 
been suggested as sources of circulating DNA. Because of the structured and non-chaotic 
nature of apoptosis, specific stages occur in succession, including the formation of apoptotic 
bodies, which contain either DNA or RNA (Halicka, Bedner and Darzynkiewicz, 2000). The 
ability to detect stabilized circulating RNA within patients suffering from malignant 
melanoma and breast cancer provides evidence that cell-free nucleotides are contained in 
protective vesicles or apoptotic bodies, since plasma is rich in RNase activity (Kopreski et 
al., 1999; qi Chen et al., 2000). However, alternative forms can also be present within the 
maternal circulation including shed cells, nucleosomes and free DNA (Bischoff, Lewis and 
Simpson, 2005). The concern for cffDNA, if assuming blunt-ended form of fragments, is that 
the maternal plasma may contain phosphatises which will remove the 5’-PO4 from the 
fragments preventing ligation, a necessary step for IPCR.   
DNA is found tightly coiled around histone proteins to form chromatin. In 1974 Roger 
Kernberg proposed that chromatin is made up of repeating units that contain two copies each 
of H2A, H2B, H3 and H4 and 200bp of DNA (histone octamer) (Kornberg, 1974).  Apoptotic 
DNA fragmentation is caused by endogenous endonuclease activity, primarily Caspase-
Activated DNase (CAD), which is usually inactivated by the Inhibitor of CAD (ICAD) (Enari 
et al., 1998). The activation of caspase 3 during programme cell death results in the cleavage 
of ICAD and subsequent activation of CAD, which digest chromatin. Consequently, CAD 
cleaves DNA at internucleosomal linker sites between nucleosomes (found in parts of the 
DNA that are not wrapped around the histone) and produces fragments around 180bp and 
multiples of 180bp (for example 360bp, 540bp and 720bp) (Widlak et al., 2000). The 
endonuclease activity is likely to be similar to deoxyribonuclease I (DNase I), which is also 
involved in DNA fragmentation during apoptosis by cutting non-specifically, yielding 5'-
phosphate-terminated polynucleotides with a free hydroxyl group on position 3' (Samejima 
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and Earnshaw, 2005). DNase I results in random cleavage of both DNA strands at roughly 
the same site, generating blunt ends or fragments with 1-2 base overhangs (incompatible 
ends). Because it is unknown as to whether cfDNA is present with blunt ends or incompatible 
ends, an additional polymerase step was carried out prior to ligation for half of each sample 
to produce blunt ended fragments if necessary. A previous study that used an alternative 
endonuclease for DNA fragmentation (MNase) for the investigation of nucleosome mapping 
also reported a pre-processing step, which involved blunt-ending DNA by filling in (Allan et 
al., 2012). The results in Figure 4-10 (B) highlight the potential of this approach, but not 
enough DNA was amplified for further sequencing analysis. However, detection using 
conventional PCR was unexpected since cffDNA represents a small fraction of the total 
cfDNA (3-6%) and it is likely that only a proportion of these fetal fragments will undergo 
successful ligation and IPCR amplification. As previously stated, the incorporation of this 
technique onto a digital platform would increase sensitivity. Rare sequence detection (RSD) 
can be determined by using a probe specific to a fetal target (e.g. SRY in mothers carrying 
male fetuses) against an alternatively labelled probe for a reference target. Consequently, 
through ratio analysis the amount of selective enrichment using IPCR can be determined. 
Ratio’s <0.1 would indicate little selective enrichment, since a high proportion of maternal 
cfDNA is still being amplified. Alternatively, a ratio of >0.5 demonstrate a more equal 
proportion of the fetal target to the reference target, indicating that IPCR is selectively 
amplifying the shorter fetal fragments. In order to confirm selective enrichment, fetal 
fractions obtained by non-inverse PCR can be compared to IPCR cffDNA fraction results.  
Alternatively, it is possibly that the blunt-end formation of samples is preventing optimal 
ligation of fragments, therefore for future experiments the inclusion of linkers or adapters, 
which create sticky-ends, could help to improve self-ligation.  Linkers are short 
oligonucleotides (8-12 base pairs in length), which ligate via blunt ends to a DNA molecule 
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and create restriction enzyme sites upon annealing (Greene, 1998). Once cleaved this 
produces stick-ended molecules, thus enabling optimal self-ligation. Unlike linkers, adapters, 
which also bind to DNA molecules, express a cohesive end that encodes a predetermined 
restriction enzyme site allowing for direct ligation (Greene, 1998). Thus, the addition of 
adapters to the circulating DNA molecules prevents an additional restriction enzyme digests. 
The use of adapters is commonly seen in the field of MPS, where the fragmented DNA 
sequences undergo adapter ligation during library preparation ready for PCR amplification. 
To prevent dimer formation of adaptor molecules enzymatic treatment (Polynucleotide 
kinase) is used to alter the 5’-terminus (from 5’-P to 5’-OH), thus preventing the formation of 
phosphodiester bonds between the 5’OH and 3’OH ends (Chawla, 2002). This is beneficial as 
it prevents adaptors forming base pairs with themselves, which would create new DNA 
molecules that remain blunt-ended. However, for our application, self-ligation is necessary 
and therefore this enzymatic treatment should not be included within the protocol.  
The application of selective enrichment of shorter fetal-DNA for improved NIPD has been 
previously discussed (3.3.2). However, due to the limited amount of cffDNA present little 
success has been achieved and consequently a viable technique for clinical practice has not 
been determined. COLD-PCR based approaches for enrichment (Chapter 3) are associated 
with alterations in efficiencies of primers at the lower Tds, particularly for multiplexing 
experiments. The selective amplification of one target over another prevents accurate 
quantification, impeding the application of this approach as a reliable test for the NIPD of 
aneuploidy until optimal assays are achieved. IPCR for selective amplification of shorter 
fragments via self-ligation can be carried out at the optimal Td (95°C), which prevents bias in 
amplification between targets, assuming cfDNA fragments are fragmented equally and will 
consequently ligate under the same conditions.  
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The results illustrate the feasibility of IPCR for pure colony DNA fragments that express 
sticky ends. However, further testing is required to determine the utility of this approach with 
actual maternal samples. Due to time constrictions further testing was not conducted, but 
future experiments combining linkers/ adaptors with highly sensitive ddPCR detection, could 
potentially enable the analysis of selective enrichment of IPCR for shorter fetal fragments. If 
future tests prove successful further large scale validation of this approach would need to be 
conducted before clinical implementation. However, if cffDNA can be increased to >25% 
using IPCR (Lo et al., 2007), dPCR analysis in conjunction with IPCR selective enrichment 
could provide a cheaper NIPD test for fetal aneuploidy compared to current MPS approaches. 
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Chapter 5 
 
 
 
 
 
 
 
 
RHD zygosity testing for non-maternal samples and 
maternal RHD genotyping using droplet digital PCR 
(ddPCR) 
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5.1 Introduction  
5.1.1 RHD Zygosity Testing  
Of the 35 blood group systems, Rh is the most complex at the genetic level and is coded 
for by two paralogous genes (RHD and RHCE). Multiple combinations of SNPs in RHCE 
are responsible for the C/c and E/e polymorphisms. Although anti-c and anti-E can cause 
HDFN, events are rare since these antibodies (along with anti-K) only occur in 1 in 300 
pregnancies and risk of HDFN for women carrying these antibodies is only 1 in 500 
(Koelewijn et al., 2008). Contrastingly, anti-D is one of the most immunogenic antibodies 
as it is a major cause of HDFN and transfusion reactions during alloimmunisation events. 
Variation in expression of the RHD antigen can cause further complications for obstetric 
patients and transfusion recipients. Total RHD gene deletion, the RHDΨ and some hybrid 
RHD-RHCE genes are responsible for D-negative phenotypes, but SNPs and other hybrid 
RHD-RHCE genes are responsible for D-positive phenotypic D-variants (Avent and Reid, 
2000). All known mutations in both RHD and RHCE have been well catalogued (Reid, 
Lomas-Francis and Olsson, 2012), however, each year the number of variants can 
increase as novel alleles emerge.  
D-variants can be categorised into two classes: weak D and partial D (Daniels, 2013). 
Even though weak D antigens express all D epitopes and as a consequent rarely produce 
anti-D, negative results can still arise using serological testing with a particular 
monoclonal antibody or procedure. Contrastingly, patients with partial D have the 
potential to make anti-D since antigens are lacking one or more epitopes. However, in 
rare cases some variants classified as weak D (such as types 4.2 and 15) have also been 
shown to produced alloanti-D in numerous patients (Wagner et al., 2000). Initially it was 
thought that the amino acid substitutions that occur in weak D individuals appear within 
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the membrane-spanning domains or the cytoplasmic loop and are therefore not expressed 
externally (Flegel, 2007; Wagner et al., 1999). However, the exact locations of the amino 
acid residues are not known and different models predict different locations, which could 
result in the lack of at least one D epitope and consequent anti-D production (Daniels, 
2013). Prior to blood transfusion, determining the D antigen status of individuals can help 
to identify individuals with D variants who can safely receive D+ blood, and also 
determine individuals with a partial D type that are at risk of anti-D alloimmunisation and 
therefore require D- blood (Denomme et al., 2005). Alternatively, determining D antigen 
status in pregnancy can allow for RAADP treatment to be targeted to women at risk of 
alloimmunisation. Since women who are weak D express all D epitopes and display a 
reduction in the D antigen rather than complete or partial deletion, it is recommended that 
anti-D is not given. However, as previously stated some rare weak D-variants can 
produce alloanti-D (Wagner et al., 2000). Therefore, providing accurate maternal RHD 
genotyping using molecular techniques, which can detect various exons, as opposed to 
serological testing, could be used to detect the D-variant, and thus determine risk of 
alloimmunisation. 
Paternal zygosity testing to define hemi- or homozygosity of RHD can allow clinical 
management to be focused on pregnancies that are at risk of HDFN, with the assumption 
of paternity. Further fetal RHD genotyping is not required in pregnancies with RHD 
homozygous fathers, and anti-D can be given since the fetus will be hemizygous RHD 
positive. Further testing is only required if the father is RHD hemizygous as the fetus has 
a 50% chance of being RHD negative, and thus, anti-D treatment is not required. 
Previously published methods to determine paternal zygosity have included real-time 
PCR assessment of RHD gene dosage, assessment of the hybrid Rhesus box found in D-
negative individuals with the RHD gene deletion genotype and allele-specific PCR 
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methods (Perco et al., 2003; Grootkerk‐Tax et al., 2005; Pirelli et al., 2010; Haer‐
Wigman et al., 2013b). However, it is important to note that zygosity testing by targeting 
the hybrid Rhesus box found in RHD-deletion type cde haplotypes is complicated because 
of differences in the hybrid box amongst individuals of African descent (Matheson and 
Denomme, 2002; Grootkerk‐Tax et al., 2005).  
Determining the precise population frequencies of the different Rh haplotypes (CDE, 
cDE, CDe, cDe, cde, Cde, cdE, CdE) is complicated due to the inability to differentiate 
between CDe/Cde; cDE/cdE; cDe/cde; CDE/CdE haplotypes. Differentiation is not 
possible between these haplotypes since the hemi- or homozygosity of the RHD gene in 
individuals with any of these phenotypes has not been established. For example an 
individual with the haplotype CDe would be designated as the most common presumed 
genotype CDe/CDe rather than CDe/Cde. Thus presumed genotype, based on probability, 
is the manner in which donor and patient red cells are labelled. Zygosity determination of 
the above would define which haplotype (D-positive or D-negative) is carried by a 
particular individual. In this study, the ability of ddPCR, a more accurate quantitative 
PCR platform than conventional qPCR to determine patient RHD zygosity in a relatively 
small cohort of samples was evaluated.   
5.1.2 Fetal RHD genotyping  
Initially, definitive diagnosis of fetal sex and RHD status could only be achieved through 
invasive procedures such as amniocentesis and chorionic villus sampling (CVS), which 
are both associated with a small but significant risk of miscarriage. However, since the 
discovery of cffDNA within the maternal circulation non-invasive prenatal testing (NIPT) 
is now a clinical reality (Lo et al., 1997; Avent and Chitty, 2006). Unlike fetal cells, 
which are also found in the maternal circulation and can persist for many years 
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postpartum, cffDNA is rapidly cleared following delivery (around 20 minutes) (Bianchi et 
al., 1996; Nelson, 1996; Rijnders et al., 2003). 
Fetal sex determination using non-invasive methods through the analysis of cffDNA is 
currently available for families at risk of X-linked genetic disorders, such as haemophilia 
and DMD using qPCR platforms (Lewis et al., 2012). Fetal sexing is especially beneficial 
in cases of congenital adrenal hyperplasia (CAH), which enables treatment to be targeted 
to female fetuses only (refer to 1.3.3.1). Many labs worldwide currently provide non-
invasive fetal RHD genotyping (refer to 1.3.3.2) for alloimmunised women as part of 
routine practice, allowing the necessary management to be targeted to pregnancies at risk 
of HDFN (Gautier et al., 2005; Van der Schoot et al., 2006; Daniels et al., 2009). 
Currently, most non-alloimmunised RHD negative mothers carrying RHD negative 
fetuses still receive RAADP unnecessarily. However, routine NIPT of fetal RHD 
genotype using qPCR is now implemented in the Netherlands and Denmark for the 
targeted administration of RAADP (De Haas et al., 2012; Banch Clausen et al., 2014). 
The cost analysis of introducing RAADP has seen mixed results. While some studies state 
that routine testing is cost effective since it will reduce the amount of Anti-D IgG 
administered thus lowering assay costs (refer to 1.3.3.2) (Chilcott et al., 2003; Chilcott et 
al., 2004; Van der Schoot et al., 2006), others have argued that the introduction of this 
service would not result in the reduction in use of Anti-D IgG since postnatal serological 
testing may also be required for RHD negative fetuses determined by NIPD (Szczepura, 
Osipenko and Freeman, 2011). The second study only recorded savings for the 
introduction of RAADP if genotyping assays were also used to determine RHD status for 
postnatal analysis as opposed to serological testing. This highlights the requirement for 
consistencies for the application of cost-analysis decision making within the NHS. 
Though most cases do illustrate financial benefits and also illuminate the risk of infection 
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for RHD-negative mothers with RHD-negative fetuses (refer to 1.3.3.2), it is important to 
note that risk of sensitisation is reduced from 1.9-2.2% to 0.2% when prophylaxis is 
administered to all pregnancies (Liumbruno et al., 2010).  
Streck BCTs have been shown to increase the relative proportion of cffDNA compared to 
EDTA tubes (Wong et al., 2013; Sillence et al., 2015) (refer to 1.3.3.5). In this study, 
initial experiments were conducted to optimise the ddPCR platform for sexing and RHD 
genotyping of non-maternal samples. Consequently, the approach was developed for 
NIPT of fetal sex and RHD status, comparing the sensitivity of this approach to current 
qPCR based approaches. Due to technical reasons samples collected in EDTA tubes, 
despite being third trimester, expressed suboptimal cffDNA fractions (<2%). Whereas 
samples collected in Streck BCTs expressed optimal cffDNA fractions (>3%). However, 
all samples were included to thoroughly test the capability of the ddPCR assay against the 
current gold-standard qPCR approach.  
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The aims of this study were:  
 To optimise the ddPCR platform for two sexing multiplex reactions and two RHD 
genotyping multiplex reactions.  
 To test the sensitivity of ddPCR for low level copy target detection using spiked 
samples.  
 To determine the ratio of each single-copy target multiplex reaction on individual 
(non-pooled) samples (refer to 2.1.2).  
 To determine the RHD zygosity of known and unknown DNA samples extracted 
from both the plasma and buffy coat of human whole blood (refer to 2.1.2).  
 To compare the sensitivity of qPCR to ddPCR for the NIPD of fetal sex and RHD 
status for samples expressing optimal (>3%) and suboptimal (<3%) cffDNA 
fractions.  
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5.2 Results  
5.2.1 Optimising of ddPCR multiplex reactions   
For sex and RHD determination four multiplex reactions were designed (Figure 5-1). 
Initial experiments were carried out to define the optimum annealing temperature for each 
reaction, which was decided based on the separation of positive droplets and the ratio 
achieved for single-copy target genes (See 2.9). For multiplex reaction 1 (SRY
  (H.P.T)
 
(FAM)/ Xp22.3 (HEX)) an annealing temperature gradient from 62°C down to 56°C was 
tested. Separation of the SRY
 (H.P.T) 
target was visible from annealing temperature 58.4°C 
and below, whereas the Xp22.3 target illustrated visible separation from 59.8°C and 
below (Figure 5-2). The best ratio was seen when amplifying multiplex reaction at 56.5°C 
(0.978), and therefore this temperature was determined to be the optimum annealing 
temperature. However, acceptable ratios were also visible at 58.4°C (0.927) and 56°C 
(0.975) (Figure 5-2). The annealing temperature gradient for the second multiplex 
reaction for detection of the 30x multiple copy target region (TSPY1) against the Xp22.3 
reference was also tested from 62°C down to 56°C. The results illustrated droplet 
separation for both amplicons at 59.8°C, however; improved separation was visible at 
58.4°C and 56°C (Figure 5-3).  
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Figure ‎5-1: The four multiplex reactions used for sexing (multiplex reactions 1 and 
2) and RHD genotyping (multiplex reactions 3 and 4). For both sexing experiments, 
the Xp22.3 (HEX-labelled) internal oligonucleotides were used as a reference for a single 
copy target (SRY) (multiplex reaction 1) and a multiple copy target (TSPY1) (multiplex 
reaction 2). For both RHD genotyping experiments, the EIF2C1 (HEX-labelled) 
oligonucleotides were used as a reference for two single copy targets located on RHD 
exon 5 (multiplex reaction 3) and RHD exon 7 (multiplex reaction 4). All target genes 
(blue) were labelled with FAM fluorescent dye.  
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Figure ‎5-2: ddPCR data showing annealing temperature gradient (from 62°C down 
to 56°C) results for  SRY 
(H.P.T)
 (FAM) and Xp22.3 (HEX) multiplex reactions. One 
NTC was tested at 57.3°C Ta and Male gDNA was tested at all other Tas.  The result 
illustrated clear separation of positive and negative droplets begins at 59.8°C and 58.4°C 
for Xp22.3 and SRY, respectively. The ratio was determined by dividing SRY positive 
droplets by Xp22.3 droplets for at each annealing temperature. The results revealed ratios 
0.927, 0.978 and 0.975 when amplified at Ta 58.4°C, 56.5°C and 56°C, respectively.   
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Figure ‎5-3: ddPCR data showing the annealing temperature gradient (62°C, 59.8°C, 
58.4°C and 56°C) results for TSPY1 (FAM) and Xp22.3 (HEX) multiplex reactions. 
Male gDNA and a NTC were tested at each temperature. The results illustrate that 
separation is visible from 59.8C and lower, however optimal separation is seen at 58.4°C 
and 56°C.  
The annealing temperature was then optimised for both RHD genotyping experiments. 
Since poor droplet separation was visible for both previous reaction at 62 °C, for 
multiplex reactions 3 and 4, a gradient was tested from 60°C down to 56°C.  The 
results in Figure 5-4 showed successful droplet separation of the RHD5 (FAM) target at 
all annealing temperatures, but the EIF2C1 (HEX) reference showed less optimal 
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separation at 60°C. The NTC controls tested were clean for all temperatures and the ratios 
for each annealing temperature were only 0.03-0.04 away from a ratio of 1, which was 
expected. This illustrated acceptable amplification at all temperatures. Droplet separation 
for multiplex reaction 4 (RHD7 (FAM)/ EIF2C1 (HEX)) demonstrated the same pattern 
as previously discussed for the RHD5/EIF2C1 multiplex reaction (Figure 5-5). However, 
the optimal ratio was visible at 58.4°C (0.995). Therefore, for future experiments all 
multiplex reactions were tested at 58°C since this temperature illustrated successful 
droplet separation for all target and reference regions and also enabled all four multiplex 
reactions to be tested on a single plate.  
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Figure ‎5-4: ddPCR data showing the annealing temperature gradient (62°C, 58.4°C, 
57.4°C and 56°C) results for RHD5 (FAM) and EIF2C1 (HEX) multiplex reactions. 
Sample 1347 (homozygous for RHD) extracted from human whole blood (refer to 2.1.2) 
and a NTC were tested. The results illustrate that separation is visible for both targets at 
all annealing temperatures. Marginally higher separation is visible at 56°C, but all 
annealing temperatures give a ratio (determined by: RHD5 (FAM) positive droplets / 
EIF2C1 (HEX) positive droplets) close to a ratio of 1.  
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Figure ‎5-5: ddPCR data showing the annealing temperature gradient (62°C, 58.4°C, 
57.4°C and 56°C) results for RHD7 (FAM) and EIF2C1 (HEX) multiplex reactions. 
Sample 1437 (homozygous for RHD) extracted from human whole blood (refer to 2.1.2) 
and a NTC were tested. The results illustrate that separation is visible for both targets at 
all annealing temperatures. However, optimal separation was determined to be 58.4°C 
since this temperature expressed a ratio closer to 1 (0.995). Ratio determined by; RHD7 
(FAM) positive droplets / EIF2C1 (HEX) positive droplets. 
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In previous experiments a final concentration of 300nM of each primer was used. 
However, other dPCR studies have reported using higher primer concentrations (900nM) 
(Lo et al., 2007b). Therefore, both primer concentrations (300nM and 900nM) were 
tested using multiplex reaction 1 (SRY 
(H.P.T)
 (FAM) and Xp22.3 (HEX)) using a constant 
concentration of each probe (250nM final concentration). The results in Figure 5-6 
illustrate effective droplet separation for both primer concentrations. However, a ratio of 
1 was achieved when using 300nM of each primer, whereas higher primer concentration 
(900nM) expressed a ratio of 1.07. Consequently, all future experiments were carried out 
using the lower (300nM) final primer concentration, since higher concentrations did not 
improve the assay.  
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Figure ‎5-6: ddPCR 1D amplitude plots (1), histogram plots (2) and 2D amplitude 
plots (3) showing results for lower (300nM) and higher (900nM) primer 
FAM/ 
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Ratio: 1 
FAM/ 
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3 
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B) 900nM final concentration of each primer 
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concentrations for SRY 
(H.P.T)
 (FAM) and Xp22.3 (HEX) targets. The results illustrate 
effective size separation for both primer concentrations and achieved a ratio of 1 and 1.07 
for 300nM (A) and 900nM (B) final primer concentrations, respectively. Since an 
improved ratio was seen when using the lower concentration and no improvements were 
recorded with higher primer concentrations, 300nM final primer concentrations were used 
throughout.  
5.2.2 Sex determination of non-maternal samples and spiked samples using ddPCR  
 Previous optimisation experiments using sexing multiplex reactions (Figure 5-1) were 
carried out using pooled Male gDNA (refer to 2.1.1). Therefore, analysis of plasma 
extracted DNA from human whole blood samples was carried out following the same 
ddPCR procedure (refer to 2.9) to determine the ratios of individual samples. The results 
for three male samples (8023, 936C and 768A), a Female gDNA (Y-negative) control and 
a Male gDNA (Y-positive) control are illustrated in Figure 5-7. For these initial 
experiments a single reaction was carried out for each sample. The results only 
demonstrated amplification of the reference (Xp22.3) for the female control sample, but 
expressed amplification of both targets for all male samples tested. The Male gDNA 
control expressed a ratio of 0.94, and the ratio for the individual male sample; 8023, 936C 
and 768A were 1.08, 1.03 and 1.05, respectively.  
Consequently, spike experiments were carried out using Male gDNA, but to increase 
reliability of result and encourage more accurate ratio analysis each sample was tested in 
duplicate. Prior to ddPCR experiments, male and Female gDNA were diluted to 2ng/ µL 
and diluted Male gDNA was spiked into the diluted Female gDNA at 50%, 10%, 5%, 3% 
and 1%. The results for the initial spike experiment using multiplex reaction 1 (SRY 
(H.P.T)
 
(FAM)/ EIF2C1 (HEX)) are illustrated in Figure 5-8. The NTC showed no amplification 
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and the Male gDNA control sample illustrated an equal representation (ratio of 0.98) of 
SRY and Xp22.3. The Female gDNA control sample only demonstrated amplification of 
the Xp22.3 target, which expressed twice the number of positive droplets (2359 events) 
compared to number of positive droplets for Xp22.3 amplification from the Male gDNA 
sample (1194 events). This is expected since females express two copies of X and males 
only express one copy of X.  The expected fractional abundance of Y-target was 
determined by dividing the spike percentage by two, since males express one copy of the 
Y-target and one copy of the X-target. The actual fractional abundance and ratio achieved 
for each samples are summarised in table 5-1. The results illustrated that all samples were 
within 0.6% of the expected fractional abundance, illustrating the ability of ddPCR for 
highly precise quantification even when the target region is present at 1% (compared to 
99% of the reference region).   
 
 
Figure ‎5-7: Bar chart illustrating the concentration (copies/ µL) of the SRY (H.P.T) 
(FAM) target (blue) and the Xp22.3 (HEX) reference (green). The scatter plot 
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illustrates the ratio of SRY/Xp22.3 (black). The Male gDNA control and the human 
whole blood samples (8023, 936C and 768A) all illustrate a ratio ~1 (0.94 – 1.08), 
whereas the Female gDNA control gave a ratio of 0 since no SRY target was amplified. 
The female aliquot gives a significantly lower concentration for the Xp22.3 reference 
compared to Male gDNA. Although 10ng/ µL concentration, female sample had been 
freeze-thawed multiple times which could explain lower amount of available target DNA.   
Table ‎5-1: SRY (FAM) and Xp22.3 (HEX) multiplex ddPCR results for control 
samples
1
 and female samples spiked with Male gDNA (50% (wt/wt) down to 1% 
(wt/wt)). The results show the number of positive events for SRY (FAM) and Xp22.3 
(HEX), the ratio calculated (SRY/ Xp22.3), expected fractional abundance of SRY and 
actual fractional abundance of SRY.  
 
SRY 
(H.P.T)
 
FAM 
(events) 
Xp22.3 
HEX 
(events) 
Ratio 
Expected 
fractional 
abundance of SRY 
(H.P.T)
 
Actual  
fractional 
abundance of 
SRY 
(H.P.T)
 
NTC
1 1 1 - - - 
Male 2ng/µl 
(100%)
1 
1181 1207 0.98 50% 49.46% 
Female 2ng/µl
1 0 2359 - 0% 0% 
50% Spike 604 1849 0.31 25% 24.62% 
10% Spike 118 2363 0.05 5% 4.76% 
5% Spike 49 2427 0.02 2.5% 1.98% 
3% Spike 55 2660 0.02 1.5% 2.03% 
1% Spike 17 2167 0.01 0.5% 0.79% 
 
On average around 11,000 – 12,000 droplets were produced per well. The results reveal 
that out of these droplets only around 25% of these droplets were positive for each sample 
(e.g. 2359 for female sample). To further increase the sensitivity, more sample per well 
could be loaded or the number of targets included in each multiplex reaction could be 
increased to expand the number of informative droplets. However, this approach is limit 
since only two fluorescent dyes can be detected (FAM and HEX/VIC), although 
variations in assay dilutions can enable amplitude separation using the same fluorophore.    
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Figure ‎5-8: Bar chart illustrating the number of events (positive droplets) for SRY 
(H.P.T) 
(FAM), Xp22.3 (HEX) and the total (FAM + HEX positive droplets) in a 
generated by ddPCR in a multiplex experiment. Female gDNA samples spiked with a 
decreasing proportion of Male gDNA (50% down to 1%) were tested against the 
following control samples; pure Male gDNA, pure Female gDNA and NTC. The results 
illustrated no amplification for the NTC and only amplification of Xp22.3 (HEX) for the 
female control samples. The number of positive events for the Male gDNA control 
sample was roughly equal for Xp22.3 (1194) and SRY (1180), as expected. The reduced 
amount of Male gDNA spiked into Female gDNA is shown, and even when spike in at 
1% (wt/wt) 26 copies of the SRY target were still detected.  
The spike experiment was subsequently repeated. However, in this instance the multiple 
copy target, TSPY1 (multiplex reaction 2 (Figure 5-1) was tested. Since this target is 
presented multiple times within the genome, spike samples (using the same diluted Male 
and Female gDNA) were produced starting at 50% (wt/wt) Male gDNA down to 0.1% 
(wt/wt) Male gDNA. The results are illustrated in Figure 5-9. The results illustrated a 
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decrease in number of events for the TSPY1 target (Figure 5-9 A and B) but still showed 
successful detection of the Y-specific target even when present at 0.1%. The 
concentration of Male gDNA at 100% was 812 copies/ µL, which continued to decrease 
in relation to each spike down to 0.1% Male gDNA, which expressed a concentration of 
1.22 copies/ µL (Figure 5-9 (C)). In contrast, the Xp22.3 concentration remained close to 
200 copies/ µL for all samples except the 100% and 50% Male gDNA samples, which 
express higher concentrations of the TSPY1 target (Figure 5-9 (C)).    
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Figure ‎5-9: ddPCR results for TSPY1 Spike experiments. A) Bar chart illustrating the 
events (positive droplets) for TSPY1 (FAM) and Xp22.3 (HEX) for NTC, Female gDNA 
(2ng/ µL), Male gDNA and Female gDNA spiked with a decreasing proportion of Male 
gDNA (50% down to 1%). B) 1D amplitude plot for all samples, which illustrated a 
relatively constant number of droplets for the Xp22.3 (HEX) reference and a decreasing 
number of droplets for the TSPY1 (FAM) target. C) Concentration (copies/ µL) of each 
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sample for Ch1 (TSPY1 (FAM)) and Ch2 (Xp22.3 (HEX)). The result illustrated that the 
concentration of the Xp22.3 reference increased and the concentration of the TSPY1 
target decreased as the proportion of Male gDNA declined.  
5.2.3 Determination of RHD zygosity for non-maternal samples   
Multiplex reactions 3 and 4 (Figure 5-1) were designed to determine the presence of RHD 
in a number of samples. Before zygosity testing, to determine ratio analysis of both 
multiplex reactions on the ddPCR platform, a D-negative sample (831G (rr)) and three 
samples thought to be homozygous (R1R1) D-positive (464E, 9393, 694Y and 778B) were 
tested. Male gDNA was used as a positive control (since previous experiments optimised 
using this sample) alongside a NTC. The results for the RHD5 (FAM) / EIF2C1 (HEX) 
multiplex reaction are illustrated in Figure 5-10 and the results for the RHD7 (FAM) / 
EIF2C1 (HEX) multiplex reaction are illustrated in Figure 5-11. Both experiments exhibit 
no amplification for the NTC. Multiplex reaction 3 (RHD5/ EIF2C1) and multiplex 
reaction 4 (RHD7/ EIF2C1) expressed ratios of 0.69 and 0.70, respectively, for the Male 
gDNA sample. Since the Male gDNA positive control sample (Promega) is produced 
from multiple donors, some of which are likely to be D-negative, but all of which will 
express two copies of the EIF2C1 reference gene, a ratio of less than 1 was expected. 
However, the individual samples, which were, homozygous for RHD all illustrated a ratio 
close to 1 (See Figure 5-10 C and Figure 5-11 C). Sample 831G, which was homozygous 
D-negative, only illustrated amplification of the reference gene (EIF2C1). The 
concentration of each target for both multiplex reactions and ratio produced are 
summarised in Table 5-2.  
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Figure ‎5-10: ddPCR data for RHD5 (FAM)/ EIF2C1 (HEX) multiplex reaction for 
control samples (NTC, Male gDNA and Female gDNA) and four unknown DNA 
samples extracted from plasma of human whole blood (refer to 2.1.2). A) 1D 
amplitude plot for RHD5 (FAM) target, B) 1D amplitude plot for EIF2C1 (HEX) 
reference and C) Bar chart illustrating the number of RHD5 (FAM) and EIF2C1 (HEX) 
positive droplets (events) for all samples. The results illustrated that sample 831G was 
RHD negative, since no RHD5 target was amplified and the remaining samples (464E, 
9393, 649Y and 778B) were all RHD positive, since the RHD5 target is expressed. The 
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results also illustrate that that 464E, 9393, 649Y and 778B are all homozygous for the 
RHD gene since ratios (RHD5/ EIF2C1) close to 1 were recorded for all samples (1.03, 
0.99, 0.97 and 0.99, respectively). The ratio and concentration of each target for all 
samples is recorded in Table 5-2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎5-11: ddPCR data for RHD7 (FAM)/ EIF2C1 (HEX) multiplex reaction for 
control samples (NTC, Male gDNA and Female gDNA) and four unknown DNA 
samples extracted from plasma of human whole blood (refer to 2.1.2). A) 1D 
amplitude plot for RHD7 (FAM) target, B) 1D amplitude plot for EIF2C1 (HEX) 
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reference and C) Bar chart illustrating the number of RHD5 (FAM) and EIF2C1 (HEX) 
positive droplets (events) for all samples. The results illustrated that sample 831G is RHD 
negative, since no RHD7 target is amplified and the remaining samples (464E, 9393, 
649Y and 778B) are all RHD positive, since the RHD7 target is detected. The results also 
illustrate that samples 464E, 9393, 649Y and 778B are all homozygous for the RHD gene 
since ratios close to 1 were recorded for all samples (1.01, 1.01, 1.01 and 1.04, 
respectively) N/A well loaded incorrectly.  
Table ‎5-2: The concentration of each target and the ratio generated for each 
multiplex reaction; RHD5 (FAM)/ EIF2C1 (HEX) and RHD7 (FAM)/ EIF2C1 
(HEX). Summary of data shown in Figure 5-9 and Figure 5-10.  
Sample  
RHD5 
(copies/ µL) 
EIF2C1 
(copies/ µL) 
Ratio 
(RHD5/ 
EIF2C1) 
RHD7 
(copies/ µL) 
EIF2C1 
(copies/ µL) 
Ratio 
(RHD5/ 
EIF2C1)  
NTC  0 0 0 0 0 0 
Male 
gDNA  98.2 144 0.69 95.2 138 0.70 
831G 0 777 0 0 732 0 
464E 274 264 1.04 274 271 1.01 
9393 242 246 0.99 243 240 1.01 
649Y 216 224 0.97 231 229 1.01 
778B 297 299 0.99 306 293 1.04 
 
For zygosity testing experiments DNA was extracted from both the buffy coat (carried 
out by Amr Halawani) and the plasma fraction of separate batches of human whole blood 
samples (refer to 2.1.2). Samples extracted from buffy coat were quantified using the 
NanoVue™ Plus Spectrophotometer (GE Healthcare) (refer to 2.6.1) and diluted to 10ng/ 
µL. Some of the samples extracted from the plasma were quantified using the Qubit (refer 
to 2.6.2) and due to lower yields of DNA concentrations (Table 5-3) none of the plasma-
extracted samples were diluted. Subsequently, samples were run on the ddPCR platform 
as described in section 2.9.  
251 
 
Table ‎5-3: Concentration of DNA extracted from the plasma of human whole blood.  
Sample Presumed RHD genotype 
determined by serological 
analysis
1 
Concentration 
(ng/ µL) 
065S R1r 7.82 
118Z R1r 6.58 
1226 R1r 10.3 
1306 R1r 3.35 
0670 R1R1 3.53 
1347 R1R1 2.72 
138R R1R1 6.24 
9673 R0r 2.54 
069F R0r 6.73 
740B R0r 5.26 
1
Determined by NHS BT (Filton).  
The presence or absence of the RHD genes was used to determine whether the sample 
was RHD positive or RHD negative, respectively. The ratio of RHD5/ EIF2C1 and 
RHD7/ EIF2C1 was used to determine whether the samples were hemizygous or 
homozygous for the RHD gene. Samples homozygous for RHD would have expressed 
ratios close to one, since they have two copies of RHD5 and RHD7 and two copies of 
EIF2C1. Samples hemizygous for the RHD gene would express ratios closer to 0.5, since 
they only express one copy of RHD5 and RHD7 and two copies of EIF2C1. Twenty 
plasma-samples (refer to 2.1.2.1) were tested all with known serologically determined RH 
status (as given by NHS BT (Filton)) and the ddPCR zygosity testing results are 
illustrated in Figure 5-12 (A). Three rr presumed genotypes were tested (147J, 1660, 
7807) and results show no amplification of either D-specific target (Figure 5-12 (A). 
Three R0r and seven R1r presumed genotypes were also tested and all samples, except 
sample 1777, expressed a ratio close to 0.5 (Figure 5-12 (A) and Figure 5-13) (Table 5-4). 
Sample 1777, which was previously classified as being R1r, expressed ratios of 0.97 and 
1.04 for multiplex reactions 3 and 4, respectively. This result contradicted previous 
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classification and indicated that the sample expressed two copies of the RHD gene. 
Therefore, it is possible that this sample may actual carry the R1R0 genotype.   
DNA extracted from twenty buffy coat samples were also tested (refer to 2.1.2.2), but in 
this instance only 9 were analysed with known Rh haplotypes and 11 were tested blind. 
Of the nine known samples the following Rh haplotypes were tested; two R1R1, three 
R2R2 and three R1r (Figure 5-12 (B)). The R1R1 samples and the R1r samples expressed 
ratios close to 1 and 0.5, respectively (Figure 5-12 (B) and Figure 5-13) (Table 5-4). Two 
of the R2R2 samples expressed a ratio close to one, but sample 729M (R1R2, weak D) 
illustrated a ratio of 0.49 and 0.5 for the RHD5/ EIF2C1 and RHD7/ EIF2C1 multiplex 
reactions, respectively (Figure 5-12 (A) and Figure 5-13) (Table 5-4). This indicated that 
sample 729M only expresses one copy of the RHD gene, and could also have been 
previously misclassified as R1R2 and actually express the R1r’’ (DCe/dcE) or R2r’ 
(DcE/dCe) genotype.  
The amplification and ratio analysis of all unknown targets are illustrated in Figure 5-12 
(B) and Table 5-4. Seven of these samples expressed ratios close to 1 for both multiplex 
reactions (Figure 5-13) (Table 5-4). Four of these samples were confirmed to express the 
R1R1 haplotype (078U, 103N, 1461 and 877L), two were confirmed to express the R2R2 
haplotype (132H and 689Y) and one was confirmed to express the R2RZ haplotype (746P) 
(Figure 5-13) (Table 5-4). The remaining four samples (3093, 572R, 7687 and 087W) all 
expressed ratios closer to 0.5 for both multiplex reactions (Figure 5-13) (Table 5-4). 
Three of these samples were confirmed to express the R1r haplotype (3093, 572R and 
7687), but sample 087W had been previously classified as having an R2R2 haplotype. The 
ddPCR results demonstrate that sample 087W is actually hemizygous for the D-antigen 
and is likely to exhibit the R2r’’ Rh haplotype as opposed to the R2R2 haplotype initially 
stated.  
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Figure ‎5-12: Bar chart demonstrating the mean concentration (copies/ µL) and SD 
for RHD5 (FAM), RHD7 (FAM) and EIF2C1 (HEX) for DNA samples extracted 
from the plasma (A) and buffy coat (B) of human whole blood (2.1.2 and 2.1.3). The 
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RHD status of each sample was determined by the presence of RHD5 (FAM) and RHD7 
(FAM) in multiplex reaction 3 (RHD (FAM) / EIF2C1 (HEX)) and multiplex reaction 4 
(RHD7 (FAM) / EIF2C1 (HEX)), respectively. Positive samples that illustrated a ratio 
close to 1 for both multiplex reactions were classified as homozygous for the RHD gene 
and samples that expressed a ratio closer to 0.5 were classified as being hemizygous for 
the RHD gene. These results are summarised in Table 5-4. Samples 1777, 729M and 
087W all show disparity with NHS BT (Filton) presumed genotype (red). Sample 1777 
(R1r) showed an equal amount of both RHD targets against the reference (EIF2C1), which 
indicated that this case was RHD homozygous. Alternatively, samples 729M (R1R2) and 
087W (R2R2) showed half the concentration of both RHD targets compared to the 
reference (EIF2C1), which demonstrated that these samples were hemizygous for RHD 
(refer to table 5-4 for ratio analysis of each RHD target (FAM/HEX).  
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Table ‎5-4: Zygosity testing results for multiple samples extracted from both the 
plasma and buffy coat of human whole blood samples. The RHD ratios (RHD5 and 
RHD7) for each sample was calculated by dividing the RHD (FAM) concentration 
(copies/ µL) by the reference (HEX) concentration (copies/ µL). Sample zygosity 
(homozygous RHD positive, hemizygous RHD positive or homozygous RHD negative) 
was determined by the detecting whether the  RHD targets displayed equal representation 
(ratio ~1), 50% representation (ratio ~0.5) or 0% representation (ratio 0) compared to the 
reference (EIF2C1), respectively.  These results were compared against the presumed 
genotype determined by NHS BT (Filton) and for three cases (red) the RHD genotype 
was altered.  
Sample 
Ratio 
(RHD5 (FAM) 
/ EIF2C1 
(HEX)) 
Ratio 
(RHD7 (FAM) 
/ EIF2C1 
(HEX)) 
ddPCR defined 
genotype 
(Hemizygous or 
homozygous)
 
Presumed 
RH genotype 
determined 
by serological 
analysis 
Altered 
genotype 
based on 
ddPCR 
data 
147J
1 
0 0 
Homozygous RHD 
negative 
rr n/a 
1660
1 
0 0 
Homozygous RHD 
negative 
rr n/a 
7807
1 
0 0 
Homozygous RHD 
negative 
rr n/a 
9763
1 
0.45 0.43 Hemizygous R0r n/a 
069F
1 
0.5 0.49 Hemizygous R0r n/a 
740B
1 
0.47 0.46 Hemizygous R0r n/a 
065S
1 
0.49 0.49 Hemizygous R1r n/a 
118Z
1 
0.5 0.49 Hemizygous R1r n/a 
1226
1 
0.52 0.51 Hemizygous R1r n/a 
1306
1 
0.51 0.53 Hemizygous R1r n/a 
1777
1 
0.97 1.04 
Homozygous RHD 
positive 
R1r R1R0 
180H
1 
0.52 0.52 Hemizygous R1r n/a 
181F
1 
0.52 0.49 Hemizygous R1r n/a 
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1220
1 
0.98 1.01 
Homozygous RHD 
positive 
R1R1 n/a 
131Z
1 
0.99 1.04 
Homozygous RHD 
positive 
R1R1 n/a 
165F
1 
0.94 0.9 
Homozygous RHD 
positive 
R1R1 n/a 
1793
1 
0.99 1 
Homozygous RHD 
positive 
R1R1 n/a 
0670
1 
0.91 0.85 
Homozygous RHD 
positive 
R1R1 n/a 
1347
1 
0.99 1.03 
Homozygous RHD 
positive 
R1R1 n/a 
138R
1 
0.95 0.98 
Homozygous RHD 
positive 
R1R1 n/a 
052M
2 
0.99 1.03 
Homozygous RHD 
positive 
R1R1 n/a 
247X
2 
1.02 1 
Homozygous RHD 
positive 
R1R1 n/a 
658G
2 
1.02 1.03 
Homozygous RHD 
positive 
R2R2 n/a 
738W
2 
1.02 1.04 
Homozygous RHD 
positive 
R2R2 n/a 
729M 
2,3 
0.5 0.49 Hemizygous R1R2 R1r’’ or R2r’ 
5481 
2,3 
0.5 0.51 Hemizygous R2r n/a 
148R 
2,3 
0.5 0.5 Hemizygous R1r n/a 
6418 
2,3 
0.51 0.49 Hemizygous R1r n/a 
3093
2,4 
0.51 0.51 Hemizygous R1r n/a 
078U 
2,4 
0.99 1.01 
Homozygous RHD 
positive 
R1R1 n/a 
103N 
2,4 
1 1.03 
Homozygous RHD 
positive 
R1R1 n/a 
1461
2,4 
0.99 1.01 
Homozygous RHD 
positive 
R1R1 n/a 
877L
2,4 
1.01 0.98 
Homozygous RHD 
positive 
R1R1 n/a 
087W 
2,4 
0.51 0.49 Hemizygous R2R2 R2r’’ 
132H 
2,4 
1 1.03 
Homozygous RHD 
positive 
R2R2 n/a 
689M 
2,4 
0.99 1 
Homozygous RHD 
positive 
R2R2 n/a 
572R 
2,3,4 
0.5 0.5 Hemizygous R1r n/a 
7687 
2, 3,4 
0.5 0.51 Hemizygous R1r n/a 
746P
 2,4 
1.02 0.99 
Homozygous RHD 
positive 
R2Rz n/a 
1 
DNA extracted from either plasma of human whole blood samples (refer to 2.1.2).  
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2
 DNA extracted from buffy coat of human whole blood samples (refer to 2.1.2). 
3
 Sample is Weak D.  
4
 Sample was tested blind.  
 
Sample (presumed genotype by NHSBT Filton)
1
4
7
J 
(r
r)
1
6
6
0
 (
rr
)
7
8
0
7
 (
rr
)
9
7
6
3
 (
R
o
r)
0
6
9
F
 (
R
o
r)
7
4
0
B
 (
R
o
r)
0
6
5
S
 (
R
1
r)
1
1
8
Z
 (
R
1
r)
1
2
2
6
 (
R
1
r)
1
3
0
6
 (
R
1
r)
1
7
7
7
 (
R
1
r)
1
8
0
H
 (
R
1
r)
1
8
1
F
 (
R
1
r)
1
2
2
0
 (
R
1
R
1
)
1
3
1
Z
 (
R
1
R
1
)
1
6
5
F
 (
R
1
R
1
)
1
7
9
3
 (
R
1
R
1
)
0
6
7
0
 (
R
1
R
1
)
1
3
4
7
 (
R
1
R
1
)
1
3
8
R
 (
R
1
R
1
)
0
5
2
M
 (
R
1
R
1
)
2
4
7
X
 (
R
1
R
1
)
6
5
8
G
 (
R
2
R
2
)
7
3
8
W
 (
R
2
R
2
)
7
2
9
M
 (
R
1
R
2
)
5
4
8
1
 (
R
2
r)
1
4
8
R
 (
R
1
r)
6
4
1
8
 (
R
1
r)
3
0
9
3
 (
R
1
r)
0
7
8
U
 (
R
1
R
1
)
1
0
3
N
 (
R
1
R
1
)
1
4
6
1
 (
R
1
R
1
)
8
7
7
L
 (
R
1
R
1
)
 0
8
7
W
 (
R
2
R
2
)
1
3
2
H
 (
R
2
R
2
)
6
8
9
U
 (
R
2
R
2
)
5
7
2
R
 (
R
1
r)
7
6
8
7
 (
R
1
r)
7
4
6
P
 (
R
2
R
z)
R
a
ti
o
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
RHD5 ratio
RHD7 ratio
 
Figure ‎5-13: Bar chart illustrated ratio analysis generated by ddPCR to determine 
RHD zygosity using multiplex reaction 3 (RHD5 (FAM / EIF2C1 (HEX)) (grey) and 
multiplex reaction 4 (RHD7 (FAM) / EIF2C1 (HEX)) (black). DNA samples extracted 
from plasma (right) and buffy coat (left) of whole human blood samples with varying 
rhesus status were tested. The data illustrates three significant data sets, hemizygous RHD 
negative (D+/ D+, dashed line at ratio 1), hemizygous RHD positive (D+/ D-, dashed line 
at ratio 0.5) and homozygous RHD positive (D-/ D-, at ratio 0) (p<0.001). Three samples 
illustrated discordant results (shown in red). For sample 1777 (a) the presumed genotype 
was R1r (DCe/dce), but the ddPCR data illustrated that this sample was homozygous for 
D, and is therefore more likely to have the R1R0 (DCe/Dce) genotype. The presumed 
genotype for sample 729M (b) was R1R2 (DCe/DcE). However, ddPCR showed that this 
a 
 b c 
                   Plasma extracted DNA (refer to 2.1.2.1)             Buffy coat extracted DNA (refer to 2.1.2.2) 
D+/ 
D+ 
 
D+/ 
D- 
D-/ 
D- 
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sample is hemizygous for RHD, and thus will display either the R1r’’ (DCe/dcE) or R2r’ 
genotype (DcE/dCe). Finally sample 087W (c), presumed to express the R2R2 (DcE/DcE) 
genotype, illustrated hemizgous inheritance of RHD, which indicates that this sample 
actually expresses the R2r’’ (DcE/dcE).  
5.2.4 Testing sensitivity of ddPCR and qPCR for fetal sex determination and RHD 
genotyping in samples expressing optimal and suboptimal cffDNA fractions  
DNA was extracted from 2ml of maternal plasma from peripheral blood samples 
collected in both EDTA tubes (n= 22) and Streck BCTs (n= 24) (refer to 2.1.5). 
Consequently, four multiplex reactions were tested to determine fetal sex (multiplex 
reaction 1 and 2) and fetal RHD genotype (multiplex reaction 3 and 4) (Figure 5-14). The 
multiplex reactions used are the same as described previously (Figure 5-1); however, due 
to repeated amplification of SRY
 (H.P.T) 
 in female samples for initial optimisation 
experiments (data not shown), the primers for the single copy SRY target was changed 
and in this experiment; SRY oligonucleotides were taken from Lo et al. (1997) (Figure 5-
14). All samples were then tested (in duplicated) on the qPCR platform and the ddPCR 
platform on the same day (refer to 2.7 and 2.9, respectively).  
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Figure ‎5-14: Experimental overview of fetal sex determination and fetal RHD 
genotyping for maternal samples collected in both EDTA tubes (n=22) and Streck 
BCTs (n=24). Four multiplex reactions were used to determine fetal sex (multiplex 
reaction 1 and 2) and fetal RHD genotype (multiplex reaction 3 and 4). All four reactions 
were tested on the ddPCR and qPCR platform to compare sensitivity for samples with 
optimal cffDNA fractions (≥3%) (Streck BCTs) and suboptimal cffDNA fractions (<3%) 
(EDTA tubes).  
For ddPCR in 100% of cases the fetal sex predicted by the presence of Y-specific targets 
was the same as determined by physical examination at birth. Both the single target gene 
(SRY) and the multiple-copy target gene (TSPY1) were correctly identified in all male 
fetuses and absent in all female cases for all samples (EDTA and Streck BCTs) (Table 5-
5). Because SRY was not detected for any samples (except male positive control) on the 
Maternal blood samples from RHD negative mothers were tested for fetal sex and RHD-
genotype (n=46). 
EDTA tube collection (n=22).  Streck BCT collection (n=24).  
Samples were tested for fetal sex and RHD status on the ddPCR and qPCR platforms on the 
same day.    
a) Fetal Sexing  
Reference:  Xp22.3‎(chromosome X) 
(Designed using Primer 3/ Oligo analyser 
Software) 
1.‎Target:‎
SRY‎(chrY) 
 
(Taken from 
Lo et al. 
(1997; 
2.‎Target:‎
TSPY1‎(chrY) 
(Designed 
using Primer 3/ 
Oligo Analyser 
Software) 30x 
b) Fetal RHD genotyping 
Reference:  EIF2C1‎(chromosome‎1) 
(Taken from Fan et al. (2009) 
3.‎Target:‎
RHD5‎(chr1) 
 
(Taken from 
Finning et al. 
(2008, ) 
4.‎Target:‎
RHD7 (chr1) 
 
(Taken from 
Finning et al. 
(2008, ) 
Multiplex 
Reaction 1 
Multiplex 
Reaction 2 
Multiplex 
Reaction 3 
Multiplex 
Reaction 4 
1. Target: SRY 
(chrY) 
 
(Taken from Lo 
et al. (1997) 
Single copy 
target 
2. Target: TSPY1 
(chrY) 
(Designed using 
Primer 3/ Oligo 
Analyser Software)
30x Multiple copy 
target  
3. Target: RHD5 
(chr1) 
(Taken from 
Finning et al. 
(2008) 
Single copy 
target 
4. Target: RHD7 
(chr1) 
(Taken from 
Finning et al. 
(2008) 
Single copy 
target 
H
E
X
 
F
A
M
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qPCR platform, fetal sex was ascertained by the presence TSPY1 only (Table 2). The 
results also illustrated 100% accuracy (Table 5-5) in this instance when only the multiple-
copy target gene was considered. Since, the samples collected in Streck BCTs expressed 
higher cffDNA fractions (4-24%), whereas the samples collected in EDTA tubes 
illustrated lower cffDNA fractions (0.1%-2%) each sub-set of samples were classified as 
optimal and suboptimal, respectively.  
Fetal RHD genotyping on the qPCR platform demonstrated accuracies of 100% and 83% 
for the RHD7 and RHD5 target assays, respectively when testing optimal (Streck BCT) 
samples. Four samples (16.6%) were classified as inconclusive since qPCR did not detect 
the RHD5 target but did show acceptable amplification (<45 Ct) of the RHD7 target 
(Table 5-6). The qPCR platform was unable to detect both RHD-specific markers (RHD7 
and RHD5) in the suboptimal samples (<2% cffDNA) despite serological and ddPCR 
analysis confirming that 59% (13/22) of these EDTA-collected samples were carrying an 
RHD-positive fetus. Figure 5-15 illustrates the mean Ct value and upper and lower 
interquartile ranges (IQR) for all targets (SRY, TSYP1, RHD5 and RHD7) generated by 
qPCR for maternal samples collected in EDTA tubes (A) and Streck BCTs (B).  
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Table ‎5-5: Fetal sexing and RHD genotyping results obtained from both ddPCR and qPCR against results recorded following delivery. 
 
Gestation 
weeks 
EDTA/ 
Streck 
gDNA 
(ng/µl) 
qPCR fetal 
sexing results a  
ddPCR fetal sexing 
results Fetal Sex 
at Birth b 
qPCR Fetal RHD 
Genotyping  
ddPCR Fetal RHD 
Genotyping 
Fetal 
RHD 
Statusc TSPY1 Sex
 
SRY TSPY1 Sex
 
RHD5 RHD7 
RHD 
Status 
RHD5 RHD7 
RHD 
Status 
+ve control N/A EDTA 2.0 POS M POS POS M N/A POS POS POS POS POS POS N/A 
-ve control N/A EDTA 2.0 NEG F NEG NEG F N/A NEG NEG NEG NEG NEG NEG N/A 
NTC N/A N/A N/A NEG - NEG NEG N N/A NEG NEG NEG NEG NEG NEG N/A 
                 
1 30+0 EDTA 7.91 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
2 29+0 EDTA 14.76 NEG F NEG NEG F F 
NEG NEG NEG  NEG NEG NEG NEG 
3 29+2 EDTA 9.72 POS M POS POS M M 
NEG NEG NEG  NEG NEG NEG NEG 
4 27+6 EDTA 7.15 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
5 28+2 EDTA 12.01 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
6 28+0 EDTA 6.72 POS M POS POS M M 
NEG NEG NEG  NEG NEG NEG NEG 
7 29 EDTA 27.11 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
8 28 EDTA 6.61 POS M POS POS M M 
NEG NEG NEG  NEG NEG NEG NEG 
9 28+1 EDTA 12.03 POS M POS POS M M 
NEG NEG NEG  NEG NEG NEG NEG 
10 28+3 EDTA 6.97 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
11 27+6 EDTA 9.36 NEG F NEG NEG F F 
NEG NEG NEG  NEG NEG NEG NEG 
12 28+1 EDTA 9.03 NEG F NEG NEG F F 
NEG NEG NEG  NEG POS INC NEG 
13 28+0 EDTA 10.22 POS M POS POS M M 
NEG NEG NEG  NEG NEG NEG NEG 
14 28+0 EDTA 12.25 NEG F NEG NEG F F 
NEG NEG NEG NEG NEG NEG NEG 
15 28+5 EDTA 16.88 POS M POS POS M M 
NEG NEG NEG  POS POS POS POS 
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16 28+1 EDTA 13.01 POS M POS POS M M 
NEG NEG NEG  POS POS POS POS 
17 28+5 EDTA 15.72 POS M POS POS M M 
NEG NEG NEG  POS POS POS POS 
18 28+0 EDTA 19.09 POS M POS POS M M 
NEG NEG NEG  POS POS POS POS 
19 28 EDTA 11.51 POS M POS POS M M 
NEG NEG NEG  POS POS POS POS 
20 28+5 EDTA 11.87 NEG F NEG NEG F F 
NEG NEG NEG  NEG NEG NEG NEG 
21 28+0 EDTA 15.02 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
22 28+5 EDTA 20.59 NEG F NEG NEG F F 
NEG NEG NEG  POS POS POS POS 
                
            
23 30+3 Streck 0.74 NEG F NEG NEG F F 
POS POS POS POS POS POS POS 
24 28+3 Streck 0.798 POS M POS POS M M 
NEG NEG NEG  NEG NEG NEG NEG 
25 27+5 Streck  0.524 POS M POS POS M M 
POS POS POS POS POS POS POS 
26 28+2 Streck  0.68 POS M POS POS M M  
POS POS POS POS POS POS POS 
27 28+2 Streck  0.552 POS M POS POS M  M 
NEG NEG NEG  NEG NEG NEG NEG 
28 28+2 Streck  0.607 NEG F NEG NEG F F 
NEG POS INC POS POS POS POS 
29 28+4 Streck  0.729 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
30 28+2 Streck  0.605 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
31 27+5 Streck  0.666 POS M POS POS M  M 
POS POS POS POS POS POS POS 
32 38+1 Streck 0.643 POS M POS POS M M 
POS POS POS POS POS POS POS 
33 29+2 Streck 0.656 POS M POS POS M  M  
NEG POS INC POS POS POS POS 
34 29+2 Streck 0.515 NEG F NEG NEG F  F 
NEG POS INC POS POS POS POS 
35 28+2 Streck  0.664 POS M POS POS M  M 
POS POS POS POS POS POS POS 
36 29+0 Streck  0.622 POS M POS POS M  M 
NEG POS INC POS POS POS POS 
37 28+1 Streck  0.573 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
38 28+2 Streck  0.521 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
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Legend: M, male; F, female; POS, positive; NED, negative. 
 
39 28+1 Streck  0.506 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
40 28+6 Streck  0.465 POS M POS POS M  M  
NEG NEG NEG  NEG NEG NEG NEG 
41 28+4 Streck  0.405 POS M POS POS M  M  
NEG NEG NEG  NEG NEG NEG NEG 
42 28 Streck 0.657 NEG F NEG NEG F  F 
NEG NEG NEG  NEG NEG NEG NEG 
43 27+5 Streck  0.707 POS M POS POS M  M  
POS POS POS POS POS POS POS 
44 28+4 Streck  0.444 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
45 28+5 Streck  0.401 POS M POS POS M  M 
POS POS POS POS POS POS POS 
46 28+6 Streck 0.558 NEG F NEG NEG F  F 
POS POS POS POS POS POS POS 
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Table ‎5-6: Sensitivity, specificity and accuracy results of maternal samples collected in 
EDTA tubes and Streck BCTs on both ddPCR and qPCR platforms for fetal sex and 
RHD genotyping.  
 
 
 
 
Platform  
Blood 
Collection 
Tube  
cffDNA (%) 
in maternal 
plasma a 
Target  Sensitivity 
False 
Negative 
Results  
Specificity 
False 
Positive 
Results  
Accuracy 
(%) b  
ddPCR 
Streck 
BCTs 
4 - 24% 
TSPY1 100% - 100% - 100% 
SRY 100% - 100% - 100% 
RHD5 100% - 100% - 100% 
RHD7 100% - 100% - 100% 
EDTA 
Tubes  
0.1 – 2% 
TSPY1 100% - 100% - 100% 
SRY 100% - 100% - 100% 
RHD5 100% - 95.5% 
4.5%  
(1/22) 
95.6% 
RHD7 100% - 95.5% 
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qPCR  
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RHD5 83.4% 
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100% - 83.4% 
RHD7 100% - 100% - 100% 
EDTA 
Tubes 
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SRY 0% 
45.5% 
(10/22) 
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RHD5 0% 
59.1% 
(13/22) 
100% - 40.9% 
RHD7 0% 
59.1% 
(13/22) 
100% - 40.9% 
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Figure ‎5-15: Box Plot of raw Ct values obtained from qPCR analysis showing SRY, 
TSPY1 (multiple copy target), RHD5 and RHD7 targets for A) samples collected in 
EDTA tubes and B) samples collected in Streck BCTs. The horizontal line central to each 
box represents the median of; 10 samples for TSPY1 (EDTA), 13 samples for TSPY1 (Streck 
BCTs) and 18 samples for RHD5 and RHD7 (Streck BCTs). The limits of each box denotes 
the 25
th
 and 75
th
 percentiles. The whiskers signify the 5
th
 and 95
th
 percentiles and the circles 
mark the outliers. Note: Four samples (28, 33, 34, 36) collected in Streck BCTs expressed Ct 
values above the upper baseline threshold (45 Ct) for target RHD5 and were therefore 
determined as negative. 
Figure 5-16 illustrates droplet separation for male fetuses (maternal samples 18 and 27), 
female fetuses (maternal samples 20 and 30), RHD positive fetuses (maternal samples 15 and 
32) and RHD negative fetuses (maternal samples 11 and 27) for samples collected in both 
EDTA tubes and Streck BCTs, respectively. Samples were classified as positive depending 
on the presence of each FAM-labelled target (Figure 5-14). The fetal RHD genotype was 
correctly identified in 100% (24/24) and 95.5% (21/22) of cases by ddPCR for samples 
collected in Streck BCTs and EDTA tubes, respectively (Table 5-5 and Table 5-6). One 
EDTA-collected sample (sample 12) produced a false positive result, since serological 
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analysis revealed the fetus to be RHD-negative but ddPCR showed clear amplification of the 
RHD7 target (18 droplets) and minimal amplification of the RHD5 target (3 droplets) (Figure 
5-16).The concentration (copies/ µL) obtained from both target genes (RHD5 and RHD7) and 
the reference gene (EIF2C1) for control samples (NTC, RHD+ control, RHD- control) and 
2b), EDTA-collected samples  and Streck BCTs-collected samples  are illustrated in Figure 5-
17 (A) and 5-17 (B), respectively. The results show successful amplification of all three 
targets for the RHD positive control sample and only show amplification of the reference 
EIF2C1 gene for the RHD-negative control sample, whereas the NTC sample showed no 
amplification (Figure 5-17). In addition to the false positive result (1/46 (2%)), 31 samples 
were correctly classified as RHD-positive (67%) and 14 samples were correctly classified as 
RHD-negative (31%) (Figure 5-17).  
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Figure ‎5-16: ddPCR 2D amplitude plots for fetal sex determination (A) and RHD 
genotype (B) for samples collected in Streck BCTs (left) and EDTA tubes (right). A) 
Fetal sex determination for control positive male sample, male and female fetus. Plots 1 to 6 
shows the 2D amplification plot for SRY-FAM against Xp22.3-HEX and plots 7 to 12 shows 
the 2D amplification plot for TSPY1-FAM against Xp22.3-HEX. Plots 3 and 9 represent 
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maternal sample 27 and plots 4 and 10 represent maternal sample 18 for Streck BCT and 
EDTA collected samples, respectively. The results for these plots (3, 9, 4, and 10) illustrate 
male fetuses since there is amplification of both the Y-specific (FAM) targets alongside the 
reference (Xp22.3-HEX) target. Plots 5 and 11 represent maternal sample 30 and plots 6 and 
12 represent maternal sample 20 for Streck BCT and EDTA collected samples, respectively. 
These results illustrate female fetuses since only the reference (Xp22.3-HEX) is successfully 
amplified. B) Fetal RHD genotyping for control RHD-positive sample, RHD positive fetuses 
and RHD negative fetuses. Plots 1 to 6 shows the 2D amplification plot for RHD5-FAM 
against EIF2C1-HEX and plots 7 to 12 shows the 2D amplification plot for RHD7-FAM 
against EIF2C1-HEX. Plots 3 and 9 represent maternal sample 32 and plots 4 and 10 
represent maternal sample 15 for Streck BCT and EDTA collected samples, respectively. The 
results for these plots (3, 9, 4, and 10) illustrate RHD-positive fetuses since there is 
amplification of both the RHD-specific (FAM) targets alongside the reference (EIF2C1-
HEX) target. Plots 5 and 11 represent maternal sample 27 and plots 6 and 12 represent 
maternal sample 11 for Streck BCT and EDTA collected samples, respectively. These results 
illustrate RHD-negative fetuses since only the reference (EIF2C1-HEX) is successfully 
amplified. Clusters did not show any outlying results were observed for any samples. 
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Figure ‎5-17: ddPCR results showing concentration (copies/ µL) of RHD5, RHD7 and 
EHF2C1 to determine the fetal RHD genotyping from 46 maternal plasma samples. The 
concentration (copies/ul) (+SD) was identified for both target regions (RHD5 and RHD7) and 
the reference region (EIF2C1) for multiplex reactions 3 and 4 (Figure 5-14). The presence or 
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absence of the target regions were used to determine fetal status (RHD+ or RHD-, 
respectively). a) Maternal Samples collected in EDTA tubes (n = 22). b) Maternal samples 
collected in Streck BCTs (n = 24). The same controls were represented in both graphs. The 
control non-maternal cfDNA RHD positive sample (399X) exhibit a ratio of 0.51 and 0.47 for 
RHD5/ EIF2C1 and RHD7/EIF2C1, respectively. 
The cffDNA fraction using both Y-specific and RHD-specific targets was calculated based on 
the concentration (copies/ µL) generated by ddPCR for each multiplex reaction. According to 
Poisson distribution, the original number of molecules derived from each chromosome can be 
calculated using the following equation:  
Number of Molecules = - In [(N – n)/N] × N 
Where N is the total number of wells counted and n is the number of target or reference 
positive wells.  
The fractions of positive counts were fitted to a Poisson algorithm automatically by the 
software (Bio-Rad QuantaSoft v1.2) to determine the absolute concentration (presented as 
copies per µL).Once the concentration had been determined for all target and reference 
regions, the cffDNA fraction within the maternal plasma (%) was calculated. For single-copy 
targets (SRY, RHD5 and RHD7) the following equation was used:  
2 x Target-FAM (copies/ µL) 
 Total copies/ µL*  
  
x 100  
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The multiple copy target cffDNA calculations were based on the assumption that there are 30 
copies of DYS14 (on the TSPY1 gene) in the genome (Barrett et al., 2012).  
 2 x (Target-FAM (copies/µl) / 30)  
Total copies/ µL* 
*Target-FAM (copies/µl) + Reference-HEX (copies/µl). 
The cffDNA fractions (%) and concentration of reference targets for blood collection 
methods using EDTA tubes and Streck BCTs were compared using ddPCR results. Figure 5-
`8 (A) shows the average cffDNA fraction (%) in maternal plasma for all four target regions 
(SRY, TSPY1, RHD5 and RHD7) for both collection methods. The Streck BCT-collected 
samples show significantly higher cffDNA fraction means (9-16%) for all target regions 
compared to EDTA collected samples (0.5-1%) (p<0.001). The mean cffDNA fractions 
generated by the EDTA-collected samples shows no significant difference between all four 
targets (p>1). However, the cffDNA fraction calculated based on the SRY-target is 
significantly lower than the TSPY1- and RHD7- cffDNA fractions generated (p<0.01).  
The concentration (copies/µL) of each reference gene, Xp22.3 and EIF2C1 (Figure 5-18 (B)), 
is a combination of maternal and fetal cfDNA, however is predominantly maternal in origin 
(90-95%). Samples collected in Streck BCTs showed similar mean concentrations for the 
Xp22.3 and the EIF2C1 reference genes (16.18 copies/µL and 17.39 copies/µL, respectively 
(p>0.1)) (Figure 2b). The concentrations (copies/ µL) of both reference targets (Xp22.3 and 
EIF2C1) were over 40-fold higher for maternal samples collected in EDTA tubes compared 
to Streck BCTs (mean concentrations 548.04 copies/ µL and 869.25 copies/ µL, 
respectively), suggesting maternal leucocyte degradation (Figure 5-18 (B)). The 2D 
amplification plots (Figure 5-16) also show a significantly higher number of reference (HEX-
labelled) droplets for maternal samples collected in EDTA tubes compared to maternal 
x 100  
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samples collected in Streck BCTs (p<0.001). The fetal concentration determined from the 
RHD5 and RHD7 multiplex reactions showed no significant difference for samples collected 
in EDTA tubes or Streck BCTs (p>0.1), ranging from 0.9 to 4.2 copies/ µL and 0.3 to 3.7 
copies/ µL, respectively (Figure 5-17).  
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Figure ‎5-18: A comparison of 
mean cffDNA fractions (based 
on SRY, TSPY1, RHD5 and 
RHD7 fetal targets) and mean 
concentrations of the reference 
targets (Xp22.3 and EIF2C1) 
for maternal samples collected 
in EDTA tubes and Streck 
BCTs. A) Mean cffDNA fraction 
in maternal plasma calculated by 
each target gene (refer to 2.9.4). 
The Streck BCT collected 
samples show a significantly 
higher mean cffDNA fraction 
compared to samples collected in 
EDTA tubes for all four target 
regions (***, p<0.001). The 
cffDNA fraction based on the RHD7 and TSPY1 target genes are significantly higher than the 
cffDNA fraction determined by the SRY target gene (**, p<0.01).  B) Mean concentration of 
reference gene regions Xp22.3 and EIF2C1 for maternal samples collected in EDTA tubes 
and Streck BCTs. The average concentration of both regions were significantly higher in 
EDTA tube samples than in Streck BCTs (***, p<0.001). There was no significant difference 
between mean concentrations of Xp22.3 and EIF2C1 within each sample collection method. 
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5.3 Discussion  
5.3.1 RH zygosity testing for non-maternal samples  
The Rh blood group system is the most polymorphic of the human blood groups, and second 
to ABO, it is the most clinically significant in transfusion medicine and the primary cause of 
HDNF (Avent and Reid, 2000). The principle antigen of the RH system is the D antigen and 
the majority of D-negative phenotypes, particularly in Caucasian populations, are a result of 
complete deletion of the RHD gene (Westhoff, 2004). The RHCE gene of the Rh blood group 
system encodes for the C, c, E and e antigens, however, patients are not routinely typed for 
these antigens. The determination of whether a patient is homozygous (D/D) or hemizygous 
(D/d) for RHD cannot be determined using serological analysis since the difference in 
reactivity between RBCs with a single or double dose of D-antigen is not reliably detected 
(Hillyer et al., 2008). Table 5-7 illustrates the various Rh nomenclature and incidence of 
common haplotypes in Caucasian, African black and Asians populations. Serological analysis 
will often predict the RH genotype based on the frequency of each haplotype within a specific 
population. Here we have described a rapid approach to determine RHD zygosity using 
ddPCR for the accurate determination of RHD genotype. 
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Table ‎5-7: Rh Nomenclature and incidence of common haplotypes for Caucasian, 
African black and Asian populations. [Adapted from Provan, Newland and Court (2015)]. 
  Incidence (%) 
Fisher-Race 
haplotype 
Modified Wiener 
haplotype 
Caucasian African Black Asian 
RHD positive 
DCe R1 42 17 70 
DcE R2 14 11 21 
Dce R0 4 44 3 
DCE RZ <0.01 <0.01 1 
RHD negative 
ce r 37 26 3 
Ce r’ 2 2 2 
cE r'’ 1 <0.01 <0.01 
CE r
y 
<0.01 <0.01 <0.01 
 
To determine the RHD zygosity, DNA molecular testing by assaying for RHD deletions or 
inactive RHD is required and is currently available in specialised blood bank laboratories. 
Molecular genotyping for transfusion medicine has been available since the mid 1990’s and 
its application enables zygosity to be determined by assaying for the presence of a recessive 
allele (Westhoff, 2006). In a prenatal setting, paternal zygosity testing can be important to 
predict the fetal D status when the mother is given RAADP, since multiple genetic events 
other than complete deletion can result in a D-negative phenotype. These assays must include 
detection of the 37-bp insertion present in RHD pseudogene samples and the D-negative 
RHD-CE-D hybrid gene common in African black populations (Westhoff, 2006). If the father 
is homozygous for RHD then the fetus will be RHD positive and anti-D is required. In cases 
where fathers exhibit heterozygosity of the RHD gene, the fetal RHD status should be 
determined.  
Determination of human RHD gene rhesus box has also been used for determination of 
zygosity. In one study, a PCR- sequence-specific polymorphism (PCR-SSP) approach was 
used to determine the upstream box, downstream box and hybrid box of RHD (Zhou et al., 
2005). The results revealed that only the hybrid box could be determined in homozygous 
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RHD- samples, all the upstream, downstream and hybrid box could be detected in 
hemizygous RHD+ samples and in homozygous RHD+ samples the upstream box and 
downstream box (but not the hybrid box) could be detected. In a more recent study the PCR-
SSP approach was also tested against a qPCR approach specific for RHD exon 5 (Kacem et 
al., 2012). The results illustrated that qPCR was the most convenient method with the highest 
positive and negative predictive values (100% and 98%, respectively). However, it is 
important to note that out of the 370 samples tested, the zygosity of 32 patients remained 
unknown because of a lack of heterozygous SNPs or technical failure (Kacem et al., 2012).  
In addition, as previously stated (refer to 5.1.1), zygosity testing is complicated due to 
differences in the hybrid Rhesus box found in African populations. (Matheson and 
Denomme, 2002; Grootkerk‐Tax et al., 2005). 
The results from the current study show that ddPCR provides a novel method for the 
determination of RHD zygosity, without the need for targeting recessive D-negative alleles. 
By using ratio analysis, the concentration of fetal specific targets can be compared to a 
conserved reference gene (such as EIF2C1) to identify whether the patient expresses one or 
two copies of the RHD gene. The buffy-coat and plasma samples tested were collected from 
the NHS BT (Filton), which provided information on the presumed RH status of each sample 
based upon serological testing. The results illustrated 92.5% concordance with the original 
serological information provided, showing either a ratio of 0, 0.5 or 1 for homozygous RHD 
negative samples, hemizygous RHD positive samples or homozygous RHD positive samples, 
respectively. However, three samples (1777, 729M and 087W) illustrated discrepancies in 
results. Serological and allele frequency analysis determined sample 1777, 729M and 087W 
to be R1r, R1R2 and R2R2, respectively. However, the ddPCR RHD zygosity results revealed 
ratios close to 1 for sample 1777 indicating that this sample is homozygous for the RHD gene 
and therefore is likely to exhibit the R1R0 haplotype (Table5-4). Alternatively, samples 729M 
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and 087W expressed ratios closer to 0.5 indicating RHD hemizygosity (Table 5-4). These 
results indicate that samples 729M and 087W are likely to exhibit R1r’’/ R2r’ and R2r’’ 
genotypes, respectively, rather than serologically predicted genotypes (R1R2 and R2R2, 
respectively). Sample 729M was recorded as being weak D, and therefore it is likely that only 
one haplotype exhibits a mutation encoding an amino acid change (Westhoff, 2007), 
indicating incorrect serological classification for this sample. Position effects can alter anti-D 
expression, for instance the amount of D-antigen in the membrane is reduced when a Ce 
allele is found in trans to RHD (Westhoff, 2007). Samples that exhibit this phenomenon 
either have R1r’ (DCe/dCe), R0r’ (Dce/dCe) or R2r’ (DcE/dCe). Sample 729M was mistyped 
serologically as R1R2, and the ddPCR results also revealed that this sample was hemizygous 
for RHD (Figure 5-13). It is difficult to tell whether this sample is R1r’’ or R2r’ since both 
will possess the DdCcEe genotype. However, as sample 729M was also typed as weak D, 
since the phenomenon of reduced anti-D expression is commonly found in R2r’ and not 
R1r’’, we can predict R2r’’as the most likely genotype. Consequently, sequencing data 
carried out by Amr Halawani (unpublished) revealed that sample 729M displayed the exon 9 
Gly385Ala 1154G>C SNP, and thus was classified as weak D type 2. In addition the sample 
illustrated multiple intronic SNPs which appear to be associated with the R2 haplotype, which 
demonstrates that sample 729M is likely to be R2r’.  
For accurate determination, developing assays which include R1 and R2 SNPs will be 
required to differentiate between the two haplotypes using ddPCR, or alternatively, diagnosis 
could be achieved by sequencing the RHD/ RHCE genes as described above (Halawani et al., 
2014). In cases where samples inherit hybrid genes, in which portions of the RHD are 
replaced with portions of the RHCE gene, RBCs can display partial D phenotypes. 
Developing highly accurate ddPCR/ MPS assays to detect all types of D-variants will prevent 
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wrongful classification of these samples as RHD-, and thus avoid sensitisation during 
pregnancy or blood transfusion. 
Routine testing for C, c, E and e antigens is not available and is only offered in cases where 
the patient has developed atypical antibodies or if they are facing long-term transfusing (for 
example sickle cell disease patients) (Avent and Reid, 2000). The assay described in this 
chapter is specific for RHD genotyping, however developing specific targets for C and E 
would enable the same approach to be applied for reliable RH genotyping. In addition, the 
Kell antigen system is important in transfusion medicine and HDFN since anti-Kell can be 
produced. The KEL1 antigen is determined in all blood donors in the Netherlands, in a 
genotyping experiment it was identified two variants (KEL*02null or KEL*02mod allele) in 
7.4% of Dutch donors (Ji et al, 2015). By designing an assay included a wild-type KEL-target 
and a target for both mutations; ddPCR genotyping could enable rapid determination of 
zygosity and thus could be used to accurate determine the frequency of various Kell 
haplotypes within multiple populations.  
This method is relatively cheap, being only marginally more expensive than qPCR (£6.25 and 
£5.27 per sample, respectively) and can be carried out rapidly for multiple samples. In 
addition, due to the linear nature of quantification on the ddPCR platform, two-fold increases 
are more reliably detected compared to qPCR approaches that detect exponential increases in 
copy number. MLPA was initially described as the first assay able to determine the copy 
number of blood group alleles. The MPLA approach can multiplex up to 50 targets in a single 
tube, which enables an extensively large number of blood groups to be tested (Haer‐
Wigman et al., 2013a). Currently, the blood-MLPA can determine the largest set of blood 
groups antigens in a single test out of all available genotyping assays (Hashmi et al., 2007; 
Gassner et al., 2013; Haer‐Wigman et al., 2013a; Haer‐Wigman et al., 2013b). However, 
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the total time to generate these results takes a minimum of 25 hours. Though, ddPCR cannot 
detect all blood group antigens on a single plate, it provides a quick response to RHD 
genotyping and like MPLA, ddPCR can also reliably determine copy number of RH blood 
group alleles in the same test. 
Serological RBC agglutination tests have many limitations, including; tests cannot determine 
RHD zygosity, discordant results can occur when patients are multiply transfused, there is a 
reduced availability of specific reagents and also reports have identified discrepancies in 
serologic reactivity between different manufacturers’, which complicates RH determination 
(Legler et al., 1999; Liu et al., 1999). While blood-MLPA approaches can be used for 
extensive typing of a patient, RH genotyping using dPCR will enable for rapid determination 
of RHD zygosity and fetal typing from amniocytes or cffDNA. This study illustrates high 
reproducibility and reliability, since different sample types tested on different days all exhibit 
a significant difference between hemizygous RHD positive and homozygous RHD positive 
samples (p<0.01) (Figure 5-13).  
To summarise, these results demonstrate that ddPCR provides a reliable platform for the 
determination of RHD zygosity from both buffy-coat and plasma DNA extractions. The 
application of this assay in a clinical setting would allow for rapid paternal zygosity testing, 
in cases where the mother is RHD negative. In addition, developing further assay targets 
would enable accurate analysis of partial D genotyping, preventing the risk of HDFN or the 
production of anti-D in cases transfused with RHD positive blood. Since serological 
agglutination tests cannot distinguish D-variants, this ddPCR provides a novel test for RH 
genotyping, although further assay targets need to be included for complete RH profiling.   
281 
 
5.3.2 ddPCR vs qPCR for the NIPT of fetal sex and RHD genotyping  
We have shown that ddPCR could be used to provide a more sensitive and robust platform 
for routine antenatal RHD genotyping. Both the fetal sexing and RHD genotyping assays 
included in this study illustrated 100% sensitivity despite low levels of cffDNA being 
expressed by a number of samples (<2%) (Table 5-6) (Figure 5-18A).  We tested 46 samples 
and achieved concordance between presumed genotype (from NHS BT (Filton)) and ddPCR 
defined genotype in 97.8% of test samples using ddPCR (EDTA and Streck samples 
combined). One sample (2.2%) was classified as inconclusive since the concentration of 
RHD7 was seven-fold higher than RHD5, which exhibited a very low concentration (<0.3 
copies/ µL). Fetal sexing illustrated 100% accuracy since all 46 samples were correctly 
classified and no false-positive or false-negative results were recorded for any of the assays 
on the ddPCR platform.  
Non-invasive fetal RHD genotyping from maternal serum or plasma using qPCR analysis has 
shown high levels of accuracy (average 97.4%) for many studies and is currently 
implemented in the Netherlands and Denmark for targeted administration of prophylaxis anti-
D (Gautier et al., 2005; Van der Schoot et al., 2006; Finning et al., 2008; De Haas et al., 
2012). However, in a prospective multicentre cohort study it was determined that for samples 
taken before 11 weeks gestations 16/865 samples (1.8%) were incorrectly classified as RHD-
negative and fetal RHD genotyping was also inconclusive for 393/4913 samples tested (8%) 
(Chitty et al., 2014). Studies have also shown that false negative results can occur using 
qPCR when low cffDNA fractions are present, limiting the sensitivity of this platform (Lo et 
al., 2000; Zhong et al., 2000; Müller et al., 2008). In this study we have shown that for 
suboptimal samples the single copy targets (SRY, RHD5 and RHD7) were not detectable by 
qPCR, but we achieved 100% sensitivity (95% CI) on the ddPCR platform. Contrastingly, the 
qPCR results displayed 100% and 83.4% accuracy for fetal sexing (TSPY1 only) and RHD 
282 
 
genotyping, respectively, for samples that expressed optimal cffDNA fractions (>3%) 
(collected in Streck BCTs).  
The cffDNA fraction of these third trimester samples are expected to be >5% (Lo et al., 
1997). However, the results indicate maternal DNA degradation for EDTA-collected samples 
(Figure 5-18), which is likely to have caused the low cffDNA fractions. Fetal DNA in 
maternal plasma is relatively stable but the amount of total cell-free DNA has been shown to 
increase in positive correlation with time before processing (Angert et al., 2003). The 
cffDNA fraction can be preserved for samples collected in EDTA tubes by quick processing 
(<6 hours) and storing the samples at 4°C before plasma extraction. However, though 
samples were processed within 6 hours, due to logistical reasons samples were transported 
and extracted at room temperature. The results for samples collected in Streck BCTs, which 
contain cell-preserving reagents, show a significant reduction in maternal red blood cell 
degradation compared to samples collected in EDTA tubes (p<0.001) (Figure 5-18B).  
The EDTA tubes are currently standard practice as they contain chelating agents which 
prevent blood coagulation. One study identified that EDTA blood samples stored at 4-8°C led 
to remarkable changes in morphology and osmotic fragility over a four day period (Antwi-
Baffour et al., 2013). Other animal studies have also identified an increase in red blood cell 
size over time, due to changes in morphology which permit osmosis into the cell, 
subsequently leading to haemolysis (Gulati et al., 2002; Walencik and Witeska, 2007). This 
effect of prolonged time between venepuncture and cfDNA recovery has also shown 
increases in haemolysis for studies analysing maternal plasma (Houfflin-Debarge et al., 2000; 
Finning and Chitty, 2008; Hidestrand et al., 2012). Although the samples in this current study 
were processed within 6 hours, the increased temperature is likely to speed up this process of 
maternal erythrocyte degradation. Norton et al. (2013) determined that Streck BCTs 
minimize cellular DNA release during sample storage and shipping compared to standard 
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EDTA tubes. The result illustrated that samples collected in Streck BCTs remain stable for up 
to 14 days at all temperatures (6°C, 22°C and 37°C). Within a four-day window the EDTA 
tube samples showed a significant increase in cfDNA when incubated at the higher 
temperature (22°C and 37°C). The amount of total cfDNA also increased for samples stored 
at 6°C but not as dramatically (Norton et al., 2013).  
This novel ddPCR data indicates that qPCR false negative results were not caused by low 
absolute cffDNA concentrations, since levels are similar to that expressed by optimal samples 
(Figure 5-17), but are instead a result of low relative concentrations of cffDNA. The assay 
used is highly specific and theoretically non-specific amplification should not occur, but 
since RHD5 and RHD7 probes are 96.5% and 100% consensus to the RHCE gene, 
respectively, it is possible that the probes are binding to the abundant maternal RHCE, 
depleting probe availability for fetal-specific RHD-targets. Nonetheless, when the cffDNA 
copy number is very low false negative results are more likely, particularly for the detection 
of fetal single nucleotide polymorphisms (SNPs) for rare mutation detection. qPCR is more 
susceptible to non-specific amplification of the maternal allele, and ddPCR maybe more 
powerful in the detection of alleles associated with conditions such as β-thalassemia and 
cystic fibrosis. 
 Manual extractions of Streck-collected samples generated low gene copy numbers (Table 5-
5).  Brojer et al. (2005) determined that Ct values for automated extractions were 
significantly lower than that for manual extractions (indicating increased gene copy number) 
when starting with ≤2ml of maternal plasma. However, if larger starting quantities of 
maternal plasma are used (4-5ml), higher concentrations can be achieved using the QIAamp 
Circulating Nucliec Acid Kit (Qiagen) (Devonshire et al., 2014). Previous analysis has 
identified that manual extractions yield 23.4% more total cell-free DNA (cffDNA and 
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maternal cfDNA), however, automated approaches yield 40.7% more cffDNA fraction 
(Huang et al., 2005). Despite following the manufacturer’s instructions for extraction, the 
manual approach of extraction used in this study combined with the initiation of maternal 
sample experimentation for this institution, yielded variable samples some of which were 
suboptimal for qPCR analysis.  
The ddPCR data was used to determine cffDNA fraction, as it is associated with higher levels 
of sensitivity and improved accuracy for low template copy numbers (Jones et al., 2014). 
Since some droplets may contain multiple targets, Poisson statistics were incorporated to 
determine the copy number (Pinheiro et al., 2011). The proportion of the fetal specific targets 
were relatively low (average number of droplets; 12084, average number of RHD molecules; 
20.8 and 17.8 for samples from EDTA tubes and Streck BCTs, respectively (refer to Figure 
5-16)). However, higher proportions of dual positive droplets are visible for EDTA samples 
since the reference targets (EIF2C1 or Xp22.3) express a higher number of mean copies per 
partition (e.g. 0.62 mean copies per partition of EIF2C1 for sample 15) compared to Streck 
BCTs (e.g. 0.023 mean copies per partition of EIF2C1 for sample 32) (Figure 5-16).  
Multiple studies have been carried out since the release of the QX100™ ddPCR system in 
2012 to compare whether its application can enhance or replace conventional qPCR-based 
approaches (Hindson et al., 2011; Dodd, Gagnon and Corey, 2013; Hayden et al., 2013; 
Hindson et al., 2013; Strain et al., 2013; Kim, Jeong and Cho, 2014). While some studies 
revealed equal sensitivities for ddPCR and qPCR (Hayden et al., 2013; Hindson et al., 2013), 
a number of studies in various biomedical, pharmaceutical and biotechnological fields have 
shown considerable improvements of sensitivity and specificity on the ddPCR platform 
compared to qPCR approaches (Hindson et al., 2011; Dodd, Gagnon and Corey, 2013; Strain 
et al., 2013; Kim, Jeong and Cho, 2014). This study also illustrates significant improvements 
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in sensitivity for the ddPCR platform, particularly for samples expressing low cffDNA (<3%) 
(Table 5-6). 
In a previous study, unequal representation of reference targets (TERT and ERV) was shown 
in cfDNA compared to genomic DNA (Devonshire et al., 2014).The chosen references 
(Xp22.3 and EIF2C1) were based on assumptions that cfDNA is fragmented equally across 
the genome. The ddPCR data demonstrated a ratio close to 1 for all target and reference 
multiplex reactions, which shows they are present in equal abundance (Figure 5-2, Figure 5-4 
and Figure 5-5). In addition, the equal representation of targets for the RHD5/ EIF2C1 and 
RHD7/ EIF2C1 multiplex reactions has been shown, since ratio analysis to determining 
whether samples in a previous study were hemizygous or homozygous for RHD was highly 
accuracy (Figure 5-13).  
Based on the qPCR data, false negative results were shown in 54% of patients. In a clinical 
setting these cases would not of received RAADP, and thus could potentially lead to the onset 
of HDFN. Contrastingly, no false negative results were recorded when analysed using the 
ddPCR, and as a consequence, if applied routinely, administration of this assay would have 
prevented 31.1% of patients receiving anti-D unnecessarily in our study cohort. Not only 
would this approach prevent around 1/3 women having to receive the anti-D, it would 
provide financial benefits. One published study looking at the cost analysis of mass testing 
for the targeted administration of RAADP in England and Wales identified that if non-
invasive testing replaced currently serological tests an annual saving of £507,154 could be 
achieved (Szczepura, Osipenko and Freeman, 2011).However, this is only achieved if NIPD 
is also used to replace postnatal serology testing if an RHD negative fetus is determined. If 
NIPD is used in conjunction with postnatal serological testing, no savings were recorded 
(Szczepura, Osipenko and Freeman, 2011). In addition, previous studies have also reported 
false positive/ inconclusive results when the fetus expresses D-variants (Rouillac-Le Sciellour 
286 
 
et al., 2004; Finning et al., 2008; De Haas et al., 2012). In contrast to false negative results, 
false positive results do not lead to alloimmunisation and subsequent HDFN onset. Instead 
anti-D is administered unnecessarily. For qPCR analysis, four inconclusive results would of 
received anti-D, which in this instance was necessary since fetuses were confirmed to be 
RHD positive. Based on the ddPCR data only one mother (2%) would have received anti-D 
that was not required.  
The oligonucleotide primers used in this study for the RHD targets (Finning et al., 2008). 
should distinguish between RHD positive and RHDΨ/ DVI (type 1-4) fetal genotypes, by 
amplifying exon 7 but not exon 5 for the latter (Figure 5-17). From this study, based on the 
ddPCR data, only one sample (sample 12) would have received anti-D unnecessarily. 
However, the true RHD genotype could not be confirmed due to constraints on ethical 
approval which prevented follow up. To improve the sensitivity of RHDΨ detection 
additional experiments could also include primers designed to incorporate the C674T 
missense and T807G nonsense mutations in exon 6 (Daniels et al., 1998). In this instance the 
RHDΨ would present only amplification of exon 7, with no amplification of RHD exon 5 or 
6. Both ddPCR and qPCR will express similar levels of false positive results due to D-
variants, however, this study illustrates that ddPCR has the potential to eliminate or reduce 
the occurrence of false negative results, particularly for samples with suboptimal cffDNA 
fractions (<2%). First trimester testing is preferable since it can be carried out with other 
routine blood test, but as long as a diagnosis is determined before 28 weeks gestation 
prophylaxis anti-D can be successfully targeted to mothers carrying D-positive fetuses. 
Currently, around 40% of women in the UK still receive anti-D unnecessarily. Our results 
show that the sensitivity of ddPCR is considerably higher, particularly for suboptimal 
samples (<2% cffDNA). Therefore, this ddPCR assay should be able to accurately and 
reliably determine fetal RHD genotype from an EDTA-collected maternal blood sample from 
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as early as 8 weeks gestation. Women receive their initial blood tests to check for 
immunization against rubella and other infections (syphilis, hepatitis B and HIV) at 8-10 
weeks gestation and this this test could be carried out at the same time. The Rh status of the 
mother is also determined and to distinguish between RHD-positive mothers and RHD-
positive fetuses carried by RHD-negative mothers would be relatively easy. The RHD-
positive mother would express high concentrations of the RHD-target gene that are very close 
to the concentrations of the reference gene. The RHD-positive fetus (carried by an RHD-
negative mother) would express a significantly lower concentration of RHD-target compared 
to the reference gene. Future experiments will examine the feasibility of ddPCR for first and 
second trimester samples. 
In conclusion, these results show that ddPCR illustrates improved accuracy compared to 
qPCR for fetal sex determination and RHD genotyping. Though this assay demonstrated 
improved sensitivity of ddPCR compared to qPCR it is important to note that our qPCR 
assays do not reflect the sensitivity levels commonly achieved (>99%). Initially it was 
thought that the reduced quality of maternal samples resulted in lower qPCR accuraries, 
although it could also be a result of lower PCR efficiencies, indicating that further assay 
optimisation is required. Therefore, an improved method for comparing the sensitivity of 
ddPCR to qPCR, could be achieved by spiking male gDNA/ RHD positive gDNA into female 
genomic DNA/ RHD negative gDNA, repsectively, at different ratios, all the way down to 
0.1%, which would enable a comparison of sensitivity without the external influence of 
maternal sample quality. The low but significant presence of false negatives in current qPCR 
assays for samples expressing low cffDNA fractions demonstrate the need for improved 
accuracy, which could be achieved using ddPCR. This preliminary data highlights of ddPCR 
for targeted adminstration of RAADP. However, validation studies are now required to 
determine the feasibility and cost-effectiveness of ddPCR for larger cohorts of samples.  
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Chapter 6 
 
 
 
Determining the feasibility of Pippin Prep™ size 
selective gel electrophoresis for cffDNA enrichment 
in conjunction with ddPCR analysis for the detection 
of T21 in spiked samples 
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6.1 Introduction  
The size difference between maternal cfDNA and cffDNA has been previously discussed 
(refer to 1.3.3.5), and initial approaches for size-selective amplification of the shorter 
cffDNA fragments using COLD-PCR (refer to Chapter 3) and IPCR (refer to Chapter 4) 
have been examined. Despite the initial success associated with the COLD-PCR approach 
using pseudo-maternal samples (refer to 3.2.4), transferring this protocol to real maternal 
samples revealed too much variation in amplification efficiencies between the reference 
and target genes at the lower Tds (refer to 3.2.5). In contrast, the inverse PCR approach is 
dependent upon the DNA exhibiting cohesive ends. Further investigations are required to 
initially define the properties of cfDNA ends before optimisation of the selective IPCR 
approach can be continued (refer to 4.3). In this chapter the application of a third 
alternative selective-enrichment approach, using the Pippin Prep™ (PP) DNA Size 
Selective System (Sage Science) is described.  
The PP System is an automated preparative gel electrophoresis system, which contains a 
fluorescent-based DNA detection unit. During electrophoresis, the optical system enables 
detection of DNA fractions within a particular size range set up by the user. By altering 
the voltage, the system allows for selected DNA fragments to be electroeluted into a 
buffer-filled elution module. The principle application of this platform is for facilitating 
library construction for MPS since target sizes or even ranges of target sizes can be 
selected without the need for gel extraction (Borgstrom, Lundin and Lundeberg, 2011; 
Duhaime et al., 2012; Quail et al., 2012). One study, focusing on the optimization of 
quantitative metagenomics of ultra-low concentration samples, compared three size 
fractioning methods to test for target recovery efficiency, throughput and risk of cross-
sample contamination. These methods included; PP, Solid Phase Reversible 
Immobilization (SPRI) (using Agencourt AmPure XP beads) and standard gel extraction. 
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The results illustrated that the PP was the most efficient and reproducible (94-96% of 
input DNA) with the most specific sizing. In contrast standard gel extraction exhibited 
moderate target recovery efficiency (64-74%) and the SPRI was the least efficient, only 
recovering 46-50% of the targeted size fraction (Duhaime et al., 2012).  
In this study, the PP gel electrophoresis was used as a tool for size selective enrichment of 
shorter cffDNA fragments over maternal fragments rather than as a platform for library 
preparation. The system was set to collect DNA fragments within the range of 100-200bp, 
with a target of 150bp. Based upon the principles discussed in Chapter 3 (refer to 3.1), it 
was hypothesized that this would enable selection and enrichment of the shorter fetal-
DNA fragments, whilst larger maternal DNA fragments >200bp would be depleted. 
Unlike previous enrichment strategies, this technique did not require alteration to the PCR 
Td and was not dependent on specific characteristics of cffDNA, such as cohesive ends 
for self-ligation.  
The aims of this study were: 
 To selectively enrich shorter fetal DNA fragments using the PP Size Selective 
System.  
 To determine enrichment by analysing the cffDNA fraction (%) before and after 
PP gel electrophoresis using the ddPCR platform.  
 To produce pseudo-maternal samples carrying a ‘T21’ fetus at varying cffDNA 
fractions in order to determine the minimal cffDNA fraction required for reliable 
diagnosis using ddPCR.  
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6.2 Results  
6.2.1 Pippin Prep™ gel electrophoresis enrichment  
6.2.1.1 Initial PP size-selective experiments using qPCR and ddPCR analysis  
Two maternal samples, one carrying a female fetus (maternal sample 8) and one carrying 
a male fetus (maternal sample 9) were run on the PP gel electrophoresis System with a 
target size selection of 150bp (refer to 6.2.1). The eluted PP samples were then collected 
and analysed using qPCR and ddPCR platforms (refer to 6. 2.2) against non-Pippin Prep 
(non-PP) aliquots of the same sample, male gDNA, female gDNA and a NTC. The non-
PP samples were extracted from a single 1mL aliquot of plasma (8A and 9A) and the PP 
samples were extracted from three 1mL aliquots of plasma (8BCD and 9BCD), since it 
was anticipated that a relative proportion of cell-free DNA would be lost following PP gel 
electrophoresis. The concentration of each aliquot determined by Qubit analysis is 
illustrated in Table 6-1 and is higher for both maternal samples when extracted from 3 
mL of plasma as expected. Due to limited amounts of sample available and previous low 
levels of sensitivity achieved with qPCR (see Chapter 5), the multiple copy target (TSPY1 
(FAM)) was multiplexed with the HBB (HEX) reference on the qPCR platform, while the 
single copy target  multiplex assay (SRY
 (H.P.T)
 (FAM)/ Xp22.3 (HEX))  was tested on the 
ddPCR platform for this initial experiment (2.9).   
Table ‎6-1: DNA concentration of maternal sample aliquots. 
Sample  Concentration (ng/ µL) 
8A 0.82 
8BCD 1.61 
9A 0.42 
9BCD 2.33 
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The qPCR data revealed amplification of both targets for the male control sample, while 
the female control and NTC illustrated HBB amplification only and no amplification, 
respectively. The non-maternal (female) sample (147W) illustrated no TSPY1 
amplification but did illustrate successful amplification of the reference gene (HBB). The 
HBB amplification for sample 147W demonstrated reduced amplification for the PP 
aliquot (29.71 Ct) compared to the non-PP aliquot (25.14 Ct). The results also 
demonstrated a decline in amplification of all targets following PP electrophoresis (Figure 
6-1), which led to lower concentration yields (Table 6-2) despite higher starting 
concentrations (Table 6-1). This result was expected since DNA is lost with additional 
processing. Maternal sample 8 (female fetus) illustrated contamination on the qPCR 
platform since late amplification of the Y-specific target (TSPY1) was detected (Figure 6-
1). Maternal sample 9 (male fetus) illustrated reduced amplification of the TSPY1 target 
gene for the PP aliquot (30.51 Ct) compared to the non-PP aliquot (29.65 Ct), but 
demonstrated an even greater decline in amplification of the HBB reference gene for the 
PP aliquot (27.39 Ct) compared to the non-PP aliquot (25.11 Ct) However, despite higher 
depletion of ‘maternal’ reference, the cffDNA fraction calculated (refer to 2.9.4) was 
higher for maternal sample 9A non-PP (1.54%) compared to maternal sample 9BCD PP 
(1.17%). This result illustrated that the sample had not been successfully enriched.  
Contrastingly, the ddPCR results illustrated >3-fold increase in cffDNA fraction 
for maternal sample 9 following PP enrichment when using the single copy 
target assay (SRY 
(H.P.T) 
(FAM) / Xp22.3 (HEX)) (Figure 6-2). The male gDNA 
control demonstrated a ratio of 0.99, showing equal proportion of the Y-specific 
(SRY) and X-specific (Xp22.3) targets. The female control sample only 
illustrated amplification of the Xp22.3 target and the NTC was clean since no 
amplification was visible. Similarly to qPCR, the PP aliquots of maternal sample 
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8 (BCD) and maternal sample 9 (BCD) illustrated a decline in concentration 
compared to the non-PP aliquots (8A and 9A) (Figure 6-2). Due to limited 
quantities, non-maternal sample (147W) was not analysed on the ddPCR 
platform. Maternal sample 8BCD (PP) showed low amplification of Y-specific 
target despite carrying a female fetus indicating sample contamination as seen in 
qPCR (Figure 6-2 compared to Figure 6-1).  
The results illustrated higher cffDNA fractions when using ddPCR analysis with the 
single copy Y-specific target. Due to the partitioning nature of the ddPCR platform 
precise quantification of nucleic acid can be achieved allowing small percentage 
differences in cffDNA fractions to be detected. Therefore, all subsequent experiments to 
determine PP gel electrophoresis enrichment were conducted using ddPCR. In addition, 
to reduce variability, DNA was extracted from the same maternal plasma aliquots and 
later separated for PP and non-PP analysis (unless stated otherwise).    
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Figure ‎6-1: qPCR amplification of TSPY1 (A-D) and HBB (E-H) for non-
maternal sample 147W (A and E), maternal sample 8 (female fetus) (B and 
F), maternal sample 9 (male fetus) (C and G) and Male and Female gDNA 
control samples (D and H). Samples were tested prior to PP-enrichment 
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(labelled non-PP) and after PP size selective gel electrophoresis (labelled PP). 
Threshold was set at 0.05 for both assays for consistency when quantifying 
samples (refer to Table 6-2). Female sample 147W illustrated no amplification 
of TSPY1 but did illustrate a reduction in amplification for the HBB reference 
following PP gel electrophoresis (29.71Ct) compared to the non-PP sample 
(25.14Ct). Both maternal samples also illustrated a decline (~2Ct) in 
amplification following PP gel electrophoresis (Sample 8 (F) and Sample 9 (G)). 
Maternal sample 8 illustrated contamination since Y-specific amplification was 
visible at 37.67Ct and 39.14 for PP and non-PP aliquots, respectively (B). 
Maternal sample 9 showed a less substantial reduction in amplification for the 
SRY target between the non-PP aliquot (29.65 Ct) and the PP aliquot (30.51 Ct) 
(C) compared to the decline in amplification visible for the HBB reference (G). 
The male control illustrated successful amplification of both targets, while the 
female control only illustrated successful amplification of the reference (HBB) 
(D and H).  
Table ‎6-2: Sample concentration following qPCR analysis and cffDNA fractions for 
maternal sample 9.  
Sample TSPY1 Concentration 
(ng/ µL) 
HBB 
Concentration (ng/ 
µL) 
cffDNA fraction 
(%) 
147W  0 2.92 N/A 
147W PP 0 1.32 N/A 
8A non-PP <0.01 2.68 N/A 
8BCD PP <0.01 2.13 N/A 
9A non-PP 0.66 2.85 1.54 
9BCD PP 0.37 2.11 1.17 
Male gDNA 3.2 2.55 N/A 
Female gDNA 0 1.77 N/A 
NTC 0 0 N/A 
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Figure ‎6-2: Bar Chart illustrating the concentration (copies/ µL) of SRY (H.P.T) 
(FAM) target (blue) and Xp22.3 (HEX) reference (green) generated by ddPCR 
platform. The following samples were tested; control samples (NTC, Male gDNA and 
Female gDNA), a maternal sample carrying a female fetus with no selective PP 
enrichment (8A) and following PP enrichment (8BCD PP), and a maternal sample 
carrying a male fetus with no selective PP enrichment (9A) and following PP enrichment 
(9BCD). The result illustrated a ratio of 0.99 for the Male gDNA (SRY (copies/ µL) 
divided by EIF2C1 (copies/ µL)), which is expected since males will carry a single SRY 
(H.P.T)
 target region and a single Xp22.3 target region. The Female control did not show 
any SRY 
(H.P.T)
 amplification and the NTC showed no amplification. Sample 8A did not 
show any amplification following extraction from 1 mL of maternal plasma, but sample 9 
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showed an increase in cffDNA fraction from 1.37% to 4.92%. However, since samples 
were extracted from varying volumes of maternal plasma. 
6.2.1.2 ddPCR analysis of PP gel electrophoresis cffDNA enrichment using a multiple-
copy Y-specific target (TSPY1) 
Since the initial qPCR results did not illustrate an increase in cffDNA fraction when using 
the multiple-copy Y-target (TSPY1), this experiment was repeated on the ddPCR platform 
with four new maternal samples carrying a male fetus (13AB, 24AB, 36AB and 43AB). 
However, since previous ddPCR experiments had been optimised using the TSPY1 
(FAM)/ Xp22.3 (HEX) assay, the Xp22.3 reference was used in replacement of HBB.  
Prior to PP gel electrophoresis, DNA was extracted from two 1mL aliquots of plasma and 
eluted in 70 µL of Buffer AVE (refer to 2.1.5). The maternal samples were then equally 
split into two aliquots. One aliquot, labelled ‘PP’, was run on the PP System, while the 
second aliquot, labelled ‘non-PP’, was stored at 4°C. To pre-determine any drop out of 
larger DNA fragments and assess sample quality, both maternal sample aliquots (PP and 
non-PP) were run on the Bioanalyzer (refer to 2.6.3) prior to ddPCR analysis. The 
electropherograms for each sample are illustrated in Figure 6-3 and the electrophoresis 
gel-like image generated by the Bioanalyzer is shown in Figure 6-4. The results 
demonstrated that all PP maternal aliquots only showed a single peak/band between 187-
208bp, whereas non-PP maternal samples also illustrated multiple peaks/ bands between 
350-400bp, 500-600bp and <850bp (Figure 6-3 and 6-4). For unknown reasons maternal 
sample 13AB PP, did not align to the Ladder and therefore the size (bp) of peak/ band 
generated could not be determined (Figure 6-3 and 6-4).  
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Figure ‎6-3: Agilent 2100 Bioanalyzer electropherograms for four maternal samples 
(13AB, 24AB, 36AB and 43AB) before (non-PP, left column) and after (PP, right 
column) PP gel electrophoresis. The non-PP aliquots show multiple peaks (4), whereas 
the PP aliquots only show a single peak (between 189bp to 192 bp) for all samples. The 
peak generated by maternal sample 13AB (PP) could not be determined. 
  Non-PP                                               PP 
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Figure ‎6-4:Electrophoresis gel-like image generated by the Bioanalyzer showing the 
ladder (L) and results for all four maternal samples (13AB, 24AB, 36AB and 43AB) 
before (non-PP) and after PP gel electrophoresis (PP). The non-PP maternal samples 
aliquots (Lane 1 (13AB), Lane 3 (24AB), Lane 5 (36AB) and Lane 7 (43AB)) 
demonstrated multiple bands at around 200bp, 400bp, 500bp, 700bp and 1000bp. 
Contrastingly, the PP maternal samples (Lane 4 (24AB PP), Lane 6 (36AB PP) and Lane 
8 (43AB PP)) only show a strong band at around 200bp, all the larger fragments are 
absent or very faint. The results illustrated that sample 13AB PP (Lane 2) did not align to 
the Ladder and therefore peak size was not determined. However, the gel-like image 
illustrated that the larger bands present for the non-PP aliquot (Lane 1) were also absent.  
Following the Bioanalyzer run, maternal samples were analysed on the ddPCR platform 
to determine if selective enrichment of shorter fetal fragments had been achieved using 
PP size selective gel electrophoresis (2.9). The results illustrated that all maternal samples 
illustrated a dramatic drop in number of Events for the reference gene (Xp22.3) and a 
3000bp 
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declined reduction in number of Events for the fetal Y-specific target (TSPY1) for 
samples that had undergone PP gel electrophoresis (Figure 6-5). The fold-decrease from 
non-PP to PP aliquot of each maternal sample was consequently calculated and the mean 
±SD fold-decrease in number of Events for both TSPY1 and Xp22.3 are illustrated in 
Figure 6-6. The results demonstrated that the decline in number of positive droplets 
(Events) was significantly higher for the Xp22.3 reference (Figure 6-6). This illustrated 
that despite losing some of the fetal specific target through PP gel electrophoresis, the gel 
was successfully and selectively depleting the larger maternal DNA fragments.  
To confirm if enrichment had been achieved the cffDNA fraction using the TSPY1 
multiple-copy target equation was calculated for PP and non-PP maternal DNA aliquots 
(refer to 2.9.4). The results illustrated that all PP maternal samples expressed a 2- to 5-
fold increase in cffDNA fraction (Figure 6-7). Maternal sample 43AB illustrated the 
highest increase in cffDNA (5-fold increase) from 2.67% to 13.43% for non-PP and PP 
aliquots, respectively Before PP enrichment, maternal samples 24AB, 36AB and 43AB 
all illustrated cffDNA fractions of <1%. These maternal samples were collected in EDTA 
tubes, which have shown previous low cffDNA fractions (Chapter 5). Therefore, 
subsequent experiments to test enrichment following PP gel electrophoresis were 
conducted using maternal samples collected in Streck BCTs, which are associated with 
higher cffDNA fractions (Chapter 5) (Sillence et al., 2015). Despite extremely low 
starting quantities of cffDNA, these results illustrate that the PP System can successfully 
enrich the proportion of cffDNA through size selective gel electrophoresis. 
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Figure ‎6-5: Bar chart illustrating the number of Events (positive droplets) for SRY 
(H.P.T) 
(FAM, blue)
 
and Xp22.3 (HEX, green) generated by ddPCR for maternal 
samples 13AB (A), 24AB (B), 36AB (C) and 43AB (D) before and after PP selective 
enrichment. The results clearly show an increase in cffDNA fraction for all samples 
following PP gel electrophoresis. 
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Figure ‎6-6 Bar chart illustrated the mean ±SD fold-decrease in number of Events 
(positive droplets) for TSPY1 (FAM, blue) and Xp22.3 (HEX, green) generated by 
ddPCR following PP size selective gel electrophoresis. The results illustrated that the 
number of Events for the reference gene were significantly lower following PP gel 
electrophoresis compared to the decline in Events for the fetal-specific TSPY1 target 
(*p<0.05).  
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Figure ‎6-7: Bar chart illustrating the cffDNA fraction calculated using the 
TSPY1 multiple-copy target equation (refer to 2.9.4) for maternal samples 
before (non-PP, plain colour) and after (PP, striated colour) PP gel 
electrophoresis. The results illustrate a 2.1-fold increase, 4.7-fold increase, 4-
fold increase and 5-fold increase following PP size selective enrichment for 
maternal samples 13AB, 24AB, 36AB and 43AB, respectively.  
6.2.1.3 ddPCR analysis of PP gel electrophoresis cffDNA enrichment using a single 
copy RHD specific targets for samples extracted using Streck BCTs  
To analyse the increase in cffDNA fractions through PP gel electrophoresis using fetal 
targets specific for the RHD gene, DNA was extracted from 2x three 1 mL maternal 
plasma aliquots. In the previous experiment DNA was extracted from 1x two 1 mL 
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maternal plasma aliquots and separated. However, since each maternal sample was going 
to be analysed by two assays (RHD5 (FAM) / EIF2C1 (HEX) and (RHD7 (FAM) / 
EIF2C1 (HEX)) an increased amount of DNA was required. Therefore, DNA was 
extracted from two sets of three 1 mL plasma aliquots. The aliquot showing the highest 
concentration following Qubit quantification was run on the PP System, while the aliquot 
expressing the lower concentration was stored at -4°C (non-PP) (Table 6-3). For this 
experiment eleven maternal samples were tested, ten of these samples (117, 118, 119, 
120, 122, 123, 124, 131, 132 and 133) were carrying an RHD positive fetus and one 
sample (130) was carrying an RHD negative fetus.  
Table 6-3 summarises the results for control samples and all maternal samples before 
(non-PP) and after (PP) PP gel electrophoresis, including; sample concentration (ng/ µL), 
RHD5, RHD7 and EIF2C1 concentration (copies/ µL) following ddPCR amplification for 
each multiplex reaction and calculated cffDNA fraction (refer to 2.9.4). The results show 
that both NTC samples tested illustrated no contamination. Each repeat of the RHD 
negative control (7807) only showed amplification of the reference gene (EIF2C1), while 
each repeat of the RHD positive control (131Z) showed amplification of the RHD target 
genes and the reference gene in both assays.  
The RHD5/ EIF2C1 assay demonstrated ratios of 1.04 and 1.01 for experiment 1 and 
experiment 2, while the RHD7/ EIF2C1 assay illustrated a ratio of 0.99 for both 
experiments. This illustrates that the control sample is homozygous and has two copies of 
the RHD gene, since all ratios are close to 1 (Table 6-3). Maternal sample 130 did not 
illustrate RHD amplification since this sample was carrying an RHD- fetus. Sample 119 
only detected a small number of RHD7 targets and no RHD5 targets following PP gel 
electrophoresis, illustrating depletion of all cffDNA. Maternal sample 133 was the only 
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sample to show a reduction in cfDNA fraction, while the remaining maternal samples 
(n=8), all demonstrated an increase in cffDNA fraction (Table 6-3).  
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Table ‎6-3: cffDNA fractions 
for maternal samples before 
(non-PP) and after (PP) PP 
gel electrophoresis.  The 
cffDNA fractions were 
calculated based on the 
concentration (copies/ µL) of 
each target for multiplex 
reaction 3 (RHD5 (FAM)/ 
EIF2C1 (HEX) and multiplex 
reaction 4 (RHD7 (FAM)/ 
EIF2C1 (HEX) (refer to 2.9.4). 
control samples (RHD+ (131Z), 
RHD- (7807) and NTC) were 
also tested.  
 
 
Sample  
Conc 
(ng/ uL) 
RHD5/ EIF2C1 RHD7/ EIF2C1 
RHD5-FAM 
(copies/µl) 
EIF2C1-HEX 
(copies/µl) 
Fetal 
Fraction  
/*ratio 
RHD7-FAM 
(copies/µl) 
EIF2C1-HEX 
(copies/µl) 
Fetal 
Fraction/ 
*ratio 
C
o
n
tro
ls 
0
5
/0
3
/1
5
 
NTC - 0 0 - 0 0 - 
7807 -  - 0 132 - 0 133 - 
131Z + - 81.7 78.6 1.04* 72.1 72.8 0.99* 
C
o
n
tro
ls 
0
6
/0
3
/1
5
 
NTC - 0 0 - 0 0 - 
7807 - - 0 119 - 0 116 - 
131Z + - 77.2 76.7 1.01* 77.9 78.2 0.99* 
M
atern
al S
am
p
les 0
5
/0
3
/1
5
 
120HIJ 2.79 2.91 23.2 25.09 2.93 23.10 25.37 
120EFG PP 3.53 0.503 2.79 36.06 0.72 3.52 40.85 
122EFG 0.476 0.31 6.84 9.06 0.59 5.76 21.07 
122HIJ PP 3.43 0.0406 0.325 24.98 0.05 0.24 41.75 
123EFG 3.53 0.751 22.7 6.62 1.26 23.00 10.96 
123HIJ PP 4.06 0.253 2.07 24.44 0.34 1.26 53.49 
124EFG 2.05 1.25 26.9 9.29 0.97 27.10 7.17 
124HIJ PP 2.13 0.505 3.58 28.21 0.31 3.38 18.40 
M
atern
al S
am
p
les 0
6
/0
3
/1
5
 
130DEF 0.893 0 22 0 0 19.00 0 
130ABC PP 4.49 0 28.4 0 0 28.90 0 
131DEF 2.36 1.22 61.8 3.95 2.06 58.21 6.83 
131ABC PP 5.57 0.248 7.03 7.06 0.29 7.43 7.51 
132DEF 4.26 1.85 50.8 7.28 30.50 48.70 125.26 
132ABC PP 4.9 0.34 4.14 16.43 3.93 4.79 164.09 
133ABC 3.71 1.08 23.1 9.35 1.31 22.2 11.80 
133DEF PP 3.77 0.106 3.08 6.88 0.31 3.37 18.46 
M
atern
al S
am
p
les 
0
2
/0
2
/1
5 
117HIJ 0.92 0.752 51 2.95 1.41 48.00 5.88 
117EFG PP 1.06 0.348 3.22 21.61 0.47 3.22 29.38 
118EFG 0.55 2.02 25.5 15.84 2.70 26.60 20.30 
118HIJ PP 0.55 0.99 3.24 61.11 1.62 4.79 67.64 
119EFG 0.50 1.31 27.5 9.53 0.55 23.90 4.59 
119HIJ PP 0.57 0 0.54 0.00 0.11 1.11 20.00 
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Prior to ddPCR analysis, maternal samples were run on the Agilent 2100 Bioanalyzer. 
However, despite multiple attempts, only one experiment was successful, all other runs were 
unsuccessful due to a problem associated with the alignment of the ladder. The Bioanalyzer 
results for maternal samples 117- 119 are illustrated in Figure 6-8 6-9 alongside a non-
maternal control sample (2454). For non-maternal sample 2454 and maternal sample 118 the 
Agilent Bioanalyzer results revealed four peaks/bands (at 189bp, 381bp, 570bp and 1,379bp) 
and three peaks/ bands (181bp, 359bp and 494bp) respectively, before (non-PP) PP gel 
electrophoresis (Figure 6-8 and 6-9). Following PP gel electrophoresis (PP) all peaks/ 
bands >200bp were removed (Figure 6-8 and 6-9). Maternal sample 117 showered clear 
peaks/ bands before (non-PP) PP gel electrophoresis at 181bp, 359bp and 494bp, but 
following PP gel electrophoresis (PP), although a clear peak/ band is shown around 180bp a 
result (bp) the Agilent 2100 Bioanalyzer did not generate a bp result (Figure 6-8 and 6-9). 
Finally, the results for maternal sample 119 showed no peaks/ bands for the PP aliquot 
(Figure 6-8 and 6-9). This indicated that potentially the entire cell-free DNA, including 
shorter fetal DNA, had been depleted following PP gel electrophoresis. 
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Figure ‎6-8: Agilent 2100 Bioanalyzer electropherograms for three maternal samples 
(117, 118 and 119) and non-maternal sample (2454) before (non-PP, left column) and 
after (PP, right column) PP gel electrophoresis. The peak generated by maternal sample 
117 (PP) could not be determined. 
181bp 
359bp 
494bp 
177bp 
361bp 175bp 
206bp 
339bp 
2,323b
p 
189bp 
381bp 
570bp 
1,379b
p 
150bp 
170bp 
  Non-PP                                                           PP 
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Figure ‎6-9: Electrophoresis gel-like image generated by the Agilent 2100 Bioanalyzer 
showing the ladder  (L) and results for three maternal samples (117, 118 and 119) and 
one non-maternal sample (2454) before (non-PP) and after (PP) PP gel electrophoresis. 
The non-PP aliquots of maternal samples 117 (Lane 1 and 2) and 118 (Lane 4 and 5) all 
demonstrated multiple bands at around 200bp, 400bp and 500bp. Non-PP aliquot of sample 
117 was unsuccessful and the non-PP aliquot of maternal sample 118 only demonstrated a 
clear band at ~200bp. The non-PP aliquots of maternal sample 119 (Lane 7 and 8) illustrated 
variations in banding patterns. Sample 119EFG showed a similar pattern to non-PP aliquots 
of samples 118 and 119. However, the 119HIJ aliquot demonstrated two clear bands at 200bp 
and 1000bp. The PP aliquot of sample 119HIJ illustrated no clear banding. Non-maternal 
sample 2454 illustrated bands at 200bp, 400bp, 500bp and 700bp, but also illustrated a thick 
band at 1000bp for the non-PP aliquot. In contrast, the PP aliquot of non-maternal sample 
2454 only demonstrated a fine clear band at 150bp and a thicker less intense band at 170bp.  
 Ladder  117        117       117       118      118      118      119        119      119     2454     2454 
              EFG     HIJ    EFG     EFG    HIJ     HIJ     EFG     HIJ      HIJ 
3000bp 
700bp 
400bp 
200bp  
 EFG  EFG  HIJ  HIJ  EFG  HIJ  HIJ 
                   Non- PP           PP         Non- PP         PP          Non- PP          PP   Non-PP     PP 
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The cffDNA fractions were calculated based on the concentration of the RHD target in 
comparison the reference gene (EIF2C1) and the results are shown in Table 6-3 and Figure 6-
10. The results illustrated no RHD amplification for maternal sample 130 as expected since 
both the mother and the fetus are RHD negative. Eight of the Maternal samples (117, 118, 
120, 122, 123, 124, 131 and 132) illustrated an increase in cffDNA fraction for both target 
assays (RHD5/ EIF2C1 and RHD7/ EIF2C1) (Table 6-3) (Figure 6-10). The increase in 
cffDNA fraction was highly varied (Figure 6-11), ranging from 1.9% (maternal sample 131) 
to 46.3% (maternal sample 118) based on the mean of both assays. Maternal sample 133 
illustrated a 6.7% increase in cffDNA fraction following PP gel electrophoresis when 
calculated using the RHD7/ EIF2C1 assay, but demonstrated a 2.7% decrease in cffDNA 
when calculated using the RHD5/ EIF2C1 assay (Figure 6-11). However, the non-PP aliquot 
of maternal sample 133 illustrated similar cffDNA fractions of 9.35% and 11.80% for the 
RHD5 and RHD7 multiplex assays, respectively.  
Maternal sample 119 illustrated amplification of RHD fetal specific targets for the non-PP 
aliquot (Table 6-3) (Figure 6-12 A and C). However, the PP aliquot of maternal sample 119 
only illustrated one positive droplet for the RHD7 target (Figure 6-12 D) and no positive 
droplets for the RHD5 target (Figure 6-12 B). Demonstrating that too much fetal DNA was 
lost for this sample during PP gel electrophoresis, which is likely to be attributed to low 
starting concentrations of total cell-free DNA (Table 6-3).  
Maternal sample 132 illustrated typical cffDNA fractions when calculated based upon the 
RHD5/ EIF2C1 assay (7.28% and 16.43% for non-PP and PP aliquots, respectively) (Figure 
6-12 E and F). However, the cffDNA fractions calculated using the RHD7/ EIF2C1 assay 
illustrated cffDNA >100% (125.26% and 164.09%, respectively) (Table 6-3). Figure 6-12 E-
H demonstrates the increased number of RHD7 positive droplets in comparison to the number 
of RHD5 positive droplets. These results illustrated that maternal sample 132 expresses more 
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than one copy of the RHD7 target region, one of which must be maternal in origin. This 
demonstrates that the mother from sample 132 must be a carrier for an RHD variant (the 
RHDΨ or DVI type 1-3) since only RHD7 is expressed. By using the concentrations of each 
target gene and the reference gene, we were able to determine that only one of the maternal 
alleles expressed the variant RHD genotype, see below: 
 RHD5 = 1.85 copies/ µL  
 RHD7 = 30.5 copies/ µL  
 EIF2C1 = 49.75 copies/ µL (maternal + fetal) 
 EIF2C1 (maternal only) = 49.75 – (2 x 1.85) = 46.05 copies/ µL (assuming RHD5 
and EIF2C1 are equally expressed).  
If we assume that RHD5 and RHD7 are present in equal proportions and that the fetus 
expresses either one or two copies of the RHD7 target, we can subtract this from the RHD7 
concentration to determine the maternal proportion (30.5 – 1.85 = 28.65 copies/ µL (one fetal 
copy of RHD7)) or 30.5 – (2 x 1.85) = 26.8 copies/ µL (two fetal copies of RHD7)). By using 
the maternal only concentrations, the maternal specific ratio of RHD7/ EIF2C1 was then 
calculated:  
 Ratio based on single fetal RHD7 expression calculation: Maternal RHD7 / 
Maternal EIF2C1 = 28.65 copies/ µL / 46.05 copies/ µL = 0.62. 
 Ratio based on dual fetal RHD7 expression calculation: Maternal RHD7/ Maternal 
EIF2C1 = 26.8 copies/ µL / 46.05 copies/ µL = 0.58.  
Since both ratios illustrated a ratio closer to 0.5 than 1, it showed that the mother of sample 
132 is hemizgous for the RHD7 gene loci rather than homozygous. It is difficult to determine 
whether the fetus expresses one or two copies of the RHD7 target. However, since the ratio 
calculated based upon the fetus displaying two copies of RHD7 is closer to 0.5, it is more 
feasible that the fetus is homozygous for RHD7. In this instance the fetus would have 
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inherited D-variant allele rather than the D-negative allele from the mother in addition to the 
paternally inherited RHD allele.  
 
Figure ‎6-10: Bar chart illustrating the cffDNA fraction (%) for maternal samples 
collected in Streck BCTs (n=11) before (non-PP (plain colour)) and after (PP (striated 
colour)) PP gel electrophoresis using concentrations (copies/ µL) generated by ddPCR. 
The cffDNA fraction was calculated by dividing each target concentration (copies/ µL), 
RHD5 (blue) and RHD7 (red), by the reference (EIF2C1) concentration (copies/ µL) (refer to 
2.9.4). The dashed lines at 15%, 20% and 25% illustrate three cut-off points for fetal T21 
NIPD (Table 6-5). For example, all eleven maternal samples (PP) had at least one target 
above the 15% threshold, whereas the non-PP aliquots only had four maternal samples that 
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displayed at least one target above the 15% cut-off. At 25% cut-off, none of the non-PP 
maternal samples displayed cffDNA fractions >25%, whereas seven of the PP aliquots had at 
least one target above this threshold.  
  
Figure ‎6-11: Bar chart illustrating the cffDNA fraction (%) change following PP gel 
electrophoresis for nine maternal samples (117, 118, 120, 122, 123, 124, 131, 132 and 
133). Sample 130 was excluded since this fetus was RHD-, and maternal sample 119 was 
excluded since RHD5 target was not detected following PP gel electrophoresis. The results 
illustrated that all cffDNA fractions increased when calculated using the RHD7/ EIF2C1 
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assay. The cffDNA fractions calculated using the RHD5/ EIF2C1 assay illustrated an 
increase in cffDNA fractions for eight maternal samples. However, for maternal sample 133 a 
2.47% decrease in cffDNA fraction following PP gel electrophoresis was seen.  
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EIF2C1 
A) Sample 119 (RHD5/ EIF2C1 Assay) non-PP maternal aliquot 
B) Sample 119 (RHD5/ EIF2C1 Assay) PP maternal aliquot 
316 
 
 
 
  
 
  
 
  
 
RHD7 
RHD7 
EIF2C1 
EIF2C1 
EIF2C1 
Negative 
Negative 
Negative 
Dual positive  
Dual positive  
Dual positive  RHD5 
C) Sample 119 (RHD7/ EIF2C1 Assay) non-PP maternal aliquot 
D) Sample 119 (RHD7/ EIF2C1 Assay) PP maternal aliquot 
E) Sample 132 (RHD5/ EIF2C1 Assay) non-PP maternal aliquot 
317 
 
 
 
  
 
 
 
RHD5 
RHD7 
RHD7 
EIF2C1 
EIF2C1 
EIF2C1 
Dual positive  
Dual positive  
Dual positive  
Negative 
Negative 
Negative 
F) Sample 132 (RHD5/ EIF2C1 Assay) PP maternal aliquot 
G) Sample 132 (RHD7/ EIF2C1 Assay) non-PP maternal aliquot 
H) Sample 132 (RHD7/ EIF2C1 Assay) PP maternal aliquot 
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Figure ‎6-12: 2D Amplitude plots generated by ddPCR for maternal samples 119 (A-D) 
and 132 (E-H) for non-PP aliquots (A, C, E and G) and PP aliquots (B, D, F and H). The 
Results illustrated that the non-PP aliquot of sample 119 showed positive droplets for both 
RHD5 (A) and RHD7 (C) targets. However, the PP aliquot of sample 119 did not show any 
positive RHD5 amplification (B) and only illustrated a single positive droplet for RHD7 
amplification (D). The results for sample 132 illustrated amplification of RHD5 for both non-
PP (E) and PP (F) aliquots indicative of cffDNA fractions (7.28%  and 16.4%, respectively). 
Contrastingly, analysis of maternal sample 132 using the RH7/ EIF2C1 assay illustrated a 
dramatic increase in number of positive RHD7 targets for both non-PP and PP aliquots, 
resulting in cffDNA fractions >100% (Table 6-3). 
 
The results illustrated low numbers of positive droplets for maternal samples, particularly 
following PP gel electrophoresis (Figure 6-12), and sample 119 following PP there were no 
positive fetal specific droplets. Therefore, to enhance sensitivity more data target points need 
to be determined. This could be achieved in future assays by increasing the starting amount of 
DNA added, firstly by extracting from larger volumes of maternal plasma (and eluting in the 
same volume (40 µL)) and secondly by increasing primer/ probe starting concentrations so 
that a larger volume (>5 µL) of DNA can be added  per 20 µL reaction. In addition, merging 
multiple wells help to increase the number of informative droplets.  
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PP gel electrophoresis and ddPCR analysis was repeated for three maternal samples: 131HIJ 
(as previous results illustrated low increase in cffDNA fraction), 132HIJ (as previous result 
illustrated potential maternal D-variant status) and 133HIJ (as previous result illustrated 
decline in cffDNA fraction based upon RHD5 calculation). Previous optimisation 
experiments using maternal sample 119HIJ prevented repeat experiment for this sample. The 
results illustrated that maternal sample 133HIJ still illustrated a decline in cffDNA fraction 
based upon the RHD5 assay (Table 6-4) (Figure 6-13) and also illustrated a lower increase in 
cffDNA fraction for the RHD7 assay (from a 6.7% increase to a 1.7% increase in cffDNA 
fraction).  
The repeat experiment for maternal sample 132HIJ also illustrated cffDNA fractions >100% 
for the RHD7 assay and a relatively normal cffDNA for the RHD5 assay (21.8%) (Table 6-4) 
(Figure 6-13). The repeat experiment for maternal sample 131HIJ showed an improved 
increase in cffDNA fraction compared to the initial run for both the RHD5 assay (from a 
3.1% increase to a  7.1% increase in cffDNA fraction) and the RHD7 assay (from a  0.68% 
increase to a 19.3% increase in cffDNA fraction) (Figure 6-13).  
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Table ‎6-4: Results for repeat ddPCR experiment for maternal samples 131-133HIJ (PP) showing cffDNA fractions based on 
concentration of target (FAM) and reference (EIF2C1) genes for multiplex reactions RHD5 (FAM)/ EIF2C1 (HEX) and RHD7 (FAM)/ 
EIF2C1 (HEX). The results for the first run following PP gel electrophoresis and non-PP aliquots are shown in Table 6-3. 
 
 
 
 
 
Sample  
Conc 
(ng/ul) 
RHD5/EIF2C1 RHD7/EIF2C1 
RHD5-FAM 
(copies/µl) 
EIF2C1-HEX 
(copies/µl) 
Fetal 
Fraction*  
/ratio 
RHD7-FAM 
(copies/µl) 
EIF2C1-HEX 
(copies/µl) 
Fetal Fraction 
(%)/ *ratio 
C
o
n
tro
ls 
1
2
/0
3
/1
5
 
NTC - 0 0 - 0 0 - 
276R - - 0 72.6 - 0 71.3  
2470 + - 110 111 0.994 96.1 93.1 1.03 
M
atern
al 
S
am
p
les 
1
2
/0
3
/1
5
 
131HIJ PP 5.2 0.221 3.1 
14.2 
0.363 2.7 
26.8 
132HIJ PP 4.4 0.532 4.88 
21.8 
3.66 3.87 
189 
133HIJ PP 2.9 0.0412 2.39 
3.44 
0.173 2.56 
13.5 
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Figure ‎6-13: Bar chart illustrating the cffDNA fraction (%) for maternal 
samples 131HIJ, 132HIJ and 133HIJ based on calculations using the RHD5 (A) 
and RHD7 (B) fetal target concentrations (copies/ µL) generated by ddPCR for 
a single non-PP aliquot (black) and two repeats of the PP aliquot (grey).  
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In a previous study, it was determined (using spiked samples) that cffDNA fractions of ≥25% 
are required to accurately determine fetal trisomy using a digital PCR platform (~770 
partitions) (Table 1-4). However, since more partitions are produced using the ddPCR 
platform (up to 20,000), it is feasible that lower cffDNA fractions could be required for 
accurate diagnosis of fetal Trisomy from maternal plasma samples. Table 6-5 illustrates the 
number of samples that would have been feasible for T21 analysis before and after PP gel 
electrophoresis based on cut off cffDNA fractions at 15%, 20% and 25%. The results 
illustrated that if cffDNA fractions of 25% were required only 2/10 samples would have been 
acceptable for T21 analysis. However, following PP gel electrophoresis, 8/10 samples 
produced cffDNA fractions ≥25%. If the cut off cffDNA fraction could be lowered to 15%, 
then all samples would have been valid for T21 analysis when enriched using PP gel 
electrophoresis. Alternatively, a cut off of 15% cffDNA, only 4/10 samples would have been 
adequate for T21 analysis without any prior enrichment (Table 6-5). To determine the 
cffDNA fraction required for NIPT of fetal trisomy subsequent spiking experiments were 
conducted (6.3.2).  
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Table ‎6-5: Number of samples acceptable for T21 analysis (with at least one target 
above threshold) before (non-PP) and after (PP) PP gel electrophoresis for cffDNA 
fraction cut-offs of 15%, 20% and 25%. For graphic representation of cffDNA fractions 
determined for each target (RHD5 and RHD7) against each threshold (dashed line) refer to 
Figure 6-10.  
cffDNA 
fraction cut-off 
(%) 
Number of samples with at least 
1 target over threshold (before 
PP) 
Number of samples with at least 
one target over threshold (after 
PP) 
25% 
4/10 
(maternal samples; 118, 120, 122* 
and 132*) 
10/10 
(maternal samples 117, 118, 119*, 
120, 122, 123, 124, 131, 132 and 
131) 
20% 
3/10 
(maternal samples; 120, 122* and 
132*) 
10/10 
(maternal samples 117, 118, 119*, 
120, 122, 123, 124, 131, 132 and 
131) 
15% 
2/10 
(maternal samples; 120 and 132*) 
10/10 
(maternal samples 117, 118, 119*, 
120, 122, 123, 124, 131, 132 and 
131) 
*Sample only illustrated cffDNA fraction >threshold based on RHD7 and not RHD5 
calculation (refer to 2.4.9). For sample 119, no RHD5 target was detected for PP sample. 
** Sample only illustrated cffDNA fraction >threshold based on RHD5 and not RHD7 
calculation (refer to 2.4.9). 
6.2.2 Spiking Experiments  
6.2.2.1 Male gDNA spike experiments to determine detection of low copy targets  
Before determining the cffDNA fraction required for T21 analysis, male gDNA spike 
experiments were conducted to determine the ability of ddPCR to detect a) a single copy 
(SRY) and b) a multiple-copy (TSPY1) Y-specific target, when male gDNA is spiked into 
female gDNA (3.2.3) down to 1% and 0.1%, respectively. Figure 6-14 illustrates the ddPCR 
results for the SRY (FAM) / Xp22.3 (HEX) multiplex reactions. The results showed one dual 
positive droplet in the NTC and the 100% male control sample illustrated a 49.46% fractional 
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abundance of the Y-target (50% expected) (Table 6-6). The results illustrated 1181 SRY 
events and 1207 Xp22.3 events for the male control sample (2388 total) and the female 
control illustrated twice as many Xp22.3 events (2359) and no SRY events as expected 
(Figure 6-14). Since there was only a 1.2% difference between the total number of events for 
male and female gDNA control samples, this illustrated accurate dilution of both samples. If 
the results had revealed slightly higher concentrations of either the male gDNA or the female 
gDNA the data generated from the spiked samples would have been skewed.  
Figure ‎6-14: Clustered bar-chart illustrating the number of positive droplets (Events) 
for SRY (FAM) (blue), Xp22.3 (HEX) (green) and the total (grey) generated by ddPCR 
for NTC, 100% male gDNA, 100% female gDNA and male gDNA spikes from 50% 
(wt/wt) down to 1% (wt/wt). The NTC shows no amplification and the Female control 
shows only amplification of the Xp22.3 (HEX) reference, which generated roughly twice as 
many positive droplets compared to the Xp22.3 number of events generated by the Male 
control (refer to Table 6-6). The Male control also illustrated a similar number of events for 
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SRY and Xp22.3 (refer to Table 6-6). The spikes demonstrated a decrease in SRY events, but 
still detect 16 positive droplets for the 1% Male to 99% Female gDNA spike (wt/wt).  
Table 6-6 summarises the number of events for SRY and Xp22.3 (Figure 6-14) for all samples 
and also illustrated the expected and actual fractional abundance of SRY. The results 
demonstrated that even when spiked into female gDNA at 1%, the ddPCR platform could still 
detect 17 droplets containing The Y-specific target. Chi-squared analysis of the expected and 
observed SRY fractional abundance (Table 6-6) revealed that only the 100%, 50% and 10% 
(wt/wt) Male gDNA spikes illustrated no significant difference. Although, the 5%, 3% and 
1% (wt/wt) Male gDNA spiked samples showed similar expected and observed values (Table 
6-6), the Chi-squared test revealed that there was significant differences between the 
observed and expected SRY fractional abundance for the 5% (wt/wt) Male spike (<0.05), the 
3% Male spike (<0.001) and the 1% Male spike (<0.001). This indicates that more care is 
required when producing spikes <10%. However, it is important to note that for values less 
than 5, the Chi-squared test can be quite inaccurate. Lower droplet amplification was visible 
for the 5% spike compared to the 3% spike. This is likely to be due to handling error rather 
than decreased sensitivity, therefore it may be beneficial to include more replicates and 
exclude outlying results as commonly practiced with qPCR.  
Table ‎6-6: Events (positive droplets) for SRY (FAM) and Xp22.3 (HEX) illustrating the 
actual fractional abundance of SRY against the expected fractional abundance.   
 
SRY 
(H.P.T)
 
FAM 
(events) 
SD 
Xp22.3 
HEX 
(events) 
SD Ratio 
Expected 
Fractional 
abundance 
of SRY (%) 
Actual 
fractional 
abundance 
of SRY (%) 
NTC 1 - 1 - - - - 
Male 2ng/ µL 
(100%) 
1181 18.33 1207 21.21 0.977 50% 49.46% 
Female 
2ng/µL  
0 - 2359 52.27 - 0% 0% 
50% Male 
Spike 
604 5.53 1849 12.77 0.31 25% 24.62% 
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10% Male 
Spike 
118 5.29 2363 22.34 0.0457 5% 4.76% 
5% Male 
Spike 
49 5.29 2427 32.51 0.0183 2.5% 1.98% 
3% Male 
Spike 
55 7.21 2660 51.97 0.0184 1.5% 2.03% 
1% Male 
Spike 
17  2167  0.00711 0.5% 0.79% 
 
Figure 6-15 shows the 1D amplitude plots for SRY (A) and Xp22.3 (B) for all samples. The 
plots highlight the decline in number of positive droplets for the SRY target as the proportion 
of male gDNA is reduced from 50% down to 1% and the relative stability of positive droplets 
(events) for the Xp22.3 reference. In addition to being able to detect low levels of copy target 
number, these results also show the ability of ddPCR to accurately calculate the abundance of 
target in relation to the reference gene.  
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6-15: 1D amplitude plots showing SRY (FAM) (blue) and Xp22.3 (HEX) (green) 
positive droplets (events) for NTC, female gDNA (100%), male gDNA (100%), 50% 
male spike, 10% male spike, 5% male spike, 3% male spike and 1% male spike. The 
            100%    100%     50%     10%       5%         3%       1% 
             Male   Female    Male    Male    Male      Male      Male 
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pink line in each plot demonstrated the threshold set manual to best discriminate between 
positive (blue/ green) and negative (grey) droplets.  
Subsequently, male gDNA was spiked into female gDNA at the following concentrations: 
50%, 10%, 5%, 0.5% and 0.1%. These spiked samples, along with NTC, 100% male gDNA 
and 100% female gDNA were analysed on the ddPCR platform using the TSPY1 (FAM)/ 
Xp22.3 (HEX) multiplex assay. In this assay lower fetal fractions were tested (0.5% and 
0.1%) since the TSPY1 is a multiple-copy target, and thus more droplets should be detectable 
at lower ‘cffDNA fractions’.  However, the data was only used to detect presence of TSPY1 
down to 0.1%, fractional abundance was not calculated due to the repetitive nature (up to 30 
repeats, (Barrett et al., 2012))  of the TSPY1 fragment, and thus more reliable ‘cffDNA 
fractions’ are likely to be calculated using single-copy targets. Figure 6-16 illustrates the 
number of events for amplicon. The 100% female gDNA (2ng/ µL) sample only showed 
amplification of the Xp22.3 reference and the NTC did not show any amplification. The 
100% male gDNA sample and the male-spiked samples illustrated a decline in number of 
events as the fraction of male gDNA decreased as expected. The results demonstrated that 
even when male gDNA was spiked into female gDNA at 0.1%, the ddPCR platform could 
still detect 16 positive droplets.  
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Figure ‎6-16: Clustered bar-chart illustrating the number of positive droplets (Events) 
for TSPY1 (FAM) (blue), Xp22.3 (HEX) (green) and the total (grey) generated by 
ddPCR for NTC, 100% male gDNA, 100% female gDNA and male gDNA spikes from 
50% down to 0.1%. The results illustrate no amplification for the NTC and only 
amplification of Xp22.3 for the Female gDNA control sample. Though, 30 copies of TSPY1 
were expected, the Male gDNA control sample only illustrated ~10x the number of events for 
the TSPY1 target against the single-copy reference target (Xp22.3). The spike samples 
illustrate a decline in the number of positive droplets as the percentage (wt/wt) of Male 
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gDNA decreases. However, even when spiked at 0.1%, 16 TSPY1 positive droplets were 
detected.  
The concentration (copies/ µL) of TSPY1 and Xp22.3 for each sample is shown in Figure 6-
17. The results demonstrated an 11.3-fold increase in the proportion of TSPY1 compared to 
the reference (Xp22.3) for the 100% male gDNA (2ng/ µL) sample (Figure 6-17). This is 
lower than expected since previous studies have identified that 30 repeats of the DYS14 
region on the TSPY1 gene are present (Barrett et al., 2012). Based on the concentration of 
TSPY1 at 100% (812 copies/ µL), Table 6-7 illustrates the expected and actual concentration 
of TSPY1 for the 50%, 10%, 0.5% and 0.1% male-spiked samples. The results illustrated that 
larger variations in actual concentrations relative to the expected value were seen when lower 
amounts of male gDNA were present (Table 6-7). Figure 6-18 shows the 1D amplitude plots 
for TSPY1 (A) and Xp22.3 (B) for all samples. The plots highlight the decline in number of 
positive droplets for the TSPY1 target as the proportion of male gDNA is reduced from 50% 
down to 1% and the relative stability of positive droplets (events) for the Xp22.3 reference. 
Figure ‎6-17: Concentration (copies/ µL) of TSPY1 (blue) and Xp22.3 (green) for NTC, 
100% female gDNA, 100% male gDNA, 50% male spike, 10% male spike, 5% male 
spike, 0.5% male spike and 0.1% male spike.  
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Table ‎6-7: Expected concentrations (copies/ µL) of TSPY1 based on concentration value 
for 100% male gDNA and actual concentration (copies/ µL). 
Sample 
Actual 
concentration 
(A) 
(copies/ µL) 
Expected 
concentration 
(E)  
(copies/ µL) 
a
 
Difference 
((A-E)/ A)*100 
(%) 
b 
100% male 
gDNA 
812 812 n/a 
50% male 
gDNA 
437 406 7.1% increase 
10% male 
gDNA 
97.4 81.2 16.7% increase 
5% male 
gDNA 
37 40.6 8.9% decrease 
0.5% male 
gDNA 
6.08 4.06 33.2% increase 
0.1% male 
gDNA 
1.22 0.812 33.4% increase 
a 
based on 100% male gDNA  
b 
Change in concentration (copies/ µL) from expected concentration (based upon result for 
100% male gDNA)  to actual concentration.   
 
 
 
 
 
 
 
Figure ‎6-18: 1D amplitude plots showing TSPY1 (FAM) (blue) and Xp22.3 (HEX) 
(green) positive droplets (events) for NTC, female gDNA (100%), male gDNA (100%), 
50% (wt/wt) Male gDNA spike down to  0.1% (wt/wt) Male gDNA spike. 
              100%   100%      50%       10%       5%      0.5%     0.1% 
              Male   Female   Male       Male     Male     Male    Male 
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6.2.2.2 T21 gDNA spike experiment to determine the minimal cffDNA fraction required for 
NIPT of fetal T21 
To determine the minimal cffDNA fraction required to detect a significant difference between 
the T21 gDNA spike samples and the control D21 sample, two multiplex reactions were used. 
The first reaction involved a previously optimised ddPCR assay (APP (FAM)/ EIF2C1 
(HEX)) and the second introduced a new chromosome 21 target, DSCR3, also labelled with 
FAM and multiplexed against the EIF2C1 (HEX) reference gene. Final concentrations of 
300nM and 250nM were used for all primers and probes, respectively, for oligonucleotide 
information refer to Table 2-1. To evaluate the new chromosome 21 target amplicon 
(DSCR3), singleplex and multiplex reactions for DSCR3 (FAM) and EIF2C1 (HEX), were 
initially carried out at 60°C Ta. The results illustrated a ratio of 1.46 for the T21 gDNA for 
both the singleplex and multiplex reactions, but a ratio closer to 1 was observed for the D21 
cfDNA sample when carried out in a singleplex reaction (0.98) compared to the multiplex 
reaction (0.91) (Figure 6-19). Consequently, an annealing temperature gradient (from 57.8°C 
down to 55°C) was run to determine the optimum Ta for the multiplex reaction. The clarity of 
droplet separation and the DSCR3/ EIF2C1 ratio achieved for D21 sample (110W) was 
analysed to determine the optimum Ta. The results illustrated that a ratio of 1 was achieved 
when amplified at 56°C and slightly higher ratios were obtained for the other Ta’s (Figure 6-
20). Since 57.8°C illustrated the second best ratio (1.01), droplet separation at this Ta was 
compared to droplet separation at 56°C (Figure 6-21). The results demonstrated superior 
droplet separation at 56°C and therefore this Ta was determined to be optimum for the DSCR3 
(FAM)/ EIF2C1 (HEX) multiplex assay.  
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Figure ‎6-19: Concentration (copies/ µL) of DSCR3 (FAM) (blue) and EIF2C1 (HEX) 
generated by ddPCR for D21 and T21 samples set up in both singleplex and multiplex 
reactions. The graph also illustrated the DSCR3/ EIF2C1 ratio for all samples. This 
reaction was carried out at 60°C Ta. The NTC did not illustrate any amplification. The T21 
singleplex and multiplex reactions both generated a ratio (DSCR3/ EIF2C1) of 1.46, whereas 
the singleplex reaction for the D21 sample expressed a ratio closer to 1 (0.98) than the D21 
multiplex reaction (0.91).  
Ratio:  
0.98 
Ratio:  
0.91 
Ratio:  
1.46 
Ratio:  
1.46 
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Figure ‎6-20: Concentration (copies/ µL) of DSCR3 (blue) and EIF2C1 (green), and the DSCR3/ EIF2C1 ratio (red) generated by ddPCR 
for disomy sample 110W at 57.8°C, 56.7°C, 56°C and 55°C. The results showed that the optimum ratio (closest to 1) was achieved at 56°C, 
which demonstrated 241 copies/ µL of DSCR3 and 241 copies/ µL of EIF2C1, giving a ratio of exactly 1 (241/241). 
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Figure ‎6-21: 2D amplitude plot for multiplex reaction (DSCR3 (FAM)/ EIF2C1 (HEX)) 
showing droplet separation for Male gDNA amplification at 56°C Ta (top) and 57.8°C 
Ta (bottom).  
The primer aliquots of the APP-FAM/ EIF2C1-HEX multiplex assay were re-tested against 
pooled male (D21) and pooled female (D21) gDNA. The ddPCR run was carried out at 
56.5°C, since this was determined to be optimum temperature in previous experiments 
(3.2.5). Both samples were tested in triplicate against NTC and the mean (±SD) concentration 
for the chr21-specific (APP) and chr1-specific (EIF2C1) target for each sample is illustrated 
in Figure 6-22. The results illustrated a ratio of 1.03 for both male and female gDNA 
DSCR3 
EIF2C1 
Dual positive  
Negative 
DSCR3 
EIF2C1 
Dual positive  
Negative 
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samples, which illustrated effective amplification since a ratio of 1 was expected. Previous Ta 
optimisation experiments illustrated a less desirable ratio (1.11) at 56°C (3.2.5). It is likely 
that the improved ratios could have been attributed to increased experience, since previous 
results were obtained shortly after the instillation of the ddPCR system or alternatively slight 
contamination of sample used in previous experiments.  In addition, in this experiment results 
were carried out in triplicate, whereas the initial experiment was only carried out in duplicate. 
Sample
NTC Disomy Female Disomy Male 
C
o
n
c
en
tr
at
io
n
 (
c
o
p
ie
s/
 
L
)
0
50
100
150
200
250
300
APP concentration (copies/ L) 
EIF2C1 concentration (copies/ L) 
 
Figure ‎6-22: Mean concentration (copies/ µL) ±SD of APP (FAM) (dark blue) and 
EIF2C1 (HEX) (green) generated by ddPCR for disomy (pooled) female gDNA (2ng/ 
µL) and disomy (pooled) male gDNA (2ng/ µL). The results illustrated a ratio (APP/ 
EIF2C1) of 1.03 for both male and female gDNA. 
Ratio: 
1.03 
Ratio: 
1.03 
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Once both multiplex assays had been optimised, DNA was extracted from the buffy coat of 
human whole blood from sample 3135 (refer to 2.1.2), which was used for spiking 
experiments as opposed to pooled male or female gDNA samples (refer to 2.1.1). This is 
preferred since the T21 gDNA, obtained from a single patient, can be spiked into a single 
D21 sample, which is more representative of a maternal sample than pooled Female gDNA. 
The D21 sample (3135) was spiked with T21gDNA (refer to 6.2.3) from 50% down to 10%. 
These spiked samples were then tested in triplicate, alongside 100% D21 cfDNA (3135), 
100% T21 gDNA and NTC. The first experiment was carried out for the DSCR3-FAM/ 
EIF2C1-HEX multiplex assay, which was amplified at 56°C Ta. Consequently, the 
experiment was repeated (using the same samples) but this time using the APP-FAM/ 
EIF2C1-HEX multiplex assay, which was run at previously optimised Ta (56.5°C). The 
concentration (copies/ µL) of each target and the consequent ratio (and ratio means) 
calculated for each sample are summarised in Table 6-8 and Table 6-9 for the DSCR3/ 
EIF2C1 and APP/ EIF2C1 assays, respectively. The expected ratio for each spiked and non-
spiked sample are also shown (Table 6-8 and Table 6-9). 
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Table ‎6-8: Summary of results illustrating the concentration (copies/ µL) of DSCR3 
(FAM) and EIF2C1 (HEX) and the ratios calculated based upon concentration for each 
triplicate reaction and the mean concentration. The mean ratio calculated (blue) is shown 
next to the expected ratio (green) for each non-spiked and T21 gDNA –spiked sample (from 
50% down to 10%). 
DSCR3/ EIF2C1 
Samples 
DSCR3-
FAM 
(copies/µl) 
Mean 
EIF2C1-
HEX 
(copies/µl) 
Mean Ratio 
Mean 
Ratio* 
Expected 
Ratio* 
NTC 0 
0 
0 
0 
- 
- - NTC 0 0 - 
NTC 0 0 - 
Disomy 455 
406 
446 
388 
1.02 
1.05 1.00 Disomy 320 304 1.05 
Disomy 454 422 1.07 
T21 100% 602 
606 
394 
394 
1.53 
1.54 1.50 T21 100% 613 388 1.58 
T21 100% 603 400 1.51 
T21 50% 546 
536 
424 
427 
1.29 
1.26 1.25 T21 50% 533 437 1.22 
T21 50% 530 421 1.26 
T21 25% 526 
503 
455 
444 
1.16 
1.13 1.13 T21 25% 496 432 1.15 
T21 25% 486 444 1.09 
T21 20% 484 
478 
428 
430 
1.13 
1.11 1.10 T21 20% 462 432 1.07 
T21 20% 487 430 1.13 
T21 15% 489 
489 
438 
435 
1.11 
1.12 1.08 T21 15% 493 436 1.13 
T21 15% 485 429 1.13 
T21 10% 472 
462 
438 
438 
1.08 
1.05 1.05 T21 10% 455 436 1.04 
T21 10% 460 441 1.04 
* To 2 decimal places  
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Table ‎6-9: Summary of results illustrating the concentration (copies/ µL) of APP (FAM) 
and EIF2C1 (HEX) and the ratios calculated based upon concentration for each 
triplicate reaction and the mean concentration. The mean ratio calculated (blue) is shown 
next to the expected ratio (green) for each non-spiked and T21 gDNA –spiked sample (from 
50% down to 10%). 
APP/ EIF2C1 
Samples 
APP-FAM 
(copies/µl) 
Mean 
EIF2C1-
HEX 
(copies/µl) 
Mean Ratio 
Mean 
Ratio* 
Expected 
Ratio* 
NTC 0.117 
0.208 
0 
0.0297 
- 
- - NTC 0.186 0.093 - 
NTC 0.257 0 - 
Disomy 352 
368 
369 
367 
0.955 
1.00 1.00 Disomy 374 369 1.01 
Disomy 374 367 1.02 
T21 100% 520 
515 
349 
347 
1.49 
1.49 1.50 T21 100% 509 345 1.48 
T21 100% - - - 
T21 50% 440 
440 
355 
356 
1.24 
1.24 1.25 T21 50% 440 357 1.23 
T21 50% - - - 
T21 25% 397 
397 
345 
353 
1.15 
1.13 1.13 T21 25% 396 360 1.10 
T21 25% - - - 
T21 20% 402 
404 
367 
365 
1.09 
1.11 1.10 T21 20% 406 364 1.12 
T21 20% - - - 
T21 15% 377 
381 
354 
353 
1.06 
1.08 1.08 T21 15% 385 351 1.1 
T21 15% - - - 
T21 10% 367 
369 
352 
353 
1.04 
1.05 1.05 T21 10% 371 354 1.05 
T21 10% - - - 
* To 2 decimal places 
 
The results illustrated that the ratios generated for both multiplex assays were extremely close 
to the expected ratio for all spiked and non-spiked samples (Table 6-8 and Table 6-9) (Figure 
6-21). The results illustrated no amplification of targets for the NTC in both assays and THE 
D21 control demonstrated ratios of 1.05 and 1 for the DSCR3/ EIF2C1 multiplex assay and 
the APP/ EIF2C1 multiplex assay, respectively. The 100% T21 gDNA control sample also 
illustrated a ratio closer to 1.5 for the APP/ EIF2C1 assay compared to the DSCR3/ EIF2C1 
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assay (1.49 and 1.54, respectively). The DSCR3/ EIF2C1 assay ratios for the 50%, 25%, 20% 
and 10% spiked samples were within 0.01 of the expected ratio (Table 6-8). The result for the 
15% spike was slightly higher than expected (Table 6-8) (Figure 6-23). The results for all 
spiked (and non-spiked) samples generated from the APP/ EIF2C1 assay all demonstrated 
ratios within 0.01 of what was expected, with three spiked samples (10%, 15% and 25%) 
giving the exact expected ratio. Since the 100% D21 sample and 10% spike sample gave the 
same ratio (1.05) for the DSCR3/ EIF2C1 assay, but the APP/EIF2C1 assay achieved a ratio 
of 1 for the 100% D21 sample, statistical analysis was carried on the second assay.  
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Figure ‎6-23: Clustered bar chart illustrating the mean ratio ±SD calculated from 
quadruplet replicates based upon the DSCR3/ EIF2C1 (blue) assay and the 
APP/EIF2C1 assay (purple) compared to the expected ratio for each T21 spike and 
controls (black). The following samples were tested; NTC, 100% D21 cfDNA (3135) (2ng/ 
µL), 100% T21 gDNA (2ng/ µL), and D21 cfDNA (3135) spiked with 50%, 25%, 20% 15% 
and 10% T21 gDNA. The dashed lines illustrate the expected ratio for 100% D21 gDNA 
(bottom) at ratio 1 and the expected ratio for 100% T21 gDNA (top) at ratio 1.5.   
Statistical analysis using a comparative t-test on SigmaPlot v13.0 was used to compare ratio 
results achieved for the D21 cfDNA sample against all other samples containing 100% 
T21gDNA down to 10% T21gDNA. The results revealed that a significant increase in ratio 
100% T21 
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was observed for samples that expressed 100% T21 gDNA down to 15% T21 gDNA (Figure 
6-22). The 10% T21 gDNA sample did not show a significant increase in ratio compared to 
the D21 gDNA sample (p>0.05) (Figure 6-22). This preliminary data, using pseudo-maternal 
samples in triplicate indicated that when using the APP/ EIF2C1 assay T21 could be detected 
when the pseudo-fetal proportion constituted ≥15% of the total sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6-24: Bar chart illustrating the APP/ EIF2C1 expected ratio (black) and actual 
ratio (purple) for NTC, 100% D21, 100% T21 and spike samples (50% down to 10%). 
Comparative t-tests revealed a significant increase in ratio value (compared to the 100% D21 
gDNA) for the following samples: 100% T21 gDNA (P<0.001) 50% T21 gDNA (p<0.001), 
25% T21 gDNA (p<0.005), 20% T21 gDNA (p<0.005) and 15% T21 gDNA (p<0.05).  The 
10% spiked-sample did not illustrate a significant increase in ratio compared to the D21 
control sample.  
*** 
** 
** 
* 
*** 
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6.3 Discussion  
6.3.1 Pippin Prep™ Size Selective Enrichment  
The results illustrated successful cffDNA enrichment for all samples (excluding 
119) when analysed using the SRY (maternal sample 9), TSPY1 (maternal sample 
13, 24, 36 and 43) and the RHD7 (maternal samples 117, 118, 120, 122, 123, 124, 
131, 132 and 133) assays (Figure 6-2, Figure 6-5 and Figure 6-11) (Table 6-3). 
Despite previous studies identifying high target recovery efficiencies using the PP 
size-selective approach (refer to 6.1) (Duhaime et al., 2012), one maternal sample 
(119) illustrated total loss of cffDNA following PP gel electrophoresis when 
analysed using the RHD5/ EIF2C1 assay. The aliquot analysed directly following 
DNA extraction illustrated cffDNA fractions of 9.53% and 4.59% for the RHD5 and 
RHD7 assay, respectively. However, analysis of the aliquot that was run on the PP 
platform only illustrated amplification of a single RHD7 target (Figure 6-12). 
Automated DNA extractions from maternal plasma/ serum have been shown to 
achieve significantly higher yields of cffDNA (Huang et al., 2005; Müller et al., 
2008). By combining this automated approach with increased starting quantities of 
maternal plasma (up to 5 mL) higher yields of cfDNA (particularly fetal) can be 
achieved. Consequently, by loading higher quantities of total cfDNA, the amount of 
cfDNA eluted following PP gel electrophoresis is also likely to increase.  
The Agilent 2100 Bioanalyzer results illustrated drop out of larger fragments 
following PP gel electrophoresis (Figure 6-3, Figure 6-4, Figure 6-8 and Figure 6-
9). Consequently, the ddPCR analysis revealed a significant decrease in 
concentration of the reference gene (Xp22.3) compared to the fetal specific target 
(TSPY1) (Figure 6-6) confirming selective enrichment of cffDNA. This results 
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reveals that whilst maternal DNA exhibits fragments at <200bp (Stephanie et al., 
2014), when additional maternal DNA is released by degradation of leucocytes, as 
seen with EDTA collected samples (refer to 1.3.3.5), a higher abundance of larger 
fragments are visible (Figure 6-3 and Figure 6-4) than when samples are collected 
in Streck BCTs (Figure 6-8 and Figure 6-9).  
In contrast, the RHD5 assay illustrated a decrease in cffDNA fraction (2.47%) for 
maternal sample 133, but did show successful enrichment for all other RHD+ 
fetuses tested (n=8) (Figure 6-11). The variation in cffDNA fraction for maternal 
sample 133 could be due to differences in assay efficiencies, since cffDNA fraction 
for all samples except 124 was higher based on the RHD7 assay (Figure 6-10). 
Previous results revealed similar cffDNA fractions, but illustrated a slightly higher 
average for the RHD7 assay also (Figure 5-18). It is possible that a SNP within the 
exon 5 target is affecting amplification. However, this does not explain the increase 
in cffDNA fraction seen for maternal sample 124. Whole genome sequencing has 
revealed that the entire fetal genome is present within the maternal circulation (Lo et 
al., 2010; Snyder et al., 2013) with predominant size-peaks for fetal (~143 bp) and 
maternal cfDNA (~166 bp) fragments (Lo et al., 2010). The increase in cffDNA 
was predominantly improved for samples using the RHD7 assay (n=7), however, 
two maternal samples (124 and 131) did illustrate greater improvements in cffDNA 
fraction for the RHD5 assay (Figure 6-11).  
It is possible that fragmentation differs between individuals; however, this 
preliminary data only illustrates the feasibility of PP gel electrophoresis for 
selective enrichment. Further larger scale studies are required to validate the 
reproducibility of this enrichment method. Consequently, visibility of patterns of 
selective enrichment of one target over the other would be enhanced with increased 
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sample size. Alternatively, it is likely that variation in enrichment between assays is 
a result of initiation of such a novel procedure and further testing is required to 
define the optimum parameters. To increase the reliability of the current PP 
experiments there are multiple steps that can be carried out in future experiments. 
Firstly, increasing the amount of cfDNA ran on the PP would increase in proportion 
collected in the elution phase. In addition, performing a brief current reversal at the 
end of sample elution can help to increase sample recovery by up 10% for 100-
200bp fragments. Alternatively, increasing the amount of DNA added per well for 
ddPCR analysis and increasing the number of replicates for each sample could 
increase the number of data points generated and improve detection and subsequent 
cffDNA fraction analysis. In the previous chapter it was determined that manual 
extractions led to reduced quality of maternal samples. Therefore, by implementing 
an automated approach may help to improve cffDNA recovery at the initial phase, 
which is likely to improve downstream ddPCR detection of fetal specific targets 
even following PP gel electrophoresis. It is important that fetal specific targets are 
identified for all samples to accurately determine cffDNA fraction and ensure that a 
false negative result is truly false negative and not a result of low cffDNA levels. 
Maternal sample 132 illustrated a dramatic increase in cffDNA fraction (>100%) for 
the RHD7 multiplex assay only. This indicated that the mother of this sample was 
not homozygous for a complete deletion of RHD since the RHD exon 7 amplicon 
was clearly expressed fetal from and maternal origin. In discordance, the RHD exon 
5 only illustrated fetal origin since cffDNA fractions of 7.28% and 16.43% were 
seen before and after PP, respectively. It is likely that patient 132 expressed either 
an RHD pseudogene or D variant allele (refer to 5.1.1). The RHD pseudogene is 
prevalent in Rh D- negative Africans (67%) (Singleton et al., 2000); however, the 
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ethnicity of maternal sample 132 is recorded as white British and is therefore 
unlikely to exhibit this genotype.  
Figure 6-25 illustrates the RHD and RHCE hybrid genes in some D variants. Since 
the results illustrated presence of maternal RHD exon 7, but not RHD exon 5, it is 
likely the mother expresses either a DVI or DVa variant (highlighted in red). Based 
on the genotype, RHD DVI has been subdivided into four types (1-4), which 
express variations in RHCE derived exons (Figure 6-25). The encoded phenotype of 
each DVI variant all differ, which consequently alters the strength and expression of 
the BARC antigen (Mouro et al., 1994; Avent et al., 1997).  BARC was first 
reported in 1989 as a low-prevalence antigen associated with some DVI RBCs 
occurring in <0.01% of all populations (Reid, Lomas-Francis and Olsson, 2012). In 
European populations, DVI types 1 and 2 are more prevalent, whereas DVI type 3 
and DVI type 4 are more predominant in specific regions such as Germany and 
Spain, respectively (Reid, Lomas-Francis and Olsson, 2012).  Further analysis of 
maternal sample 132 using commercially available kits, which test for a number of 
partial and D alleles, would have been desirable for confirmation of D variant. If we 
assume maternal sample expresses either a D
VI
 type 1 or type 2 variant, determining 
the presence of the BARC antigen would have enabled confirmation since type 1 
does not express BARC and type 2 does express BARC (Avent et al., 1997; Reid, 
Lomas-Francis and Olsson, 2012). However, lack of ethical approval for collection 
and storage of maternal buffy coat prevented further analysis.  
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Figure ‎6-25: RHD exons (black) and RHCE exons (white) of hybrid genes in 
some D variants. [Adapted from Daniels (2013)].  
6.3.2 Determining cffDNA fraction for aneuploidy detection  
The results illustrated successful detection of single-copy target (SRY) even when spiked at 
1% into female gDNA (151 GE’s of male DNA) and the multiple-copy target was detectable 
even when spiked at 0.01% (454.5 GE’s of male DNA). The digital PCR managed to detect 
48.4 copies and 24.4 copies per 20 µL reaction for the SRY-spike (1%) and TSPY1-spike 
(0.1%), respectively. Many studies have researched the capability of dPCR to detect rare or 
low copy targets in comparison to qPCR approaches (Pinheiro et al., 2011; Hayden et al., 
2013; Hindson et al., 2013; Strain et al., 2013; Kim, Jeong and Cho, 2014; Miotke et al., 
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2014; Sillence et al., 2015). While some studies illustrated improved precision and 
reproducibility of dPCR but similar levels of sensitivity (Hayden et al., 2013; Hindson et al., 
2013), many studies have shown improved sensitivity using dPCR over qPCR approaches 
(Pinheiro et al., 2011; Strain et al., 2013; Kim, Jeong and Cho, 2014; Miotke et al., 2014; 
Sillence et al., 2015). Previous data has also revealed the improved sensitivity of ddPCR 
(100%) to determine fetal sex and RHD genotype for samples expressing low cffDNA 
fractions (<2%) compared to qPCR (0%) (Chapter 5) (Sillence et al., 2015). Whilst this 
demonstrated the ability of ddPCR to detect low copy targets, determination of fetal 
aneuploidy is considerably more complicated since reliable and accurate quantification of 
small copy number changes between target and reference DNA is required.  
In addition to detection of low copy number targets, dPCR also enables accurate 
quantification using both microfluidic (Pinheiro et al., 2011; Sanders et al., 2011) and 
droplet-based (Strain et al., 2013; Ludlow et al., 2014; Miotke et al., 2014; Contente-Cuomo 
and Murtaza, 2015; Tsao et al., 2015) techniques. In one study, multiplex primers were 
designed to amplify short (67-71 bp) and long (439-522 bp) PCR products from independent 
regions of the human genome each labelled with FAM and TET, respectively (Contente-
Cuomo and Murtaza, 2015). Through analysis using picoliter ddPCR, the study revealed that 
the relative quantities of short and long fragments mirrored the integrity of sheared DNA 
input and accurate quantification could be achieved when using as few as 200 pg of cell-free 
DNA. In an alternative study, microfluidic dPCR was able to measure a smaller CNV 
compared to conventional qPCR for the investigation of HER2 gene amplification in breast 
cancer cell lines (Whale et al., 2012). This research was conducted using the BioMark HD 
(Fluidigm) dPCR instrument, which partitions each reaction into 770 x 0.84 nL chambers. 
Data published by Lo et al. (2007b), which produced simulations of pseudo-maternal samples 
containing 50%, 25% and 10% fetal DNA (obtained from placenta), used 384-well reaction 
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plates to carryout digital RCD using SPRT analysis. By constructing a range of SPRT curves 
based on the number of reference molecules per well (mr), chromosomal imbalance could be 
determined by plotting the proportion of informative wells containing the over-represented 
allele (Pr) against the total number of informative wells. The study revealed that at 25% 
‘cffDNA’, with a combined total of 7,680 PCR analyses, 97% of both euploid and aneuploidy 
cases would be classifiable, with 3% requiring further analyses until classification can be 
achieved (Lo et al., 2007b). The results revealed that with a decreasing fractional 
concentration of fetal DNA, a larger number of informative counts are required for digital 
RCD. However, to obtain cffDNA fractions of ≥25%, selective enrichment methods are 
required (Li et al., 2004). 
For samples expressing 100% T21, the RCD ratio should be 1.5, since there are three copies 
of chromosome 21 and two copies of any other autosomal reference chromosome. For 
maternal samples containing 10% cffDNA the RCD decreases to 1.05 (Lo et al., 2007b). The 
results in this study reveal accurate quantification on the QX100 ddPCR System, since all 
T21 spiked samples from 100% down to 10% illustrated the expected RCD ratio (or within 
0.01) (Figure 6-23 and Figure 6-24). Rather than carry out SPRT analysis, a comparative t-
test was used to determine significant difference between each individual spike sample 
against the 100% disomy control sample. The results illustrated that significant difference 
between the disomy sample (ratio: 1) and spiked samples were detectable down to 15% 
‘cffDNA’ using the QX100 (Bio-Rad) ddPCR platform for samples tested in triplicate 
(p<0.05) (Figure 6-24). In future experiments, increasing the number of replicates per run 
could help to decrease the minimal cffDNA fraction required for aneuploidy detection since 
averaging across more replicates reduces variability, improves precision and allows smaller 
changes to be detected (Yang and Speed, 2002). 
349 
 
The QX100 ddPCR System, which was used in this study, generates a 20-fold increase in the 
number of partitions (14,000 to 16,000 droplets per sample) compared to the Fluidigm 
BioMark HD platform (770 chambers). In addition, this method allows for increased sample 
partitions and higher throughput compared to the 384-well approach as described by Lo et al. 
(2007b). Alternatively, the RainDrop Digital PCR (RainDance™ Technologies, MA, USA) 
produces the highest number of partitions with up to 10,000,000 droplets per sample.  
Increasing the number of partitions per reactions enables detection of lower copy number 
targets and allows for improved quantification and subsequent detection of low level CNV. 
Our results illustrated that when tested in triplicate on the QX100 ddPCR System a minimum 
of 15% cffDNA fraction is required. As previously mentioned this could be improved by 
increasing the number of replicates or alternatively by transferring the assay onto the 
RainDrop Digital PCR (RainDance). However, the RainDance platform is costly (£7-£20 per 
sample) with lower throughput (8 samples per run) in comparison to the QX100 ddPCR 
system (£2 per sample; 96 samples per run) (Baker, 2012).  
6.3.3 Future work  
 To achieve a fetal fraction of 25%, enrichment techniques are required in most cases. The 
initial data from our research highlights the capability of PP gel electrophoresis to increase 
the cffDNA fractions. In addition, spike experiments conducted on the QX100 ddPCR 
System have identified that significant differences between disomy control samples and 15% 
T21 spiked samples are capable of being detected. The results from this study reveal that if a 
cut-off of 15% was accepted all maternal samples collected in Streck BCTs (117, 118, 119, 
120, 122, 123, 124, 131, 132 and 133) would have been eligible for aneuploidy analysis 
following PP enrichment (Table 6-5).   
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Future experiments combining multiple repeats per sample and higher starting quantities of 
maternal plasma could help to further reduce the minimum cffDNA fraction required for 
reliable detection of foetal aneuploidy using the QX100 ddPCR system. The enrichment 
results in this study were obtained from a maximum of 3 mL of maternal plasma. However, 
this can be further increased to up to 8 mL of plasma when collecting around 15mL of 
maternal blood, which is at the limit of routine practice (Lo et al., 2007).  
Alternatively, MLPA approaches have been used to determine aneuploidy from CVS, which 
revealed over 95% concordance with traditional karyotyping (Kooper et al., 2009). The 
advantage of MLPA is that many targets can be multiplexed in a single reaction, which 
makes it ideal for blood group typing, including RHD zygosity testing (Haer‐Wigman et al., 
2013a). The advantage of including multiple target loci is that if fragmentation does differ 
between individuals selective bias is reduced, increasing quantification reliability and 
consequently the digital RCD calculated. However, the approach is associated with lower 
sample throughput and longer run times (up to 25 hours) (Haer‐Wigman et al., 2013a). The 
results shown here illustrated excellent ratio analysis for the APP/ EIF2C1 multiplex 
reaction, but revealed slightly less optimal digital RCD using the DSCR3/ EIF2C1 multiplex 
reaction (Figure 6-23). Rather than develop MLPA based approaches for aneuploidy 
determination, future ddPCR experiments could combine multiple chromosome 21 targets 
(all labelled with FAM) against multiple references targets (all labelled with VIC/ HEX) to 
reduce fragmentation bias. Consequently, it is fundamental that the ddPCR RCD approach 
following PP enrichment is validated for actual maternal samples carrying T21 fetuses.  
It has been previously discussed that despite declines in the cost of NGS for NIPT of fetal 
aneuploidy, tests are still too expensive for implementation into routine clinical practice 
(refer to 1.3.3.3.2). The total cost of the PP enrichment assay combined with ddPCR analysis 
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(<£13.00 per sample) is considerably cheaper than commercial NIPT, which ranges from 
£400-£900 in the UK (Morris et al., 2014) making it a more economically viable test.  
6.3.4 Conclusion  
This data highlights the application of ddPCR for the detection of ‘fetal’ aneuploidy 
in samples expressing ≥15% ‘cffDNA’. Consequently, by using 15% cffDNA 
fraction as a cut-off, all maternal samples (collected in Streck BCTs) enriched by PP 
gel electrophoresis would have been viable for aneuploidy analysis. Further 
optimisation studies are required to define the limits of this ddPCR system for the 
determination of aneuploidy for spiked samples, and consequently actual maternal 
samples carrying T21 fetuses. However, the preliminary data demonstrates the 
feasibility of combining PP enrichment with ddPCR for the detection of fetal 
aneuploidy. The reduced costs associated with this procedure compared to 
established targeted MPS approaches, along with rapid turn-around times, makes 
this concept a legitimate competitor for routine testing.  
 
351 
 
Chapter 7 
 
 
 
 
 
 
 
 
 
Discussion 
  
352 
 
7.1 Size-selective enrichment of cffDNA  
The discovery of cffDNA within the maternal circulation revolutionised prenatal testing 
and created a platform for NIPD (Lo et al., 1997). NIPD of fetal sex and RHD status is 
already available (Chitty et al., 2008) and platforms to test for aneuploidy are also 
available commercially as secondary screening tests (Benn, 2014). Providing NIPD for 
such conditions eradicates the need for invasive tests, which are associated with a small 
but significant risk of miscarriage. While MPS approaches currently provide highly 
sensitive commercially available screening, developing a cost effective platform to 
accurately test for aneuploidy and single gene disorders, which can be applied to routine 
testing, is highly sought after. While NIPD is effective for fetal specific targets, detection 
of fetal chromosomal abnormalities cannot be used as a definitive diagnostic platform at 
present due to the small but significant risk of discordant results, which often arise due to 
low cffDNA fractions (refer to 1.3.3). Therefore, we set out to analyse a number of 
molecular techniques, other than gel extraction methods previously described (Li et al., 
2004), which could be used to size-select smaller fragments and consequently enrich 
cffDNA.   
Initially, it was determined that cffDNA was considerably shorter (<300bp) than maternal 
cfDNA (>1kb) (Li et al., 2004). Fragmentation differences were exploited for the 
selective enrichment of cffDNA (up to 50% total cffDNA), permitting the detection of 
fetal genetic loci, such as SNPs and paternally inherited mutations, which would have 
been undetectable prior to selective amplification (Li et al., 2004). However, since these 
initial studies, it has been determined that the variation between cffDNA and maternal 
cfDNA is lower (143bp to 166bp, respectively) than first described (Stephanie et al., 
2014). Consequently, enrichment approaches have not been used for detection of any 
genetic condition (Liao et al., 2011). Though the maternal cfDNA also constitutes smaller 
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fragments that are closer to the fragment sizes expressed by the fetus, the concept of size-
selective enrichment is still feasible since samples that show degradation can express a 
higher proportion of larger maternal cfDNA fragments (Qin, Williams and Fernando, 
2013; Qin, Bassett and Fernando, 2014; Sillence et al., 2015). The data in this thesis 
analyses the development of three different strategies to increase the relative proportion 
of cffDNA, including COLD-PCR (Chapter 3), IPCR (Chapter 4) and PP size-selective 
gel electrophoresis (Chapter 6). 
The initial COLD-PCR data using fragments containing STRs demonstrated that at lower 
denaturation temperatures shorter products were formed, most likely as a result of hairpin 
formation (refer to 3.3.1). Consequently, experiments were conducting on pseudo-
maternal DNA samples for sequences that contained non-polymorphic sites of interest. 
The results highlighted the success of this approach on a qPCR platform since non-
maternal samples showed no amplification and pseudo-maternal samples illustrated late 
amplification (Figure 3-16). The procedure was subsequently transferred onto a ddPCR 
platform to improve counting of the Chr21 target against the Chr1 target for accurate ratio 
analysis. Further optimisation on the ddPCR platform was carried out using actual 
maternal samples due to the recent availability of these samples within the department at 
this time. However, the results did not show variation in dropout for maternal and non-
maternal samples, though smaller temperature differences (<1°C) were not tested. This 
suggests that the temperature dropout (Tc) for larger maternal fragments is likely to been 
marginally higher, if at all, compared to temperature drop out (Tc) for slightly short 
cffDNA fragments.  
The concept of the IPCR method was successfully shown using pure Rh fragments (refer 
to 4.2.2). However, time constraints prevented further developments to determine the 
nature of cfDNA fragment ends and subsequently optimise dilute ligation reactions. 
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Although the true capability for selective enrichment using this technique was not fully 
established, the advantage of IPCR as opposed to COLD-PCR is that selective enrichment 
does not require amplification at lower Td’s, which is associated with alterations in 
efficiencies of primers, particularly for multiplexing experiments. Consequently, if one 
target amplifies more efficiently at the critical Td this creates a bias which alters the RCD 
calculated for determination of fetal aneuploidy. Target amplification at lower Td’s is 
feasible, but only if reactions are carried out separately at individual optimum conditions 
not in a multiplex reaction. Alternatively, IPCR selective amplification is achieved by 
determining a dilute ligase reaction, which allows for self-ligation of shorter fragments 
only, and thus reaction can be carried out at optimal Td (95°C). This prevents bias 
amplification assuming equal fragmentation of cffDNA, which will enable ligation of all 
fragments under the same conditions. However, it is likely that small variations in 
concentrations of DNA ligase will lead to ligation of both maternal and fetal cfDNA 
fragments as opposed to just smaller fetal DNA fragments, and therefore, very precise 
and accurate laboratory conduct is required in future experiments.  
Enrichment using size-selective gel electrophoresis on the PP System was also carried out 
using actual maternal samples. By using a size selective range of 100bp to 200bp the data 
illustrated than on average the PP approach increased the cffDNA by 16.1% and 18.8% 
when using the RHD5 and RHD7 assays, respectively (Table 6-3). Figure 6-5 highlights 
the loss of both cffDNA fragments and maternal cfDNA fragments following PP size-
selective gel electrophoresis for samples collected in EDTA tubes, which are more 
susceptible to maternal DNA degradation as opposed to Streck BCTs. Though this 
approach does lose valuable fetal DNA (average of 4-fold decrease), this decrease is 
significantly lower than the loss of the reference target (Xp22.3, average of 18-fold 
decrease), which is predominantly maternal (p<0.001) (Figure 6-6). This suggests that 
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even though the PP system selects both maternal and fetal cfDNA fragments since size 
differences are minimal, a greater proportion of maternal DNA is being removed 
compared to cffDNA prior to ddPCR amplification. The initial data demonstrates 
successful fetal enrichment and its application for T21 detection in spike samples is 
promising (refer to 7.4). However, extracting from larger volumes of maternal plasma or 
altering the size range on the PP system could increase the amount of cffDNA available 
and improve cffDNA enrichment in future experiments, respectively.  
Despite the relative success of gel-extraction based methods for the selective enrichment 
of cffDNA (Li et al., 2004), these approaches are labour-intensive, inefficient and prone 
to contamination (Eslami and Salehi, 2014). Consequently, enrichment approaches have 
not been implemented in a clinical setting for NIPD of genetic disorders in conjunction 
with MPS analysis (Liao et al., 2011). The PP system is less probe to contamination, is 
relatively easy to carry out with little hands on time, and is more efficient and 
reproducible than conventional gel extraction (see 6.1) (Duhaime et al., 2012). In addition 
to the methods described here, alternative methods of enrichment, such as peptide-nucleic 
acid-mediated PCR enrichment, have also been described (Galbiati et al., 2008). Galbiati 
et al. (2008) focused on the NIPD of β-thalassaemia, which clamped maternal wild-type 
alleles using peptide nucleic acids (PNAs), allowing mutant enrichment amplification 
since microchip analysis was not sufficiently sensitive to directly determine fetal mutated 
alleles in maternal plasma. The results illustrated proportional inhibition and using 
microarray analysis demonstrated 100% concordance with CVS analysis, but such 
analysis can only be carried out in couples which express different mutations (Galbiati et 
al., 2008).  
Methylation DNA immunoprecipitation (MeDIP) approaches have also been described, 
which target differentially methylated regions (DMRs) between the fetus and mother, to 
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increase the proportion of DMRs that are specifically hypermethylated in the fetal DNA 
(Papageorgiou et al., 2009; Papageorgiou et al., 2011; Tsaliki et al., 2012; Kyriakou et 
al., 2013; Ioannides et al., 2014). Consequently, following on from DNA methylation 
enrichment ratio analysis can be used to determine the overrepresentation of chr21 for 
NIPD of DS with 100% sensitivity and 100% specificity (Papageorgiou et al., 2011). In a 
recent study, the robustness of the current methodology was improved by identifying 
further DMRs within intergenic and intragenic regions to expand the DMR panel 
available for use with MeDIP qPCR (Ioannides et al., 2014). However, in an alternative 
study concerns about the robustness of this approach were raised, and also determined 
that there were theoretical deficiencies (Tong et al., 2012). However, at present no large-
scale validation studies using this approach have been reported. In addition, the 
implementation of MeDIP-qPCR approaches for routine use within the clinic is limited by 
labour-intensive and time-consuming bisulphite conversion or restriction enzyme 
digestion, which makes this approach less practical (Twiss et al., 2014).  
On the other hand, methods to deplete maternal cfDNA using formaldehyde have been 
developed, but since the initial experiment (Dhallan et al., 2004), subsequent evaluation 
studies have not seen great improvements in cffDNA fraction (Chinnapapagari et al., 
2005; Chung et al., 2005) (refer to 1.3.3.5). Streck BCTs contain unknown cell preserving 
agents that prevent maternal leukocyte degradation and preserve higher cffDNA 
fragments (refer to 1.3.3.5). Though my study revealed great improvements in cffDNA 
fraction for Streck BCTs compared to EDTA tubes within 6 hours of extraction (Figure 5-
18) (Sillence et al., 2015), most studies have determined that Streck BCTs are most 
effective for preservation when extracting DNA/RNA from older samples collected ≥7 
days earlier (Wong et al., 2013; Qin, Bassett and Fernando, 2014; El Messaoudi and 
Thierry, 2015). However, we did not test variation in sample storage times.  
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Determining fetal genetic conditions, such as aneuploidy, during the first trimester is 
advantageous since it allows a longer time frame for prospective parents to receive 
genetic counselling and make an informed decision. Consequently, if parents choose to 
abort pregnancy, earlier determination is often seen as more acceptable, but only if a 
gradualist view is adopted (refers to 1.1). Despite the widespread analysis of NIPD using 
MPS techniques (refer to 1.3.3.3.2), at present, diagnosis is only achieved using invasive 
procedures, which are associated with a 1% risk of miscarriage (Ehrich et al., 2011) (refer 
to 1.2). Currently, one of the major disadvantages of NIPD/ NIPT of fetal conditions, 
such as T21, is that inconclusive and false negative results can arise due to low levels of 
cffDNA within the maternal circulation, particularly during the first trimester (cffDNA 
~3%) (Wright and Burton, 2009). In addition, the fraction of cffDNA during early 
pregnancy and throughout pregnancy can also vary depending on multiple factors 
including maternal weight, ethnicity and other pregnancy related disorders, such as pre-
eclampsia as described in section 1.3.3.  
Once a reliable method for cffDNA enrichment or maternal depletion can be 
identified, size fractioning methods can be used in conjunction with highly 
sensitive detection systems, such as the ddPCR, for the NIPD of fetal aneuploidy 
at a fraction of the cost compared to MPS techniques (refer to 7.4). The amount 
of cffDNA enrichment required for accurate analysis is dependent upon the 
number of events for each gene region; the higher the number of data points, the 
less cffDNA is required for diagnosis. For example, one study determined that a 
cffDNA fraction of 5% requires a minimum of 100,000 data points (Sun, Jiang 
and Chan, 2015). Initially it was described that cffDNA must be increased to ≥
25% to enable accurate determination of T21 (Lo et al., 2007b). However, when 
using more sophisticated, digital platforms, which generate a significantly higher 
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number of reads per sample, less enrichment is required (Sun, Jiang and Chan, 
2015) (refer to 7.4). 
7.2 Determination of RHD zygosity  
Serological testing of patient red blood cells readily defines each sample as D-
positive or D-negative in the majority of cases. However, some patients carry 
RHD genetic variant alleles, which produce a range of partial D, weak D or 
severely weak D (Del) phenotypes (Hyland, 2013). Therefore, it is important to 
select the appropriate monoclonal antibodies for typing and develop strategies to 
efficiently detect partial and weak D phenotypes with high sensitivity. With 
current serological testing, patients with weak D are typed D-positive via direct 
agglutination when using anti-D testing. However, studies have shown that 
serology can often type variant patients as D-negative, either due to insufficient 
antibody selection or variation in interpretation of the data, which can initiate 
immunisation upon transfusion (Sandler et al., 2014). The D
VI
 variant is the 
clinically most important and most frequent partial D (Wagner et al., 1998). 
Some studies have identified that D
VI
 (and some other variants) do not react with 
monoclonal antibodies, such as RUM-1, and can therefore often be mistyped as 
D-negative (Polin et al., 2009; Credidio, Pellegrino Jr and Castilho, 2011). This 
is detrimental for blood transfusion since D
VI
 variants incorrectly typed as 
negative should not be given to D-negative recipients as some of the D-epitopes 
that are expressed may lead to alloimmunisation. In addition, for institutes that 
target anti-D administration, incorrect classification (D-negative) of a D
VI 
fetus 
could lead to HDFN. However, for prenatal testing, D
VI
 variant mothers are 
typed D-negative deliberately to ensure than anti-D is administered since the 
absence of some D-epitopes, which will be present on fetal RBCs (if D-positive), 
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could lead to sensitisation and haemolysis of fetal RBCs.  Routine serological 
methods can determine most weak D’s, but the Del RBCs can only be detected 
by absorption and elution tests, which are time consuming and consequently not 
feasible for routine testing (Sun et al., 2008).  Therefore, qPCR methods have 
been developed to identify SNPs for biallelic discrimination of genomic 
sequences (Gibson, 2006). In this study we used a ddPCR platform, which has 
been shown to express higher levels of sensitivity and precision than qPCR 
(Baker, 2012), combined with a standard assay for two RHD exons (5 and 7) to 
determine zygosity (Finning et al., 2008). These alleles are often chosen since 
RHD 7 is amplified in wild-type D+, D
VI
 variant and RHD pseudogene samples, 
whereas RHD exon 5 is only amplified in wild-type D+ samples.  
The results revealed 92.5% concordance with the original serological 
information for determination of homozygous and hemizygous RHD positive 
individuals. Figure 5-13 illustrates the ratios generated by each sample, and the 
data displayed shows an instant and clear diagnosis of zygosity. Three samples, 
1777, 729M and 087W, illustrated discrepancies between serological phenotype 
and molecular genotype (Table 5-4) (refer to 5.2.3). Sample 729M was typed 
serologically as weak D with the phenotype R1R2. Since serological data only 
provides qualitative results, determining the actual phenotyping is often achieved 
based on frequency of particular alleles within a population. However, the 
ddPCR data illustrated a ratio close to 0.5 for both the exon 5 and exon 7 RHD 
targets, illustrating that this sample was hemizygous for RHD and therefore is 
more likely to express the R1r’’ or R2r’ phenotype. Designing an assay which 
amplifies SNPs for R2 would enable determination of actual phenotype. Since 
sample 729M is classified as weak D and D-variant haplotypes are rare within 
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the population (2.2%) (Wang, Lane and Quillen, 2010), it is unlikely this 
individual is homozygous for weak D. If the patient expressed a normal RHD 
positive allele then serological analysis would not have typed this sample as 
weak D. This supports the result obtained by ddPCR and suggests that the most 
likely phenotype determined serologically was incorrect for sample 729M. 
Therefore, this suggest that the ddPCR provides a more accurate and reliable 
platform for detection of partial and weak D variants, and provides accurate 
assessment of RHD zygosity. Including more targets to detect all known RHD/ 
RHCE variants would enable accurate determination of the true phenotype, and 
this may indicate that the frequencies of r’, r’’ and R0 haplotypes may be higher 
than previously suspected based on serological data.   
The ddPCR provides an accurate and cost-effective platform for rapid 
determination of RHD zygosity, and has wide implications on current screening 
used for blood transfusion and administration of anti-D within pregnancy in D-
negative mothers. This initial study used two targets which can be used to 
discriminate between RHD positive and RHD pseudogene samples. However, 
there are multiple SNPs and hybrid RHD-RHCE genes that are responsible for 
D-variants (Figure 6-25). Developing a broad spectrum of exon targets would 
enable detection of multiple D-variant haplotypes for a reliable and accurate 
determination of all weak, partial and Del variants. Alternative approaches using 
microarrays, MLPA based approaches or NGS sequencing may prove to be 
better platforms for accurate analysis of the entire RHD gene or multiple exon 
analysis.  However, for quick zygosity determination, ddPCR provide the most 
rapid and cost effective technique currently available.  
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MLPA based approaches can multiplex up to 50 targets in a single tube, and can 
therefore detect multiple RHD targets. In one study, 70 RHD and 17 RHCE 
variant targets were used for RHD genotyping. The results revealed correct 
classification in 99% of cases, three cases were not determined due to the 
presence of two new RHD variant alleles (RHD*DCS2 (a novel partial RHD 
allele) and RHD*443G (a novel D-null allele) and consequent lack of detecting 
probes (Haer‐Wigman et al., 2013b). In addition, this study also revealed that 
MLPA is effective for zygosity testing since the RHD copy number is 
determined on the signals generated from 17 RHD wild-type probe 
combinations. Thus, the RH-MLPA assay is more suitable for detecting zygosity 
than qPCR (Krog, Clausen and Dziegiel, 2007b) or amplification of the hybrid 
Rh box (Grootkerk‐Tax et al., 2005). The MLPA approach can determine exon 
copy number to detect hybrid RHD/RHCE alleles compared to normal RHD 
alleles, but whilst multiple targets can be run in a single reaction results take a 
minimum of two days to obtain (Haer‐Wigman et al., 2013b).  
Alternatively, this exon-targeted approach is transferable to a ddPCR platform. 
Though this platform may only be able to detect a smaller number of exon 
targets, since some variants are very rare in certain ethnic groups, population 
specific assays could be used for rapid (<4 hours) zygosity testing. The 
importance of zygosity testing is clinically relevant in pregnancies for women 
who are RHD negative. In such cases the paternal zygosity can be determined to 
assess whether RHD typing is required in RhD alloimmunised women (Haer‐
Wigman et al., 2013b).  Sample 1777 was mistyped serologically as R1r, 
whereas the digital PCR data demonstrated a ratio of close to 1, which indicates 
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that this sample is actually R1R0. If we hypothesise that sample 1777 was being 
tested to determine paternal zygosity, the homozygous status of RHD determined 
using molecular ddPCR analysis would have indicated that the fetus would be 
RHD-positive, whereas the hemizygous status determined serologically would 
have led to unnecessary additional RHD typing.  
7.3 NIPD of fetal sex and RHD genotype  
Fetal sex and RHD genotyping using maternal plasma samples is already 
implemented within the clinic (Chitty et al., 2008; De Haas et al., 2012).  
However, within the UK routine prenatal genotyping is not enforced across all 
hospitals, and as a result all RHD negative mothers receive anti-D (The UK 
National Screening Committee, 2015). This is undesirable since anti-D treatment 
is costly, and the intramuscular injection in RHD negative mothers carrying 
RHD negative fetuses (~30%) exposes them to potential pathogens and causes 
unnecessary discomfort. Though qPCR approaches for determination of fetal sex 
and RHD status are highly sensitive, false negative or inconclusive results can 
arise when samples express low cffDNA fractions (Daley, Hill and Chitty, 
2014). Therefore, we developed an assay which compared sensitivity of ddPCR 
vs qPCR for the NIPD of fetal sex and RHD genotype in samples expressing 
optimal (>3%) and sub-optimal (<3%) levels of cffDNA.  
The qPCR results were only successful for samples expressing cffDNA 
fractions >3% (excluding the multiple copy target TSPY1) and achieved 
sensitivities of 100% (TSPY1 only) and 83.4% for fetal sex and RHD genotype 
for optimal samples, respectively. In contrast ddPCR achieved 100% sensitivity 
for fetal sex and RHD genotype in all samples. This data highlights that for 
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samples expressing low cffDNA fractions, ddPCR provides a more robust 
platform with improved accuracy. One sample did illustrate an inconclusive 
result, which was indicative of an RHDΨ or DVI (type 1-4) variant (refer to 
5.3.2). By including a wider range of targets across all exons of the RHD gene 
would enable accurate determination of multiple RHD variants (refer to 7.2). 
MPLA methods can be used to select a wider range of RHD and RHCE exon 
targets, among other blood group antigens (such as KEL) in a single run, and in 
a prenatal sense is advantageous for broad screening of multiple RBC antigens, 
not just RhD, that could initiate HDFN (Haer‐Wigman et al., 2013a). However, 
digital approaches may be advantageous to MPLA assays for quick 
determination of the presence of RHD using standard assays that include RHD 
exon 5, 7 and 10. In addition, digital PCR approaches can be used to develop 
population specific assays for rapid analysis of most frequent RH variant alleles 
(refer to 7.2).  
Reliable and accurate determination of fetal RHD status including detection of 
weak, partial and Del variants enables anti-D treatment to be targeted to women 
that require treatment. One study that looked at the cost analysis of 
implementing NIPD for the targeted administration of anti-D, revealed that only 
minor savings would be achieved (Szczepura, Osipenko and Freeman, 2011). It 
is also predicted that generation of false negative or inconclusive results 
associated with qPCR analysis, particularly during the first trimester, will 
increase maternal sensitisation events. The study concluded that the reliability of 
NIPD must be demonstrated in various ethnic minority populations, and in 
regard to first trimester testing it is likely that emerging technologies may need 
to be developed to improve accuracy (Szczepura, Osipenko and Freeman, 2011). 
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It is important that the systems available for the NIPD of fetal RHD status are 
highly sensitive, since false positive results are not detrimental, but incorrectly 
diagnosing a fetus as RHD negative can lead to a sensitisation event and 
subsequent HDFN. The results in this study highlight the application of ddPCR 
for the highly sensitive detection of RHD specific targets compared to 
conventional qPCR approaches. Since the cost of each ddPCR assay is similar to 
qPCR, it is feasible that this platform could replace current qPCR methods for 
routine testing prior to the decision of whether to administer anti-D within the 
clinic.  
7.4 NIPD/ NIPT of fetal aneuploidy 
Routine definitive diagnosis of fetal aneuploidy is achieved using invasive testing for 
women considered high risk, but non-invasive tests are being developed to improve the 
sensitivity and specific of current screening approaches (refer to 1.1). NIPT using MPS 
based approaches are available within the private sector, but presently these methods are 
too costly (>£400) to replace current DS screening tests (Allyse et al., 2015) (refer to 
1.3.3.3.2). In this study we developed an alternative method for the NIPD/ NIPT of fetal 
aneuploidy by combining a selective enrichment strategy using the PP size selective gel 
electrophoresis with a highly sensitive molecular detection system (QX100 ddPCR).  
Firstly, the results demonstrated that the PP successful enriched cffDNA (up to 45%) for 
the majority of samples (14/16) (Table 6-3) (refer to 7.1). However, due to depletion of 
cffDNA following PP enrichment one sample lost all cffDNA and one samples showed a 
decrease in cffDNA (~3%) (Table 6-3) (Figure 6-10). Despite the relative success of this 
approach, further optimisation is required to ensure reliability of cffDNA enrichment 
(refer to 7.5).  
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Secondly, spike samples were used to represent maternal samples containing various 
levels of cffDNA (from 10% to 50%) to determine the lowest cffDNA fraction that is 
required to determine significant difference between the ratio achieved for a T21 fetus 
and a reference euploid fetus. The experiment revealed that a significant difference 
(<0.05) could be detected for pseudo-maternal samples containing 15% or higher cffDNA 
(Figure 6-24). The 10% pseudo-cffDNA spike sample did not express a significant 
difference. Though further optimisation tests are required to improve sensitivity to detect 
significant difference in samples expressing lower cffDNA fractions(<15%), this initial 
data improves on previous methods which suggest 25% cffDNA is required (Lo et al., 
2007b). 
Theoretically, if we applied the 15% cffDNA fraction cut off, 100% of samples would 
have been acceptable for T21 detection following PP enrichment (Table 6-5). 
Alternatively, only 40% of samples illustrated >15% cffDNA fraction without selective 
enrichment (Table 6-5). Though this data is promising, it is vital that tests are optimised 
to increase accuracy and reliability. Consequently, testing novel assays on actual maternal 
samples is essential to truly determine the feasibility of this approach (refer to 7.5).  
Initially, in 2008 s-MPS was the first proof of concept study for the introduction of NIPT 
for T21 (Fan et al., 2008). Since then, more cost-effective t-MPS approaches have been 
validated for NIPT of T21 showing high levels of sensitivity (98.6%-100%) and 
specificity (97.9%-100%) (Boon and Faas, 2013). These targeted approaches have also 
been described for other aneuploidies including T13, T18 and sex chromosome 
anomalies, although the accuracy of these tests are often lower than for T21 testing 
(Bianchi et al., 2012; Futch et al., 2013). NIPT is not considered to be diagnostic since 
confined placental mosaicism (Lau et al., 2013), maternal chromosome rearrangements 
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(Osborne et al., 2013) and low cffDNA fractions (refer to 1.3.3.3.2) can result in 
conflicting results.  
Currently, establishing MPS-based approaches that can detect unbalanced chromosomal 
aberrations, such as duplications or deletions, is under development. Despite 
incorporation of these approaches within the private sector, the limits of detection have 
not been defined, making pre-test counselling challenging (Daley, Hill and Chitty, 2014). 
NIPT of aneuploidy is only available privately, and as previously mentioned high costs 
prevent implementation to all pregnancies as an alternative to current screening tests. 
Alternatively, providing NIPT as a secondary test following current DS screening tests 
may prove to be more cost effective (Chitty et al., 2012). However, at present uptake of 
NIPT as a secondary screening tool is only available to higher income families raising 
concerns for equality of access for all women. Developing our NIPT, which uses cffDNA 
enrichment (if required) in conjunction with ddPCR, provides a considerably cheaper 
alternative to MPS (refer to 1.3.3.3.1), and thus could potentially be employed as a 
secondary screening tool for T21. In addition to T21, this approach can also be developed 
for other aneuploidies, and is currently already being developed for single gene disorders, 
such as haemophilia (Tsui et al., 2011) and sickle cell anaemia (Barrett et al., 2012) (refer 
to 1.3.3.4). The approach for detecting single gene disorders can be universally applied 
for any type of disorder provided assays for wild-type and mutated alleles can be 
developed. Consequently this highlights the capability of digital PCR for determination of 
cancer biomarkers, which could allow for early diagnosis and consequently improved 
prognosis (Dawson et al., 2013; Taly et al., 2013; White et al., 2014).  
Studies have also developed assays that can analyse the entire fetal genome, which 
enables diagnosis of multiple conditions in a single run (Lo, 2013). However, not only is 
this approach expensive and time-consuming, but it also raises a wide number of ethical 
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concerns since extensive data on multiple disorders can hinder both pre-test and post-test 
counselling (refer to 1.4). This illustrates that it would be more cost-effective, and 
ethically and socially acceptable, to offer testing for analysis of fetal genetic material for 
certain disorders in families with a previous history or that are shown to be at high risk 
for specific genetic conditions. The dPCR platforms are not capable of analysing the 
entire fetal genome. However, if targeted testing is required for distinct single gene 
disorders, dPCR has the capability to provide a rapid and cheaper alternative to MPS-
based methods.  
7.5 Potential gene therapy for fetal aneuploidy  
Currently, NIPT is carried out to determine fetal aneuploidy during early pregnancy to 
allow prospective parents a longer period of time to seek counselling and come to a 
difficult decision. However, the long-term aim is that non-invasive diagnosis can be used 
to detect affected pregnancies and target therapeutic treatment to prenatally reduce 
symptoms associated with aneuploidies such as congenital anomalies of the heart, 
immunodeficiencies and developmental delay in DS (Epstein, 2013). The most promising 
results have been provided by a research group in Worcester, who have determined that 
the additional chromosome in T21 can be silenced by inserting a large (non-coding) RNA 
gene, known as XIST, into the extra chr21 in human stem cells (Jiang et al., 2013). XIST 
is crucial during pregnancy since it modifies chromatin and architecture by silencing one 
X chromosome (in females) to compensate for differences in X-linked genes between 
males and females (Levenson, 2013). Jiang et al. (2013, used zinc finger nucleases 
(ZFNs), which enable genome editing by generating a double-stranded DNA break at 
specific sites to target the insertion of the XIST gene ,and subsequently silence all genes 
across the chromosome. Though these results make prenatal gene therapy for DS 
conceivable, its application is not certain. However, this method will at least provide an 
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improved understanding behind the biology involved in the onset of DS and possibly 
allow for determination of certain genes responsible for multiple dysfunctional 
developments. This may enable administration of drugs that can alleviate the effects of 
the condition. 
7.6 Future Work  
Future experiments to optimise COLD-PCR conditions and IPCR conditions are 
required to fully determine the feasibility of these two enrichment strategies. It is 
important that initial test focus on the nature of cffDNA fragment ends, which 
will determine whether additional steps are required prior to self-ligation. The 
relative size difference between cffDNA and maternal cfDNA is not as 
significant as previously thought (refer to 7.1). Therefore, both the COLD-PCR 
and IPCR approaches may only be feasible for enrichment when maternal 
leukocyte degradation has occurred and larger maternal fragments are visible. 
However, with regard to IPCR it is feasible that if all fragments are ligated 
following IPCR, sequencing smaller fetal product against larger maternal 
products could provide additional information on how DNA is fragmented. This 
may provide information on pattern variation between maternal cfDNA 
fragments and cffDNA fragments, and thus help provide an explanation as to 
why size variations are visible.  
Though the PP approach was relatively successful, further optimisations are 
likely to improve overall cfDNA yield and consequent downstream analysis. 
This could be achieved by extracting from 5mL of maternal plasma as opposed 
to 3mL, in conjunction with optimisation of size range selected to see if smaller 
ranges could further deplete maternal fraction. Once optimal conditions have 
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been defined for maximum cffDNA enrichment on this platform, the reliability 
and accuracy of this assay for size-selective enrichment must be analysed by 
testing larger cohorts of maternal samples.   
The initial spiking data demonstrated significant variation between euploid 
control and pseudo-T21 pregnancy cases when cffDNA fractions of 15% were 
visible. This was achieved by carrying out each reaction in quadruplet. Including 
multiple repeats (up to 10) of each sample is one way in which this assay could 
be developed to improve test reliability and sensitivity. Not only will this 
increase the number of data sets per sample, but by combining multiple wells 
more target reads can be generated. An alternative approach to increase number 
of reads per sample in future experiments is to combine multiple Chr21-targets 
(FAM-labelled) against multiple reference targets (HEX-labelled) in a single 
reaction. Increasing the number of reads will reduce the cffDNA fraction 
required for T21 detection. If this can be achieved for samples containing 5% 
cffDNA, then additional enrichment will not be required. Once T21 detection 
can be reliably determined in spike samples, tests must be repeated for actual 
maternal samples. Unless the fetus expresses triploidy, it is highly unlikely a 
fetus will express T21 and T18, therefore, labelling Chr21-targets with FAM and 
18-targets with HEX could allow for the simultaneous diagnosis of T21 and T18. 
In addition, Chr21 is the smallest chromosome (represents 1.5% of the total 
DNA) and Chr18 is also one of the smallest (represents 2.5% of the total DNA), 
whereas Chr1 is the largest chromosome (represents 9% of the total DNA) 
(Genetics Home Reference, 2014). Multiplexing Chr18 and Chr21 is likely to 
give more reliable results since it is possible that the difference in size may alter 
the amount of cffDNA fragments released into the maternal circulation. 
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Alternatively, Chr21 could also be multiplex with Chr13 (represents 3.5% of the 
total DNA) to detect for DS and Patau’s syndrome simultaneously.   
7.7 Conclusion  
The size-selective enrichment of cffDNA is complicated by the limited variation 
in maternal cfDNA and cffDNA fragment size, which is possibly why COLD-
PCR and IPCR experiments using actual maternal samples were unsuccessful. 
However, despite the size limitations, the PP assay did express successful 
enrichment in the majority of samples, and thus is the most likely approach for 
future selective-enrichment experiments, although IPCR could provide a 
valuable technique for analysing cfDNA fragments. The identification of fetal 
specific targets can be detected with improved accuracy using ddPCR as 
opposed to qPCR for the determination of fetal sex, RHD status and potentially 
certain single gene disorders. Though MPS is the current gold standard for non-
invasive detection of fetal aneuploidy, the combination of ddPCR along with 
selective enrichment (if required) has the potential to provide a cheaper 
alternative that could be offered to all high-risk cases following initial screening. 
Alternatively, it is more financially feasible that this digital-PCR approach could 
be used to replace current screening tests as opposed to MPS-based NIPT, which 
is only commercially available. Providing a highly accurate, low cost first 
trimester screening test, would reduce the number of mothers offered invasive 
testing and reduce the number of affected pregnancies missed. Consequently, if 
consistently high PPVs can be achieved in large scale validation studies it is 
possible that this technique could be used to replace invasive testing.  
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APPENDICES 1 
 
Genome Equivalent Calculations for 21APP and 1EIF2C1 for a 5% Spike  
 
 Plasma sample 936C (R2R2) = 16.4 ng/ µL  
 Fetal Chr 21 APP sample A (1) = 14.5 ng/ µL 
 Fetal Chr 1 EIF2C1 sample B (2) = 17.5 ng /µL 
 
1. Plasma DNA sample 936C and pseudo-fetal DNA samples were diluted to 2ng/ 
µL.  
 
 
2. The molecular equivalent of genomic DNA and fake fetal DNA for a 5% spike 
was calculated as follows:  
 
Note: To work this out you need to know the concentration of plasma, and you 
also need to know that 1 genome equivalent is 6.6pg of genomic DNA.  
 
For example, if the plasma is 16.4ng/ µL (aka 16400 pg/ µL) then we can 
calculate the genome equivalent for plasma by dividing 16400 pg/ µL by 6.6pg: 
 
16400 / 6.6 = 2485 genome equivalents per microliter 
 
Therefore, we can calculate the following spike genome equivalents: 
 
5% fetal spike = 124.25 genome equivalents per microliter  
 
3. Calculate the molecular mass of the fake fetal fragment 
 
Each base pair = 650 Da therefore for a 286 bp fragment (chromosome 21) the 
molecular mass =  
Chr 21 APP: 650 x 286 = 1.86 x 10
5  
Chr 1 EIF2C1: 650 x 317 = 2.06 x 10
5 
 
4. Calculate moles per litre of fetal fragment:  
To calculate moles/ L you need to know the concentration of the fake fetal fragment (e.g. 
Chr 21 APP = 14.5 ng/ µL, Chr 1 EIF2C1 = 17.5 ng/ µL), you then divide this by the 
molecular mass (above answer in step 2). (Convert ng/ul to grams e.g. 14.5 ng/ µL = 14.5 
x 10
-9  
g/ µL): 
 Chr 21 APP: (14.5 x 10
-9 
g) / (1.86x 10
5
 g/ litre) = 7.79 x 10
-14
 moles/ litre  
Chr 1 EIF2C1: (17.5 x 10
-9
g) / (2.06 x 10
5
 g/ litre) = 8.49 x 10
-14
 moles/ litre  
4. Then calculate molecules per microliter of fetal fragment:  
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To do this you need to multiply moles/litre (above answer for step 3) by Avogadro’s 
Constant (6.023 x 10
23
): 
Chr 21 APP: (7.79 x 10
-14
) x (6.023 x 10
23
) = 4.7 x 10
10  
Chr 1 EIF2C1: (8.49 x 10
-14
) x (6.023 x 10
23
) = 5.1 x 10
10
 
5. Dilute fetal fragment:  
Complete a serial dilution by taking 1uL of fake fetal DNA (4.6 x 10
10
 molecules/uL) and 
add to 1mL of water, then take 1uL of that solution and add to 1mL of water etc….    
Chr 21 APP:  
4.7 x 10
10
 molecules/ µL 
Dilute 1:1000 = 4.7 x 10
7
 
Dilute 1:1000 = 4.7 x 10
4 
Dilute 1:1000 = 47 molecules/ µL  
Chr 1 EIF2C1: 
5.1 x 10
10
 molecules/ µL 
Dilute 1:1000 = 5.1 x 10
7
 
Dilute 1:1000 = 5.1 x 10
4 
Dilute 1:1000 = 51 molecules/ µL  
 
6. Work out how much fetal fragment you need to add to 1 µL of plasma (based on 
genomic equivalents (GEs).  
For this you need to refer back to calculation 1. You need to divide the molecular 
equivalent value for each spike by the number of molecules per microliter.   
Chr 21 APP: 5% Spike = 124.25 / 47 = 2.64 µL  
Therefore add 2.64 µL to every 1 µL of plasma 
We need 33 µL (30 µL +10%) of spike therefore multiple both by 10: (1 µL of plasma x 
10 = 10 µL) + (2.33 µL of diluted fetal fragment x 10 = 23.3 µL) = 33.3 µL in total for 
experiment 1.   
Chr 1 EIF2C1: 5% Spike = 124.25 / 51 = 2.44 µL  
Therefore add 2.44 µL to every 1 µL plasma 
373 
 
We need 33 µL (30ul +10%) of spike therefore multiple both by 10: (1ul of plasma x 10 = 
10 µL) + (2.33 µL of diluted fetal fragment x 10 = 23.3 µL) = 33.3 µL in total for 
experiment 1.   
To produce fake trisomy spike:  
 
Chr 21APP: (124.25 GE’s / 5) x 3 = 74.55 GE’s/ Spike 
 
Therefore for 21 (APP) to 1 µL of plasma add: 
 
74.55 / 47 molecules/ µL = 1.59 µL 
 
Chr 1 EIF2C1: (124.25 GE’s/ 5) x 2 = 49.7 GE’s/ Spike 
 
Therefore for 1 (EIF2C1) to 1 µL of plasma add: 
 
49.7 / 51 = 0.97 µL 
 
5% ‘DS’-spike: 1 µL genomic plasma DNA, 1.59 µL of chromosome 21 fetal DNA 
fragment (APP) and 0.97 µL of chromosome 1 pseudo-fetal DNA fragment (EIF2C1). 
This was then multipled by volume required per assay.  
 
To produce normal spike:  
 
Chr 21 APP (124.25 GE’s / 5) x 2.5 = 62.125 GE’s/ Spike 
 
Therefore for 21 (APP) to 1 µL of plasma add: 
 
62.125 / 47 molecules/ µL = 1.32 µL 
 
Chr 1 EIF2C1 (124.25 GE’s / 5) x 2.5 = 62.125 GE’s/ Spike 
 
Therefore for 1 (EIF2C1) to 1 µ of plasma add: 
 
62.125 / 51 = 1.22 µL 
 
5% ‘normal’-spike: 1 µL genomic plasma DNA, 1.32 µL of chromosome 21 pseudo-fetal 
DNA fragment (APP) and 1.22 µL chromosome 1 pseudo-fetal DNA fragment (EIF2C1). 
This was then multipled by volume required per assay.  
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APPENDICES 2 – Primer Analysis (Legend: Int, Internal; Ext, External) 
Chromosome 21 Primer Analysis 
 DSCR3 
Ext 
Forward  
DSCR3 
Ext  
Reverse 
DSCR3 
Int 
Forward  
DSCR3 
Int 
Reverse  
RCAN1 
Ext 
Forward  
RCAN1 
Ext 
Reverse 
RCAN1 
Int 
Forward 
RCAN1 
Int 
Reverse 
APP 
Ext 
Forward  
APP  
Ext 
Reverse  
APP 
Int 
Forward 
APP 
Int  
Reverse 
Primer 
Length 
(bp) 
20 20 20 21 20 19 19 20 20 20 20 20 
Tm °C 57 55.4 57.1 56.2 52.8 56.7 58.5 58.4 56.3 51 54.7 57 
Annealing  
Temp °C 
60.96 59.82 56.13 55.86 59.74 60.91 40.90 40.87 60.79 59.2 57.51 58.2 
GC 
content % 
55 50 55 47.6 45 57.9 57.9 55 55 40 50 55 
GC clamp 
(need to 
be ≤ 4) 
3 3 2 3 2 3 3 1 3 3 3 3 
Hairpins  
(Delta G) 
-0.47 -0.28 -1.36 2.89-2.98 1.58-2.55 -1.65 1.69-1.99 1.1-1.99 1.04-1.6 2.16-2.79 -0.54 -0.54 
Self-
Dimer 
(Delta G) 
-6.76  -3.14 -4.64 -3.14 -3.61 -5.19 -4.62 -3.14 -3.14 -1.94 -3.61 -3.14 
Cross-
Dimer 
(Delta G) 
-5.99 -5.99 -6.24 -6.24 -5.19 -5.19 -3.14 -3.14 -1.94 -1.94 -5.12 -5.12 
Repeats  None None  1 (2) 1 (2) None 1 (2) 1 (2) 1 (2) None None None  1 (2) 
Runs 
(need to 
be ≤ 4) 
2 4 3 3 3 2 2 2 2 5 2 2 
3’ End 
Stability 
(Max 
Delta G)   
-8.13 -9.47 -6.84 -6.46 -8.53 -7.87 -7.96 -5.85 -3.14 -8.19 -3.61 -8.65 
BLASTed 
to test 
specificity  
NC_0189
32.2 
(0.017 
100%) 
NC_0000
22.11 
NC_0189
32.2 
(0.017 
100%) 
NC_0189
32.2 
(0.006 
100%) 
NC_0189
32.2 
(0.017 
100%) 
NC_0189
32.2 
(0.044 
100%) 
NC_0189
32.2 
(0.044 
100%) 
NC_0189
32.2 
(0.017 
100%) 
NC_0189
32.2 
(0.017 
100%) 
NC_018932
.2 (0.006 
100%) 
NC_0189
32.2 
(0.017 
100%) 
NC_018932.2 
(0.017 100%) 
Product 
size  
315 87 292 97 286 96 
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Chromosome 18 Primer Analysis  
 
 APCDD1 
Ext 
Forward  
APCDD1 
Ext  
Reverse 
APCDD1 
Int 
Forward  
APCDD1 
Int 
Reverse  
TTR 
Ext 
Forward  
TTR 
Ext 
Reverse 
TTR 
Int 
Forward 
TTR 
Int 
Reverse 
TNFRSF-
11A, Ext 
Forward  
TNFRSF- 
11A, Ext 
Reverse  
TNFRSF- 
11A,Int 
Forward 
TNFRSF- 
11A,Int 
Reverse 
Primer 
Length 
(bp) 
20 20 20 22 20 20 19 22 20 20 20 20 
Tm °C 55.9 55.6 55.9 54.5 53.4 55.3 56.4 55.8 55.4 55.2 54.6 55.6 
Annealing  
Temp °C 
62.77 62.68 61.37 60.95 55.72 56.29 56.62 56.44 61.22 61.16 56.78 57.08 
GC 
content % 
55 50 55 45.5 50 50 57.9 45.5 55 55 50 50 
GC clamp 
(need to be 
≤ 3) 
3 3 1 2 2 1 3 2 3 3 2 3 
Hairpins  
(Delta G) 
-1.22- -
0.39 
-0.23 – 
0.4 
-0.23 – 
0.4 
1.96 – 2.89 -0.49 - -
0.33 
-0.38 - -
0.14 
-1.38- -
0.42 
0.08 – 
0.59 
-0.27- 0.53 -0.99 -0.71 -0.67 
Self-Dimer 
(Delta G) 
 -4.67 -3.14 -1.47 -3.61 -4.64 -5.13 -4.67 -5.09 -3.17 -5.38 -3.14 -3.14 
Cross-
Dimer 
(Delta G) 
-5.02 -5.02 -3.52 -3.52 -3.54 -3.54 -5.12 -5.12 -5.02 -5.02 -6.21 -6.21 
Repeats  None None None None  None None None None 1 (2) None None None 
Runs (need 
to be ≤ 4) 
3 3 4 3 3 3 3 2 2 3 3 3 
3’ End 
Stability 
(Max Delta 
G)   
-8.07 -6.85 -5.61 -6.46 -6.6 -6.83 -8.07 -7.65 -6.35 -7.58 -6.58 -6.85 
BLASTed 
to test 
specificity  
NC_0189
29.2 
(0.017 
100%) 
NC_0189
29.2 
(0.017 
100%) 
NC_0189
29.2 
(0.017 
100%) 
NC_018929
.2 (0.001 
100%) 
NC_0189
29.2 
(0.017 
100%) 
NC_0189
29.2 
(0.017 
100%) 
NC_0189
29.2 
(0.044 
100%) 
NC_0189
29.2 
(0.001 
100%) 
NC_018929.2 
(0.017 100%) 
NC_018929.2 
(0.017 100%) 
NC_0189
29.2 
(0.017 
100%) 
NC_018929
.2 (0.017 
100%) 
Product 
size  
297 97 282 98 285 85 
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Chromosome 13 Primer Analysis 
 
SPG20 Ext 
Forward  
SPG20 
Ext  
Reverse 
SPG20 
Int 
Forward  
SPG20  Int 
Reverse  
ZIC2 Ext 
Forward  
ZIC2 Ext 
Reverse 
ZIC2 Int 
Forward 
ZIC2 Int 
Reverse 
ATP7B 
Ext 
Forward  
ATP7B 
Ext 
Reverse  
ATP7B 
Int 
Forward 
ATP7B 
Int  
Reverse 
Primer 
Length 
(bp) 
20 20 19 21 20 20 21 20  20 20 20 20 
Tm °C 60.07    59.14 60.21    58.92 59.21    59.99 60.80    60.40    60.07 59.83    59.09     59.28 
Annealing  
Temp °C 
  56.3 56.0   59.34 59.22   56.07 56.08 
GC 
content % 
55 50 52.63 47.62 55 60 47.62 50 50 50 35 45 
GC clamp 
(need to 
be ≤ 4) 
2 4 1 3 3 3 1 2 2 3 2 none 
Hairpins  
(Delta G) 
0.44- 1.39 -0.55 -1.58 -1.53 0.31-0.83 0.63-1.49 0.25 -0.58 to  
0.35 
0.58 to 1.53 -0.37 0.35 to  
1.04 
-1.49 
Self-
Dimer 
(Delta G) 
 -4,16 -5.24 -6.62 -3.91 -3.65 -3.14 -3.91 -3.14 -5.38 -6.34 (in 
central 
region) 
-5.36 -3.91 
Cross-
Dimer 
(Delta G) 
-3.14 -3.14 -5.02 -5.02 -3.14 -3.14 -4.64 -4.64 -3.9 -3.9 -5.02 -5.02 
Repeats  3 3 3  3 none none 2 none 3 2 3 2 
Runs 
(need to 
be ≤ 4) 
2 none none 2 2 2 5 3 none 2 none 2 
3’ End 
Stability 
(Max 
Delta G)   
-5.48 -9.76 -6.59 -7.58 -7.26 -6.47 -6.82 -3.14 -6.84 -7.96 -6.96 -5.85 
BLASTed 
to test 
specificity 
NC_01892
4.2 (0.017 
100%) 
NC_0189
24.2 
(0.017 
100%) 
NC_0189
24.2 
(0.044 
100%) 
NC_018924
.2 (0.006 
100%) 
NC_0189
24.2 
(0.017 
100%) 
NC_018924
.2 (0.017 
100%) 
NC_0189
24.2 
(0.006 
100%) 
NC_0189
24.2 
(0.017 
100%) 
NC_018924
.2 (0.017 
100%) 
NC_018924
.2 (0.017 
100%) 
NC_0189
24.2 
(0.017 
100%) 
NC_018924
.2 (0.017 
100%) 
Product 
size 
297 80 297 90 300 82 
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Chromosome X Primer Analysis 
 
 
 
FOXP3 Ext 
Forward  
FOXP3 
Ext  
Reverse 
FOXP3 
Int 
Forward  
FOXP3   
Int 
Reverse  
NROB1 
Ext 
Forward  
NROB1 Ext 
Reverse 
NROB1 
Int 
Forward 
NROB1 Int 
Reverse 
PRPS1 
Ext 
Forward  
PRPS1 
Ext 
Reverse 
PRPS1 
Int 
Forward 
PRPS1 
Int 
Reverse 
Primer 
Length 
(bp) 
20 20 19 20 19 20 19 18 20 20 22 20 
Tm °C 60.05 60.35 60.24 60.69 60.25 61.79    58.98    57.48 59.96    58.52 60.88    60.13 
Annealing  
Temp °C 
  60.6 60.7   60.9 60.44   56.6 56.3 
GC 
content % 
50 55 57.89   55.0 52.63   60 57.89   55.56   55 45 50 60 
GC clamp 
(need to be 
≤ 4) 
2 2 3 2 2 2 3 1 2 2 3 3 
Hairpins  
(Delta G) 
1.04 0.98 to  
1.94 
-1.44 -0.54 1.04 -0.1 to  0.83 -0.1 to  
0.72 
-0.81 to -
0.23 
-0.14 to  -
0.98 
-0.2 to 
0.79 
0.52 to 
0.97 
-0.79 to -
0.35 
Self-Dimer 
(Delta G) 
-3.61 -3.14 -3.55 -3.14 -3.61 -3.61 -3.61 -3.55 -3.14 -3.53 -3.14 -4.64 
Cross-
Dimer 
(Delta G) 
-3.3 -3.3 -4.89 -4.89 -6.31 
(at 5’ end) 
-6.31 
(at 5’ end) 
-6.6 
(at 5’ end) 
-6.6 
(at 5’ end) 
-3.53 -3.53 -4.74 -4.74 
Repeats  none 2 2 none 2 2 2 none 2 2 3 none 
Runs (need 
to be ≤ 4) 
3 2 3 3 3 2 2 3 2 2 2 3 
3’ End 
Stability 
(Max Delta 
G)   
-6.82 -7.07 -6.73 -8.3 -7.07 -6.24 -7.96 -5.85 -6.46 -6.7 -8.2 -8.03 
BLASTed 
to test 
specificity 
NC_018934
.2 (0.017 
00%) 
NC_0189
34.2 
(0.017 
100%) 
NC_0189
34.2 
(0.044 
100%)  
NC_0189
34.2 
(0.017 
100%) 
NC_0189
34.2 
(0.044 
100%) 
NC_018934
.2 (0.017 
100%) 
NC_0189
34.2 
(0.044 
100%) 
NC_018934
.2 (0.17 
100%) 
Multiple binding do not use 
Product 
size  
288 94 293 89 259 88 
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Chromosome Y Primer Analysis 
Legend: F, Forward; R, Reverse.  
*Designed in house by Kelly Sillence. ** Designed in house by Hannah Thompson. 
 SRY* 
Ext F  
SRY* 
Ext R 
SRY*  
Int F  
SRY*  
Int R  
SRY** 
Ext F  
SRY** 
Ext R 
SRY**  
Int F  
SRY**  
Int R  
TSPY1 
Ext F 
TSPY1 
Ext R 
TSPY1 
Int F 
TSPY1 
Int R 
DDX3Y 
Ext F  
DDX3Y  
Ext R  
DDX3Y 
Int F 
DDX3Y 
Int R 
Primer 
Length 
(bp) 
20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 22 
Tm °C 52.8 52.8 56.3 56.2 52.6 54.8. 52.3 54.2 58 55.9 53.6 55.8 57.1 57.3 56.8 54.9 
Annealing  
Temp °C 
58.34 58.34 55.19 55.16 47.99 48.65 51.41 51.97 60.6 59.97 55.08 55.74 61.03 61.09 58.14 57.57 
GC 
content % 
45 45 55 50 42.9 50 45 50 55 55 50 55 55 60 55 50 
GC clamp 
(need to 
be ≤ 4) 
2 2 2 1 1 3 1 3 3 3 0 2 2 3 3 3 
Hairpins  
(Delta G) 
0.02 -0.31 
–-0.07 
-0.98- 
-.014 
0.05 0.17 -0.95 -2.57 1.01 -0.65- 
0.15 
1.47-
2.02 
2.36-
2.96 
0.57-
1.26 
-0.21- 
0.55 
0.65-2.5 0.72-
1.54 
1.19-
1.85 
Self-
Dimer 
(Delta G) 
-5.36 -3.61 -6.34 -6.3 -4.62 -5.02 -5.02 -3.61 -5.38 -1.95 -1.47 -3.14 -3.55 -4.16 -6.34 -1.95 
Cross-
Dimer 
(Delta G) 
-3.61 -3.61 -4.64 -4.64 -6.95 -6.95 -6.85 -6.85 -6.6 -6.6 -1.34 -1.34 -3.14 -3.14 -6.24 -6.24 
Repeats  None  None 2(2) None 2 (2) None None 2 (3) None None None None 2 (3) None  None None 
Runs 
(need to 
be ≤ 4) 
3 3 2 3 3 2 4 3 2 2 4 3 3 2 3 3 
3’ End 
Stability 
(Max 
Delta G)   
-8.48 -6.69 -8.19 -5.85 -6.58 -6.47 -7.32 -3.14 -7.58 -8.2 -6.32 -8.63 -7.07 -6.97 -7.96 -7.96 
BLASTed 
to test 
specificity  
NC_0
00024
.10 
(0.017 
100%) 
NC_0
00024
.10 
(0.017 
100%) 
NC_0
00024
.10 
(0.017 
100%) 
NC_0
00024
.10 
(0.017 
100%) 
NC_0
00024
.10 
(0.006 
100%) 
NC_0
00024
.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.017 
100%) 
NC_000
024.10 
(0.001 
100%) 
Product 
size 
300 89 287 96 293 88 296 89 
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Fetal Sex and RHD Genotyping with Digital PCR
Demonstrates Greater Sensitivity than Real-time PCR
Kelly A. Sillence,1 Llinos A. Roberts,2 Heidi J. Hollands,2 Hannah P. Thompson,1 Michele Kiernan,1
Tracey E. Madgett,1 C. Ross Welch,2 and Neil D. Avent1*
BACKGROUND: Noninvasive genotyping of fetal RHD
(Rh blood group, D antigen) can prevent the unnecessary
administration of prophylactic anti-D to women carry-
ing RHD-negative fetuses. We evaluated laboratory
methods for such genotyping.
METHODS: Blood samples were collected in EDTA tubes
and Streck® Cell-Free DNA™ blood collection tubes
(Streck BCTs) from RHD-negative women (n  46).
Using Y-specific and RHD-specific targets, we investi-
gated variation in the cell-free fetal DNA (cffDNA) frac-
tion and determined the sensitivity achieved for optimal
and suboptimal samples with a novel Droplet Digital™
PCR (ddPCR) platform compared with real-time quan-
titative PCR (qPCR).
RESULTS: The cffDNA fraction was significantly larger for
samples collected in Streck BCTs compared with samples
collected inEDTAtubes (P0.001). In samples expressing
optimal cffDNA fractions (4%), both qPCR and digital
PCR (dPCR) showed 100% sensitivity for the TSPY1
(testis-specific protein, Y-linked 1) and RHD7 (RHD exon
7) assays. Although dPCR also had 100% sensitivity for
RHD5 (RHD exon 5), qPCRhad reduced sensitivity (83%)
for this target. For samples expressing suboptimal cffDNA
fractions (2%), dPCR achieved 100% sensitivity for all
assays, whereas qPCR achieved 100% sensitivity only for
the TSPY1 (multicopy target) assay.
CONCLUSIONS: qPCR was not found to be an effective
tool for RHD genotyping in suboptimal samples (2%
cffDNA). However, when testing the same suboptimal
samples on the same day by dPCR, 100% sensitivity was
achieved for both fetal sex determination and RHD geno-
typing. Use of dPCR for identification of fetal specific
markers can reduce the occurrence of false-negative and
inconclusive results, particularly when samples express
high levels of background maternal cell-free DNA.
© 2015 American Association for Clinical Chemistry
Diagnosis of fetal sex, RHD (Rh blood group, D anti-
gen)3 genotype, and chromosomal abnormalities can be
achieved only through analysis of fetal DNA. Initially,
this could be achieved through invasive procedures such
as amniocentesis and chorionic villus sampling, quoted as
having a 1% risk of miscarriage (1 ). Since the discovery
of cell-free fetal DNA (cffDNA)4 in maternal plasma,
noninvasive prenatal testing is now a clinical reality (1–
5 ). Fetal sex determination is offered in the clinic for
families at risk of X-linked disorders, such as Duchenne
muscular dystrophy (6 ). Determination of fetal sex is
especially beneficial in cases of congenital adrenal hyper-
plasia, to allow therapy to be targeted to female fetuses
only (7 ). Fetal aneuploidy detection requires accurate
quantification and presently can only be determined by
next-generation sequencing, which is too costly for rou-
tine testing (8 ).
The antigens of the Rh blood group system are
coded for by 2 genes, RHD and RHCE (Rh blood group,
CcEe antigens), which are located on chromosome 1
(p34–p36) (9 ). In white populations, most D-negative
phenotypes result from a complete RHD deletion (10 ).
For D-negative individuals of African descent, only 18%
are a result of RHD deletion. Instead, 66% and 15% of
D-negative Africans have an inactive RHD gene
(RHD) or a hybrid gene (RHD-CE-DS or r’S), which do
not produce any RhD protein (10, 11 ). Many laborato-
ries currently provide noninvasive fetal RHD genotyping
for alloimmunized women as routine practice to manage
hemolytic disease of the fetus and newborn (HDFN)
1 School of Biomedical and Healthcare Sciences, Plymouth University, Plymouth Univer-
sity Peninsula Schools of Medicine and Dentistry, Plymouth, UK; 2 Department of Fetal
Medicine, Plymouth Hospitals National Health Service Trust, Plymouth, UK.
* Address correspondence to this author at: School of Biomedical andHealthcare Sciences,
Plymouth University, Plymouth, UK PL4 8AA. E-mail neil.avent@plymouth.ac.uk.
Received January 28, 2015; accepted August 24, 2015.
Previously published online at DOI: 10.1373/clinchem.2015.239137
© 2015 American Association for Clinical Chemistry
3 Human genes: RHD, Rh blood group, D antigen; RHCE, Rh blood group, CcEe antigens;
SRY, sex-determining region Y; TSPY1, testis-speciﬁc protein, Y-linked 1; AGO1, argo-
naute RISC catalytic component 1 (formerly EIF2C1); TERT, telomerase reverse transcrip-
tase; ERV3–1, endogenous retrovirus group 3, member 1.
4 Nonstandard abbreviations: cffDNA, cell-free fetal DNA; HDFN, hemolytic disease of the
fetus and newborn; qPCR, real-time quantitative PCR; dPCR, digital PCR; BCT, blood
collection tube; cfDNA, cell-free DNA; RHD5, Rh blood group, D antigen exon 5; RHD7,
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(4, 12–14). Before 1970, HDFN was a major cause of
fetal mortality (46/100 000 births in the UK alone) (15 ),
but since the introduction of routine antenatal anti-D pro-
phylaxis, incidence has decreased nearly 10-fold (16). Cur-
rently, allRHD-negativewomen in theWest are offered this
prophylaxis, which is costly, as it is produced from hyper-
immunized male volunteers. Providing a noninvasive test
for fetal RHD genotyping allows administration to be tar-
geted to RHD-negative women who are known to be carry-
ing anRHD-positive fetus. This is now routine in theNeth-
erlands and Denmark with real-time quantitative PCR
(qPCR) approaches (4, 17, 18). However, recent publica-
tions have described the application of digital PCR (dPCR)
for the detection of low-level targets with improved preci-
sion, resulting in reliable quantification well below the limit
of quantification of qPCR (19, 20).
The use of Streck® Cell-Free DNA™ blood collec-
tion tubes (BCTs) instead of conventional EDTA tubes
has been shown to increase the proportion of cffDNA
(21 ). Streck BCTs contain proprietary cell-preserving re-
agents, which prevent maternal cell lysis and conse-
quently reduce the amount of maternal cell-free DNA
(cfDNA) released into the plasma. In this study, we com-
pared the sensitivity of dPCR and qPCR for the nonin-
vasive determination of fetal sex and RHD genotype for
samples collected in both Streck BCTs and EDTA tubes.
For technical reasons, some samples, despite being col-
lected in the third trimester, expressed suboptimal
cffDNA fractions (2%). However, all samples were in-
cluded to thoroughly test the capability of the dPCR
assay against the current gold standard, qPCR.
Materials and Methods
STUDY PARTICIPANTS
RHD-negative pregnant women (28–30 weeks’ gesta-
tion), all of whom met inclusion criteria, were recruited
at Plymouth Hospitals NHS Trust, Plymouth, UK, with
informed consent, from November 2013 to September
2014. Ethics approval was granted by the United Bristol
Healthcare and Trust Research and Ethics Committee
(13/SW/0148).
SAMPLE PROCESSING
Twenty-twomaternal peripheral blood samples were col-
lected in EDTA tubes (5–10mL total blood volume) and
centrifuged at 1600g for 10 min at room temperature
(samples 1–22). The plasma was carefully removed and
transferred to a 15-mL tube. The plasma was then recen-
trifuged at 16 000g for 10 min. All samples were pro-
cessed within 4 h of collection, and plasma aliquots (1
mL) were stored at 80 °C. RHD and RHD human
whole blood, collected in EDTA tubes (5 mL total blood
volume), was supplied by National Health Service Blood
and Transplant (Bristol, UK) as positive and negative
controls, respectively. These samples were processed
within 48–96 h by following the same double-spin pro-
tocol described above.
Twenty-four maternal blood samples collected in
Streck BCTs (10–20 mL total blood volume) were cen-
trifuged at 1600g for 15 min at room temperature (sam-
ples 23–46). Plasma was carefully removed, transferred
to a 50-mL tube, and recentrifuged at 2500g for 10 min.
All samples were processed within 48 h of collection, and
plasma aliquots (1 mL) were stored at80 °C.
DNA EXTRACTION
DNA was extracted from two 1-mL aliquots of plasma
with the QIAamp Circulating Nucleic Acid kit (Qiagen)
and QIAvac 24 Plus (Qiagen). The extraction process
followed the manufacturer’s protocol, and each sample
was eluted in 60 L Buffer AVE [RNase-free water con-
taining 0.04% (wt/vol) sodium azide]. No DNase or
RNase treatment was used. After DNA extraction, we
quantified samples on the Qubit® 2.0 Fluorometer (Life
Technologies) with the Qubit dsDNA HS assay kit (Life
Technologies). Samples were stored at20 °C as 60-L
aliquots for4 weeks.
PCR PRIMERS AND PROBES
For both dPCR and qPCR, we tested 4 multiplex reac-
tions: 2 for fetal sex determination and 2 for fetal RHD
genotyping (Table 1). Primer concentrations (300 to 900
nmol/L) and annealing temperatures (56 °C to 62 °C)
were optimized for all multiplex reactions. Fig. 1 shows
Table 1. Summary of amplicon location, length, and ﬂuorescent label for each multiplex reaction.
Multiplex
reaction Amplicon Chromosome Gene Exon/intron
Fluorescent
reporter dye Length, bp Origin
1 Target Y SRY Exon FAM 137 Lo et al. (22)
2 Target Y TSPY1 Exon FAM 88 In-house
1 and 2 Reference X Xp22.3 Intron HEX 95 Fan et al. (23)
3 Target 1 RHD5 Exon (5) FAM 82 Finning et al. (24)
4 Target 1 RHD7 Exon (7) FAM 75 Finning et al. (24)
3 and 4 Reference 1 AGO1 Exon HEX 81 Fan et al. (23)
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the optimization process for TSPY1-FAM/Xp22.3-
HEX.We used Xp22.3 oligonucleotides as a reference for
2 Y-specific targets [SRY (sex-determining region Y) (22 )
and TSPY1 (testis-specific protein, Y-linked 1)] for fetal
sex determination. AGO1 (argonaute RISC catalytic
component 1; formerly EIF2C1) primers were taken
from Fan et al. (23 ) and used as a reference for 2 RHD-
specific targets [RHD exon 5 (RHD5) and RHD exon 7
(RHD7)] (24 ) since AGO1 is also located on
chromosome 1. The oligonucleotide sequences (HPLC
purified, Eurofins Genomics) and amplicon sizes for all
target [carboxyfluorescein (FAM)-labeled] and reference
[hexachlorofluorescein (HEX)-labeled] regions are
shown in Supplemental File 1, which accompanies the
online version of this article at http://www.clinchem.org/
content/vol61/issue11. Sequences for the Xp22.3 reverse
primer and all TSPY1 oligonucleotides were designed
with online software (http://primer3.sourceforge.net and
http://www.idtdna.com/calc/analyzer) and subjected to
Basic Local Alignment Search Tool (BLAST) analysis
against the National Center for Biotechnology Informa-
tion GenBank DNA database (accession nos.
NC_000024.10 and NC_000023.11).
REAL-TIME qPCR
qPCR reactions were performed in a 20-L solution con-
taining 1 TaqMan Universal PCR Master Mix (Life
Technologies), 300 nmol/L primers, 250 nmol/L probes,
and a standard volume of template DNA (5 L). Sample
concentrations are recorded in online Supplemental File
2; because of the low abundance of cffDNA in extracted
maternal plasma, the samples were not diluted. Reactions
were conducted in duplicate, with positive and negative
controls for each assay. After optimization of annealing
temperature (Ta), cycling was carried out on a Life
Technologies StepOnePlus™ qPCR System under
the following conditions: 95 °C for 10 min, 50 cycles
of 95 °C for 15 s, and 58 °C for 1 min. Fifty cycles
were used to ensure amplification of low-copy-number
target DNA. We included a standard curve of male
genomic DNA (gDNA) (Promega) in triplicate on
each plate. We used FAM-labeled fluorescent probes
for all target regions (SRY, TSPY1, RHD5, and RHD7)
and HEX-labeled fluorescent probes for both refer-
ence regions (Xp22.3 and AGO1) (Table 1; also see
online Supplemental File 1).
Fig. 1. One-dimensional amplitude plot showing optimization of annealing temperature for TSPY1-FAM/Xp22.3-HEX multiplex
reaction.
(A), Separation of positive droplets (above threshold line) fromnegative droplets (below threshold line) for TSPY1-FAMampliﬁcation (Channel
1). The threshold for TSPY1 separation was manually set at 4000 amplitude. (B), Separation of positive droplets (above threshold line) from
negative droplets (below threshold line) for Xp22.3-FAM ampliﬁcation. The threshold for Xp22.3 separation was manually set at 2300
amplitude. Results illustrate optimal separation for both targets at 58 °C and 56 °C Ta.
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Digital PCR
dPCR reactions were performed in a 20-L solution con-
taining 10 L droplet digital PCR (ddPCR) Supermix
for Probes (Bio-Rad), 300 nmol/L primers, and 250
nmol/L probes. Because samples were not diluted after
Qubit quantification, we added a standard volume of
template DNA (5 L) with positive and negative con-
trols. All reactions were conducted in duplicate and run
on the QX100™ Droplet Generator (Bio-Rad) accord-
ing to the manufacturer’s instructions. By use of an oil
emersion approach, the sample was drawn through the
cartridge under a vacuum, where approximately 20 000
1-nL droplets were formed. The droplets (40 L total
volume) were then transferred to a 96-well plate and
covered with a pierceable foil heat seal on the PX1™
Plate Sealer (Bio-Rad). Cycling was carried out on a
C1000 Touch™ Thermal Cycler (Bio-Rad) under opti-
mized conditions: 95 °C for 10 min, 40 cycles of 95 °C
for 30 s, and 58 °C for 1 min, after which a final 98 °C
step for 10 min was carried out (as recommended by
Bio-Rad). Samples were analyzed immediately on the
QX100TM Droplet Reader (Bio-Rad). To ensure unifor-
mity, samples were extracted and tested by qPCR and
dPCR on the same day by the same investigator.
DATA ANALYSIS
For qPCR, targets with a mean quantification cycle (Cq)
of 45 were recorded as positive, provided no-template
controls (NTC) remained negative (Cq 45), to ensure
inclusion of low-copy-number targets. Targets that ex-
pressed Cq values45 for both duplicates were recorded
as negative. Thresholds were set at 0.05 for all targets
(StepOne™ Software v2.3).
We analyzed the raw fluorescent data from the
dPCR platform with Bio-Rad QuantaSoft v1.2 software.
Once thresholds for each sample had been set manually
with the 2-dimensional (2D) amplification plot, positive
and negative droplets were determined (Fig. 1; also see
online Supplemental File 3). Thresholds were deter-
mined when intermediate droplets between 2 clusters did
not alter the calculated concentration (Poisson 95% CI)
(20 ). Online Supplemental File 4 shows the calculations
used for determining the cffDNA fraction by use of the
dPCR results on the basis of the concentration (copies
per microliter). All statistical analysis for comparing
Streck BCTs vs EDTA tubes for both cffDNA fractions
and reference DNA concentration were performed
with Mann–Whitney U test (SigmaPlot v12.5), and
significance was accepted at P  0.05.
CONFIRMATION OF FETAL SEX AND RHD STATUS
The accuracy of dPCR and qPCR for the prenatal detec-
tion of fetal sex was ascertained at birth (Table 2). Fetal
blood group was verified after delivery through the serol-
ogy of umbilical cord blood samples.
Results
FETAL SEX DETERMINATION
For dPCR, in 100% of cases, the fetal sex predicted by
using both Y-specific targets (TSPY1 and SRY) was the
same as that determined at birth (Table 2). The Ta gra-
dient was optimized for all targets, and despite Fig. 1
illustrating equal separation at 58 °C and 56 °C, the 2D
amplitude plot illustrated better separation at 58 °C (data
not shown). In addition, at Ta 58 °C, the SRY-FAM/
Xp22.3 multiplex reaction produced a ratio closer to 1
than at Ta 56 °C (0.931 and 0.835, respectively). The
SRY assay was successful only for the male positive con-
trol by qPCR. Therefore, fetal sex was ascertained by
TSPY1 only for qPCR (Table 2; also see online Supple-
mental File 2). The results also illustrated 100% accuracy
when only the multiple-copy target gene was considered
for qPCR analysis (Table 3). Calibration curves, slopes,
y-intercepts, R2 values, and efficiencies for qPCR data are
shown in online Supplemental File 5.
Table 2. Summary of fetal sex determination and RHD genotyping results obtained from both dPCR and qPCR against results
recorded after delivery.
Platform Samples
Sex determination RHD determination
Male Female
Inconclusive
Positive Negative
InconclusiveFetus Newborn Fetus Newborn Fetus Newborn Fetus Newborn
dPCR 46
EDTA tubes 22 10 10 12 12 0 12 12 9 10 1
Streck BCTs 24 13 13 11 11 0 19 19 5 5 0
qPCR 46
EDTA tubes 22 10 10 12 12 0 0 12 22 10 0
Streck BCTs 24 13 13 11 11 0 15 19 5 5 4
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The cffDNA fraction with both Y-specific and
RHD-specific targets was calculated on the basis of the
concentration (copies per microliter) generated by dPCR
for each multiplex reaction (see online Supplemental File
4). The samples collected in Streck BCTs expressed
higher cffDNA fractions (4%–24%) and were classed as
optimal, whereas the samples collected in EDTA tubes,
during the initial stages of sample collection, illustrated
lower cffDNA fractions (0.1%–2%) and were classified
as suboptimal (Fig. 2A).
FETAL RHD GENOTYPING
By dPCR, fetal RHD genotype was correctly identified in
100% (24/24) and 95.5% (21/22) of cases for samples col-
lected in Streck BCTs and EDTA tubes, respectively (Table
3). One EDTA-collected sample (sample 12) produced a
false-positive result, since serological analysis revealed the
fetus to be RHD-negative but dPCR showed clear amplifi-
cation of the RHD7 target (18 droplets) and minimal am-
plification of the RHD5 target (3 droplets) (Fig. 3A). Fig. 3
illustrates the concentrations obtained from both target
genes (RHD5 and RHD7) and the reference gene (AGO1)
for control samples [NTC, RHD control, RHD control
(Fig. 3, A and B); samples collected in EDTA tubes (Fig.
3A); and samples collected in Streck BCTs (Fig. 3B)]. The
results show successful amplification of all 3 targets for the
RHD-positive control sample and show amplification of
only the reference AGO1 gene for the RHD-negative con-
trol sample, whereas the NTC sample showed no amplifi-
cation (Fig. 3). In addition to the false-positive result (1/46,
2%), 31 samples were correctly classified as RHD positive
(67%) and 14 samples were correctly classified asRHD neg-
ative (31%) (Fig. 3).
Optimal samples (collected in Streck BCTs), which
expressed cffDNA fractions4%, demonstrated accura-
cies of 100% and 83% on the qPCR platform for the
Table 3. Results of testing 22 and 24 maternal samples collected in EDTA tubes and Streck BCTs, respectively, with dPCR and
qPCR for fetal sex and RHD genotyping.
Platform and target gene Sensitivity, %
False-negative
results, % (n) Speciﬁcity, %
False-positive
results, % (n) Accuracy, %c
dPCR
Streck BCTsa
TSPY1 100 100 100
SRY 100 100 100
RHD5 100 100 100
RHD7 100 100 100
EDTA tubesb
TSPY1 100 100 100
SRY 100 100 100
RHD5 100 95.5 4.5 (1) 95.6
RHD7 100 95.5 4.5 (1) 95.6
qPCR
Streck BCTsa
TSPY1 100 100 100
SRY 50 54.2 (13) 100 45.8
RHD5 83.4 16.6 (4) 100 83.4
RHD7 100 100 100
EDTA tubesb
TSPY1 100 100 100
SRY 0 45.5 (10) 100 54.5
RHD5 0 59.1 (13) 100 40.9
RHD7 0 59.1 (13) 100 40.9
a cffDNA in maternal plasma 4%–24%, calculated from dPCR results.
b cffDNA in maternal plasma 0.1%–2%, calculated from dPCR results.
c Accuracy was calculated as (true positives + true negatives)/(true positives + false positives + false negatives + true negatives).
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RHD7 and RHD5 target assays, respectively. Four sam-
ples (16.6%) were classified as inconclusive because
qPCR did not detect the RHD5 target but did show
acceptable amplification of the RHD7 target (45 Cq)
(Table 3). The qPCR platform was unable to detect both
RHD-specific markers (RHD7 and RHD5) in the subop-
timal samples (2% cffDNA), despite serological and
dPCR analysis confirming that 59% (13/22) of these
EDTA-collected samples were carrying an RHD-positive
fetus.
SAMPLE COLLECTION: EDTA VS STRECK BCT
The cffDNA fractions and concentrations of reference
targets for blood collection methods with EDTA tubes
and Streck BCTs were compared by use of dPCR results.
Fig. 2A shows the mean cffDNA fraction in maternal
plasma for all 4 target regions (SRY, TSPY1, RHD5, and
RHD7) for both collection methods. The samples col-
lected in Streck BCTs showed significantly larger mean
cffDNA fractions (9%–16%) for all target regions than
those collected in EDTA (0.5%–1%) (P  0.001). The
mean cffDNA fractions generated by the EDTA-
collected samples demonstrated no significant differences
between all 4 targets (P  1). However, the cffDNA
fraction calculated on the basis of the SRY target was
significantly smaller than theTSPY1 and RHD7 cffDNA
fractions (P  0.01).
Although the concentration of each reference gene
(Xp22.3 and AGO1) (Fig. 2B) is a combination of ma-
ternal and fetal cfDNA, it is predominantly maternal in
origin (90%–95%). Samples collected in Streck BCTs
showed similar mean concentrations for Xp22.3 and
AGO1 reference genes (16.18 and 17.39 copies/L, re-
spectively; P  0.1) (Fig. 2B). The concentrations of
both reference targets (Xp22.3 and AGO1) were 40-
fold higher for maternal samples collected in EDTA
tubes compared with Streck BCTs (mean concentrations
548.04 and 869.25 copies/L, respectively), suggesting
maternal leukocyte degradation (Fig. 2B). The 2D am-
plification plots (see online Supplemental File 3) also
showed a significantly higher number of reference (HEX-
labeled) droplets formaternal samples collected in EDTA
tubes compared with maternal samples collected in
Streck BCTs (P 0.001). The fetal concentration deter-
mined from RHD5 and RHD7 amplification was similar
for samples collected in both EDTA and Streck BCTs
(P  0.1): 0.9–4.2 copies/L and 0.3–3.7 copies/L,
respectively (Fig. 3).
Discussion
Noninvasive fetal RHD genotyping by use of qPCR anal-
ysis has shown high levels of accuracy for optimal samples
(mean 97.4%) and is currently implemented in theNeth-
Fig. 2. Comparison between maternal samples collected in EDTA tubes and Streck BCTs.
(A), Mean cffDNA fraction inmaternal plasma calculated by each target gene (see online Supplemental File 1). The samples collected in Streck
BCTs show a signiﬁcantly highermean cffDNA fraction comparedwith samples collected in EDTA tubes for all 4 target regions (aP<0.001). The
cffDNA fractions on the basis of theRHD7 and TSPY1 target genes are signiﬁcantly larger than the cffDNA fraction determined by the SRY target
gene (bP < 0.01). (B), Mean concentration of reference gene regions Xp22.3 and AGO1 for maternal samples collected in EDTA tubes and
Streck BCTs. The mean concentrations of both regions were signiﬁcantly higher in EDTA tube samples than in Streck BCTs (bP<0.001). There
was no signiﬁcant difference between mean concentrations of Xp22.3 and AGO1 within each sample collection method.
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erlands and Denmark for targeted administration of pro-
phylactic anti-D (4, 10, 11, 17, 18, 25 ). In a recent
population-based cohort study, mass-throughput fetal
RHD genotyping was sufficient from the end of the first
trimester with qPCR (26 ). However, for samples taken at
11 weeks’ gestation, 16 of 865 samples (1.8%) were
incorrectly classified as RHD negative. Fetal RHD geno-
typing was also inconclusive for 393 of 4913 samples
tested (8%) (26 ). Previous studies have identified that
low cffDNA fractions can lead to false-negative results by
qPCR, limiting the sensitivity of this approach (27–29).
The oligonucleotides used in this study for RHD geno-
typing are identical to the sequences used in Finning et al.
(24 ), but for unknown reasons worked less effectively for
our qPCR assay. However, our results clearly indicate
that for suboptimal samples, the single-copy targets
(SRY, RHD5, and RHD7) were not detectable by qPCR
but achieved 100% sensitivity (95% CI) on the dPCR
platform.
Because of the gestational ages of these samples,
cffDNA is expected to be 5% (1 ). However, results
show maternal DNA degradation for EDTA-collected
samples, since the number of positive droplets for refer-
ences (Xp22.3 and AGO1) was significantly higher com-
pared with samples collected in Streck BCTs (P 0.001)
(Fig. 2B; also see online Supplemental File 3). These
novel dPCR data indicate that qPCR false-negative re-
sults were not caused by low absolute cffDNA concen-
trations, since they are similar to those expressed by op-
timal samples (Fig. 2B), but are instead a result of low
relative concentrations of cffDNA. The assay used is
highly specific, and theoretically, nonspecific amplifica-
tion should not occur, but because RHD5 and RHD7
probes have 96.5% and 100% consensus, respectively,
with the RHCE gene, it is possible that the probes are
binding to the abundant maternal RHCE, depleting
probe availability for fetal-specific RHD targets. None-
theless, when the cffDNA copy number is very low, false-
negative results are more likely, particularly for the detec-
tion of fetal single nucleotide polymorphisms for rare
mutation detection. qPCR ismore susceptible to nonspe-
cific amplification of the maternal allele, and dPCR
maybe more powerful in the detection of alleles associ-
ated with conditions such as -thalassemia and cystic
fibrosis.
The amount of fetal DNA fraction has been shown
to increase in positive correlation with time before pro-
cessing (30 ). To preserve large cffDNA fractions, it is
recommended that samples collected in EDTA tubes
should be extracted within 6 h and kept at 4 °C before
plasma extraction. Although maternal samples collected
in EDTA were processed within 6 h, all transportation of
these samples between sites was carried out at room tem-
perature for logistical reasons. The chosen references
(Xp22.3 and AGO1) were based on assumptions that
cfDNA is fragmented equally across the genome, and
dPCR analysis showed equal abundance of reference to
target loci for nonmaternal cfDNA samples, since a ratio
of approximately 1 was expressed (see online Supplemen-
tal File 3). This is important, because a previous study has
shown unequal representation of reference targets [e.g.,
TERT (telomerase reverse transcriptase) and ERV3–1
Fig. 3. Fetal RHD genotyping results frommaternal plasma samples.
The concentration (copies per microliter) (plus SD) was identiﬁed for both target regions (RHD5 and RHD7) and the reference region (AGO1).
The presence or absence of the target regions were used to determine fetal status (RHD+ or RHD−, respectively). (A), Maternal samples
collected in EDTA tubes (n = 22). (B), Maternal samples collected in Streck BCTs (n = 24). The same controls are represented in both graphs.
The control nonmaternal cfDNA RHD-positive sample (399X) exhibited ratios of 0.51 and 0.47 for RHD5/AGO1 and RHD7/AGO1, respectively.
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(endogenous retrovirus group 3, member 1)] in cfDNA
compared to genomic DNA (31 ). In addition, the
RHD control used in Fig. 3 shows a ratio of approxi-
mately 0.5, illustrating that the control sample is hemi-
zygous for the RHD gene, whereas homozygous RHD
samples tested with the same assay expressed ratios close
to 1 (data not shown).
dPCR data were used to determine the cffDNA
fraction, since they are expected to demonstrate higher
levels of sensitivity and improved accuracy for low
template copy numbers (32 ). Poisson statistics were
incorporated to determine the copy number, since
some droplets may have contained multiple targets
(33 ). The proportion of fetal target DNA was rela-
tively low [mean number of droplets 12 084, mean
number of RHD molecules 20.8 and 17.8 for samples
from EDTA tubes and Streck BCTs, respectively (data
not shown)]. However, increases in the mean number
of copies per partition for the references (e.g., AGO1),
which is shown in EDTA maternal samples [e.g., 0.62
mean copies per partition (sample 15)], result in
higher proportions of dual-positive droplets compared
to samples collected in Streck BCTs [e.g., 0.023 mean
copies per partition (sample 32)] (see online Supple-
mental File 3). Since the release of the QX100™
ddPCR system in 2012, various studies have been
conducted to find out whether its application can en-
hance or replace current qPCR-based approaches
(19, 20, 33–36). Some studies have shown equal sensi-
tivity for dPCR and qPCR, but with improved levels of
precision and day-to-day reproducibility with dPCR ap-
proaches (35, 36 ). However, several studies have shown
considerable improvements of sensitivity and specificity
on the dPCR platform compared with qPCR approaches
(19, 20, 33, 34 ). The current study also illustrates signif-
icant improvements in sensitivity for the dPCR platform,
particularly for samples expressing low relative propor-
tions of fetal DNA (2%) (Table 3).
On the basis of the qPCR data, 54% of patients
had false-negative results and in a clinical setting
would not have received required anti-D, risking allo-
immunization and subsequent HDFN. However,
dPCR results revealed no false-negative results, and
routine administration of this assay would have pre-
vented unnecessary anti-D administration in 31.1% of
patients in our study cohort. Previous studies have also
reported false-positive or inconclusive results when the
fetus expresses D-variants (4, 20, 24 ). False-positive
results do not pose a risk of alloimmunization but
result in unnecessary anti-D administration. If applied
to a clinical setting, anti-D would have been adminis-
tered to the 4 women with inconclusive results found
with qPCR for samples collected in Streck BCTs,
which in these cases was necessary since the fetuses
were RHD. On the basis of the dPCR data, only 1
woman (2%) would have received anti-D that was not
required. The oligonucleotide primers used in this
study for the RHD targets were as described by
Finning et al. (24 ). These primers should distinguish
between RHD-positive and RHD/DVI (type 1–4)
fetal genotypes by amplifying exon 7 but not exon 5
for the variant samples. However, constraints on ethics
approval prevented follow-up confirmation of the in-
conclusive result (sample 37) via analysis of fetal cord
DNA to determine the true RHD genotype of this
fetus. Both dPCR and qPCR will express similar levels
of false-positive results owing to D-variants, but our
results show that dPCR has the potential to eliminate
or reduce the occurrence of false-negative results, es-
pecially in cases in which low cffDNA fractions
(2%) are expressed.
In conclusion, this study illustrates that dPCR
shows improved accuracy for fetal sex determination
and RHD genotyping compared with qPCR, particu-
larly for suboptimal samples that express low relative
proportions of fetal DNA (2%). Despite the accu-
racy of qPCR being relatively high in most large-scale
validation studies (3, 9, 24 ), false-negative results are
still present and have been attributed to maternal
DNA degradation. Further large-scale studies are now
necessary to determine the accuracy of dPCR for fetal
RHD genotyping, but these results illustrate that
dPCR has the potential to provide a safer and more
reliable noninvasive diagnostic test for the targeted
administration of prophylaxis anti-D.
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Abstract: Down syndrome (DS) is the most common genetic cause of developmental 
delay with an incidence of 1 in 800 live births, and is the predominant reason why women 
choose to undergo invasive prenatal diagnosis. However, as invasive tests are associated 
with around a 1% risk of miscarriage new non-invasive tests have been long sought after. 
Recently, the most promising approach for non-invasive prenatal diagnosis (NIPD) has 
been provided by the introduction of next generation sequencing (NGS) technologies.  
The clinical application of NIPD for DS detection is not yet applicable, as large scale 
validation studies in low-risk pregnancies, that express the same levels of sensitivity as the 
existing invasive techniques, need to be completed. Currently, prenatal screening is still the 
first line test for the detection of fetal aneuploidy. Screening cannot diagnose DS,  
but developing a more advanced screening program can help to improve detection rates, 
and therefore reduce the number of women offered invasive tests. This article describes 
how the prenatal screening program has developed since the introduction of maternal age 
as the original “screening” test, and subsequently discusses recent advances in detecting 
new screening markers with reference to both proteomic and bioinformatic techniques. 
Keywords: screening; Down syndrome; non-invasive; biomarkers; sonographic markers; 
next-generation-sequencing 
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1. Introduction 
Down syndrome (DS) is the most common chromosomal aneuploidy and is the leading genetic 
cause of developmental delay. The overall incidence of DS is around 1 in 800 live births [1,2], but the 
risk of fetal trisomy is directly related to maternal age, increasing gradually up to age 33 and 
subsequently increasing exponentially (Figure 1). Women in their late 40s have an incidence rate of 
around 1 in 32 live births [3].
 
Between 1989 and 2008, the percentage of women conceiving aged  
35 years and over increased from 9% to 20%, respectively, which led to a 71% rise in the number of 
DS pregnancies [2,4]. Despite an expected 1.32 fold increase in the number of DS live births as a 
result of this, the reported rate in England and Wales fell by 1% from 736 live births in 1989 to  
750 live births in 2008 [2,5]. In the UK the National Down Syndrome Cytogenetic Register (NDSCR) 
indicate that without improved screening tools between 1989 and 2008, the continuous rise in maternal 
age would have caused a 48% increase in live births with DS [3]. Although there are clear ethical 
issues surrounding prenatal screening, with the majority of women terminating affected pregnancies 
the evidence provided clearly illustrates the effectiveness of screening for DS. 
Figure 1. The estimated risk of Down syndrome (DS) according to maternal age (adapted from [3]).  
 
In addition to advanced maternal age, other risk factors include previous family history and 
gestational age, as 43% of DS pregnancies miscarry between 10 weeks and term [6,7]. The gradual 
introduction of various biochemical and sonographic markers since the early 1980s, has greatly 
improved the sensitivity of current screening programs to around 95% [6]. Women with a high risk 
following screening are offered invasive procedures such as amniocentesis or chorionic villus 
sampling (CVS) for a definitive diagnosis. However, these invasive procedures are associated with 
around a 1% risk of iatrogenic fetal loss [1,8,9].
 
Advances in screening tools could further improve the 
specificity and sensitivity of current screening methods, thus reducing the number of women offered 
invasive diagnostic tests. In spite of the huge recent advances in non-invasive prenatal diagnostics 
using next generation sequencing (NGS) [1], screening will remain an essential first line test in the 
clinical management of aneuploid pregnancies. This review will outline the development of screening 
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over the last four decades up to present day and discuss possible new screening tools that could 
potentially be used in a clinical setting.  
2. Definitions  
There are various measurements that can be used to determine the success of a screening program 
including; the detection rate (DR), the false positive rate (FPR), screen positive rate (SPR), and the 
odds of a positive result (OAPR). The DR (sensitivity) of the test identifies the proportion of affected 
cases successfully identified by the screening program, for example a DR of 90% means that the 
screening test will successfully detect 9 out of 10 cases of DS. However, high sensitivity alone is not 
sufficient for DS detection. The test must also display a low FPR, which is defined as the rate of 
occurrence of positive results in non-affected cases. More recently, the SPR has been used as an 
alternative to the FPR, The screen positive rate identifies those with a result above the cut off risk  
(for example 1 in 150) and will include both true positives and false positives [5]. It is important that 
the FPR/SPR is kept as low as possible so to minimize the number of women offered invasive 
procedures which will in turn reduce the number of miscarriages of healthy fetuses. The likelihood of a 
woman having a DS pregnancy confirmed by CVS or amniocentesis if her screen risk is high is known 
as the OAPR. If a screening test has a high OAPR, more affected pregnancies will be successfully 
diagnosed for every miscarriage caused by invasive testing [10,11]. Both the DR and the FPR/SPR are 
influenced by the risk threshold above which invasive testing is offered. In an ideal screening test the 
DR would be high (>90%) and the SPR would be low (<2%). However, increasing the threshold  
(for example to 1 in 100) would cause both the DR and the SPR to decline, and decreasing the 
threshold (for example to 1 in 300) would cause both the DR and SPR to increase [5].  
Figure 2. The screening process, potential outcomes and measures of accuracy. Detection 
rate (DR): Proportion of affected cases successfully identified by the screening test. 
TSP/(TSP + FSN) = 85%. False positive rate (FPR): Proportion of positive results in  
non-affected cases identified by the screening test. FSP/(FSP + TSN) = 6.7% (adapted 
from [10,11]).
  get permission from 11.
 http://www.down-syndrome.org/editorials/2087/?page=1
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Since the introduction of screening for DS the DR has greatly improved parallel to a decrease in the 
SPR [10]. Therefore more affected cases of DS are being detected via screening and fewer  
non-affected cases are being identified as high risk. This has led to an overall increase in OAPR  
and consequently a decline in the number of invasive tests offered to women. Although there is still 
room for improvement, Figure 2 illustrates the possible outcomes and measures of accuracy of the 
screening process [11]. 
3. Screening: Past to Present  
3.1. Historical Overview  
In the early 1980s, maternal age was effectively the only screening tool available for detection of 
DS and invasive diagnostic tests were offered to all women aged 35 years and above. These tests were 
only offered to women younger than 35 years if there was known family history of the disorder [12]. 
However this approach was inappropriate and unsustainable for numerous reasons. Firstly, maternal 
age alone is not an effective screening test as it has a DR of less than 35%, meaning that most fetuses 
with DS were undetected and many women with unaffected fetuses were subjected to unnecessary 
invasive testing [5,13]. Secondly, as the average maternal age was beginning to rise, resources to 
perform invasive testing for all these women were unavailable [5].
  
To improve the sensitivity of screening for DS, sonographic and biochemical screening tests were 
developed that could be combined with maternal age to increase the accuracy of risk assessment.  
The initial opportunity to improve screening arose in 1984, when several studies identified an 
association between low alpha-fetoprotein (AFP) levels (around a 25% reduction) in maternal serum 
and fetal aneuploidy [14–16]. AFP is a large serum glycoprotein produced by both the yolk sac and the 
fetal liver, and is considered to function in a similar way as albumin in adults [17]. DiMaio et al. 
identified that using a cut-off for risk at which 5% of women under 35 are offered invasive testing, 
around 25–30% of pregnancies in which the fetus has DS will be detected using AFP serum biomarker  
alone [18]. The identification of this marker for DS detection was a serendipitous scientific discovery, 
initially raised AFP levels were used to identify pregnancies that were potentially affected by fetal 
neural tube defects particularly anencephaly, it was only during this cohort that the link between low 
AFP levels and an increased incidence of DS was identified. Now AFP is used clinically worldwide 
for screening of DS after the first trimester as one of the biochemical serum markers used in the 
quadruple test.  
Since then, various pregnancy-associated maternal serum markers for DS have been evaluated. Key 
markers that have been incorporated into the screening program include human chorionic gonadotropin 
(hCG), estriol, inhibin A and pregnancy associated plasma protein A (PAPP-A). hCG is a hormone 
initially produced by the embryo and later by the syncytiotrophoblast. Its function is to enable the 
secretion of progesterone, which promotes the maintenance of the corpus luteum [19]. During very 
early pregnancy hCG levels increase rapidly until 12 weeks gestation, at which point the hCG levels 
off, normal hCG values during the second trimester range between 4,060 and 165,400 mIU/mL. In 1987, 
Bogart et al. identified an association between an increase in serum levels of hCG and DS pregnancies 
(approximately double the normal values), which led to the introduction of the second trimester double 
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test a year later in the UK [20]. This test measured maternal serum concentrations of both AFP and 
hCG between 15 and 20 weeks gestation alongside maternal age. With a risk threshold of 1 in 250,  
the DR was approximately 60% with a SPR of 5% [5]. 
 
Shortly after the double test was established in the UK, studies reported a 25% reduction of 
unconjugated estriol in DS pregnancies (normal value at 15 weeks gestation is around 4nmol/L) [21]. 
The addition of estriol as a third marker was the basis for the “Triple test’’ [22,23]. In the early 1990s 
the triple test was adjusted by the replacement of hCG with the free beta subunit of hCG (fβ-hCG) as it 
is this which is more markedly increased in DS pregnancies [24]. Although the triple test was 
associated with higher sensitivity (67% DR), it was not considered to be a great improvement on the 
double test, as the SPR was not lowered and the costs of screening were increased [25]. However,  
in the early 1990s, inhibin A was found to be significantly elevated in DS pregnancies, leading to the 
generation of the quadruple test with an improved DR of 75% [26].
 
The double, triple and quadruple test 
all offer a greater DR than maternal age alone but can only be performed during the second trimester.  
In 1991 maternal serum associated plasma protein-A (PAPP-A) was shown to be reduced by around 
50% in DS pregnancies and was detectable from as early as 8 weeks gestation [22,27]. Between 17 and 
19 weeks gestation maternal serum PAPP-A levels in DS affected pregnancies returned to those values 
observed with unaffected pregnancies [28,29].
 
Throughout the 1990s the emphasis was to perform 
screening in the first trimester, allowing parents to decide at an earlier stage in the pregnancy whether 
to undergo invasive testing.  
In addition to these biochemical markers, the risk of DS pregnancies can also be evaluated by the 
identification of physical markers using sonographic imaging. In 1992 the ultrasound screening test of 
nuchal translucency (NT) was developed by Nicolaides et al. [30], the ultrasound NT is the 
sonographic appearance of a collection of fluid under the skin behind the fetal neck in the first 
trimester between 11 and 13 weeks gestation. The maturation of the fetal lymphatics often occurs later 
during the second trimester in fetuses with DS and other chromosomal abnormalities, which causes an 
increase in fluid collection. 
During the early 1990s a number of reports identified an association between DS and increased NT.
 
In 1994, Nicolaides et al. reported that an NT value ≥2.5 mm was seen in 84% of fetuses with DS and 
4.5% of normal fetuses in a study involving 1,273 pregnancies [31]. However, it is important that 
when measuring the NT thickness care is taken when aligning the calipers, as an error of 0.4 mm can 
significantly alter the risk. For example, at 12 weeks gestation the risk of having a DS fetus when NT 
values of 2.6 mm and 3.0 mm are recorded is quoted as 1 in 1,394 and 1 in 563, respectively [32]. 
When maternal age alone was used as a screening tool, only two out of 11 cases of DS were detected, 
however following the introduction of NT measurement, three out of four cases of DS were detected 
by karyotyping because of an increased NT, this illustrates then when obtained by well-trained 
professionals, NT measurement is a highly reproducible screening tool [33,34].  
The combination of NT, maternal age and early detectable serum biomarkers (fβ-hCG and  
PAPP-A) was referred to as the first trimester combined test [35].
 
Studies have identified that with the 
first trimester combined test around 85–90% of all DS cases could be detected with a 5% FPR [36–39]. 
Figure 3 illustrates a short summary of key DS screening developments incorporated in a clinical 
setting from the early 1980s to date.  
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Figure 3. Timeline summarising the key developments in UK DS screening, from the early 
1980s when maternal age was effectively the only screening tool used up to the 
identification of the Model of Best Practice identified by the UK National Screening 
Committee (NSC) in 2011.  
 
3.2. Current Methods 
In 2008 the UK National Screening Committee’s (UK NSC) Model of Best Practice for DS 
screening set a target for 2010/11 to achieve a DR of 90% and a FPR/SPR of 2%, however this is yet 
to be achieved (Figure 3). The test currently closest to achieving standards set by the MoBP is the first 
trimester combined screening test (DR 85–90% and FPR 5%). However, women who miss first 
trimester screening can only be offered second trimester quadruple testing, which has a slightly lower 
sensitivity (75% DR) and a higher FPR (6.9%) than the first-trimester combined test [5].
 
Some hospitals also offer the integrated test [40], which is performed in two stages. Firstly the 
combined test is performed followed by second-trimester biochemistry (quad test) a few weeks  
later [41]. This test is used to help reduce the FPR, as women that are high risk following the 
combined test may become a low risk following the result of the integrated test. In 2013 the 
International Society for Prenatal Diagnosis (ISPD) identified that integrated screening can be offered 
when CVS is not available [41]. However, the UK NSC does not recommend integrated testing for two 
fundamental reasons. Firstly a woman who is considered to be high risk following the combined test 
may not return for her quad test and therefore may be lost within the system without having been 
counseled properly and secondly, there are higher cost and service implications associated with 
combining the two screening tests [42]. A possible compromise to this problem is Contingency 
screening, which allows pregnant women with a significantly high risk following first-trimester 
screening to be offered invasive diagnostic tests immediately. In contrast, pregnant women that 
indicate extremely low risk after first trimester screening are reassured. It is only those women with an 
intermediate risk value (between 1 in 50 and 1 in 1,000) that are offered further testing with other 
ultrasound markers including nasal bones, tricuspid regurgitation and ductus venous Doppler to further 
refine the risk before offering invasive testing. This approach results in a DR of 90% for a FPR of  
3% [37]. Currently, the UK NSC has also not supported the Contingency screening test despite 
improvements to DR and FPR/SPR, because of the complexity associated with the technique and the 
implications for service reconfiguration [5].
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In the United States, the Society for Maternal-Fetal Medicine (SMFM) completed a survey in 2007 
to determine changes in screening and numbers of invasive diagnostic procedures performed since 
2001. The results showed that over this time frame the evolution and increased uptake of DS screening 
between 2001 and 2007 led to a 20% reduction in invasive diagnostic procedures [43]. The ISPD 
recognizes that the use of maternal age alone to assess fetal DS risk in pregnant women is insufficient 
and has stated that a combination of ultrasound NT measurement and serum markers in the first 
trimester should be available to all women who desire early risk assessment. For women that first 
attend their prenatal care after 13 weeks 6 days gestation, the ISPD recommends that the quadruple test 
should be provided [44].
 
4. Further Developments  
Since the early 1980s enormous progress for DS screening has been made, however further 
improvements are still required. The problem associated with current screening tests is that 5% or 
more of screened women need to undergo invasive testing in order to detect 60–80% of fetuses with 
DS, resulting in large numbers of false screen-positives. In 2008 it was estimated that approximately 
400 babies without DS were miscarried following invasive procedures on women with false positive 
screening results in England and Wales [11].
 
Here we look at new screening techniques that are being 
developed that could potentially raise sensitivity of current screening methods (to around 90% DR) 
and lower the FPR/SPR (to around 2%), allowing more DS cases to be detected and less invasive 
testing to be offered, thus reducing the number of miscarriages in affected and unaffected pregnancies.  
4.1. Sonographic Markers of DS  
The role of sonographic markers in the risk assessment of DS has been extensively investigated at 
the 11–14 week scan and at the time of the mid-trimester fetal anomaly scan. Sonographic markers at 
the 11–14 week scan include structural abnormalities (exomphalos, cystic hygroma, etc.) and more 
subtle markers such as presence or absence of nasal bones, tricuspid regurgitation and reversed flow in 
the ductus venosus. Markers at the mid-trimester scan can again be divided into structural anomalies 
(congenital heart disease, anterior abdominal wall defects, ventriculomegaly, etc.) and more subtle 
markers (choroid plexus cysts, echogenic foci in the heart, increased nuchal fold, etc.) traditionally 
referred to as “soft markers”.  
The association between structural anomalies and aneuploidy detected during the first trimester or 
mid-trimester scan is well established. Fetal exomphalos or Fallot’s tetralogy for example has a 
significant association with Down’s Syndrome. Detection of structural anomalies at the time of either 
the 11–14 week scan or the mid-trimester scan should lead to the offer of amniocentesis or CVS. 
Atrioventricular septal defects (AVSD) are an example of second-trimester structural anomaly.  
In pregnancies that demonstrate a normal fetal karyotype, the frequency of AVSD is 1 in 10,000 live 
births, but in DS pregnancies this increases significantly to 2,000 in 10,000 live births (1 in  
5 incidence) [45].
 
However, repeated studies have shown that less than 25% of affected fetuses 
demonstrate major structural abnormalities, whereas 1 or more “soft markers” could be observed in 
50% or more cases [46–48]. 
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The presence or absence of the more subtle features at the 11–14 week scan has been used to refine 
the risks generated by combined screening. Hypoplasia of the nasal bone is identified in 65% of 
fetuses with DS between 11 and 14 weeks gestation. However, this marker shows significant  
inter-racial variation. In Caucasian populations only 1–3% of normal pregnancies have an absent nasal 
bone during late first-trimester whereas in African populations this increases to around 10% [5].
 
Incorporating nasal bone assessment into combined screening therefore gives better results in 
Caucasian populations. Doppler flow examination across the tricuspid valve and in the ductus venosus, 
have also proved useful markers. In 2009, Kagan et al. performed a large scale study involving  
20,000 euploid pregnancies which included 122 cases with DS. Reversed flow in the a-wave of the 
ductus venosus and tricuspid regurgitation were observed in 55% and 60% of DS cases, and in 3.2% 
and 0.9% of euploid cases, respectively [49]. Incorporation of these markers into a first-trimester 
combined screening test can increase the DR to 93–96% with a FPR of 2.5% [47]. Figure 4 illustrates 
the occurrence of these sonographic features in euploid and trisomy foetuses. Checking for these 
additional markers is not only challenging but also very time- consuming and they have not been 
adopted into routine clinical practice for widespread screening. They may have a role, however, in a 
contingent screening model, whereby they are offered to women with an intermediate risk from 
combined screening who need further information before deciding whether to opt for invasive testing [37]. 
Figure 4. Sonographic features of trisomies 21, 18 and 13 (adapted from [50]). 
 
The significance of the identification of soft markers at the time of the mid-trimester scan has been 
far more contentious. In the 1990s it was common place for women to be offered invasive procedures 
when choroid plexus cysts, echogenic foci in the fetal heart, mild renal pelviceal dilatation were noted 
at the time of the 20 week scan. However, a review of the importance of these soft markers in 2001 
confirmed their very low sensitivity and specificity for DS with the exception of an increased nuchal 
fold (the thickness of skin at the back of the fetal neck noted at the time of the mid-trimester scan,  
not to be confused with nuchal translucency measurements at the time of the first trimester scan) which 
had a likelihood ratio of 17 for DS [51]. One of the reasons why the importance of soft markers has 
diminished is because of the widespread adoption of first and second trimester screening over the last 
10 years. Poor uptake in screening in the early 1990s meant that the prevalence of DS at the time of the 
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mid-trimester scan was much greater than in current practice. Screening tests perform better when the 
prevalence the condition being screened for is high. With the increasing uptake of effective DS 
screening before 20 weeks the efficacy of screening using soft markers is now much less.  
A combination of these factors led to the National Screening Committee in the UK in 2009 
recommending that the a prior risk for DS should not be adjusted depending on the presence of 
absence of single or multiple soft markers (choroid plexus cysts, dilated cisterna magna, echogenic 
cardiac foci and a 2 vessel cord). 
4.2. New Serum Biomarkers  
Despite recent advances in ultrasound technology allowing current screening techniques to achieve 
detection rates >90% with FPRs <5%, improvements to these rates is still a priority for current 
research in prenatal assessment. In addition to identifying new possible ultrasound markers, novel 
biochemical screening markers to improve current DRs and FPRs/SPRs have been extensively  
studied [52–58]. Since the discovery of cell-free fetal DNA (cffDNA) within the maternal circulation 
many advances have been made in prenatal screening [52].
 
Recent studies exploring the proteomic 
profile of maternal serum have identified both non-epigenetic and epigenetic screening markers that 
could potentially be used as an alternative or in addition to current screening tools to provide greater 
specificity and lower FPRs/SPRs [53–58]. The SAFE (Special Non-Invasive Advances in Fetal and 
Neonatal Evaluation) NoE (Network of Excellence) was established by the European Union (EU) in 
2004 to implement routine, cost-effective non-invasive prenatal diagnosis (NIPD) and neonatal 
screening through the formation of long term partnerships worldwide [59,60]. The program played a 
key role in the standardization of RhD genotyping, and also set out to identify a panel of new, more 
informative, biomarkers for fetal DS detection. Despite the program ending in March 2009, the long 
term goals set out by the SAFE NoE are still a key area of research [59]. 
Non-epigenetic markers, such as maternal serum markers (MSMs) used in the combined screening 
test, simply show a marked increased or decreased level in affected cases in comparison to normal 
pregnancies. Novel biochemical markers are currently under investigation but so far there has been no 
formal large scale evaluation of new markers by the UK NSC to inform policy. Epigenetic approaches 
have also been examined in an attempt to discriminate the fetal DNA molecules from the high 
background of maternal DNA fragments (around 90% of total DNA). Difference in DNA methylation 
between the mother and fetus is currently the most characterized epigenetic modification studied for 
possible prenatal detection of DS [61,62]. Targeting fetal-specific markers allows for the generated 
signal to be completely fetal in origin, subsequent chromosomal dosage can then be carried out for 
trisomy identification. Table 1 illustrates various studies over the past few years that have published 
results on potential new biomarkers (both non-epigenetic and epigenetic) that could be used to improve 
the sensitivity of current screening programs. For both PIGF and ADAM12 (Table 1) detection needs 
to occur prior to 10 weeks gestation, as they are both almost non-existent by this time. Though it 
would be ideal to screen for DS this early in pregnancy, these tests are fairly unpractical because 
women have often not had their first pregnancy appointment with either their doctor or midwife. 
However if early screening is a possible it has been identified that the addition of PIGF to the 
combined test can help to increase the DR by 4–7% [63]. Alternatively, the results for the CA15-3 and 
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CA19-9 (Table 1) were not affected by maternal age [54]. Kamyab et al. identified that both the 
accuracy and specificity were improved by using two target genes (DSCAM and DYRK1A), producing 
an overall specificity of 96% and sensitivity of 80% [56]. Providing further validation studies are 
carried out it is possible that these biochemical markers may help to improve current screening tests. 
Table 1. Summary of studies identifying potential new biochemical markers for prenatal 
screening of DS. 
Non-Epigenetic Markers 
Study Marker Assay Results 
Cowens et al. [54] 
Placental 
growth factor 
(PIGF) 
DELFIA Xpress immunoassay 
platform. 
Increase during early first trimester in 
affected DS pregnancies (1 MoM in 
unaffected pregnancies, 1.3 MoM in DS 
pregnancies, p < 0.0001). 
Wang et al. [64] ADAM12 
Auto DELFIA/DELFIA 
ADAM12 Research kit 
(PerkinElmer Life and 
Analytical Sciences, Finland). 
Reduction during early first-trimester in 
affected DS pregnancies (1 MoM in 
unaffected pregnancies, 1.26 MoM in DS 
pregnancies, p < 0.05). 
Akinlade et al. [55] 
CA15-3 
CA19-9 
Quantified by the Kryptor 
Analyzer. 
No difference between euploid and DS 
pregnancies. 
Significantly elevated in DS pregnancies. 
(0.98 MoM in euploid, 1.16 MoM in 
trisomy 21, p = 0.024). 
Kamyab et al. [56] 
DSCAM 
 
DYRK1A 
Multiplex assay with 
cytogenetic analysis and  
QF-PCR. 
The mean gene dosage rate was 
significantly increased for both genes in DS 
pregnancies compared to euploid 
pregnancies (p < 0.001). 
Epigenetic Markers 
Lim et al. [57] PDE9A 
Quantitative methylation 
specific-PCR. 
M-PDE9A (maternal) did not differ 
between pregnancies, but levels of  
U-PDE9A (fetal) were significantly higher 
in DS pregnancies. 
Du et al. [58] DSCR4 
Methylation specific primers 
and digital PCR. 
Hypomethylated in placental tissue and 
methylated in maternal cells. Can detect 
and quantify unmethylated DSCR4 in the 
first-trimester maternal plasma, 
successfully detect DS by RCD against a 
reference gene (e.g., ZFY). 
Chim et al. [65] 
SERPINB5 
(coding for 
Maspin) 
Bisulphite genomic sequencing 
and RT-Quantitative 
methylation-specific PCR. 
Hypomethylated in placental tissue and 
methylated in maternal cells. SERPINB5 
was the first fetal-specific hypomethylated 
gene to be identified in maternal plasma. 
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The phosphodiesterase gene, PDE9A, is an example of an epigenetic marker, as it is completely 
methylated in maternal blood (M-PDE9A) and unmethylated in the placenta (U-PDE9A). In 2011,  
Lim et al. report a DR of 77.8% of DS pregnancies for this marker and a 5% FPR, demonstrating that  
U-PDE9A is an effective biomarker for the non-invasive diagnosis of DS during the first-trimester of 
pregnancy [57]. Other studies have also identified epigenetic markers (Table 1) for DS screening,  
but before any can be approved by the UK NSC, large validation studies must be carried out.  
Currently there are many developments occurring in integrated proteomics and bioinformatics 
analysis in an attempt to identify multiple candidate protein biomarkers from maternal serum for 
detection of DS. Kang et al. identified 31 DS differentially expressed maternal serum proteins  
(DS-DEMSPs) using the latest proteomic techniques to identify proteins differentially expressed in the 
maternal serum of women carrying a DS fetus, ten of which were considered as potential biomarkers 
(Alpha-2-macroglobulin, Apolipoprotein A1, Apolipoprotein E, Complement C1s subcomponent, 
Complement component 5, Complement component 8, alpha polypeptide, Complement component 8, 
beta polypeptide and Fibronectin) [66]. Initial bioinformatics analysis by SAFE NoE has identified 
differences of known placental and DS markers, such as genes located in the DSCR region of 
chromosome 21. The SAFE project identified that the combination of both bioinformatics and 
proteomic approaches could be used to find previously unidentified biomarkers of aneuploidy [59]. 
The integration of proteomics and bioinformatics would not only provide a useful tool for prenatal 
screening of DS, but would also provide a mechanism for the detection of other birth defects or 
pregnancy related disorders. However, is important to appreciate that plasma proteomics is extremely 
complicated due to the huge “noise” present when looking for new screening targets. Only a small 
number of studies have attempted to identify new biomarkers for DS, therefore it is essential that larger 
scale studies are conducted using newer technology, such as liquid chromatography-mass spectrometers, 
which can identify larger numbers of peptides in one analysis with great sensitivity [67]. It is likely 
however, that with the rapid advances in DNA technology developments in this area will be  
somewhat marginalized.  
4.3. Digital PCR and Next Generation Sequencing (NGS)  
Since the identification of cffDNA in maternal plasma [52], the goal is to detect DS and other 
aneuploidy disorders, such as trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome) and 
Monosomy X (Turners syndrome), using NIPD. Unlike screening, NIPD does not identify the risk of 
DS but allows for a definitive diagnosis. Currently, cffDNA has allowed for successful NIPD of 
gender determination [68] and RhD status [69,70], and is available on a research basis for some single 
gene disorders such as sickle cell anemia [71]. Recently, studies have identified new sophisticated 
analytical methods, such as digital PCR and massively parallel sequencing (MPS) (also known as 
NGS) which are capable of detecting chromosomal aneuploidy from maternal plasma [1,8,72–74]. 
However, until these techniques pass the scientific and regulatory hurdles required to be considered 
diagnostic they could potentially be used to significantly improve current screening strategies.  
There have been various molecular techniques developed for non-invasive aneuploidy detection, 
which are allele dependent and labor intensive [75,76]. As maternal plasma only contains up to 10% 
fetal DNA, to detect the presence of a DS fetus the screening test would need to be able to detect a 5% 
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difference in plasma DNA concentrations for a sequence located on chromosome 21. In conventional 
real-time PCR, a difference of one cycle threshold (Ct) value corresponds to a 2-fold change in copy 
number, making it very difficult to detect a 1.5-fold increase in only 10% of the total DNA [77]. 
Digital PCR quantifies nucleic acids by counting amplification from single molecules [78], allowing 
copy number changes less than 2-fold to be easily detected. Digital PCR can be performed manually, 
but can be labor intensive and replication levels are limited by format of plate used (96 well or 384 well). 
Alternatives to the manual approach are now emerging. One of these methods is the use of 
microfluidic chips, which splits the original sample into 765 reaction chambers [79].  
Figure 5. False-color images of microfluidic digital PCR chips. FAM signal is shown in 
green, which represents the target chromosome (chromosome X, Y or 21), and HEX signal is 
shown in red, which represents the reference chromosome (chromosome 1). Yellow squares 
indicate overlapping of HEX and FAM. (A) Normal female fetus (46 XX). The ratio of 
chromosomes X and 21 are equal to reference chromosome 1 (2:2). There is no target  
Y chromosome identified. (B) DS male fetus (47 XY + 21). Ratio of chromosomes Y and X 
is half of reference chromosome 1 (1:2 ratios for X or Y and chromosome 1, respectively).  
This fetus indicates an increase of chromosome 21 in comparison to reference chromosome 1 
(3:2 ratio, respectively), indicating trisomy 21 (adapted from [80]).  
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Figure 5, adapted from Fan et al. illustrates a mock microfluidic digital PCR chip image of a 
normal female fetus and a DS male fetus. Detection of DS pregnancies can be identified by 
determining the allelic ratio. The ratio between the 21-target chromosome (FAM-labeled) against the 
reference chromosome 1 (HEX-labeled) is 3:2 and 2:2 in DS male fetus and normal female fetus, 
respectively [80]. However, these results were achieved using CVS samples. To achieve this level of 
accuracy using maternal plasma samples is more challenging due to the high level of background 
maternal DNA.  
Microfluidic digital PCR does not rely on data that is collected during the exponential PCR phase 
and it does not require a standard for absolute quantification (unlike RT-PCR), which allows for 
improved precision and accuracy [81]. Lun et al. successfully detected fetal-derived Y-chromosomal 
DNA in maternal plasma using microfluidic digital PCR, which showed higher sensitivity compared 
with non-digital real-time PCR, 100% and 90%, respectively, and lower imprecision [82]. Later in 
2009, Lo et al. identified an approach using digital PCR for the non-invasive detection of DS. Firstly, 
the report identifies a digital RNA-SNP strategy, which uses digital PCR to determine the imbalance of 
a single nucleotide polymorphism (SNP) on PLAC4 mRNA, a placentally-expressed transcript on 
chromosome 21, in women bearing DS fetuses. Secondly, it identifies an alternative method known as 
the digital relative chromosome dosage (RCD) method. The RCD method is advantageous to the 
RNA-SNP approach as it does not require polymorphisms for analysis; it simply detects over- or 
underrepresented alleles by comparing copy numbers variation between chromosomes. However, DS 
could only be detected in samples containing 25% fetal DNA [83]. If a 25% fetal enhancement is 
achieved, 7,680 molecules would need to be analyzed to achieve successful characterization of trisomy 
status [84]. Evans et al. reported that if fetal DNA is enriched to 20%, then 2,609 counts would be 
sufficient to achieve a 99% DR for a 1% FPR. However, if fetal DNA is only enriched by 2%,  
over 110,000 counts would be needed to achieve a 95% DR for a 5% FPR [85]. Due to the high level 
of sensitivity achieved (99% DR), provided efficient prior-fetal enrichment, it is possible that digital 
PCR could potentially replace current screening methods. However, even though digital PCR could 
provide a cheaper alternative to NGS-NIPT, confirmation of the high-throughput possibilities and 
costs of digital PCR by large validation studies are still required. 
The development of non-invasive tests based on cffDNA within the maternal circulation provides 
substantial new opportunities to improve prenatal screening. To date, the most convincing data for a 
generally applicable test for aneuploidy detection from cffDNA have been generated through MPS. 
This technology allows cffDNA obtained from maternal plasma to produce millions of short-sequence 
tags that can be aligned and uniquely mapped to a reference human genome that are by definition 
mapped to a specific chromosome [86]. The DR for fetal aneuploidy using this method is determined 
by the depth of sequencing and subsequent counting statistics. Fan et al. were the first to propose 
counting chromosomes using high-throughput massively parallel shotgun sequencing (MPSS) 
technology. In this study 5 million sequence tags were obtained per patient, providing sufficient data to 
detect the over- or under- representation of chromosomes and allow for correct classification of an 
aneuploidy fetus [87]. Table 2 illustrates the DR and FPR associated with large scale clinical trials of 
NIPT by MPS for fetal DS detection.  
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Ehrich et al. revealed that MPSS managed to detect all 39 cases of DS samples (in a cohort of 449); 
however one normal sample was misclassified as DS (Table 2) [1]. The method described by Chiu et al. 
diagnosed a DS fetus when the Z-score for the proportion of chromosome 21 DNA molecules was >3, 
which indicates a 99% chance of statistical significance (Table 2) [8]. This method simply normalizes 
the number of sequence tags on the chromosome of interest by the number of tags in the sequencing 
run. However, it has been identified that using MPS, intra-run and inter-run variability can alter the 
chromosomal distribution of sequence reads for each sample. Some of the variability can come from 
sample handling, such as the DNA extraction procedure or the sequencing itself can lead to small 
shifts in the distribution of tags [88]. To minimize the intra- and inter-run sequencing variation, a study 
by Sehnert et al. developed an optimized algorithm by using normalized chromosome values (NCVs) 
from the sequence data [72]. When chromosome ratios are normally distributed, the NCV is equivalent 
to a statistical Z-score for the ratios. Threshold values for trisomy were established for all 
chromosomes of interest (13, 18 and 21). NCV values >4.0 were required for classification of affected 
aneuploidy state, and NCV values <2.5 were used to classify unaffected cases. NCV values between 
2.5 and 4 were classified as “no call”. Using these parameters, this study demonstrated 100% correct 
classification of samples with DS and Trisomy 18. However, one sample for chromosome 13 was 
classified as a “no call” [72]. Some speculation exists that the poor detection rate using NGS for 
trisomy 13 may be due in part to the lesser level of fragmentation of this larger chromosome [89].  
Table 2. Clinical trials of NIPT by massively parallel sequencing (MPS) for fetal DS 
(adapted from [41]).  
Study  Method  DR (%) FPR (%) 
Chiu et al. [90] Shotgun (2-plex protocol) 100 2.1 
Chiu et al. [90] Shotgun (8-plex protocol) 79.1 1.2 
Ehrich et al. [1] Shotgun  100 0.2 
Bianchi et al. [91] Shotgun  100 0 
Jensen et al. [92] Shotgun  100 0.9 
Sparks et al. [93] Targeted 100 0.8 
Ashoor et al. [88] Targeted 100 0 
Norton et al. [94] Targeted 100 0.1 
Liang et al. [95] Targeted 100 0 
MPS technologies have successfully enabled the NIPT of fetal chromosomal aneuploidies.  
The identification of DS was primarily identified, and currently many recent clinical studies have 
indicated detection rates >99% [1,90]. The incorporation of MPS for the detection of trisomy 18 and 
trisomy 13 was proved to be more difficult than detecting DS due to the relatively lower GC content 
expressed by these two chromosomes in comparison to chromosome 21. However, when the 
coefficient of variance (CVs) was adjusted with GC content, it was noted that trisomy 18 and trisomy 
13 can be detected accurately [87]. Chromosome 21 only represents less than 1.5% of the genome  
(in disomy cases) and as MPSS is not selective, millions of DNA fragments must be sequenced in 
order to detect statistically significant differences between trisomic and normal fetuses [96]. Therefore 
targeted methods have been developed, which count only specific sequences in contrast to shotgun 
sequencing, which counts all free DNA. In a recent statement from the Aneuploidy Screening 
Committee on behalf of the ISPD, it was noted that only cfDNA analysis based on MPS with either 
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“shotgun” or “targeted” counting have been sufficiently validated to be considered analytically  
sound [41]. Targeted sequencing can allow for more samples to be multiplexed at once, proving a 
cheaper alternative to whole genome sequencing (WGS). However, the limitation of this method is that 
only the region of interest can be studied. 
Aria Diagnostics (San Jose, CA, USA) have developed a multiplex MPS assay, termed ‘‘Digital 
Analysis of Selected Regions’’ (DANSR) which sequences regions from target chromosomes. In a 
study by Sparks et al. DANSR was used to develop an algorithm, the Fetal-fraction Optimized Risk of 
Trisomy Evaluation (FORTE), which combines both the age-related risks and the proportion of 
cffDNA in the samples to provide an individual risk score for trisomy. The low proportion of cffDNA 
within the maternal circulation can make quantification of fetal chromosome imbalances difficult and 
potentially inaccurate, however, the FORTE algorithm factors in the fetal fraction when calculation the 
risk of aneuploidy. When there is a high proportion of cffDNA the difference between trisomic versus 
disomic chromosomes is greater, making it easier to detect trisomy [93]. This approach was also 
reported by Ashoor et al. which included a cohort of 400 samples from pregnancies with known 
karyotypes, 300 euploid (normal), 50 trisomy 18 (Edwards syndrome) and 50 trisomy 21 (DS). Both 
these reports which used the DANSR/FORTE assay identified high degrees of accuracy (Table 2) [88]. 
However, in these trials the test was only offered to high-risk pregnancies, but the future aim is to 
deliver this assay to all pregnancies as a highly accurate screening test for aneuploidies [97]. Chui et al. 
identified that if referrals for amniocentesis or CVS were based on sequencing test results; 
approximately 98% of the invasive diagnostic procedures could be avoided [90].
 
In 2012 Aria 
Diagnostics announced the launch of a U.S. clinical study involving 25,000 pregnancies to compare 
FORTE with the current combined screening test for DS [98].  
Table 3 illustrates some of the NGS platforms that are currently available. The HiSeq2000 has a 
significantly higher number of single end reads per run, which makes this platform very suitable for 
multiplexing samples and thus high throughput runs. However with the development of targeted 
counting smaller bench-top platforms such as the MiSeq and Ion Torrent could be used for more rapid 
testing due to reduced sample-prep time and faster run times, however these platforms will exert lower 
throughput due to lower number of single end reads per run. Even though the initial costs are cheaper 
for the bench-top platforms (MiSeq and Ion Torrent), because of the increased number of base reads 
per run with high throughput platforms (HiSeq2000), the cost per Mb is actually cheaper for the 
HiSeq2000 ($0.07) than the Illumina MiSeq ($0.5) and Ion Torrent ($0.64) [99,100].  
Table 3. NGS Platforms suitable for NIPT (adapted from [96,101]).  
 PCR-based sequencing  
Single end reads per 
run 
Run Time  
HiSeq™2000 (Illumina, Inc.)  Sequencing-by-synthesis 3 billion 5–14 days  
HiSeq™2500 (rapid run) (Illumina, Inc.) Sequencing-by-synthesis  ~300 million (10 Gb)  7 h  
SOLiD4™ (Life Technologies™/ 
Applied Biosystems ™) 
Sequencing-by-ligation  ~0.7 billion  5–10 days  
HeliScope® Single Molecule Sequencer 
(Helicos™Biosciences) 
Single-molecule-
sequencing-by-synthesis  
~840 million (28 Gb) 8 days  
Benchtop: MiSeq™ (Illumina, Inc.)  Sequence-by-synthesis  ~12 million (3.4 Gb) 16.5 h  
Benchtop: Ion Torrent™  
(Life Technologies™)  
Semiconductor sequencing 
technology 
~5 million (1 Gb) 4.4 h  
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The International Society for Prenatal Diagnosis (ISPD) has reported that before routine MPS 
population screening can be introduced additional trials are needed. These trials need to confirm that 
there is efficacy in low-risk populations, that it is cost-effective and suitable for diverse subpopulations 
(such as twin or IVF pregnancies) [102]. Commercial MPS-based testing for prenatal detection of DS 
has been introduced into some areas of the United States, China and more recently the European Union 
(EU). Currently there are three commercial providers of NIPT within the USA who have received 
Clinical Laboratory Improvement Amendments (CLIA) certification; however more recently an 
additional competitor, Natera, has entered the market (Table 4) [103,104]. The Harmony test (provided 
by Aria Diagnostics) is currently the cheapest ($795); however this test uses selective sequencing in 
comparison to the Verifi test and the MaterniT21 Plus test, which are MPSS-based test for aneuploidy 
detection. According to a study published earlier this year, with reference to WGS, the sequencing 
alone can already be done for less than $1,000, however soon it is likely the entire process will drop 
below the $1,000 mark [105]. The ISPD has outlined that this NIPT should be offered to high-risk 
pregnancies only and not offered as an initial test as screening via MPS for all pregnancies as it is not 
currently cost effective [102].
 
It is vital that all women undergoing MPS-based testing are offered 
prenatal counseling, so that the benefits and limitations of the test can be explained.  
Table 4. Commercial tests available for the NIPT of trisomies (adapted from [104]). 
Company Test  Released  Trisomies Tested  
Genetic Testing 
Method  
Accuracy  Sensitivity  Cost  
Sequenom  
MaterniT21 
Plus  
February 
2012 
13, 18, 21, sex 
chromo-somes  
MPSS >99% 92–99% $2,762 
Verinata 
Verifi 
Prenatal 
Test  
March 
2012  
13, 18, 21, sex 
chromo-somes  
MPSS 100% 87–99% $1,500 
Aria 
Diagnostics  
Harmony 
Prenatal 
Test  
May 2012  13, 18, 21  
Chromosome-
selective 
sequencing 
>99% 80–99% $795 
Natera Panorama  
March 
2013 
13, 18, 21 
Single 
nucleotide 
polymorph-ism 
100% 92–99% $1,495 
5. Conclusions 
This review demonstrates how screening for the detection of DS has improved since the early 1980s 
when maternal age was the only “tool” available. It also provides an insight into how new physical and 
biochemical markers may play a role in future routine screening to allow for increased test sensitivity 
with fewer false screen positives. Although this is still a key area of research, the main focus is to 
provide a definitive diagnosis through non-invasive techniques, such as digital PCR and NGS.  
A recent trial conducted within the UK to assess the performance of NIPT for fetal trisomy in a 
routinely screened first-trimester population identified a DR of >99% and a false positive rate of 0.1% 
for trisomy 21 and trisomy 18, which is a significant improvement on current screening DRs and FPRs 
(85–90% and 5%, respectively) [50,106]. Although the sensitivity of NGS currently provides DRs 
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similar to that provided by CVS, before even considering the replacement of IPD with NIPD,  
further large scale validation studies of low-risk populations are required to confirm that NGS test 
sensitivity is consistent with current invasive testing (97.8% and 99.4% for CVS and amniocentesis, 
respectively) [107]. It is also important that the economic aspects, counseling requirements and 
turnaround times are also considered [97].  
The cost of NIPD is likely to vary by country due to variations in the accuracy of the NIPD test, the 
cost of the NIPD test and the numbers undergoing NIPD [97]. However for fetal aneuploidy testing, 
whole genome MPS is still quite expensive, therefore to lower costs targeted approaches are being 
developed [96]. Using MPS in high-risk pregnancies following initial screening increases the OAPR, 
causing fewer women with unaffected fetuses to miscarry. Furthermore, providing NGS to all 
pregnancies would not only increase the OAPR but also reduce the number of unidentified trisomy 
fetuses, however this would be associated with a dramatic increase in cost due to a substantial rise in 
the numbers undergoing NIPD.  
Developments in proteomics to detect multiple novel biomarkers could provide a cheaper screening 
alternative to NGS but will most likely display a reduction in sensitivity. However, new biomarkers 
can only be used for screening purposes, whereas MPS directly identifies fetal DNA providing a NIPD 
approach that could potentially replace current IPD techniques. With the continuous decline in MPS 
costs, NIPD of fetal aneuploidy is an exciting area of research that could become a clinical reality for 
all pregnancies in the near future.  
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